A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 634

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 634
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Invalid argument supplied for foreach()

Filename: controllers/Trial.php

Line Number: 671

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 671
Function: _error_handler

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Cannot modify header information - headers already sent by (output started at /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/system/core/Exceptions.php:271)

Filename: controllers/Trial.php

Line Number: 705

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 705
Function: header

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Cannot modify header information - headers already sent by (output started at /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/system/core/Exceptions.php:271)

Filename: controllers/Trial.php

Line Number: 706

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 706
Function: header

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: Cannot modify header information - headers already sent by (output started at /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/system/core/Exceptions.php:271)

Filename: controllers/Trial.php

Line Number: 707

Backtrace:

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/application/controllers/Trial.php
Line: 707
Function: header

File: /Library/filemaker.ne.jp/Users/Main/Data/Web/diabetes/index.php
Line: 315
Function: require_once

Trial,trial_fullname,書誌表示用,サマリー,PubMedリンク,糖尿病TDB詳細リンク "4-T","the Treating to Target in Type 2 Diabetes","Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC, 4-T Study Group: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357: 1716-1730.","最大耐容量のmetforminおよびスルホニル尿素薬投与下で血糖コントロール不良の2型糖尿病患者において,二相性インスリン,食前インスリン,基礎インスリン併用の有効性および安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/17890232","http://diabetes.ebm-library.jp/trial/detail/51013" "4-T","Treating to Target in Type 2 Diabetes study","Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC, 4-T Study Group: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2009; 361: 1716-1730.","最大耐容量のmetforminおよびスルホニル尿素薬投与下で血糖コントロール不良の2型糖尿病患者において,二相性インスリン,食前インスリン,基礎インスリン併用の有効性および安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/19850703","http://diabetes.ebm-library.jp/trial/detail/51145" "4S","the Scandinavian Simvastatin Survival Study","Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 1997; 20: 614-620.","冠動脈心疾患を有する糖尿病患者において,simvastatinによる脂質低下療法の予後改善効果と,冠動脈心疾患および動脈硬化イベントに対する効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9096989","http://diabetes.ebm-library.jp/trial/detail/50569" "4S","the Scandinavian Simvastatin Survival Study","Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyorala K: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999; 159: 2661-2667.","糖尿病あるいは空腹時血糖異常を伴う患者に対するsimvastatinの冠動脈心疾患イベント抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10597756","http://diabetes.ebm-library.jp/trial/detail/50304" "4S","the Scandinavian Simvastatin Survival Study","Pyorala K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, Mitchel YB, Pedersen TR, Kjekshus J, Scandinavian Simvastatin Survival Study (4S): Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 2004; 27: 1735-1740.","非糖尿病の冠動脈心疾患患者において,simvastatinの心血管イベントリスクに対する有効性を,メタボリックシンドロームの有無により比較した。","https://www.ncbi.nlm.nih.gov/pubmed/15220255","http://diabetes.ebm-library.jp/trial/detail/50653" "6-year Malmo feasibility study","-","Eriksson KF, Lindgarde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991; 34: 891-898.","早期2型糖尿病患者とIGT患者において,長期の食事療法と運動療法の効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/1778354","http://diabetes.ebm-library.jp/trial/detail/50245" "ABCD","the Appropriate Blood pressure Control in Diabetes trial","Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652.","高血圧のNIDDM患者に対するnisoldipine,enalapril の合併症抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9486993","http://diabetes.ebm-library.jp/trial/detail/50003" "ABCD","the Appropriate Blood pressure Control in Diabetes trial","Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23: B54-B64.","2型糖尿病の高血圧患者に対する降圧療法が糖尿病性合併症に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10860192","http://diabetes.ebm-library.jp/trial/detail/50349" "ABCD","the Appropriate Blood Pressure Control in Diabetes trial","Havranek EP, Esler A, Estacio RO, Mehler PS, Schrier RW, Appropriate Blood Pressure Control in Diabetes Trial: Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. Am Heart J 2003; 145: 993-998.","高血圧を伴う2型糖尿病患者において,enalaprilまたはnisoldipineが左室肥大の心電図所見および心血管イベントに及ぼす影響を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12796754","http://diabetes.ebm-library.jp/trial/detail/50610" "Abd El Aziz MS, et al.","−"," Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab. 2017; 19: 216-227.","経口血糖降下薬投与下の2型糖尿病患者において,GLP-1受容体作動薬(GLP-1 RA)を追加した場合の臨床転帰をインスリン治療の追加と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/27717195","http://diabetes.ebm-library.jp/trial/detail/51615" "Abrahami D, et al.","-","Abrahami D, Douros A, Yin H, Yu OHY, Renoux C, Bitton A, Azoulay L. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ. 2018; 360 :k872.","2型糖尿病患者において,DPP-4阻害薬の使用が炎症性腸疾患と関連するか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29563098","http://diabetes.ebm-library.jp/trial/detail/51716" "Abualsuod A, et al.","−","Abualsuod A, Rutland JJ, Watts TE, Pandat S, Delongchamp R, Mehta JL: The Effect of Metformin Use on Left Ventricular Ejection Fraction and Mortality Post-Myocardial Infarction. Cardiovasc Drugs Ther. 2015; ","急性心筋梗塞(AMI)後の患者において,metforminが左室駆出率(LVEF)および死亡率に与える影響を検討し,さらに糖尿病合併の有無によるmetforminの影響についても検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26068409","http://diabetes.ebm-library.jp/trial/detail/51481" "ACC","Asia Cohort Consortium","Chen Y, Wu F, Saito E, Lin Y, Song M, Luu HN, Gupta PC, Sawada N, Tamakoshi A, Shu XO, Koh WP, Xiang YB, Tomata Y, Sugiyama K, Park SK, Matsuo K, Nagata C, Sugawara Y, Qiao YL, You SL, Wang R, Shin MH, Pan WH, Pednekar MS, Tsugane S, Cai H, Yuan JM, Gao YT, Tsuji I, Kanemura S, Ito H, Wada K, Ahn YO, Yoo KY, Ahsan H, Chia KS, Boffetta P, Zheng W, Inoue M, Kang D, Potter JD. Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium. Diabetologia. 2017; 60: 1022-32.","東アジアと南アジアにおける2型糖尿病とがん死リスクの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28265721","http://diabetes.ebm-library.jp/trial/detail/51672" "ACCOMPLISH","Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension trial","Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.","心血管イベントリスクの高い高血圧患者において,benazepril+amlodipine併用とbenazepril+hydrochlorothiazide併用の心血管イベント低減効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19052124","http://diabetes.ebm-library.jp/trial/detail/51114" "ACCOMPLISH","Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension trial","Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B: Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013; 381: 537-45.","高血圧患者において,降圧治療の種類別の心血管アウトカム改善効果を,BMI別に検討した。ACCOMPLISHのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/23219284","http://diabetes.ebm-library.jp/trial/detail/51312" "ACCORD","the Action to Control Cardiovascular Risk in Diabetes Study","Action to Control Cardiovascular Risk in Diabetes Study Group, , Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.","心血管疾患または心血管リスク因子を有する2型糖尿病患者において,HbA1c値を正常範囲に低下させる強化療法の心血管イベント減少効果を標準療法と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18539917","http://diabetes.ebm-library.jp/trial/detail/51069" "ACCORD","the Action to Control Cardiovascular Risk in Diabetes trial","Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, et al.: The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010; 340: b4909.","2型糖尿病患者において,低血糖と死亡率との関連を検討した。ACCORDの疫学的レトロスペクティブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/20061358","http://diabetes.ebm-library.jp/trial/detail/51151" "ACCORD","the Action to Control Cardiovascular Risk in Diabetes trial","Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, Childress RD, Craven TE, Cuddihy RM, Dailey G, et al.; ACCORD Investigators: The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010; 340: b5444.","重度の低血糖の決定因子を調査し,重度低血糖と試験期間のHbA1c変化との関連を検討した。ACCORDの疫学的事後解析。","https://www.ncbi.nlm.nih.gov/pubmed/20061360","http://diabetes.ebm-library.jp/trial/detail/51150" "ACCORD","Action to Control Cardiovascular Risk in Diabetes trial","Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Corson MA, Prineas R; Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010; 33: 1578-84.","心血管疾患イベントリスクの高い2型糖尿病患者において,心自律神経障害の死亡リスクに対する影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20215456","http://diabetes.ebm-library.jp/trial/detail/51196" "ACCORD","Action to Control Cardiovascular Risk in Diabetes trial","Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, et al.; for the ACCORD trial group: Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010; 376: 419-30. ","2型糖尿病患者において,強化血糖コントロールにより細小血管障害が低下するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20594588","http://diabetes.ebm-library.jp/trial/detail/51189" "ACCORD","the Action to Control Cardiovascular Risk in Diabetes Study","Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, et al.; ACCORD Study Group: Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011; 364: 818-28.","2型糖尿病患者において,ライフスタイル介入プログラムによる体重,fitness,血糖コントロール,心血管疾患リスク因子の変化を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21366473","http://diabetes.ebm-library.jp/trial/detail/51210" "ACCORD","Action to Control Cardiovascular Risk in Diabetes trial","Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, Ambrosius WT, Lovato L, Applegate WB; ACCORD Investigators: Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care. 2014; 37: 634-43.","2型糖尿病患者において,主要心血管アウトカム,死亡,重度有害事象に対する強化血糖コントロールと標準血糖コントロールの効果を,高齢者と若年者で比較した。ACCORDのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/24170759","http://diabetes.ebm-library.jp/trial/detail/51388" "ACCORD","the Action to Control Cardiovascular Risk in Diabetes trial","Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, Cutler JA, Evans GW, Gerstein HC, Grimm RH Jr, et al.: Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014; 37: 1721-8.","心血管疾患イベント高リスクの2型糖尿病患者において,血糖と血圧または脂質の標準療法および強化療法の組み合わせの効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24595629","http://diabetes.ebm-library.jp/trial/detail/51404" "ACCORD","Action to Control Cardiovascular Risk in Diabetes","Papademetriou V, Lovato L, Doumas M, Nylen E, Mottl A, Cohen RM, Applegate WB, Puntakee Z, Yale JF, Cushman WC; ACCORD Study Group: Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int. 2015; 87: 649-59.","高リスクの2型糖尿病患者において,軽度/中等度の慢性腎臓病(CKD)(ステージI〜III)の合併が心血管疾患および全死亡に与える影響を検討し,さらにCKD合併の有無を問わず強化血糖コントロールが心血管アウトカムにおよぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25229335","http://diabetes.ebm-library.jp/trial/detail/51465" "ACCORD ","Action to Control Cardiovascular Risk in Diabetes","Siraj ES, Rubin DJ, Riddle MC, Miller ME, Hsu FC, Ismail-Beigi F, Chen SH, Ambrosius WT, Thomas A, Bestermann W, et al.; ACCORD Investigators: Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. Diabetes Care. 2015; 38: 2000-8.","心血管高リスクの2型糖尿病患者において,インスリンが量的に心血管疾患死リスクと関連するという仮説を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/26464212","http://diabetes.ebm-library.jp/trial/detail/51529" "ACCORD BP","Action to Control Cardiovascular Risk in Diabetes blood pressure trial","The ACCORD Study Group: Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med. 2010; ","心血管イベントリスクの高い2型糖尿病患者において,SBPを正常値に低下させる強化療法の心血管イベント減少効果を標準療法と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20228401","http://diabetes.ebm-library.jp/trial/detail/51162" "ACCORD Blood Pressure Trial","Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial","Barzilay JI, Howard AG, Evans GW, Fleg JL, Cohen RM, Booth GL, Kimel AR, Pedley CF, Cushman WC: Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care. 2012; 35: 1401-5.","高血圧を有する2型糖尿病患者において,強化降圧療法と標準降圧療法の心血管疾患アウトカムを中心性肥満の程度別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22723577","http://diabetes.ebm-library.jp/trial/detail/51279" "ACCORD BP HRQL substudy","Action to Control Cardiovascular Risk in Diabetes BP trial Health-Related Quality of Life substudy","O'Connor PJ, Narayan KM, Anderson R, Feeney P, Fine L, Ali MK, Simmons DL, Hire DG, Sperl-Hillen JM, Katz LA, et al.: Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: the ACCORD trial. Diabetes Care. 2012; 35: 1479-81.","高血圧を有する2型糖尿病患者において,健康関連QOLに対する強化降圧療法と標準降圧療法の効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/22584134","http://diabetes.ebm-library.jp/trial/detail/51283" "ACCORD Eye","Action to Control Cardiovascular Risk in Diabetes Eye Study","The ACCORD Study Group and ACCORD Eye Study Group: Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. N Engl J Med. 2010; 363: 233-44.","心血管疾患リスクの高い2型糖尿病患者において,強化血糖コントロール,脂質低下療法,強化降圧療法が糖尿病網膜症の進展を予防するかを検討した。ACCORDのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/20587587","http://diabetes.ebm-library.jp/trial/detail/51187" "ACCORD HRQL","Action to Control Cardiovascular Risk in Diabetes study","Anderson RT, Narayan KM, Feeney P, Goff D Jr, Ali MK, Simmons DL, Sperl-Hillen JA, Bigger T, Cuddihy R, O'Conner PJ, et al.; Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators: Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial. Diabetes Care. 2011; 34: 807-12.","2型糖尿病患者において,健康関連QOL(HROL)に対する強化血糖コントロールと標準血糖コントロールと比較した。ACCOD試験のサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/21346183","http://diabetes.ebm-library.jp/trial/detail/51238" "ACCORD Lipid","Action to Control Cardiovascular Risk in Diabetes lipid trial","The ACCORD Study Group: Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med. 2010; ","心血管疾患リスクの高い2型糖尿病患者において,simvastatin+fenofibrate併用とsimvastatin単独の心血管疾患リスク減少効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20228404","http://diabetes.ebm-library.jp/trial/detail/51163" "ACCORD Lipid","Action to Control Cardiovascular Risk in Diabetes lipid study","Reyes-Soffer G, Ngai CI, Lovato L, Karmally W, Ramakrishnan R, Holleran S, Ginsberg HN: Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care. 2013; 36: 422-8.","2型糖尿病患者において,食後の脂質およびリポ蛋白質に対するsimvastatin+fenofibrate併用の効果を検討した。ACCORD Lipidのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/23033246","http://diabetes.ebm-library.jp/trial/detail/51335" "ACCORD Lipid Trial","the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial","Linz PE, Lovato LC, Byington RP, O'Connor PJ, Leiter LA, Weiss D, Force RW, Crouse JR, Ismail-Beigi F, Simmons DL, et al.: Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care. 2014; 37: 686-93.","2型糖尿病における重度の低HDL-C血症は,フェノフィブレートおよびチアゾリン薬による治療と関連するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24296848","http://diabetes.ebm-library.jp/trial/detail/51391" "ACCORD-MIND","Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes trial","Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, Coker LH, Murray A, Sullivan MD, Marcovina SM, et al.: Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 2009; 32: 221-226.","糖尿病患者において,HbA1c値および空腹時血漿ブドウ糖値と認知機能との関係を検討した。ACCORDのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/19171735","http://diabetes.ebm-library.jp/trial/detail/51111" "ACHOIS","the Australian Carbohydrate Intolerance Study in Pregnant Women trial","Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS, Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group: Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352: 2477-2486.","妊娠糖尿病の治療により周産期合併症が減少するかを検討し,妊婦のアウトカム,心理状態,生活の質に対する治療の効果を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/15951574","http://diabetes.ebm-library.jp/trial/detail/50733" "ACIP Database Study","Asymptomatic Cardiac Ischemia Pilot Database study","Caracciolo EA, Chaitman BR, Forman SA, Stone PH, Bourassa MG, Sopko G, Geller NL, Conti CR: Diabetics with coronary disease have a prevalence of asymptomatic ischemia during exercise treadmill testing and ambulatory ischemia monitoring similar to that of nondiabetic patients. An ACIP database study. ACIP Investigators. Asymptomatic Cardiac Ischemia Pilot Investigators. Circulation 1996; 93: 2097-2105.","冠疾患を有する糖尿病患者と非糖尿病患者について,トレッドミル運動負荷試験および48時間携帯型心電図モニタリング下における無症候性虚血の頻度と程度および血管造影所見を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8925577","http://diabetes.ebm-library.jp/trial/detail/50512" "ACT NOW","-","DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, et al.; ACT NOW Study: Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011; 364: 1104-15.","耐糖能異常患者において,2型糖尿病発症リスクと心血管リスク因子に対するpioglitazoneの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21428766","http://diabetes.ebm-library.jp/trial/detail/51655" "ACUITY","Acute Catheterization and Urgent Intervention Triage Strategy trial","Feit F, Manoukian SV, Ebrahimi R, Pollack CV, Ohman EM, Attubato MJ, Mehran R, Stone GW: Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2008; 51: 1645-52.","糖尿病を有する急性冠症候群患者において,30日後のアウトカムを非糖尿病患者と比較し,またbivalirudin治療とheparin治療のアウトカムを比較検討した。ACUITYのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18436116","http://diabetes.ebm-library.jp/trial/detail/51126" "AD-4833 Clamp-OGL Study","-","Kawamori R, Matsuhisa M, Kinoshita J, Mochizuki K, Niwa M, Arisaka T, Ikeda M, Kubota M, Wada M, Kanda T, Ikebuchi M, Tohdo R, Yamasaki Y: Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. Diabetes Res Clin Pract 1998; 41: 35-43.","NIDDM患者のインスリン抵抗性に対するpioglitazoneの効果を,経口糖負荷高インスリン血症性クランプにより検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9768370","http://diabetes.ebm-library.jp/trial/detail/50244" "ADAPT","Assessment of Detemir Administration in a Progressive Treat-To-Target Trial","Le Floch JP, Lvy M, Mosnier-Pudar H, Nobels F, Laroche S, Gonbert S, Eschwege E, Fontaine P; Assessment of Detemir Administration in Progressive Treat-to-Target Trial (ADAPT) Study Group: Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care. 2009; 32: 32-7.","1型糖尿病患者において,基礎-ボーラスインスリン療法におけるインスリンdetemirの1日1回投与と1日2回投与を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/18945928","http://diabetes.ebm-library.jp/trial/detail/51154" "ADCT","the Aldose Reductase Inhibitor-Diabetes Complications Trial","Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, et al.: Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006; 29: 1538-1544.","日本人の糖尿病性末梢神経障害患者において,epalrestatの長期的有効性および安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16801576","http://diabetes.ebm-library.jp/trial/detail/50957" "ADCT","Aldose Reductase Inhibitor-Diabetes Complications Trial","Hotta N, Kawamori R, Atsumi Y, Baba M, Kishikawa H, Nakamura J, Oikawa S, Yamada N, Yasuda H, Shigeta Y, et al.: Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. Diabet Med 2008; 25: 818-825.","糖尿病性末梢神経障害患者の症状および神経機能に対するepalrestatの長期効果を評価し,同剤の適切な投与対象を明らかにする。ADCTのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18644069","http://diabetes.ebm-library.jp/trial/detail/51073" "ADDITION-Cambridge","-","Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ: Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet. 2012; 380: 1741-8.","2型糖尿病についての地域住民を対象とした段階的スクリーニングプログラムの死亡率低下効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23040422","http://diabetes.ebm-library.jp/trial/detail/51320" "ADDITION-Europe","Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care","Herman WH, Ye W, Griffin SJ, Simmons RK, Davies MJ, Khunti K, Rutten GE, Sandbaek A, Lauritzen T, Borch-Johnsen K, et al.: Early Detection and Treatment of Type 2 Diabetes Reduce Cardiovascular Morbidity and Mortality: A Simulation of the Results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION-Europe). Diabetes Care. 2015; 38: 1449-55.","2型糖尿病のスクリーニング実施と早期治療介入の有効性を,スクリーニング非実施かつ晩期治療介入と比較した(ADDITION-Europeのサブ解析)。","https://www.ncbi.nlm.nih.gov/pubmed/25986661","http://diabetes.ebm-library.jp/trial/detail/51473" "ADDITION-Plus","Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen Detected Diabetes in Primary Care-Plus study","Lamb MJ, Westgate K, Brage S, Ekelund U, Long GH, Griffin SJ, Simmons RK, Cooper AJ; ADDITION-Plus study team: Prospective associations between sedentary time, physical activity, fitness and cardiometabolic risk factors in people with type 2 diabetes. Diabetologia. 2016; 59: 110-20.","2型糖尿病患者において,客観的に評価した身体活動エネルギー消費量,座っている時間,中等度〜強度の身体活動,心肺持久力と心代謝リスク因子の4年間の相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26518682","http://diabetes.ebm-library.jp/trial/detail/51545" "ADDITION-PRO","−","Hansen AL, Carstensen B, Helge JW, Johansen NB, Gram B, Christiansen JS, Brage S, Lauritzen T, Jrgensen ME, Aadahl M, et al.; ADDITION-Denmark Steering Committee: Combined heart rate- and accelerometer-assessed physical activity energy expenditure and associations with glucose homeostasis markers in a population at high risk of developing diabetes: the ADDITION-PRO study. Diabetes Care. 2013; 36: 3062-9.","糖尿病発症の低〜高リスク例において,身体活動量と糖代謝指標との関連を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/23757430","http://diabetes.ebm-library.jp/trial/detail/51365" "Adeyemo MA, et al.","−","Adeyemo MA, McDuffie JR, Kozlosky M, Krakoff J, Calis KA, Brady SM, Yanovski JA: Effects of metformin on energy intake and satiety in obese children. Diabetes Obes Metab. 2015; 17: 363-70.","高インスリン血症の肥満児において,metforminが食欲とエネルギー摂取量に与える影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25483291","http://diabetes.ebm-library.jp/trial/detail/51452" "ADMIT","Arterial Disease Multiple Intervention Trial","Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284: 1263-1270.","糖尿病患者において,脂質レベル改善用量のナイアシンの有効性および安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10979113","http://diabetes.ebm-library.jp/trial/detail/50375" "ADOPT","A Diabetes Outcome Progression Trial","Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.","2型糖尿病患者において,rosiglitazoneの長期血糖コントロール維持効果をmetforminおよびglyburideと比較した。","https://www.ncbi.nlm.nih.gov/pubmed/17145742","http://diabetes.ebm-library.jp/trial/detail/50944" "ADOPT","A Diabetes Outcome Progression Trial","Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, et al.; Diabetes Outcome Progression Trial (ADOPT) Study Group: Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008; 31: 845-51.","2型糖尿病患者において,rosiglitazone治療による骨折リスク増大に関連する因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18223031","http://diabetes.ebm-library.jp/trial/detail/51121" "ADVANCE","the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation trial","Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.","2型糖尿病患者において,perindoprilおよびindapamide併用による降圧治療の大血管障害および細小血管障害リスクへの有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17765963","http://diabetes.ebm-library.jp/trial/detail/51009" "ADVANCE","the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation trial","ADVANCE Collaborative Group, , MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.","2型糖尿病患者において,強化血糖コントロール療法の血管アウトカムに対する効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18539916","http://diabetes.ebm-library.jp/trial/detail/51070" "ADVANCE","the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation","de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, Neal B, Poulter N, Harrap S, Mogensen CE, et al.: Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes. J Am Soc Nephrol 2009; 20: 883-92.","2型糖尿病患者において,perindoprilおよびindapamide併用による降圧治療の腎アウトカムに対する効果を検討し,その効果が最近引き下げられた降圧目標値を達成した患者においても認められるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19225038","http://diabetes.ebm-library.jp/trial/detail/51099" "ADVANCE","Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation","Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A, Woodward M, Cooper M, Harrap S, Hamet P, et al.; ADVANCE Collaborative Group: Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J. 2009; 30: 1128-35.","2型糖尿病患者において,心房細動の全死亡および心血管リスクに対する影響,降圧療法の心血管イベント低減効果に対する影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19282274","http://diabetes.ebm-library.jp/trial/detail/51176" "ADVANCE","Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation Study","Kengne AP, Czernichow S, Huxley R, Grobbee D, Woodward M, Neal B, Zoungas S, Cooper M, Glasziou P, Hamet P, et al.; ADVANCE Collaborative Group: Blood pressure variables and cardiovascular risk: new findings from ADVANCE. Hypertension. 2009; 54: 399-404.","2型糖尿病患者において,血圧変数と心血管イベントリスクとの関連を検討した。ADVANCEのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/19470869","http://diabetes.ebm-library.jp/trial/detail/51201" "ADVANCE","Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation trial","Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A, et al.; ADVANCE Collaborative Group: Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care. 2009; 32: 2068-74.","2型糖尿病患者において,降圧療法と強化血糖コントロール療法の血管アウトカムに対する相加効果およびそれぞれの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19651921","http://diabetes.ebm-library.jp/trial/detail/51156" "ADVANCE","Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation","Hirakawa Y, Arima H, Zoungas S, Ninomiya T, Cooper M, Hamet P, Mancia G, Poulter N, Harrap S, Woodward M, et al.: Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014; 37: 2359-65.","2型糖尿病患者において,外来ごとのHbA1c値および空腹時血糖値の変動と,細小血管イベント,大血管イベント,および全死亡との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24812434","http://diabetes.ebm-library.jp/trial/detail/51417" "ADVANCE","Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation trial","Zoungas S, Woodward M, Li Q, Cooper ME, Hamet P, Harrap S, Heller S, Marre M, Patel A, Poulter N, et al.; ADVANCE Collaborative group: Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia. 2014; 57: 2465-74.","2型糖尿病患者において,大血管および細小血管合併症と全死亡に対する年齢,診断時年齢,罹病期間の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25226881","http://diabetes.ebm-library.jp/trial/detail/51441" "ADVANCE-ON","Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation Observational Study","Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, et al.; ADVANCE-ON Collaborative Group: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014; 371: 1392-406.","2型糖尿病患者において,perindopril+indapamide併用による降圧療法,および強化血糖コントロール療法の長期効果を検討した。ADVANCEの追跡研究。","https://www.ncbi.nlm.nih.gov/pubmed/25234206","http://diabetes.ebm-library.jp/trial/detail/51442" "Agardh CD, et al.","-","Agardh CD, Garcia-Puig J, Charbonnel B, Angelkort B, Barnett AH: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185-192.","高血圧の2型糖尿病患者において,lisinopril,nifedipineのアルブミン排泄率に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8733038","http://diabetes.ebm-library.jp/trial/detail/50267" "AgeCoDe study","Ageing, Cognition and Dementia in Primary Care Patients study","Khler M, Kliegel M, Kaduszkiewicz H, Bachmann C, Wiese B, Bickel H, Msch E, Weyerer S, Werle J, Fuchs A, et al.; Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe) study group: Effect of cardiovascular and metabolic disease on cognitive test performance and cognitive change in older adults. J Am Geriatr Soc. 2012; 60: 1286-91.","認知機能テストでの初期成績と認知機能の経時的低下に対する,心血管疾患と代謝性疾患の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22703453","http://diabetes.ebm-library.jp/trial/detail/51302" "Ahmad J, et al.","-","Ahmad J, Siddiqui MA, Ahmad H: Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997; 20: 1576-1581.","2型糖尿病患者に対するenalaprilの糖尿病性腎症進展予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9314638","http://diabetes.ebm-library.jp/trial/detail/50318" "AKDN","Alberta Kidney Disease Network","Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn BR; Alberta Kidney Disease Network: Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012; 380: 807-14.","慢性腎臓病が冠動脈心疾患のリスクであるかを,心筋梗塞,糖尿病,CKDの既往別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22717317","http://diabetes.ebm-library.jp/trial/detail/51273" "ALLHAT","the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, Leenen FH, Louis GT, Margolis KL, Mathis DE, et al: Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 1401-1409.","2型糖尿病患者,空腹時血糖異常例,血糖正常例において,Ca拮抗薬またはACE阻害薬による降圧治療は,利尿薬による治療よりも合併症抑制効果が高いかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15983290","http://diabetes.ebm-library.jp/trial/detail/50760" "ALLHAT","the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J, et al.: Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166: 2191-2201.","サイアザイド系利尿薬,Ca拮抗薬,ACE阻害薬による降圧薬治療が空腹時血糖値に及ぼす影響を比較し,さらにそれらの薬剤投与下における空腹時血糖値上昇および糖尿病発症が心血管疾患リスクおよび腎疾患リスクに及ぼす影響を検討した。ALLHATのpost hoc解析。","https://www.ncbi.nlm.nih.gov/pubmed/17101936","http://diabetes.ebm-library.jp/trial/detail/50952" "ALLHAT","the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","Black HR, Davis B, Barzilay J, Nwachuku C, Baimbridge C, Marginean H, Wright JT, Basile J, Wong ND, Whelton P, et al.: Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008; 31: 353-360.","高血圧の非糖尿病患者において,各種降圧薬の代謝,心血管疾患,腎アウトカムに及ぼす影響がメタボリックシンドロームの有無により異なるかを検討した。ALLHATのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18000186","http://diabetes.ebm-library.jp/trial/detail/51105" "ALSWH","Australian Longitudinal Study on Women's Health","Mishra GD, Carrigan G, Brown WJ, Barnett AG, Dobson AJ: Short-term weight change and the incidence of diabetes in midlife: results from the Australian Longitudinal Study on Women's Health. Diabetes Care 2007; 30: 1418-1424.","中年女性において,BMIおよび短期間の体重変化が糖尿病の新規発症に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17351279","http://diabetes.ebm-library.jp/trial/detail/51018" "ALTITUDE","Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints","Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012; 367: 2204-13.","ACE阻害薬またはAII受容体拮抗薬による標準治療を受けている心血管イベントおよび腎イベントリスクの高い2型糖尿病患者において,aliskiren追加の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23121378","http://diabetes.ebm-library.jp/trial/detail/51289" "ALTITUDE","Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints trial","Heerspink HJ, Persson F, Brenner BM, Chaturvedi N, Brunel P, McMurray JJ, Desai AS, Solomon SD, Pfeffer MA, Parving HH, et al.: Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial. Lancet Diabetes Endocrinol. 2016; 4: 309-17.","2型糖尿病患者において,腎アウトカムに対するaliskirenの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26774608","http://diabetes.ebm-library.jp/trial/detail/51567" "AMD-Annals Study","Associazione Medici Diabetologi-Annals Study","Ceriello A, De Cosmo S, Rossi MC, Lucisano G, Genovese S, Pontremoli R, Fioretto P, Giorda C, Pacilli A, Viazzi F, Russo G, Nicolucci A; AMD-Annals Study Group. Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. Diabetes Obes Metab. 2017; 19: 1570-8.","腎機能正常の2型糖尿病患者において,HbA1c,血圧,脂質パラメータ,血清尿酸の個人内変動性と,アルブミン尿発症または推算糸球体濾過量低下のリスクの関連および相互作用について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28432733","http://diabetes.ebm-library.jp/trial/detail/51687" "Andersohn F.","-","Andersohn F, Schade R, Suissa S, Garbe E: Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009; 166: 591-8.","うつ病患者において,抗うつ薬使用と糖尿病リスクの相関を,治療期間または用量別に評価した。","https://www.ncbi.nlm.nih.gov/pubmed/19339356","http://diabetes.ebm-library.jp/trial/detail/51297" "Andersson C.","-","Andersson C, Lyngbk S, Nguyen CD, Nielsen M, Gislason GH, Kber L, Torp-Pedersen C: Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. JAMA. 2012; 308: 882-9.","糖尿病を有する心筋梗塞患者において,clopidogrelの臨床的有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22948698","http://diabetes.ebm-library.jp/trial/detail/51275" "APOLLO","A Parallel design comparing an Oral antidiabetic drug combination therapy with either Lantus once daily or Lispro at mealtime in type 2 diabetes patients failing Oral treatment study","Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T: Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073-1084.","経口血糖降下薬投与下で血糖コントロール不良の2型糖尿病患者において,インスリンglargine 1日1回投与を併用することがインスリンlispro 1日3回食前投与を併用した場合に比較して劣っていないかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18374840","http://diabetes.ebm-library.jp/trial/detail/51054" "ARIC","the Atherosclerosis Risk in Communities study","Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus. N Engl J Med 2000; 342: 905-912.","各種降圧薬の新規2型糖尿病発症に対する影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10738048","http://diabetes.ebm-library.jp/trial/detail/50340" "ARIC","the Atherosclerosis Risk in Communities study","Wong TY, Klein R, Sharrett AR, Schmidt MI, Pankow JS, Couper DJ, Klein BE, Hubbard LD, Duncan BB; the ARIC Investigators: Retinal arteriolar narrowing and risk of diabetes mellitus in middle-aged persons. JAMA 2002; 287: 2528-2533.","中年の健常人における網膜細動脈の狭窄と糖尿病発症との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12020333","http://diabetes.ebm-library.jp/trial/detail/50523" "ARIC","the Atherosclerosis Risk in Communities study","Liao D, Carnethon M, Evans GW, Cascio WE, Heiss G: Lower heart rate variability is associated with the development of coronary heart disease in individuals with diabetes: the atherosclerosis risk in communities (ARIC) study. Diabetes 2002; 51: 3524-3531.","心臓の自律調節機能の異常を示す心拍変動の低下と冠動脈心疾患発症および非CHD死のリスクの関係を,特に2型糖尿病患者において検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12453910","http://diabetes.ebm-library.jp/trial/detail/50560" "ARIC","the Atherosclerosis Risk in Communities study","Carnethon MR, Golden SH, Folsom AR, Haskell W, Liao D: Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: the Atherosclerosis Risk In Communities study, 1987-1998. Circulation 2003; 107: 2190-2195.","自律神経系の障害(心拍変動の低下および安静時心拍数高値)と2型糖尿病発症リスクの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12695289","http://diabetes.ebm-library.jp/trial/detail/50592" "ARIC","the Atherosclerosis Risk in Communities Study","Schmidt MI, Duncan BB, Vigo A, Pankow J, Ballantyne CM, Couper D, Brancati F, Folsom AR, ARIC Investigators: Detection of undiagnosed diabetes and other hyperglycemia states: the Atherosclerosis Risk in Communities Study. Diabetes Care 2003; 26: 1338-1343.","糖尿病およびその他の高血糖状態(空腹時血糖異常,耐糖能異常)を検出するために,空腹時血漿ブドウ糖値,臨床情報,OGTTを用いたスクリーニング法を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/12716785","http://diabetes.ebm-library.jp/trial/detail/50590" "ARIC","the Atherosclerosis Risk in Communities study","Folsom AR, Chambless LE, Duncan BB, Gilbert AC, Pankow JS, Atherosclerosis Risk in Communities Study Investigators: Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care 2003; 26: 2777-2784.","成人糖尿病患者において,10年間の冠動脈心疾患の発症リスクを評価し,その発症予測能を評価する基本的リスク因子および新たなリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14514579","http://diabetes.ebm-library.jp/trial/detail/50622" "ARIC","the Atherosclerosis Risk in Communities study","Golden SH, Williams JE, Ford DE, Yeh HC, Paton Sanford C, Nieto FJ, Brancati FL: Depressive symptoms and the risk of type 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2004; 27: 429-435.","抑うつ症状が2型糖尿病発症の予測因子であるか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14747224","http://diabetes.ebm-library.jp/trial/detail/50634" "ARIC","the Atherosclerosis Risk in Communities study","Lee CD, Folsom AR, Pankow JS, Brancati FL, Atherosclerosis Risk in Communities (ARIC) Study Investigators: Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004; 109: 855-860.","心筋梗塞既往のない糖尿病患者が,既往のある非糖尿病患者と同等の冠動脈心疾患イベント,脳卒中イベント,心血管疾患死のリスクを有するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14757692","http://diabetes.ebm-library.jp/trial/detail/50692" "ARIC","the Atherosclerosis Risk in Communities study","Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G: Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 204; 53: 2473-2478.","脂肪細胞から分泌されるアディポネクチンと2型糖尿病発症の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15331562","http://diabetes.ebm-library.jp/trial/detail/50674" "ARIC","the Atherosclerosis Risk in Communities study","McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, Ballantyne CM, Heiss G: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385-390.","NCEP ATP III基準によるメタボリックシンドロームと心血管疾患の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15677797","http://diabetes.ebm-library.jp/trial/detail/50709" "ARIC","the Atherosclerosis Risk in Communities study","Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Brancati FL: Vital capacity as a predictor of incident type 2 diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2005; 28: 1472-1479.","肺活量とインスリン抵抗性および2型糖尿病新規発症との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15920070","http://diabetes.ebm-library.jp/trial/detail/50773" "ARIC","the Atherosclerosis Risk in Communities study","Selvin E, Coresh J, Golden SH, Boland LL, Brancati FL, Steffes MW, Atherosclerosis risk in communities study: Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 1965-1973.","糖尿病患者において,HbA1c値,頸動脈内膜-中膜壁肥厚,心血管リスク因子の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16043740","http://diabetes.ebm-library.jp/trial/detail/50795" "ARIC","the Atherosclerosis Risk in Communities study","Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH, Folsom AR, Chambless LE, The Atherosclerosis Risk in Communities Investigators: Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 2005; 28: 2013-2018.","中年成人において,糖尿病発症リスクの予測方法を構築し,その予測能を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/16043747","http://diabetes.ebm-library.jp/trial/detail/50805" "ARIC","the Atherosclerosis Risk in Communities study","Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR: HbA1c and peripheral arterial disease in diabetes: the atherosclerosis risk in communities study. Diabetes Care 2006; 29: 877-882.","糖尿病患者において,HbA1c値と末梢動脈疾患との関連を検討し,その関連性を重篤な症候性のものと無症候性のものとで比較した。","https://www.ncbi.nlm.nih.gov/pubmed/16567831","http://diabetes.ebm-library.jp/trial/detail/50824" "ARIC","the Atherosclerosis Risk in Communities study","Nicholson WK, Asao K, Brancati F, Coresh J, Pankow JS, Powe NR: Parity and risk of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes Care 2006; 29: 2349-2354.","妊娠・出産経験と糖尿病発症リスクの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17065666","http://diabetes.ebm-library.jp/trial/detail/50986" "ARIC","The Atherosclerosis Risk In Communities Study","Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY: Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care 2007; 30: 1742-1746.","中年の2型糖尿病患者において,糖尿病性網膜症と冠動脈心疾患の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17389333","http://diabetes.ebm-library.jp/trial/detail/51024" "ARIC","Atherosclerosis Risk in Communities study","Lee AK, Rawlings AM, Lee CJ, Gross AL, Huang ES, Sharrett AR, Coresh J, Selvin. Severe hypoglycaemia, mild cognitive impairment, dementia and brain volumes in older adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) cohort study. Diabetologia. 2018; 61: 1956-65.","2型糖尿病患者において,重症低血糖既往の有無別に認知障害および認知症の有病率と脳体積を横断的に評価し,重症低血糖既往とドメイン特異的認知機能低下の関連を評価し,重症低血糖と認知症発症の縦断的関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29961106","http://diabetes.ebm-library.jp/trial/detail/51740" "Arjona Ferreira JC, et al.","-","Arjona Ferreira JC, Marre M, Barzilai N, Guo H, Golm GT, Sisk CM, Kaufman KD, Goldstein BJ: Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care. 2013; 36: 1067-73.","中等度〜重度の慢性腎機能障害を伴う,血糖コントロールの不十分な2型糖尿病患者において,DPP-4阻害薬sitagliptinとスルホニル尿素薬glipizideの有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/23248197","http://diabetes.ebm-library.jp/trial/detail/51351" "ARTS","the Arterial Revascularization Therapy Study","Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AG, Sousa JE, van Hout B, Hugenholtz PG, Unger F, Serruys PW: Arterial Revascularization Therapy Study Group.: Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001; 104: 533-538.","多枝冠動脈疾患をもつ糖尿病患者の治療として,CABGとステント植込み術を比較し,それぞれの治療コストを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11479249","http://diabetes.ebm-library.jp/trial/detail/50482" "ASCOT","Anglo-Scandinavian Cardiac Outcomes Trial","Stettler C, Witt N, Tapp RJ, Thom S, Allemann S, Tillin T, Stanton A, O'Brien E, Poulter N, Gallimore JR, et al.: Serum amyloid A, C-reactive protein, and retinal microvascular changes in hypertensive diabetic and nondiabetic individuals: an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy. Diabetes Care. 2009; 32: 1098-100.","高血圧患者において,血清アミロイドAおよびC反応性蛋白と網膜微小血管変成との関連を糖尿病の有無により検討した。ASCOT試験のサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/19244088","http://diabetes.ebm-library.jp/trial/detail/51184" "ASCOT-BPLA","the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm","Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR, Anglo-Scandinavian Cardiac Outcomes Trial Investigators: Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008; 31: 982-988.","高血圧患者において,新規糖尿病発症の予測因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18235048","http://diabetes.ebm-library.jp/trial/detail/51116" "ASCOT-LLA","the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm","Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, et al: Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005; 28: 1151-1157.","冠動脈心疾患既往がなく,コントロールされた高血圧を有し,総コレステロール値が平均以下の患者において,脂質低下療法の心血管アウトカムに対する有効性を検討した。糖尿病患者についてのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/15855581","http://diabetes.ebm-library.jp/trial/detail/50731" "ASIA study","the Auto-Surveillance Intervention Active study","Guerci B, Drouin P, Grange V, Bougneres P, Fontaine P, Kerlan V, Passa P, Thivolet Ch, Vialettes B, Charbonnel B, et al: Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab 2003; 29: 587-594.","血糖コントロール不良の2型糖尿病患者において,従来の血糖測定に自己血糖測定を併用した場合の血糖コントロールの変化を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14707887","http://diabetes.ebm-library.jp/trial/detail/50645" "ASPEN","the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin -Dependent Diabetes Mellitus","Knopp RH, d'Emden M, Smilde JG, Pocock SJ: Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29: 1478-1485.","LDL-C値がガイドラインで定められた目標値より低い2型糖尿病患者において,atorvastatinの心血管疾患予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16801565","http://diabetes.ebm-library.jp/trial/detail/50956" "AT.LANTUS","-","Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, ATLANTUS Study Group: Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28: 1282-1288.","糖尿病治療薬投与下でコントロール不良の2型糖尿病患者において,インスリンglargineの2つの投与アルゴリズムの低血糖発生頻度および血糖コントロールを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/15920040","http://diabetes.ebm-library.jp/trial/detail/50783" "AT.LANTUS","-","Gomis R, Storms F, Conget I, Sinnassamy P, Davies M, AT.LANTUS Study Group: Improving metabolic control in sub-optimally controlled subjects with Type 1 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Res Clin Pract 2007; 77: 84-91.","インスリンglargineの2種類の用量調整アルゴリズムにおける重度低血糖の発生を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/17097185","http://diabetes.ebm-library.jp/trial/detail/51039" "ATLANTIC DIP","Atlantic Diabetes in Pregnancy Partnership","Owens LA, O'Sullivan EP, Kirwan B, Avalos G, Gaffney G, Dunne F; ATLANTIC DIP Collaborators: ATLANTIC DIP: the impact of obesity on pregnancy outcome in glucose-tolerant women. Diabetes Care. 2010; 33: 577-9.","正常血糖の女性において,妊娠アウトカムに対する肥満の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20067952","http://diabetes.ebm-library.jp/trial/detail/51160" "ATTEST","Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes study","Katayama S, Kawamori R, Iwamoto Y, Saito I, Kuramoto K, ATTEST Study Group: In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study. Hypertens Res 2008; 31: 1499-1508.","高血圧の2型糖尿病患者において,azelnidipineとtemocapril併用の有効性および安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18971523","http://diabetes.ebm-library.jp/trial/detail/51104" "AusDiab","the Australian Diabetes, Obesity , and Lifestyle Study","Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, et al.: Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007; 116: 151-157.","糖代謝異常と全死亡リスクおよび心血管疾患死リスクの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17576864","http://diabetes.ebm-library.jp/trial/detail/51006" "AusDiab","the Australian Diabetes, Obesity , and Lifestyle Study","Al Salmi I, Hoy WE, Kondalsamy-Chennakesavan S, Wang Z, Gobe GC, Barr EL, Shaw JE: Disorders of glucose regulation in adults and birth weight: results from the Australian Diabetes, Obesity and Lifestyle (AUSDIAB) Study. Diabetes Care 2008; 31: 159-164.","オーストラリアの一般住民において,出生時体重と血糖値指標との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17934149","http://diabetes.ebm-library.jp/trial/detail/51044" "AusDiab","the Australian Diabetes Obesity and Lifestyle Study","Tapp RJ, Tikellis G, Wong TY, Harper CA, Zimmet PZ, Shaw JE; Australian Diabetes Obesity and Lifestyle Study Group: Longitudinal association of glucose metabolism with retinopathy: results from the Australian Diabetes Obesity and Lifestyle (AusDiab) study. Diabetes Care. 2008; 31: 1349-54.","オーストラリアの一般住民において,糖代謝と網膜症の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18411241","http://diabetes.ebm-library.jp/trial/detail/51136" "AusDiab","Australian Diabetes, Obesity and Lifestyle study","Williams ED, Magliano DJ, Zimmet PZ, Kavanagh AM, Stevenson CE, Oldenburg BF, Shaw JE: Area-level socioeconomic status and incidence of abnormal glucose metabolism: the Australian Diabetes, Obesity and Lifestyle (AusDiab) study. Diabetes Care. 2012; 35: 1455-61.","オーストラリア人において,糖代謝異常発症に対する地域の社会経済的状況の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22619081","http://diabetes.ebm-library.jp/trial/detail/51280" "AVOID","the Aliskiren in the Evaluation of Proteinuria in Diabetes study","Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446.","高血圧および腎症を有する2型糖尿病患者において,最大用量のlosartan+aliskiren併用療法の腎保護効果および安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18525041","http://diabetes.ebm-library.jp/trial/detail/51071" "AWARD-1","Assessment of Weekly AdministRation of dulaglutide in Diabetes-1","Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, Kuhstoss D, Lakshmanan M: Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014; 37: 2159-67.","2型糖尿病患者において週1回投与のGLP-1受容体作動薬dulaglutide,1日2回投与のexenatide,プラセボの有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24879836","http://diabetes.ebm-library.jp/trial/detail/51509" "AWARD-6","Assessment of Weekly AdministRation of dulaglutide in Diabetes-6","Dungan KM, Povedano ST, Forst T, Gonzlez JG, Atisso C, Sealls W, Fahrbach JL: Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014; 384: 1349-57.","metformin治療下でコントロール不良の2型糖尿病患者において,週1回dulaglutideと1日1回liraglutideの有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/25018121","http://diabetes.ebm-library.jp/trial/detail/51507" "AWARD-2","Assessment of Weekly AdministRation of dulaglutide in Diabetes","Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V: Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes Care. 2015; ","経口血糖降下薬でコントロール不良の2型糖尿病患者において,GLP-1受容体作動薬dulaglutideとインスリンglargineの有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/26089386","http://diabetes.ebm-library.jp/trial/detail/51511" "AWARD-1,AWARD-3","-","Reaney M, Yu M, Lakshmanan M, Pechtner V, van Brunt K: Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes Obes Metab. 2015; 17: 896-903.","2型糖尿病患者において,週1回のdulaglutideの治療満足度をexenatide,プラセボ,metforminと比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26095190","http://diabetes.ebm-library.jp/trial/detail/51510" "AWARD-5","−","Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z: Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015; 17: 849-58.","2型糖尿病患者において,GLP-1受動体作動薬dulaglutide週一回静注とDPP-4阻害薬sitagliptinの長期追跡データを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/25912221","http://diabetes.ebm-library.jp/trial/detail/51513" "AWARD-8","Assessment of Weekly Administration of LY2189265 (Dulaglutide) in Diabetes-8","Dungan KM, et al: A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes Obes Metab. 2016; 18: 475-82.","SU薬glimepiride単剤でコントロール不良の2型糖尿病患者において,GLP-1受容体作動薬dulaglutide週1回追加投与の安全性と有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26799540","http://diabetes.ebm-library.jp/trial/detail/51601" "AWARD-9","Assessment of Weekly AdministRation of LY2189265 [dulaglutide] in Diabetes-9 study","Pozzilli P, Norwood P, Jdar E,4, Davies MJ, Ivanyi T, Jiang H, Woodward DB, Milicevic Z. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab. 2017; 19: 1024-31.","血糖コントロール不良の2型糖尿病患者において,漸増インスリンglargineへの週1回dulaglutideの追加の安全性と有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28294499","http://diabetes.ebm-library.jp/trial/detail/51670" "AWARD-7","-","Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018; 6: 605-17.","中等度〜重度の慢性腎臓病を有する2型糖尿病患者において,dulaglutideの有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29910024","http://diabetes.ebm-library.jp/trial/detail/51725" "AWESOME","the Angina With Extremely Serious Operative Mortality Evaluation","Sedlis SP, Morrison DA, Lorin JD, Esposito R, Sethi G, Sacks J, Henderson W, Grover F, Ramanathan KB, Weiman D, Saucedo J, Antakli T, Paramesh V, Pett S, Vernon S, Birjiniuk V, Welt F, Krucoff M, Wolfe W, Lucke JC, Mediratta S, Booth D, Murphy E, Ward H, Miller L, Kiesz S, Barbiere C, Lewis D; Investigators of the Dept. of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME): Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. J Am Coll Cardiol 2002; 40: 1555-1566.","薬物治療抵抗性の不安定狭心症を有し,CABGに伴う有害事象が高リスクの糖尿病患者において,PCIまたはCABG後の生存率を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12427406","http://diabetes.ebm-library.jp/trial/detail/50559" "Bain S, et al.","-","Bain S, Druyts E, Balijepalli C, Baxter CA, Currie CJ, Das R, Donnelly R, Khunti K, Langerman H, Leigh P, Siliman G, Thorlund K, Toor K, Vora J, Mills EJ. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data. Diabetes Obes Metab. 2017; 19: 329-335.","2型糖尿病患者において,スルホニル尿素薬と他の血糖降下薬の心血管イベントと全死亡のリスクを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/27862902","http://diabetes.ebm-library.jp/trial/detail/51620" "Bangalore S, et al.","―","Bangalore S, Kumar S, Lobach I, Messerli FH: Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation. 2011; 123: 2799-810, 9 p following 810.","2型糖尿病または空腹時血糖・耐糖能障害を有する患者における至適血圧を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21632497","http://diabetes.ebm-library.jp/trial/detail/51203" "Bannister CA, et al.","−","Bannister CA, Holden SE, Jenkins-Jones S, Morgan CL, Halcox JP, Schernthaner G, Mukherjee J, Currie CJ: Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab. 2014; 16: 1165-73.","糖尿病患者において,一次治療としてのスルホニル尿素薬(SU)単独投与が全死亡に与える影響をmetformin単独投与と比較した。また,各治療について糖尿病患者と非糖尿病患者との比較も行った。","https://www.ncbi.nlm.nih.gov/pubmed/25041462","http://diabetes.ebm-library.jp/trial/detail/51431" "BARI","the Bypass Angioplasty Revascularization Investigation","Detre KM, Lombardero MS, Brooks MM, Hardison RM, Holubkov R, Sopko G, Frye RL, Chaitman BR: The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. Bypass Angioplasty Revascularization Investigation Investigators. N Engl J Med 2000; 342: 989-997.","心筋梗塞を発症した多枝冠動脈疾患をもつ糖尿病患者に対するCABGとPTCAの予後改善効果を心筋梗塞非発症例と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10749960","http://diabetes.ebm-library.jp/trial/detail/50486" "BARI","the Bypass Angioplasty Revascularization Investigation","Kip KE, Alderman EL, Bourassa MG, Brooks MM, Schwartz L, Holmes DR Jr, Califf RM, Whitlow PL, Chaitman BR, Detre KM: Differential influence of diabetes mellitus on increased jeopardized myocardium after initial angioplasty or bypass surgery: bypass angioplasty revascularization investigation. Circulation 2002; 105: 1914-1920.","初回PTCAまたはCABGを施行された多枝冠動脈疾患患者において,糖尿病が中〜長期の血管造影所見に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11997277","http://diabetes.ebm-library.jp/trial/detail/50519" "BARI","the Bypass Angioplasty Revascularization Investigation","Schwartz L, Kip KE, Frye RL, Alderman EL, Schaff HV, Detre KM; Bypass Angioplasty Revascularization Investigation: Coronary bypass graft patency in patients with diabetes in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 2002; 106: 2652-2658.","CABG施行後のグラフトの開存性を糖尿病患者と非糖尿病患者で比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12438289","http://diabetes.ebm-library.jp/trial/detail/50556" "BARI","the Bypass Angioplasty Revascularization Investigation trial","BARI Investigators.: The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 2007; 49: 1600-1606.","多枝冠動脈疾患患者において初回PTCAおよびCABGを比較したBARI試験の10年成績を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17433949","http://diabetes.ebm-library.jp/trial/detail/51002" "BARI 2D","Bypass Angioplasty Revascularization Investigation 2 Diabetes","Schneider DJ, Hardison RM, Lopes N, Sobel BE, Brooks MM; Pro-Thrombosis Ancillary Study Group: Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy. Diabetes Care. 2009; 32: 944-9.","安定した冠動脈疾患を有する2型糖尿病患者において,血小板反応性およびトロンビン活性に対する肥満の影響を検討した。BARI 2Dのサブ研究。","https://www.ncbi.nlm.nih.gov/pubmed/19228864","http://diabetes.ebm-library.jp/trial/detail/51179" "BARI 2D","Bypass Angioplasty Revascularization Investigation 2 Diabetes trial","Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, et al.; BARI 2D Study Group: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009; 360: 2503-15.","冠動脈疾患を有する2型糖尿病患者において,早期の血行再建術+積極的薬物治療と積極的薬物治療単独の有効性を比較し,さらにインスリン抵抗性改善薬治療とインスリン賦活治療を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/19502645","http://diabetes.ebm-library.jp/trial/detail/51149" "BARI 2D","Bypass Angioplasty Revascularization Investigation 2 Diabetes trial","Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, Sopko G, Ramires JA, Schneider D, Frye RL; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group: The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation. 2009; 120: 2529-40.","冠動脈疾患を有する2型糖尿病患者において,早期の血行再建術+積極的薬物治療と積極的薬物治療単独の心筋梗塞および心疾患死に対する有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/19920001","http://diabetes.ebm-library.jp/trial/detail/51152" "BARI 2D","Bypass Angioplasty Revascularization Investigation 2 Diabetes","Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, et al.; JAPAN-ACS Investigators: Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial). Circ J. 2010; 74: 1165-74.","BARI 2D試験の参加者において,糖尿病性血管障害を示す炎症の強さ,線溶と血栓のバランスを反映するバイオマーカーへの影響を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/20467151","http://diabetes.ebm-library.jp/trial/detail/51204" "BARI 2D","Bypass Angioplasty Revascularization Investigation 2Diabetes trial","Pop-Busui R, Lu J, Brooks MM, Albert S, Althouse AD, Escobedo J, Green J, Palumbo P, Perkins BA, Whitehouse F, et al.; BARI 2D Study Group: Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care. 2013; 36: 3208-15.","冠動脈疾患を有する2型糖尿病患者において,糖尿病性末梢神経障害の有病率と発生率をインスリン抵抗性改善薬とインスリン供給薬に分けて検討した。BARI 2Dの二次解析。","https://www.ncbi.nlm.nih.gov/pubmed/23757426","http://diabetes.ebm-library.jp/trial/detail/51366" "BARI 2D","ByPass AngioPlasty Revascularization Investigation 2Diabetes trial","Althouse AD, Abbott JD, Sutton-Tyrrell K, Forker AD, Lombardero MS, Buitrn LV, Pena-Sing I, Tardif JC, Brooks MM; BARI 2D Study Group: Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care. 2013; 36: 3269-75.","安定冠動脈疾患を有する2型糖尿病患者において,末梢動脈疾患リスクをインスリン抵抗性改善薬とインスリン供給薬に分けて検討した。BARI 2Dの二次解析。","https://www.ncbi.nlm.nih.gov/pubmed/23735723","http://diabetes.ebm-library.jp/trial/detail/51367" "BARI 2D","the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes Trial","Althouse AD, Abbott JD, Forker AD, Bertolet M, Barinas-Mitchell E, Thurston RC, Mulukutla S, Aboyans V, Brooks MM; BARI 2D Study Group: Risk factors for incident peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation in type 2 Diabetes (BARI 2D) Trial. Diabetes Care. 2014; 37: 1346-52.","BARI 2Dでインスリン供給薬(IP)ないしインスリン抵抗性改善薬(IS)で治療を受けている2型糖尿病患者において,全体および血糖コントロール治療別に末梢動脈疾患(PAD)発症と心血管疾患リスク因子の関連を検討した。BARI 2Dの二次解析。","https://www.ncbi.nlm.nih.gov/pubmed/24595631","http://diabetes.ebm-library.jp/trial/detail/51402" "BARI 2D","Bypass Angioplasty Revascularization Investigation 2 Diabetes trial","Tsujimoto T, Sugiyama T, Kajio H. Effects of β-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease. Diabetes Obes Metab. 2017; 19: 800-8.","冠動脈心疾患を有する2型糖尿病患者において,β遮断薬の有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28094466","http://diabetes.ebm-library.jp/trial/detail/51666" "Barnett AH, et al.","−","Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ: Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. 2013; 382: 1413-23.","70歳以上で血糖コントロール不良の2型糖尿病患者において,DPP-4阻害薬linagliptinの有効性,安全性,および忍容性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23948125","http://diabetes.ebm-library.jp/trial/detail/51371" "BEGIN FLEX","-","Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, Bain S, Johansen T, Begtrup K, Birkeland KI; NN1250-3668 (BEGIN FLEX) Trial Investigators: The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013; 36: 858-64.","insulin degludec(IDeg)を1日1回,朝夕交互に投与した場合の有効性と安全性を,IDegを1日1回,一定時間に投与した場合,あるいはinsulin glargine(IGlar)を1日1回,一定時間に投与した場合と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/23340894","http://diabetes.ebm-library.jp/trial/detail/51328" "BEGIN:ADD TO GLP-1 Study","-","Aroda VR, Bailey TS, Cariou B, Kumar S, Leiter LA, Raskin P, Zacho J, Andersen TH, Philis-Tsimikas A: Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study). Diabetes Obes Metab. 2016; 18: 663-70.","liraglutide+metforminでコントロール不良の2型糖尿病患者において,insulin degludec追加の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26990378","http://diabetes.ebm-library.jp/trial/detail/51583" "BENEDICT","the Bergamo Nephrologic Diabetes Complications Trial","Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, et al: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.","高血圧を有し,尿中アルブミン排泄が正常な2型糖尿病患者において,trandolaprilとverapamil併用療法,trandolapril単独療法,verapamil単独療法の微量アルブミン尿発現抑制効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15516697","http://diabetes.ebm-library.jp/trial/detail/50680" "BENEDICT","the Bergamo Nephrologic Diabetes Complications Trial","Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G, BENEDICT Study Group: Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 2006; 17: 3472-3481.","腎症を認めない2型糖尿病患者において,血圧コントロールおよびACE阻害薬治療による腎保護効果を検討した。BENEDICTの事後解析。","https://www.ncbi.nlm.nih.gov/pubmed/17082240","http://diabetes.ebm-library.jp/trial/detail/50996" "BENEDICT","the Bergamo Nephrologic Diabetes Complications Trial","Ruggenenti P, Iliev I, Costa GM, Parvanova A, Perna A, Giuliano GA, Motterlini N, Ene-Iordache B, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial Study Group: Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT). Diabetes Care. 2008; 31: 1629-34.","高血圧を有する2型糖尿病患者において,心電図で確認された左室肥大に対するACE阻害薬の効果を検討した。BENEDICTのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18443191","http://diabetes.ebm-library.jp/trial/detail/51130" "Benelux-UK Insulin Lispro Study","-","Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH: Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care 1997; 20: 1827-1832.","IDDM患者に対するinsulin lisproの血糖コントロールと低血糖発症率に対する効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9405901","http://diabetes.ebm-library.jp/trial/detail/50206" "Berkowitz SA, et al.","−","Berkowitz SA, Krumme AA, Avorn J, Brennan T, Matlin OS, Spettell CM, Pezalla EJ, Brill G, Shrank WH, Choudhry NK: Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. JAMA Intern Med. 2014; 174: 1955-62.","経口血糖降下薬の第一選択薬の種類が,その後に必要とされる治療強化時に与える影響を比較した。また,短期間に発生した有害な臨床イベントに与える影響についての比較も行った。","https://www.ncbi.nlm.nih.gov/pubmed/25347323","http://diabetes.ebm-library.jp/trial/detail/51436" "Bhattacharya R, et al.","−","Bhattacharya R, Zhou S, Wei W, Ajmera M, Sambamoorthi U: A real-world study of the effect of timing of insulin initiation on outcomes in older medicare beneficiaries with type 2 diabetes mellitus. J Am Geriatr Soc. 2015; 63: 893-901.","高齢の2型糖尿病患者において,インスリンを早期に投与開始した場合と,遅く開始した場合の臨床アウトカムおよび経済アウトカムを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/25955280","http://diabetes.ebm-library.jp/trial/detail/51480" "BIGPRO1","the Biguanides and Prevention of Risks in Obesity study","Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, Andre P, Isnard F, Cohen JM, Grandmottet P, Vague P, Safar ME, Eschwege E: The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996; 19: 920-926.","上半身肥満患者におけるmetforminの効果を測定した。","https://www.ncbi.nlm.nih.gov/pubmed/8875083","http://diabetes.ebm-library.jp/trial/detail/50084" "BIP","the Bezafibrate Infarction Prevention study","Jonas M, Reicher-Reiss H, Boyko V, Shotan A, Mandelzweig L, Goldbourt U, Behar S: Usefulness of beta-blocker therapy in patients with non-insulin- dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol 1996; 77: 1273-1277.","NIDDMと冠動脈疾患の合併例においてβ遮断薬の長期投与効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8677865","http://diabetes.ebm-library.jp/trial/detail/50296" "BIP","theBezafibrate Infarction Prevention study","Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005; 165: 1154-1160.","メタボリックシンドロームを有する冠動脈疾患患者において,心筋梗塞発症に対するbezafibrateの長期的な有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15911729","http://diabetes.ebm-library.jp/trial/detail/50743" "BLSA","Baltimore Longitudinal Study of Aging","Kalyani RR, Metter EJ, Egan J, Golden SH, Ferrucci L: Hyperglycemia predicts persistently lower muscle strength with aging. Diabetes Care. 2015; 38: 82-90.","","https://www.ncbi.nlm.nih.gov/pubmed/25392294","http://diabetes.ebm-library.jp/trial/detail/51454" "BNP Multinational Study","the Breathing Not Properly Multinational Study","Wu AH, Omland T, Duc P, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Wold Knudsen C, Storrow AB, et al: The effect of diabetes on B-type natriuretic peptide concentrations in patients with acute dyspnea: an analysis from the Breathing Not Properly Multinational Study. Diabetes Care 2004; 27: 2398-2404.","急性呼吸困難により救急部を受診した患者において,糖尿病が脳性ナトリウム利尿ペプチド値に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15451907","http://diabetes.ebm-library.jp/trial/detail/50687" "Bolinder J, et al.","-","Bolinder J, Ljunggren , Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S: Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97: 1020-31.","metformin治療下でコントロール不良の2型糖尿病患者において,dapagliflozin追加による体重減少と脂肪または液体成分の変化との相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22238392","http://diabetes.ebm-library.jp/trial/detail/51291" "Botnia Study","-","Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Nissen M, Isomaa B, Forsen B, Homstrom N, Saloranta C, et al: Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 2005; 54: 166-174.","2型糖尿病発症の予測因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15616025","http://diabetes.ebm-library.jp/trial/detail/50717" "British Regional Heart Study","-","Wannamethee SG, Shaper AG, Rumley A, Sattar N, Whincup PH, Thomas MC, Lowe GD: Lung function and risk of type 2 diabetes and fatal and nonfatal major coronary heart disease events: possible associations with inflammation. Diabetes Care. 2010; 33: 1990-6.","中年男性において,肺機能と2型糖尿病および冠動脈心疾患リスクとの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20519659","http://diabetes.ebm-library.jp/trial/detail/51197" "Britton KA.","-","Britton KA, Aggarwal V, Chen AY, Alexander KP, Amsterdam E, Fraulo E, Muntner P, Thomas L, McGuire DK, Wiviott SD, et al.: No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction. Am Heart J. 2011; 161: 657-663.e1.","HbA1c値と糖尿病および急性心筋梗塞(AMI)にJ字曲線の関連があるかについて検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21473963","http://diabetes.ebm-library.jp/trial/detail/51245" "C8 Health Project","-","George C, Ducatman AM, Conway BN. Increased risk of respiratory diseases in adults with Type 1 and Type 2 diabetes. Diabetes Res Clin Pract. 2018; 142: 46-55.","1型および2型糖尿病と呼吸器疾患リスクの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29802957","http://diabetes.ebm-library.jp/trial/detail/51734" "CABG Patch Trial","the Coronary Artery Bypass Graft Patch Trial","Whang W, Bigger JT Jr: Diabetes and outcomes of coronary artery bypass graft surgery in patients with severe left ventricular dysfunction: results from The CABG Patch Trial database. The CABG Patch Trial Investigators and Coordinators. J Am Coll Cardiol 2000; 36: 1166-1172.","重度の左室機能障害をもつ患者において,糖尿病の有無とCABG施行後の長期アウトカムとの相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11028466","http://diabetes.ebm-library.jp/trial/detail/50378" "CABRI","the Coronary Angioplasty versus Bypass Revascularization Investigation","Kurbaan AS, Bowker TJ, Ilsley CD, Sigwart U, Rickards AF: Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. Am J Cardiol 2001; 87: 947-950.","CABRI試験の患者を対象に,冠動脈疾患を有する糖尿病患者におけるPTCAもしくはCABGの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11305983","http://diabetes.ebm-library.jp/trial/detail/50466" "CADILLAC","the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications study","Stuckey TD, Stone GW, Cox DA, Tcheng JE, Garcia E, Carroll J, et al: Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). Am J Cardiol 2005; 95: 1-7.","急性心筋梗塞を発症し,初回血行再建術を施行される糖尿病患者において,ルーチンのステント留置術およびabciximabの有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15619385","http://diabetes.ebm-library.jp/trial/detail/50715" "CALDIRET","Calcium Dobesilate in Diabetic Retinopathy study","Haritoglou C, Gerss J, Sauerland C, Kampik A, Ulbig MW, CALDIRET study group: Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2009; 373: 1364-1371.","軽度〜中等度の非増殖性糖尿病網膜症を有する2型糖尿病患者において,ドベシル酸カルシウムの黄斑浮腫発症予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19376452","http://diabetes.ebm-library.jp/trial/detail/51109" "CAMELLIA-TIMI 61","cardiovascular and metabolic effects of lorcaserin in overweight and obese patients-thrombolysis in myocardial infarction 61 trial","Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD; CAMELLIA-TIMI 61 Steering Committee Investigators. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet. 2018; 392: 2269-79.","動脈硬化性血管疾患リスクの高い過体重または肥満患者において,lorcaserinの代謝的有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30293771","http://diabetes.ebm-library.jp/trial/detail/51729" "CaMos","Canadian Multicentre Osteoprosis Study","Li G, Prior JC, Leslie WD, Thabane L, Papaioannou A, Josse RG, Kaiser SM, Kovacs CS, Anastassiades T, Towheed T, Davison KS, Levine M, Goltzman, Adachi JD; CaMos Research Group. Frailty and Risk of Fractures in Patients With Type 2 Diabetes. Diabetes Care. 2019; 42: 507-13.","2型糖尿病患者において,フレイルと骨折発症リスクの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30692240","http://diabetes.ebm-library.jp/trial/detail/51760" "Canadian-European Randomized Control Trial","-","The Canadian-European Randomized Control Trial Group: Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988; 37: 1574-1582.","cyclosporinがIDDMの寛解を増強するかどうかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/2903105","http://diabetes.ebm-library.jp/trial/detail/50066" "Candesartan in Diabetic Nephropathy Study","-","Haneda M, Kikkawa R, Sakai H, Kawamori R, Candesartan in Diabetic Nephropathy Study Group: Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. Diabetes Res Clin Pract 2004; 66: 87-95.","腎症を有する日本人の2型糖尿病患者において,candesartan cilexetilの尿中蛋白排泄率に対する用量依存効果を明らかにし,その効果がACE遺伝子多型により変化するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15364166","http://diabetes.ebm-library.jp/trial/detail/50732" "CANTATA-D2 study","Canagliflozin Treatment and Trial Analysisdipeptidyl peptidase-4 inhibitor","Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, Kawaguchi M, Canovatchel W, Meininger G: Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013; 36: 2508-15.","metformin+スルホニル尿素薬でコントロール不良の2型糖尿病患者において,canagliflozin 300mg追加投与の有効性と安全性をsitagliptin 100mg追加投与と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/23564919","http://diabetes.ebm-library.jp/trial/detail/51361" "CANTATA-SU","CANagliflozin Treatment And Trial Analysis versus SUlphonylurea study","Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G: Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382: 941-50.","metforminで血糖コントロール不良の2型糖尿病患者において,SGLT2阻害薬canagliflozinの有効性と安全性をglimepirideと比較した。","https://www.ncbi.nlm.nih.gov/pubmed/23850055","http://diabetes.ebm-library.jp/trial/detail/51370" "CANVAS Program(CANVAS/CANVAS-R)","Canagliflozin Cardiovascular Assessment Study/CANVAS-Renal ","Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, et al.; CANVAS Program Collaborative Group: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377: 644-57.","2型糖尿病患者において,心血管,腎,安全性アウトカムに対するcanagliflozinの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28605608","http://diabetes.ebm-library.jp/trial/detail/51673" "CANVAS Program","Canagliflozin Cardiovascular Assessment Study","Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, et al.; CANVAS Program Collaborative Group: Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018; 137: 323-334.","2型糖尿病患者において,canagliflozinの有効性と安全性を一次予防コホートと二次予防コホートに分けて検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29133604","http://diabetes.ebm-library.jp/trial/detail/51706" "CANVAS Program","Canagliflozin Cardiovascular Assessment Study Program","Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018 ;6: 691-704.","2型糖尿病患者において,腎アウトカムに対するcanagliflozinの長期効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29937267","http://diabetes.ebm-library.jp/trial/detail/51735" "CAPPP","the Captopril Prevention Project study","Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.","糖尿病を伴う高血圧患者におけるcaptoprilの脳心血管合併症予防効果を利尿薬,β遮断薬と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10030325","http://diabetes.ebm-library.jp/trial/detail/50004" "CAPPP","the Captopril Prevention Project","Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A: Reduced Cardiovascular Morbidity and Mortality in Hypertensive Diabetic Patients on First-Line Therapy With an ACE Inhibitor Compared With a Diuretic/beta-Blocker-Based Treatment Regimen: A subanalysis of the Captopril Prevention Project. Diabetes Care 2001; 24: 2091-2096.","高血圧患者におけるcaptopril治療の心血管疾患発症および心血管死抑制効果を,利尿薬,β遮断薬と比較検討したCAPPPにおいて,糖尿病患者のアウトカムを評価した。","https://www.ncbi.nlm.nih.gov/pubmed/11723089","http://diabetes.ebm-library.jp/trial/detail/50492" "CAPPP","the Captopril Prevention Project","Niklason A, Hedner T, Niskanen L, Lanke J, Captopril Prevention Project Study Group: Development of diabetes is retarded by ACE inhibition in hypertensive patients--a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens 2004; 22: 645-652.","高血圧患者において,captopril治療と従来の降圧療法(利尿薬,β遮断薬)の糖尿病発症抑制効果を比較し,糖尿病発症のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15076172","http://diabetes.ebm-library.jp/trial/detail/50681" "CAPTIM","-","Bonnefoy E, Steg PG, Chabaud S, Dubien PY, Lapostolle F, Boudet F, Lacroute JM, Dissait F, Vanzetto G, Leizorowicz A, et al: Is primary angioplasty more effective than prehospital fibrinolysis in diabetics with acute myocardial infarction? Data from the CAPTIM randomized clinical trial. Eur Heart J 2005; 26: 1712-1718.","急性心筋梗塞患者において,糖尿病が再灌流療法の有効性に及ぼす影響を検討。CAPTIMのサブグループ解析。","https://www.ncbi.nlm.nih.gov/pubmed/15840623","http://diabetes.ebm-library.jp/trial/detail/50799" "CARDIA","the Coronary Artery Risk Development in Young Adults","Kim C, Siscovick DS, Sidney S, Lewis CE, Kiefe CI, Koepsell TD: Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women: the CARDIA Study. Coronary Artery Risk Development in Young Adults. Diabetes Care 2002; 25: 1027-1032.","若年女性において,調査時点における経口避妊薬の使用と空腹時血糖値,空腹時インスリン値,糖尿病との関係を横断的に検討し,経口避妊薬の使用が10年後の糖尿病発症に及ぼす影響を縦断的に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12032110","http://diabetes.ebm-library.jp/trial/detail/50528" "CARDIA","the Coronary Artery Risk Development in Young Adults","Carnethon MR, Jacobs DR, Sidney S, Liu K, CARDIA study: Influence of autonomic nervous system dysfunction on the development of type 2 diabetes: the CARDIA study. Diabetes Care 2003; 26: 3035-3041.","自律神経障害が,インスリン値および血糖値の上昇と2型糖尿病発症に関与しているか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14578236","http://diabetes.ebm-library.jp/trial/detail/50629" "CARDIA","the Coronary Artery Risk Development in Young Adults study","Carnethon MR, Loria CM, Hill JO, Sidney S, Savage PJ, Liu K, Coronary Artery Risk Development in Young Adults study: Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985-2001. Diabetes Care 2004; 27: 2707-2715.","メタボリックシンドロームと人口統計学的因子の関係を評価するとともに,メタボリックシンドローム発症に関する修正可能なリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15505009","http://diabetes.ebm-library.jp/trial/detail/50697" "CARDIA","Coronary Artery Risk Development in Young Adults study","Carnethon MR, Sternfeld B, Schreiner PJ, Jacobs DR Jr, Lewis CE, Liu K, Sidney S: Association of 20-year changes in cardiorespiratory fitness with incident type 2 diabetes: the coronary artery risk development in young adults (CARDIA) fitness study. Diabetes Care. 2009; 32: 1284-8.","18〜30歳の青年において,7〜20年間の心肺機能の変化と,中年期の糖尿病発症との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19324945","http://diabetes.ebm-library.jp/trial/detail/51200" "CARDS","the Collaborative Atorvastatin Diabetes Study","Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, et al: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.","LDL-C高値を認めない2型糖尿病患者において,重度の心血管イベントの一次予防におけるatorvastatin 10mg/日の有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15325833","http://diabetes.ebm-library.jp/trial/detail/50666" "CARDS","the Collaborative Atorvastatin Diabetes Study","Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Fuller JH, CARDS Investigators: Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005; 48: 2482-2485.","心血管疾患の既往のない2型糖尿病患者において,atorvastatinの心血管イベントに対する効果の発現パターンを検討した。CARDSの事後解析。","https://www.ncbi.nlm.nih.gov/pubmed/16284747","http://diabetes.ebm-library.jp/trial/detail/50829" "CARDS","the Collaborative Atorvastatin Diabetes Study","Neil HA, DeMicco DA, Luo D, Betteridge DJ, Colhoun HM, Durrington PN, Livingstone SJ, Fuller JH, Hitman GA, CARDS Study Investigators: Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 2006; 29: 2378-2384.","2型糖尿病患者において,atorvastatinの心血管疾患予防効果および安全性を,高齢者と若年者で比較した。CARDSの事後解析。","https://www.ncbi.nlm.nih.gov/pubmed/17065671","http://diabetes.ebm-library.jp/trial/detail/50954" "CARDS","Collaborative Atorvastatin Diabetes Study","Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, et al.: Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia. 2009; 52: 218-25.","2型糖尿病患者において,ApoB/ApoA-I比が冠動脈心疾患の予測因子となるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18972097","http://diabetes.ebm-library.jp/trial/detail/51155" "CARE","the Cholesterol And Recurrent Events trial","Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98: 2513-2519.","pravastatinによる脂質低下効果が冠動脈イベントに与える影響を検討したCARE trialの,糖尿病群,非糖尿病群を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9843456","http://diabetes.ebm-library.jp/trial/detail/50061" "CARMELINA","Cardiovascular and Renal Microvascular Outcome Study With Linagliptin","Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019; 321: 69-79.","心血管および腎リスクの高い2型糖尿病患者において,linagliptinの心血管および腎アウトカムを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30418475","http://diabetes.ebm-library.jp/trial/detail/51752" "Carnethon MR.","-","Carnethon MR, De Chavez PJ, Biggs ML, Lewis CE, Pankow JS, Bertoni AG, Golden SH, Liu K, Mukamal KJ, Campbell-Jenkins B, et al.: Association of weight status with mortality in adults with incident diabetes. JAMA. 2012; 308: 581-90.","糖尿病を新規発症した成人において,体重と死亡の相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22871870","http://diabetes.ebm-library.jp/trial/detail/51277" "Carter AA, et al.","-","Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM: Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013; 346: f2610.","異なる種類のHMG-CoA還元酵素阻害薬(スタチン)投与下の患者において,特定のスタチン使用による新規発症糖尿病リスクを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/23704171","http://diabetes.ebm-library.jp/trial/detail/51347" "Casale Monferrato Study","-","Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, Bruno G, Bruno G, Bruno G, Casale Monferrato Study: Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004; 27: 2689-2694.","2型糖尿病患者において,メタボリックシンドロームが従来の心血管リスク因子とは独立した全死亡および心血管死の予測能を有するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15505006","http://diabetes.ebm-library.jp/trial/detail/50696" "CASE-J","Candesartan Antihypertensive Survival Evaluation in Japan","Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T, Candesartan Antihypertensive Survival Evaluation in Japan Trial Group: Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51: 393-398.","高リスクの日本人高血圧患者において,candesartanおよびamlodipineの心血管疾患,心血管死,新規糖尿病発症に対する効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18172059","http://diabetes.ebm-library.jp/trial/detail/51084" "CASS","the Coronary Artery Surgery Study","Barzilay JI, Kronmal RA, Bittner V, Eaker E, Evans C, Foster ED: Coronary artery disease and coronary artery bypass grafting in diabetic patients aged > or = 65 years (report from the Coronary Artery Surgery Study [CASS] Registry). Am J Cardiol 1994; 74: 334-339.","CASS試験の高齢冠動脈疾患患者について,心血管リスク因子としての糖尿病を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8059694","http://diabetes.ebm-library.jp/trial/detail/50344" "Caughey GE, et al.","−","Caughey GE, Preiss AK, Vitry AI, Gilbert AL, Roughead EE: Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care. 2013; 36: 3009-14.","慢性閉塞性肺疾患を合併する2型糖尿病患者において,コルチコステロイド治療は用量依存的に糖尿病関連合併症リスクと関連するか検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23735725","http://diabetes.ebm-library.jp/trial/detail/51364" "CCSPS","China Coronary Secondary Prevention Study","Zhao SP, Lu ZL, Du BM, Chen Z, Wu YF, Yu XH, Zhao YC, Liu L, Ye HJ, Wu ZH, et al.: Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS). J Cardiovasc Pharmacol 2007; 49: 81-84.","冠動脈心疾患を有する糖尿病患者において,xuezhikangの心血管イベントに対する効果を検討した。CCSPSのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/17312447","http://diabetes.ebm-library.jp/trial/detail/50988" "CDC Diabetes Cost-effectiveness","-","The CDC Diabetes Cost-effectiveness Group: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002; 287: 2542-2551.","2型糖尿病の合併症を抑制する各種療法(厳格血糖コントロール,厳格血圧コントロール,血清脂質低下療法)の費用対効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12020335","http://diabetes.ebm-library.jp/trial/detail/50542" "CDF","the Cyclosporin/Diabetes French study","Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, Du Rostu H, Rodier M, Sirmai J, Lallemand A, et al.: Cyclosporin increases the rate and length of remissions in insulin- dependent diabetes of recent onset. Results of a multicentre double- blind trial. Lancet 1986; 2: 119-124.","発症早期の1型糖尿病に対するcyclosporinの寛解促進効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/2873396","http://diabetes.ebm-library.jp/trial/detail/50117" "CDQDPOS","the China Da Qing Diabetes Prevention Outcomes Study","Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, et al.: The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008 :371; 1783-1789.","耐糖能異常症例において,生活習慣に対する介入の2型糖尿病,大血管障害,細小血管障害,死亡に対する有効性が長期的に継続するかを検討した。CDQDPSの延長試験。","https://www.ncbi.nlm.nih.gov/pubmed/18502303","http://diabetes.ebm-library.jp/trial/detail/51064" "CDQDPS","the China Da Qing Diabetes Prevention Study","Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544.","耐糖能異常患者において,食事療法,運動療法,両者の併用療法によるNIDDM発症抑制効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9096977","http://diabetes.ebm-library.jp/trial/detail/50514" "CDQDPS","the China Da Qing Diabetes Prevention Study","Li G, Hu Y, Yang W, Jiang Y, Wang J, Xiao J, Hu Z, Pan X, Howard BV, Bennett PH, et al: Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Res Clin Pract 2002; 58: 193-200.","生活習慣改善の介入が実施されている耐糖能異常患者において,インスリン抵抗性およびインスリン分泌が2型糖尿病発症に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12413779","http://diabetes.ebm-library.jp/trial/detail/50594" "Chakraborty A.","-","Chakraborty A, Chowdhury S, Bhattacharyya M: Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract. 2011; 93: 56-62.","2型糖尿病患者において,metforminが酸化ストレス,ニトロソ化ストレス,炎症性パラメーターに与える影響について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21146883","http://diabetes.ebm-library.jp/trial/detail/51248" "Chan JC, et al.","-","Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY, Swaminathan R, Nicholls MG, Critchley JA, Cockram CS: Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590-600.","高血圧を伴う2型糖尿病患者に対するenalaprilの尿中アルブミン減少効果を,nifedipine SRと比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10652036","http://diabetes.ebm-library.jp/trial/detail/50116" "Chan SP and Colagiuri S","−","Chan SP, Colagiuri S: Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res Clin Pract. 2015; 110: 75-81.","2型糖尿病患者において,gliclazideの有効性と安全性を,その他の経口インスリン分泌促進薬(SU薬,DPP-4阻害薬,速効型インスリン分泌促進薬)と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/26361859","http://diabetes.ebm-library.jp/trial/detail/51514" "Chang SH, et al.","−","Chang SH, Wu LS, Chiou MJ, Liu JR, Yu KH, Kuo CF, Wen MS, Chen WJ, Yeh YH, See LC: Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014; 13: 123.","2型糖尿病患者において,metforminは心房細動発症を抑制するかを検討し,さらにmetforminが頻脈刺激誘発性筋融解および心房細胞の酸化ストレスに与える影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25106079","http://diabetes.ebm-library.jp/trial/detail/51432" "CHARM","the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program","Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, Olofsson B, Probstfield J, McMurray JV, Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators: Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112: 48-53.","心不全患者において,candesartanの糖尿病新規発症抑制効果をプラセボと比較した。CHARM試験の二次エンドポイント。","https://www.ncbi.nlm.nih.gov/pubmed/15983242","http://diabetes.ebm-library.jp/trial/detail/50757" "CHARM","Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Programme","MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, et al.; CHARM Investigators: Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008; 29: 1377-85.","左室駆出率良好または低左室駆出率の心不全患者において,心血管アウトカムに対する糖尿病の影響を比較検討した。CHARMのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18413309","http://diabetes.ebm-library.jp/trial/detail/51119" "CHARM","Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity program","Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, Olofsson B, Pfeffer MA, Yusuf S; CHARM Program Investigators: The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med. 2008; 168: 1699-704.","症候性慢性心不全患者において,HbA1c値と心血管イベントとの関連を検討した。CHARMのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18695086","http://diabetes.ebm-library.jp/trial/detail/51129" "CHARM","Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program","Preiss D, Zetterstrand S, McMurray JJ, Ostergren J, Michelson EL, Granger CB, Yusuf S, Swedberg K, Pfeffer MA, Gerstein HC, et al.; Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Investigators: Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care. 2009; 32: 915-20.","非糖尿病の慢性心不全患者において,糖尿病発症の予測因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19196892","http://diabetes.ebm-library.jp/trial/detail/51174" "Charpentier G, et al.","-","Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S: Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001; 18: 828-834.","metformin単独療法で血糖コントロール不良の2型糖尿病患者において,glimepiride単独療法への変更および両剤併用の血糖コントロール改善効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11678974","http://diabetes.ebm-library.jp/trial/detail/50505" "Chatterjee S, et al.","-","Chatterjee S, Peters SA, Woodward M, Mejia Arango S, Batty GD, Beckett N, Beiser A, Borenstein AR, Crane PK, Haan M, et al.: Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia. Diabetes Care. 2016; 39: 300-7.","認知症に対する2型糖尿病の影響を男性と女性で比較した。","https://www.ncbi.nlm.nih.gov/pubmed/26681727","http://diabetes.ebm-library.jp/trial/detail/51548" "Cheng J, et al.","-","Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q, Chen J: Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014; 174: 773-85.","糖尿病患者において,全死亡,心血管死,主要心血管イベントに対するACE阻害薬とAII受容体拮抗薬の効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24687000","http://diabetes.ebm-library.jp/trial/detail/51393" "CHICAGO","the Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone trial","Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB, Perez A, Provost JC, Haffner SM: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572-2581.","2型糖尿病患者において,総頸動脈における内膜-中膜壁肥厚の変化に対するpioglitazoneおよびglimepirideの効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/17101640","http://diabetes.ebm-library.jp/trial/detail/50981" "Childhood Diabetes in Finland","-","Virtanen SM, Rasanen L, Aro A, Ylonen K, Lounamaa R, Tuomilehto J, Akerblom HK: Feeding in infancy and the risk of type 1 diabetes mellitus in Finnish children. The 'Childhood Diabetes in Finland' Study Group. Diabet Med 1992; 9: 815-819.","乳児期の摂食と小児期の1型糖尿病発症リスクとの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/1473321","http://diabetes.ebm-library.jp/trial/detail/50357" "Chilton R, et al.","−","Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE: Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015; 17: 1180-93.","2型糖尿病患者において,empagliflozinが血圧,動脈壁硬化指標,および血管抵抗性に与える影響について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26343814","http://diabetes.ebm-library.jp/trial/detail/51524" "Chronic Kidney Disease Prognosis Consortium","-","Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, et al.; Chronic Kidney Disease Prognosis Consortium: Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012; 380: 1662-73.","糸球体濾過量,アルブミン尿,死亡または腎アウトカムの関連を糖尿病の有無別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23013602","http://diabetes.ebm-library.jp/trial/detail/51305" "CHS","the Cardiovascular Health Study","Barzilay JI, Kronmal RA, Gottdiener JS, Smith NL, Burke GL, Tracy R, Savage PJ, Carlson M: The association of fasting glucose levels with congestive heart failure in diabetic adults > or =65 years: the Cardiovascular Health Study. J Am Coll Cardiol 2004; 43: 2236-2241.","高齢の糖尿病患者において,空腹時血糖値がうっ血性心不全の独立したリスク因子であるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15193686","http://diabetes.ebm-library.jp/trial/detail/50657" "CHS","Cardiovascular Health Study","Scuteri A, Najjar SS, Morrell CH, Lakatta EG: The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study. Diabetes Care 2005; 28: 882-887.","高齢者におけるメタボリックシンドロームの有病率を2つの診断基準を用いて検討するとともに,それらの診断基準の予後予測能を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/15793190","http://diabetes.ebm-library.jp/trial/detail/50752" "CHS","the Cardiovascular Health Study","Smith NL, Barzilay JI, Kronmal R, Lumley T, Enquobahrie D, Psaty BM: New-onset diabetes and risk of all-cause and cardiovascular mortality: the Cardiovascular Health Study. Diabetes Care 2006; 29: 2012-2017.","高齢者において,糖尿病新規発症に伴う全死亡リスクおよび心血管死リスクの推移を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16936145","http://diabetes.ebm-library.jp/trial/detail/50953" "Chung YR, et al.","−","Chung YR, Park SW, Kim JW, Kim JH, Lee K: PROTECTIVE EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON PROGRESSION OF DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES. Retina. 2016; ","2型糖尿病患者において,DPP-4阻害薬は,血糖降下作用とは独立して糖尿病網膜症(DR)の進展を抑制するという仮説を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/27285457","http://diabetes.ebm-library.jp/trial/detail/51581" "CIDES","Cilostazol for Diabetic Patients in Drug-Eluting Stent trial","Ahn Y, Jeong MH, Jeong JW, Kim KH, Ahn TH, Kang WC, Park CG, Kim JH, Chae IH, Nam CW, et al.: Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J 2008; 72: 35-39.","2型糖尿病患者において,薬剤溶出ステント留置成功後のステント内再狭窄に対するcilostazol+aspirin併用とclopidogrel+aspirin併用の予防効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/18159096","http://diabetes.ebm-library.jp/trial/detail/51050" "CNHSS","China National HbA1c Surveillance System","Huo X, Gao L, Guo L, Xu W, Wang W, Zhi X, Li L, Ren Y, Qi X, Sun Z, et al.: Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol. 2016; 4: 115-24.","2型糖尿病患者において,早期発症例と晩期発症例で非致死的心血管疾患リスクを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/26704379","http://diabetes.ebm-library.jp/trial/detail/51555" "Coca SG, et al.","-","Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR: Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med. 2012; 172: 761-9.","2型糖尿病患者において,腎関連アウトカムに対する強化血糖コントロール療法の効果を標準療法と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/22636820","http://diabetes.ebm-library.jp/trial/detail/51311" "Coleman KJ, et al.","−","Coleman KJ, Haneuse S, Johnson E, Bogart A, Fisher D, O'Connor PJ, Sherwood NE, Sidney S, Theis MK, Anau J, Schroeder EB, O'Brien R, Arterburn D: Long-term Microvascular Disease Outcomes in Patients With Type 2 Diabetes After Bariatric Surgery: Evidence for the Legacy Effect of Surgery. Diabetes Care. 2016; 39: 1400-7. ","2型糖尿病患者において,細小血管疾患発症リスクに対する肥満手術の「レガシー効果」を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27271192","http://diabetes.ebm-library.jp/trial/detail/51595" "Collaborative Study","-","Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.","captoprilの糖尿病性腎症における降圧効果と腎保護作用について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8413456","http://diabetes.ebm-library.jp/trial/detail/50006" "Collaborative Study","-","Rodby RA, Rohde RD, Sharon Z, Pohl MA, Bain RP, Lewis EJ: The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Am J Kidney Dis 1995; 26: 904-909.","腎症を有する1型糖尿病患者において,随時尿での蛋白・クレアチニン比が24時間尿中蛋白排泄量の指標となるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/7503064","http://diabetes.ebm-library.jp/trial/detail/50152" "Collaborative Study","-","Breyer JA, Bain RP, Evans JK, Nahman NS Jr, Lewis EJ, Cooper M, McGill J, Berl T: Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 1996; 50: 1651-1658.","糖尿病性腎症における腎症進展のリスク因子を,各種統計学的手法により検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8914032","http://diabetes.ebm-library.jp/trial/detail/50274" "Collaborative Study","-","Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis 1999; 34: 809-817.","1型糖尿病患者の腎症進展に対するramiprilの血圧低下効果と腎保護作用を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10561135","http://diabetes.ebm-library.jp/trial/detail/50154" "COMET","the Carvedilol Or Metoprolol European Trial","Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Remme WJ, et al.: Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart 2007; 93: 968-973.","心不全患者において,metoprololおよびcarvedilolが糖尿病の新規発症に及ぼす影響を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/17237130","http://diabetes.ebm-library.jp/trial/detail/51011" "CONCEPTT","Continuous glucose monitoring in pregnant women with type 1 diabetes trial","Feig DS, Donovan LE, Corcoy R, Murphy KE, Amiel SA, Hunt KF, Asztalos E, Barrett JFR, Sanchez JJ, de Leiva A, Hod M, Jovanovic L, Keely E, McManus R, Hutton EK, Meek CL, Stewart ZA, Wysocki T, O'Brien R, Ruedy K, Kollman C, Tomlinson G, Murphy HR; CONCEPTT Collaborative Group. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017; 390: 2347-59.","妊娠前および妊娠早期からの持続血糖モニター使用の,母体血糖コントロール,産科アウトカム,および新生児の健康アウトカムに対する有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28923465","http://diabetes.ebm-library.jp/trial/detail/51693" "CONCEPTT","Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial","Feig DS, Corcoy R, Donovan LE, Murphy KE, Barrett JFR, Sanchez JJ, Wysocki T, Ruedy K, Kollman C, Tomlinson G, Murphy HR; CONCEPTT Collaborative Group. Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial. Diabetes Care. 2018; 41: 2471-9.","1型糖尿病の妊婦を対象に,持続血糖モニター(CGM)使用下における,インスリンポンプとインスリン頻回注射(MDI)の血糖コントロール,QOL,妊娠アウトカムを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/30327362","http://diabetes.ebm-library.jp/trial/detail/51746" "CONTROL","Collaborators on Trials of Glucose Lowering","Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017; 5: 431-437.","2型糖尿病患者において,細小血管イベントリスクに対する強化血糖コントロールの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28365411","http://diabetes.ebm-library.jp/trial/detail/51660" "CORE","the Collaborative Organization of RheothRx Evaluation trial","Alegria JR, Miller TD, Gibbons RJ, Yi QL, Yusuf S, Collaborative Organization of RheothRx Evaluation (CORE) Trial Investigators: Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy. Am Heart J 2007; 154: 743-750.","ST上昇型急性心筋梗塞に対し血栓溶解療法を実施された糖尿病患者および非糖尿病患者において,梗塞サイズ,左室駆出率,死亡率,ならびにそれらの関係を検討した。COREのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/17893003","http://diabetes.ebm-library.jp/trial/detail/51035" "Corrao G, et al.","-","Corrao G, Ibrahim B, Nicotra F, Soranna D, Merlino L, Catapano AL, Tragni E, Casula M, Grassi G, Mancia G: Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care. 2014; 37: 2225-32.","スタチン療法のアドヒアランスと糖尿病発症リスクとの関係について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24969582","http://diabetes.ebm-library.jp/trial/detail/51434" "COSMIC Approach Study","the Comparative Outcomes Study of Metformin Intervention versus Conventional Approach Study","Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV: Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care 2005; 28: 539-543.","2型糖尿病患者において,metformin投与の安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15735184","http://diabetes.ebm-library.jp/trial/detail/50720" "CPS-II Nutrition Cohort","Cancer Prevention Study-II Nutrition Cohort","Dehal AN, Newton CC, Jacobs EJ, Patel AV, Gapstur SM, Campbell PT: Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2012; 30: 53-9.","結腸直腸癌患者において,2型糖尿病と生存期間の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22124092","http://diabetes.ebm-library.jp/trial/detail/51300" "CREDENCE","Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation","Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al.; CREDENCE Trial Investigators: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019; 380: 2295-306.","アルブミン尿を有する慢性腎臓病を伴う2型糖尿病患者において,SGLT2阻害薬canagliflozinが腎アウトカムに与える影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30990260","http://diabetes.ebm-library.jp/trial/detail/51766" "CREDIT","Cardiovascular Risk Evaluation in people with type 2 Diabetes on Insulin Therapy study","Balkau B, Home PD, Vincent M, Marre M, Freemantle N: Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care. 2014; 37: 2108-13.","インスリン治療を開始した2型糖尿病患者において,体重増加の関連因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24824546","http://diabetes.ebm-library.jp/trial/detail/51411" "CTT","Cholesterol Treatment Trialists' Collaboration","Cholesterol Treatment Trialists' (CTT) Collaborators, , Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.","糖尿病患者におけるスタチン治療が主要血管イベントに及ぼす効果を検討し,さらにその効果に予後因子が及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18191683","http://diabetes.ebm-library.jp/trial/detail/51048" "CURES-2","the Chennai Urban Rural Epidemiology Study","Rema M, Mohan V, Deepa R, Ravikumar R, Chennai Urban Rural Epidemiology Study-2: Association of carotid intima-media thickness and arterial stiffness with diabetic retinopathy: the Chennai Urban Rural Epidemiology Study (CURES-2). Diabetes Care 2004; 27: 1962-1967.","糖尿病と冠動脈疾患のリスクが高いインド人において,内膜-中膜壁肥厚および動脈硬化度と糖尿病網膜症との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15277424","http://diabetes.ebm-library.jp/trial/detail/50655" "Currie CJ, et al.","-","Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL: Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013; 98: 668-77.","2型糖尿病患者において,血糖降下薬の有害アウトカムリスクを治療法別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23372169","http://diabetes.ebm-library.jp/trial/detail/51315" "Currie CJ, et al.","-","Currie CJ, Holden SE, Jenkins-Jones S, Morgan CL, Voss B, Rajpathak SN, Alemayehu B, Peters JR, Engel SS. Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival. Diabetes Obes Metab. 2018; 20: 821-30.","さまざまな低血糖リスクを有する血糖降下治療を行った2型糖尿病患者において,達成HbA1c別に全死亡リスクを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29119713","http://diabetes.ebm-library.jp/trial/detail/51718" "CVD-REAL Nordic","-","Birkeland KI, Jrgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nystrm T, Eriksson JW, Bodegrd J, Norhammar A. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017; 5: 709-17.","SGLT2阻害薬または他の血糖低下薬を開始した2型糖尿病患者において,心血管アウトカムを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/28781064","http://diabetes.ebm-library.jp/trial/detail/51676" "CVD-REAL Study","-","Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jrgensen ME, Thuresson M, et al.; CVD-REAL Investigators and Study Group*: Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017; 136: 249-259.","リアルワールドでの2型糖尿病の診療場面において,SGLT2阻害薬と他の血糖降下薬の心不全による入院,死亡,および両者の複合エンドポイントを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/28522450","http://diabetes.ebm-library.jp/trial/detail/51653" "Da Qing Diabetes Prevention Outcome Study","-","Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y, Zhang B, Feng X, Li H, Chen X, Cheng YJ, Gregg EW, Hu Y, Bennett PH, Li G; Da Qing Diabetes Prevention Study Group. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019; 7: 452-61.","耐糖能異常患者において,生活習慣介入の長期効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/31036503","http://diabetes.ebm-library.jp/trial/detail/51756" "DAFNE","the Dose Adjustment for Normal Eating trial","DAFNE Study Group: Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ 2002; 325: 746-749.","1型糖尿病患者に対する柔軟な強化インスリン療法の指導が血糖コントロールとQOLを改善するか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12364302","http://diabetes.ebm-library.jp/trial/detail/50543" "DAIS","the Diabetes Atherosclerosis Intervention Study","Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-910.","2型糖尿病患者に対するfenofibrateの冠動脈疾患進展抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11289345","http://diabetes.ebm-library.jp/trial/detail/50383" "DAIS","the Diabetes Atherosclerosis Intervention Study","Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, Hamsten A, Taskinen MR, DAIS Group: Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003; 107: 1733-1737.","2型糖尿病患者において,血漿脂質値およびLDL粒子径の変化が,fenofibrateの冠動脈疾患進展抑制効果に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12665498","http://diabetes.ebm-library.jp/trial/detail/50593" "DAIS","the Diabetes Atherosclerosis Intervention Study","Genest J, Frohlich J, Steiner G: Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol 2004; 93: 848-853.","脂質代謝異常を有する2型糖尿病患者において,fenofibrateの血漿ホモシステイン値に対する効果を検討するとともに,この効果が冠動脈疾患の進展およびその他の臨床イベントに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15050487","http://diabetes.ebm-library.jp/trial/detail/50651" "DAIS","the Diabetes Atherosclerosis Intervention Study","Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G, DAIS Investigators: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005; 45: 485-493.","2型糖尿病患者において,fenofibrateを用いた脂質低下療法によりアルブミン尿の進展抑制効果が得られるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15754270","http://diabetes.ebm-library.jp/trial/detail/50779" "DAISY","Dapagliflozin Added to Patients under Insulin Therapy trial","Araki E, Onishi Y, Asano M, Kim H, Yajima T. Efficacy and safety of dapagliflozin over 1year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial. Diabetes Obes Metab. 2017; 19: 562-570.","インスリン治療中の日本人2型糖尿病患者において,dapagliflozin追加投与の有効性と安全性を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/27987240","http://diabetes.ebm-library.jp/trial/detail/51630" "DALI","the Diabetes Atorvastatin Lipid Intervention study","Diabetes Atorvastatin Lipid Intervention (DALI) Study Group: The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001; 24: 1335-1341.","脂質代謝異常を認める2型糖尿病患者において,atorvastatin 10mg/日および80mg/日投与の有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11473066","http://diabetes.ebm-library.jp/trial/detail/50596" "DALI","the Diabetes Atorvastatin Lipid Intervention study","van Venrooij FV, van de Ree MA, Bots ML, Stolk RP, Huisman MV, Banga JD, DALI Study Group: Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2002; 25: 1211-1216.","脂質代謝異常を認める2型糖尿病患者において,atorvastatin 10mg/日および80mg/日投与による脂質低下療法の内皮機能に対する有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12087021","http://diabetes.ebm-library.jp/trial/detail/50561" "DALI","the Diabetes Atorvastatin Lipid Intervention study","van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C, DALI-Study Group: Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166: 129-135.","2型糖尿病患者において,atorvastatinのC反応性蛋白減少効果に用量依存性が認められるか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12482559","http://diabetes.ebm-library.jp/trial/detail/50612" "DAMAD","the Diabetic microangiopathy Modification with Aspirin vs Dipyridamole study","The DAMAD Study Group.: Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes 1989; 38: 491-498.","早期糖尿病網膜症に対するaspirinとdipyridamoleの治療効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/2647556","http://diabetes.ebm-library.jp/trial/detail/50067" "DANAMI-2","the Second Danish Trial in Acute Myocardial Infarction","Madsen MM, Busk M, Sondergaard HM, Bottcher M, Mortensen LS, Andersen HR, Nielsen TT, DANAMI-2 Investigators: Does diabetes mellitus abolish the beneficial effect of primary coronary angioplasty on long-term risk of reinfarction after acute ST-segment elevation myocardial infarction compared with fibrinolysis? (A DANAMI-2 substudy). Am J Cardiol 2005; 96: 1469-1475.","ST上昇型急性心筋梗塞患者において,初回経皮的冠インターベンションまたはフィブリン溶解療法実施後の長期アウトカムに糖尿病が及ぼす影響を検討した。DANAMI-2試験のサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/16310424","http://diabetes.ebm-library.jp/trial/detail/50807" "Dapagliflozin 006 Study","-","Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin 006 Study Group: Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012; 156: 405-15.","インスリン±経口抗糖尿病薬でコントロール不良の2型糖尿病患者において,dapagliflozin追加の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22431673","http://diabetes.ebm-library.jp/trial/detail/51233" "DAPIT","Diabetes and Pre-eclampsia Intervention Trial","Holmes VA, Young IS, Patterson CC, Pearson DW, Walker JD, Maresh MJ, McCance DR; Diabetes and Pre-eclampsia Intervention Trial Study Group: Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the diabetes and pre-eclampsia intervention trial. Diabetes Care. 2011; 34: 1683-8.","1型糖尿病の女性において,妊娠前および妊娠中の血糖コントロールと,子癇前症および妊娠高血圧リスクの相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21636798","http://diabetes.ebm-library.jp/trial/detail/51241" "DAPIT","Diabetes and Pre-eclampsia Intervention Trial","Maresh MJ, Holmes VA, Patterson CC, Young IS, Pearson DW, Walker JD, McCance DR; Diabetes and Pre-eclampsia Intervention Trial Study Group: Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes. Diabetes Care. 2015; 38: 34-42.","1型糖尿病の妊婦において,妊娠中期および妊娠後期の血糖コントロールと,母体および新生児アウトカムとの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25368104","http://diabetes.ebm-library.jp/trial/detail/51453" "DARTS/MEMO","Diabetes Audit and Research in Tayside, Scotland/Medicines Monitoring Unit","Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, Band MM, Reekie G, Leese GP, DARTS/MEMO Collaboration: Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med 2005; 22: 749-755.","1型糖尿病およびインスリン治療を行っている2型糖尿病患者において,自己報告の低血糖発生率を評価し,その予測因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15910627","http://diabetes.ebm-library.jp/trial/detail/50792" "DARTS/MEMO","Diabetes Audit and Research in Tayside, Scotland/Medicines Monitoring Unit","Schofield CJ, Libby G, Brennan GM, MacAlpine RR, Morris AD, Leese GP, DARTS/MEMO Collaboration: Mortality and hospitalization in patients after amputation: a comparison between patients with and without diabetes. Diabetes Care 2006; 29: 2252-2256.","下肢切断術後の死亡および大血管障害のリスクを糖尿病患者と非糖尿病患者で比較した。","https://www.ncbi.nlm.nih.gov/pubmed/17003302","http://diabetes.ebm-library.jp/trial/detail/50979" "DAVID","the Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics study","Neri Serneri GG, Coccheri S, Marubini E, Violi F, Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group: Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004; 25: 1845-1852.","末梢血管疾患を有する2型糖尿病患者において,全死亡および重度の心血管イベントに対するpicotamideとaspirinの有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/15474700","http://diabetes.ebm-library.jp/trial/detail/50725" "DCCT (1993)","the Diabetes Control and Complications Trial","The Diabetes Control and Complications Trial Research Group.: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.","IDDMにおける強化インスリン療法の細小血管合併症発症・進展予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8366922","http://diabetes.ebm-library.jp/trial/detail/50007" "DCCT (1994)","the Diabetes Control and Complications Trial","Diabetes Control and Complications Trial Research Group.: Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin- dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994; 125: 177-188.","青年期IDDMにおける強化インスリン療法の細小血管合併症発症・進展予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8040759","http://diabetes.ebm-library.jp/trial/detail/50108" "DCCT (1995)","the Diabetes Control and Complications Trial","The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol 1995; 113: 36-51.","強化インスリン療法による糖尿病網膜症の進行抑制効果を調査した。","https://www.ncbi.nlm.nih.gov/pubmed/7826293","http://diabetes.ebm-library.jp/trial/detail/50047" "DCCT (1995)","the Diabetes Control and Complications Trial","The Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561-568.","IDDMにおける強化インスリン療法の神経障害発症予防・遅延効果を,従来療法と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/7887548","http://diabetes.ebm-library.jp/trial/detail/50036" "DCCT (1996)","the Diabetes Control and Complications Trial","The Diabetes Control and Complications Trial Research Group.: Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol 1996; 174: 1343-1353.","DCCTの試験期間中に妊娠したIDDM患者に対する強化インスリン療法が母体および胎児の転帰に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8623868","http://diabetes.ebm-library.jp/trial/detail/50030" "DCCT (1998)","the Diabetes Control and Complications Trial","The Diabetes Control and Complications Trial Research Group.: Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998; 128: 517-523.","1型糖尿病における強化インスリン療法の残存膵β細胞機能に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9518395","http://diabetes.ebm-library.jp/trial/detail/50009" "DCCT (1998)","the Diabetes Control and Complications Trial","Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116: 874-886.","網膜症の早期悪化の頻度,重要性,リスク因子を調査した。","https://www.ncbi.nlm.nih.gov/pubmed/9682700","http://diabetes.ebm-library.jp/trial/detail/50051" "DCCT (2000)","the Diabetes Control and Complications Trial ","Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000; 23: 1084-1091.","女性の1型糖尿病患者で,妊娠が網膜症および微量アルブミン尿の発生と進行に及ぼす影響を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/10937502","http://diabetes.ebm-library.jp/trial/detail/50386" "DCCT (2001)","the Diabetes Control and Complications Trial","The Diabetes Control And Complications Trial Research Group: Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001; 24: 1711-1721.","成人の1型糖尿病患者で,強化インスリン療法と従来インスリン療法の体重増加および身体組成に対する効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11574431","http://diabetes.ebm-library.jp/trial/detail/50497" "DCCT (2002)","the Diabetes Control and Complications Trial","Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE: Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25: 275-278.","1型糖尿病患者におけるHbA1c値と血漿ブドウ糖値との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11815495","http://diabetes.ebm-library.jp/trial/detail/50521" "DCCT (2003)","the Diabetes Control and Complications Trial","Purnell JQ, Dev RK, Steffes MW, Cleary PA, Palmer JP, Hirsch IB, Hokanson JE, Brunzell JD: Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. Diabetes 2003; 52: 2623-2629.","1型糖尿病患者において,強化療法による体重増加と2型糖尿病の家族歴,重度の低血糖の頻度,β細胞の自己抗体との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14514648","http://diabetes.ebm-library.jp/trial/detail/50630" "DCCT (2005)","the Diabetes Control and Complications Trial","Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, Ridker PM, Nathan DM: Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation 2005; 111: 2446-2453.","1型糖尿病患者において,強化インスリン療法が心血管疾患リスクに関連する炎症性マーカーに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15867184","http://diabetes.ebm-library.jp/trial/detail/50740" "DCCT (2007)","the Diabetes Control and Complications Trial","Kilpatrick ES, Rigby AS, Atkin SL: Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care 2007; 30: 707-712.","1型糖尿病患者において,メタボリックシンドローム,インスリン抵抗性,インスリン用量が細小血管障害および大血管障害に対する予測能を有するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17327345","http://diabetes.ebm-library.jp/trial/detail/50998" "DCCT","Diabetes Control and Complications Trial"," Ku E, McCulloch CE, Mauer M, Gitelman SE, Grimes BA, Hsu CY. Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes. Diabetes Care. 2016; 39: 2218-2224.","1型糖尿病患者において,血圧レベルと糖尿病腎症リスクの関連を検討し,強化血糖コントロール療法により関連が変化するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27872156","http://diabetes.ebm-library.jp/trial/detail/51607" "DCCT/EDIC","the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications","The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-389.","強化インスリン療法による細小血管合併症の抑制効果が,試験終了後も持続するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10666428","http://diabetes.ebm-library.jp/trial/detail/50286" "DCCT/EDIC","the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications","Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S, Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294-2303.","1型糖尿病患者において,頸動脈内膜-中膜壁肥厚の変化およびそれに関与するリスク因子について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12788993","http://diabetes.ebm-library.jp/trial/detail/50591" "DCCT/EDIC","Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study","Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.","1型糖尿病患者において,強化インスリン療法の長期的な心血管疾患発症リスク抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16371630","http://diabetes.ebm-library.jp/trial/detail/50785" "DCCT/EDIC","Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study","Cleary PA, Orchard TJ, Genuth S, Wong ND, Detrano R, Backlund JY, Zinman B, Jacobson A, Sun W, Lachin JM, et al.: The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2006; 55: 3556-3565.","過去に行われた糖尿病治療がアテローム性動脈硬化の指標である冠動脈石灰化に及ぼす長期的影響を評価するとともに,CACと相関を示す因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17130504","http://diabetes.ebm-library.jp/trial/detail/50969" "DCCT/EDIC","the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study","Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, , Musen G, Ryan CM, Silvers N, Cleary P, Waberski B, Burwood A, Weinger K, Bayless M, et al.: Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007; 356: 1842-1852.","1型糖尿病患者において,糖尿病治療,HbA1c値,重度の低血糖イベントが認知機能に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17476010","http://diabetes.ebm-library.jp/trial/detail/50983" "DCCT/EDIC","Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications","Albers JW, Herman WH, Pop-Busui R, Martin CL, Cleary P, Waberski B, Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Intervention and Complications (EDIC) Research Group: Subclinical neuropathy among Diabetes Control and Complications Trial participants without diagnosable neuropathy at trial completion: possible predictors of incident neuropathy? Diabetes Care 2007; 30: 2613-2618.","DCCT終了時における潜在性神経障害を評価し,その群間差がその後の神経障害発生リスクに影響しているかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17644617","http://diabetes.ebm-library.jp/trial/detail/51085" "DCCT/EDIC","Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study","de Boer IH, Kestenbaum B, Rue TC, Steffes MW, Cleary PA, Molitch ME, Lachin JM, Weiss NS, Brunzell JD; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group: Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med. 2008; 168: 1867-73.","1型糖尿病患者において,強化インスリン療法および高血糖が,高血圧の発症に影響するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18809813","http://diabetes.ebm-library.jp/trial/detail/51139" "DCCT/EDIC","Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study","Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, de Boer IH, Zinman B, Lachin J; Epidemiology of Diabetes Interventions and Complications Study Group: Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care. 2010; 33: 1536-43.","1型糖尿病患者において,腎不全の発症および進展をアルブミン尿の有無別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20413518","http://diabetes.ebm-library.jp/trial/detail/51195" "DCCT/EDIC","Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study","Jacobson AM, Ryan CM, Cleary PA, Waberski BH, Weinger K, Musen G, Dahms W; Diabetes Control and Complications Trial/EDIC Research Group: Biomedical risk factors for decreased cognitive functioning in type 1 diabetes: an 18 year follow-up of the Diabetes Control and Complications Trial (DCCT) cohort. Diabetologia. 2011; 54: 245-55.","1型糖尿病患者において,長期的な認知機能低下に対するリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20803190","http://diabetes.ebm-library.jp/trial/detail/51264" "DCCT/EDIC","Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications ","de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD, White NH, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group: Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med. 2011; 171: 412-20.","1型糖尿病患者において,微量アルブミン尿を発症後の長期腎アウトカムを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21403038","http://diabetes.ebm-library.jp/trial/detail/51235" "DCCT/EDIC","Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study","Turkbey EB, Backlund JY, Genuth S, Jain A, Miao C, Cleary PA, Lachin JM, Nathan DM, van der Geest RJ, Soliman EZ, et al.; DCCT/EDIC Research Group: Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation. 2011; 124: 1737-46.","1型糖尿病患者において,心血管疾患リスク因子と心筋の構造,機能,瘢痕の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21947298","http://diabetes.ebm-library.jp/trial/detail/51244" "DCCT/EDIC","Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study","de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MWZinman B, ; DCCT/EDIC Research Group: Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011; 365: 2366-76.","1型糖尿病患者において,強化インスリン療法の糸球体濾過量低下の予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22077236","http://diabetes.ebm-library.jp/trial/detail/51226" "DCCT/EDIC","Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study","Purnell JQ, Zinman B, Brunzell JD; DCCT/EDIC Research Group: The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study. Circulation. 2013; 127: 180-7.","1型糖尿病患者において,強化治療による過度の体重増加と動脈硬化性疾患の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23212717","http://diabetes.ebm-library.jp/trial/detail/51310" "DCCT/EDIC","Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications","Aiello LP, Sun W, Das A, Gangaputra S, Kiss S, Klein R, Cleary PA, Lachin JMNathan DM, ; DCCT/EDIC Research Group: Intensive diabetes therapy and ocular surgery in type 1 diabetes. N Engl J Med. 2015; 372: 1722-33.","1型糖尿病患者において,強化血糖コントロールが網膜症発症リスクおよび眼科手術のコストに与える影響を標準治療と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25923552","http://diabetes.ebm-library.jp/trial/detail/51459" "DCCT/EDIC","Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study","Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group: Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care. 2016; 39: 686-93.","1型糖尿病患者において,発症早期に行った強化療法の心血管疾患(CVD)発症に対する長期効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26861924","http://diabetes.ebm-library.jp/trial/detail/51578" "DCCT/EDIC","Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications","Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group: Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population. Diabetes Care. 2016; 39: 1378-83.","1型糖尿病患者の死亡率を米国の一般住民と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/27411699","http://diabetes.ebm-library.jp/trial/detail/51593" "DCCT/EDIC","Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study","Gubitosi-Klug RA, Braffett BH, White NH, Sherwin RS, Service FJ, Lachin JM, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care. 2017; 40: 1010-6.","1型糖尿病患者において,重度低血糖(SH)に対する強化血糖コントロール療法のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28550194","http://diabetes.ebm-library.jp/trial/detail/51665" "DDCRT 18","Diabetes Distress and Care Registry in Tenri","Hayashino Y, Okamura S, Tsujii S, Ishii H; Diabetes Distress and Care Registry at Tenri Study Group. Association between diabetes distress and all-cause mortality in Japanese individuals with type 2 diabetes: a prospective cohort study (Diabetes Distress and Care Registry in Tenri [DDCRT 18]). Diabetologia. 2018; 61: 1978-84.","日本人2型糖尿病患者において,糖尿病の苦痛とその後の全死亡リスクの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29947921","http://diabetes.ebm-library.jp/trial/detail/51741" "DDCRT 5","Diabetes Distress and Care Registry at Tenri","Mashitani T, Hayashino Y, Okamura S, Tsujii S, Ishii H: Correlations between serum bilirubin levels and diabetic nephropathy progression among Japanese type 2 diabetic patients: a prospective cohort study (Diabetes Distress and Care Registry at Tenri [DDCRT 5]). Diabetes Care. 2014; 37: 252-8.","2型糖尿病患者において,血清ビリルビン値と糖尿病腎症の発症・進展との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24009299","http://diabetes.ebm-library.jp/trial/detail/51379" "De Cesaris R, et al.","-","De Cesaris R, Ranieri G, Andriani A, Lamontanara G, Cavallo A, Bonfantino MV, Bertocchi F: Effects of benazepril and nicardipine on microalbuminuria in normotensive and hypertensive patients with diabetes. Clin Pharmacol Ther 1996; 60: 472-478.","糖尿病患者において,benazeprilとnicardipineが夜間の微量アルブミン尿に及ぼす効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8873695","http://diabetes.ebm-library.jp/trial/detail/50310" "de Zeeuw D, et al.","−","de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, et al.: The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy. J Am Soc Nephrol. 2014; ","糖尿病腎症でRAS阻害薬投与下の患者において,低用量atrasentan(0.75mg,1.25mg)のアルブミン尿およびその他の腎リスク関連指標に対する有効性および安全性について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24722445","http://diabetes.ebm-library.jp/trial/detail/51386" "DECLARE-DIABETES","A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients","Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, et al.: Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol. 2008; 51: 1181-7.","薬剤溶出ステント施行後の糖尿病患者において,2剤抗血小板薬治療(aspirin,clopidogrel)と3剤抗血小板薬治療(aspirin,clopidogrel,cilostazol)を比較し,cilostazolの新生内膜増殖抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18355656","http://diabetes.ebm-library.jp/trial/detail/51127" "DECLARE-TIMI 58","Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 trial","Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARETIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019; 380: 347-57.","動脈硬化性心血管疾患を有する,またはそのリスクが高い2型糖尿病患者において,心血管および腎アウトカムに対するdapagliflozinの有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30415602","http://diabetes.ebm-library.jp/trial/detail/51749" "DECLARE-TIMI 58","Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58","Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019; 139: 2528-36.","2型糖尿病患者において,SGLT2阻害薬dapagliflozinによる心血管死/心不全による入院の抑制効果は,ベースライン時の左室駆出率により異なるか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30882238","http://diabetes.ebm-library.jp/trial/detail/51765" "DECODA","Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Asia","Qiao Q, Nakagami T, Tuomilehto J, Borch-Johnsen K, Balkau B, Iwamoto Y, Tajima N; International Diabetes Epidemiology Group; DECODA Study Group: Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia 2000; 43: 1470-1475.","アジア人対象の疫学研究データより,FPG値と75g OGTT 2時間値による糖尿病診断の相違を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11151755","http://diabetes.ebm-library.jp/trial/detail/50511" "DECODA","Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Asia","Qiao Q, Hu G, Tuomilehto J, Borch-Johnsen K, Ramachandran A, Mohan V, Iyer SR, Tominaga M, Kiyohara Y, Kato I, et al: Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care 2003; 26: 1770-1780.","アジア人において,糖尿病および血糖異常の有病率を人種別,年齢層別,男女別に比較した。","https://www.ncbi.nlm.nih.gov/pubmed/12766108","http://diabetes.ebm-library.jp/trial/detail/50601" "DECODE","Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe","The DECODE-study group on behalf of the European Diabetes Epidemiology Group: Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe. Diabetologia 1999; 42: 647-654.","欧州の疫学研究データより,FPG値126mg/dLはOGTT 2時間値200mg/dLと同等かどうかの検討,段階的スクリーニング法の感度と特異性の評価,耐糖能異常と空腹時血糖異常の比較を行った。","https://www.ncbi.nlm.nih.gov/pubmed/10382583","http://diabetes.ebm-library.jp/trial/detail/50489" "DECODE","Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe","Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 1999; 354: 617-21.","米国糖尿病学会の空腹時血糖値基準とWHOの75g経口糖負荷試験2時間値基準で,死亡率を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/10466661","http://diabetes.ebm-library.jp/trial/detail/51343" "DECODE","Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe","DECODE Study Group, the European Diabetes Epidemiology Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.","糖尿病患者の死亡の予測因子として,空腹時血糖値と75g OGTT 2時間値を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11176766","http://diabetes.ebm-library.jp/trial/detail/50585" "DECODE","Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe","DECODE Study Group, European Diabetes Epidemiology Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26: 688-696.","空腹時血漿ブドウ糖値および75g OGTT 2時間値と,全死亡,心血管疾患死,非心血管疾患死との関係を評価し,その関係が段階的なものか,閾値があるものかについて検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12610023","http://diabetes.ebm-library.jp/trial/detail/50573" "DECODE","Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe","Hyvrinen M, Qiao Q, Tuomilehto J, Laatikainen T, Heine RJ, Stehouwer CD, Alberti KG, Pyrl K, Zethelius B, Stegmayr B; DECODE Study Group: Hyperglycemia and stroke mortality: comparison between fasting and 2-h glucose criteria. Diabetes Care. 2009; 32: 348-54.","欧州で行われた13件のコホート研究データより,高血糖と脳卒中死との関連を検討し,75g OGTT 2時間値と空腹時血漿ブドウ糖値の脳卒中死予測能を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/19017775","http://diabetes.ebm-library.jp/trial/detail/51153" "DEPICT-1","-","Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschpe D, Thorn F, Xu J, Langkilde AM; DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017; 5: 864-76.","コントロール不良の1型糖尿病患者において,インスリン療法へのdapagliflozin追加の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28919061","http://diabetes.ebm-library.jp/trial/detail/51686" "DERI Mortality Study","Diabetes Epidemiology Research International Mortality Study","Asao K, Sarti C, Forsen T, Hyttinen V, Nishimura R, Matsushima M, Reunanen A, Tuomilehto J, Tajima N, Diabetes Epidemiology Research International Mortality Study Group: Long-term mortality in nationwide cohorts of childhood-onset type 1 diabetes in Japan and Finland. Diabetes Care 2003; 26: 2037-2042.","1型糖尿病の死亡率を日本およびフィンランドで比較するとともに,性別,診断時年齢,診断時期の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12832309","http://diabetes.ebm-library.jp/trial/detail/50609" "DERIS","Diabetes Epidemiology Research International Study","Morimoto A, Nishimura R, Matsudaira T, Sano H, Tajima N, Diabetes Epidemiology Research International Study Group: Is pubertal onset a risk factor for blindness and renal replacement therapy in childhood-onset type 1 diabetes in Japan? Diabetes Care 2007; 30: 2338-2340.","失明および腎代替療法のリスクを1型糖尿病の発症時期により比較した。","https://www.ncbi.nlm.nih.gov/pubmed/17575091","http://diabetes.ebm-library.jp/trial/detail/51092" "Derosa G, et al.","-","Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R: Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther. 2003; 25: 472-84.","2型糖尿病患者において,repaglinideとglimepirideの血糖コントロール,リポ蛋白a,プラスミノーゲン活性化因子-1,ホモシステインに対する効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/12749508","http://diabetes.ebm-library.jp/trial/detail/51227" "DESIR","Data from an Epidemiological Study on the Insulin Resistance Syndrome","Droumaguet C, Balkau B, Simon D, Caces E, Tichet J, Charles MA, Eschwege E, DESIR Study Group: Use of HbA1c in predicting progression to diabetes in French men and women: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care 2006; 29: 1619-1625.","HbA1c値および空腹時血漿ブドウ糖値の糖尿病予測能を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/16801588","http://diabetes.ebm-library.jp/trial/detail/50959" "DESMOND","the Diabetes Education and Self Management for Ongoing and Newly Diagnosed","Davies MJ, Heller S, Skinner TC, Campbell MJ, Carey ME, Cradock S, Dallosso HM, Daly H, Doherty Y, Eaton S, et al.: Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ 2008; 336: 491-495.","新規2型糖尿病患者において,構造化されたグループ教育プログラムが生物医学的因子,心理社会的因子,生活習慣関連因子に及ぼす効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18276664","http://diabetes.ebm-library.jp/trial/detail/51051" "DETAIL","the Diabetics Exposed to Telmisartan and Enalapril Study","Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961.","早期腎症を有する2型糖尿病患者において,telmisartanおよびenalaprilの腎保護効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/15516696","http://diabetes.ebm-library.jp/trial/detail/50686" "Detemir in Pregnancy Study","-","Mathiesen ER, Hod M, Ivanisevic M, Duran Garcia S, Brndsted L, Jovanovic L, Damm P, McCance DR; Detemir in Pregnancy Study Group: Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care. 2012; 35: 2012-7.","1型糖尿病の妊婦において,インスリンdetemirとNPHインスリンの有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/22851598","http://diabetes.ebm-library.jp/trial/detail/51319" "DEVOTE","Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events","Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017; 377: 723-32.","心血管イベントのリスクが高い2型糖尿病患者において,degludecとglargineの心血管に関する安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/28605603","http://diabetes.ebm-library.jp/trial/detail/51675" "DHS","Dallas Heart Study","Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA: Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012; 308: 1150-9.","成人の肥満患者において,肥満の表現型と前糖尿病および2型糖尿病発症リスクの相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22990274","http://diabetes.ebm-library.jp/trial/detail/51272" "DIA-AID 1","-","Raz I, Ziegler AG, Linn T, Schernthaner G, Bonnici F, Distiller LA, Giordano C, Giorgino F, de Vries L, Mauricio D, et al.; DIA-AID 1 Writing Group: Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial. Diabetes Care. 2014; 37: 1392-400.","1型糖尿病患者のβ細胞機能維持におけるDiaPep277の安全性と有効性を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/24757230","http://diabetes.ebm-library.jp/trial/detail/51397 " "DiabeDES","Randomized Diabetes and Drug-Eluting Stent Intravascular Ultrasound Trial","Jensen LO, Maeng M, Thayssen P, Christiansen EH, Hansen KN, Galloe A, Kelbaek H, Lassen JF, Thuesen L: Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: the Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial. Eur Heart J. 2008; 29: 2733-41.","糖尿病患者において,sirolimus溶出ステントとpaclitaxel溶出ステントの新生内膜過形成の程度および分布を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/18832385","http://diabetes.ebm-library.jp/trial/detail/51177" "Diabetes & Aging Study","-","Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, Karter AJ. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2019; 42: 416-6.","新たに2型糖尿病と診断された患者において,糖尿病合併症と死亡に対する早期の血糖コントロールの遺産効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30104301","http://diabetes.ebm-library.jp/trial/detail/51753" "DIABETES","the Diabetes and Sirolimus-Eluting Stent Trial","Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Gomez-Hospital JA, Alfonso F, Hernandez-Antolin R, Goicolea J, Banuelos C, Escaned J, Moreno R, et al: Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005; 112: 2175-2183.","新規冠動脈病変を有する糖尿病患者において,sirolimus溶出ステントと標準ステントの再狭窄予防効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/16203930","http://diabetes.ebm-library.jp/trial/detail/50813" "DIABETES","DIABETes and sirolimus Eluting Stent","Jimenez-Quevedo P, Sabate M, Angiolillo DJ, Alfonso F, Hernandez-Antolin R, SanMartin M, Gomez-Hospital JA, Banuelos C, Escaned J, Moreno R, et al.: Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J 2007; 28: 1946-1952.","糖尿病患者において,sirolimus溶出ステントの長期的な安全性および有効性をベアメタルステントと比較した。DIABETESの2年間の追跡結果。","https://www.ncbi.nlm.nih.gov/pubmed/17562666","http://diabetes.ebm-library.jp/trial/detail/51077" "Diabetes and Aging Study","-","Katon W, Lyles CR, Parker MM, Karter AJ, Huang ES, Whitmer RA: Association of depression with increased risk of dementia in patients with type 2 diabetes: the Diabetes and Aging Study. Arch Gen Psychiatry. 2012; 69: 410-7.","2型糖尿病患者において,うつ病の併発により認知症リスクが上昇するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22147809","http://diabetes.ebm-library.jp/trial/detail/51298" "Diabetes Surgery Study","-","Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, Thomas AJ, Leslie DB, Chong K, Jeffery RW, et al.: Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013; 309: 2240-9.","標準的な薬物治療で血糖コントロール不良の2型糖尿病患者を対象に,Roux-en-Y胃バイパス手術と生活習慣改善+薬物療法における合併症発症リスク因子のコントロール達成度を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/23736733","http://diabetes.ebm-library.jp/trial/detail/51356" "Diabetes Surgery Study","-","Ikramuddin S, Korner J, Lee WJ, Thomas AJ, Connett JE, Bantle JP, Leslie DB, Wang Q, Inabnet WB 3rd, Jeffery RW, Chong K, Chuang LM, Jensen MD, Vella A, Ahmed L, Belani K, Billington CJ. Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study. JAMA. 2018; 319: 266-78.","強化生活習慣介入+薬物療法を行っているコントロール不良の肥満2型糖尿病患者において,ルーワイ胃バイパス術の施行による糖尿病の治療目標達成の持続性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29340678","http://diabetes.ebm-library.jp/trial/detail/51707" "Diabetic Ulcer Study","-","Steed DL: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 1995; 21: 71-81.","糖尿病性慢性下腿潰瘍に対する,組み換えヒト血小板由来成長因子の効果と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/7823364","http://diabetes.ebm-library.jp/trial/detail/50269" "DIABHYCAR","type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril study","Vaur L, Gueret P, Lievre M, Chabaud S, Passa P: Development of Congestive Heart Failure in Type 2 Diabetic Patients With Microalbuminuria or Proteinuria: Observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care 2003; 26: 855-860.","尿中アルブミン値に異常を認める2型糖尿病患者において,うっ血性心不全発症のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12610049","http://diabetes.ebm-library.jp/trial/detail/50579" "DIABHYCAR","type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril study","Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J, DIABHYCAR Study Investigators: Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004; 328: 495-500.","微量アルブミン尿または蛋白尿を認める2型糖尿病患者において,低用量ramiprilの心血管イベントおよび腎イベントに対する有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14960504","http://diabetes.ebm-library.jp/trial/detail/50632" "DIABIOPSIES","-","Cordonnier DJ, Pinel N, Barro C, Maynard M, Zaoui P, Halimi S, de Ligny BH, Reznic Y, Simon D, Bilous RW: Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. J Am Soc Nephrol 1999; 10: 1253-1263.","2型糖尿病患者に対するperindoprilの腎症進展抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10361863","http://diabetes.ebm-library.jp/trial/detail/50264" "DIABRASPORT","−","Franc S, Daoudi A, Pochat A, Petit MH, Randazzo C, Petit C, Duclos M, Penfornis A, Pussard E, Not D, et al.: Insulin-based strategies to prevent hypoglycaemia during and after exercise in adult patients with type 1 diabetes on pump therapy: the DIABRASPORT randomized study. Diabetes Obes Metab. 2015; 17: 1150-7.","インスリンポンプ療法下の成人1型糖尿病患者において,運動誘発性低血糖を予防するためにインスリン用量調節による治療法が有効かを検証した。","https://www.ncbi.nlm.nih.gov/pubmed/26264812","http://diabetes.ebm-library.jp/trial/detail/51550" "DIACAN","the Diabetic Cardiovascular Autonomic Neuropathy study","Ziegler D, Gries FA, Muhlen H, Rathmann W, Spuler M, Lessmann F: Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. The Diacan Multicenter Study Group. Diabete Metab 1993; 19: 143-151.","糖尿病患者における心血管系糖尿病性自律神経障害と末梢神経障害の罹患率と,その関連因子を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/8314418","http://diabetes.ebm-library.jp/trial/detail/50063" "DIAD","the Detection of Ischemia in Asymptomatic Diabetics study","Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Heller GV, Filipchuk N, et al: Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004; 27: 1954-1961.","無症候性2型糖尿病患者において,無症候性心筋虚血の罹患率および予測因子を検討するとともに,米国糖尿病学会のガイドラインの有用性を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/15277423","http://diabetes.ebm-library.jp/trial/detail/50652" "DIAD","the Detection of Ischemia in Asymptomatic Diabetics study","Wackers FJ, Chyun DA, Young LH, Heller GV, Iskandrian AE, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Filipchuk N, et al.: Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Diabetes Care 2007; 30: 2892-2898.","2型糖尿病患者において,無症候性心筋虚血の有病率の変化を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17682123","http://diabetes.ebm-library.jp/trial/detail/51031" "DIAD","the Detection of Ischemia in Asymptomatic Diabetics study","Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, et al.; DIAD Investigators: Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009; 301: 1547-55.","2型糖尿病患者において,冠動脈疾患のスクリーニングにより,心アウトカムが減少するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19366774","http://diabetes.ebm-library.jp/trial/detail/51138" "DIAD-BAR Substudy","the Detection of Ischemia in Asymptomatic Diabetics-Brachial Artery Reactivity Study","Papaioannou GI, Seip RL, Grey NJ, Katten D, Taylor A, Inzucchi SE, Young LH, Chyun DA, Davey JA, Wackers FJ, et al: Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study). Am J Cardiol 2004; 94: 294-299.","無症候性2型糖尿病患者において,微量アルブミン尿と血管反応性障害(上腕動脈の内皮依存性・非依存性の血管拡張障害)の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15276091","http://diabetes.ebm-library.jp/trial/detail/50668" "Diamant M, et al.","-","Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, de Vries D, Hoogwerf BJ, MacConell L, Wolffenbuttel BH; 4B Study Group: Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care. 2014; 37: 2763-73.","glargineおよびmetformin投与下で血糖コントロールが不適切な患者において,exenatideあるいはインスリンlisproの有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/25011946","http://diabetes.ebm-library.jp/trial/detail/51428" "DIAMOND","-","Beck RW, Riddlesworth TD, Ruedy KJ, Kollman C, Ahmann AJ, Bergenstal RM, Bhargava A, Bode BW, Haller S, Kruger DF, McGill JB, Polonsky W, Price D, Toschi E; DIAMOND Study Group. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2017; 5: 700-8.","持続血糖モニタリング(CGM)を使用している成人1型糖尿病患者において,インスリン頻回注射(MDI)から持続的皮下インスリン注入(CSII)へ変更した際の血糖コントロール改善効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28711468","http://diabetes.ebm-library.jp/trial/detail/51658" "DIEP","the Diabetes In Early Pregnancy study","Jovanovic L, Knopp RH, Kim H, Cefalu WT, Zhu XD, Lee YJ, Simpson JL, Mills JL: Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancy: evidence for a protective adaptation in diabetes. Diabetes Care 2005; 28: 1113-1117.","1型糖尿病合併妊娠および正常妊娠において,血糖値と流産との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15855575","http://diabetes.ebm-library.jp/trial/detail/50747" "DIGAMI","the Diabetes mellitus,Insulin Glucose infusion in Acute Myocardial Infarction study","Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314: 1512-1515.","急性心筋梗塞を発症した糖尿病患者では,インスリン-グルコース点滴とインスリン反復投与が予後を改善するという仮説を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/9169397","http://diabetes.ebm-library.jp/trial/detail/50056" "DIGAMI 2","the Diabetes mellitus,Insulin Glucose infusion in Acute Myocardial Infarction study","Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, et al.: Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26: 650-661.","急性心筋梗塞を発症した糖尿病患者において,インスリンを用いた3種類の血糖コントロールの全死亡に対する効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15728645","http://diabetes.ebm-library.jp/trial/detail/50769" "DIGAMI 2","Diabetes mellitus,Insulin Glucose infusion in Acute Myocardial Infarction study","Mellbin LG, Malmberg K, Norhammar A, Wedel H, Rydn L; DIGAMI 2 Investigators: The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J. 2008; 29: 166-76.","急性心筋梗塞を発症後退院した2型糖尿病患者において,退院時の血糖降下療法と長期予後の関係を検討した。DIGAMI 2のサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18156614","http://diabetes.ebm-library.jp/trial/detail/51118" "DIPOM","the Diabetes Postoperative Mortality and Morbidity trial","Juul AB, Wetterslev J, Gluud C, Kofoed-Enevoldsen A, Jensen G, Callesen T, Norgaard P, Fruergaard K, Bestle M, Vedelsdal R, et al.: Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. BMJ 2006; 332: 1482.","主要な非心臓手術を施行された糖尿病患者において,周術期におけるβ遮断薬投与が死亡および心疾患に及ぼす長期効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16793810","http://diabetes.ebm-library.jp/trial/detail/50833" "DIRECT","Dietary Intervention Randomized Controlled Trial","Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, et al.; Dietary Intervention Randomized Controlled Trial (DIRECT) Group: Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008; 359: 229-41.","中程度の肥満者かつ2型糖尿病を有する/有さない患者において,低脂肪食,地中海食,または低炭水化物食の減量効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/18635428","http://diabetes.ebm-library.jp/trial/detail/51359" "DIRECT","Dietary Intervention Randomized Controlled Trial","Tirosh A, Golan R, Harman-Boehm I, Henkin Y, Schwarzfuchs D, Rudich A, Kovsan J, Fiedler GM, Blher M, Stumvoll M, et al.: Renal function following three distinct weight loss dietary strategies during 2 years of a randomized controlled trial. Diabetes Care. 2013; 36: 2225-32.","軽度〜中等度の腎機能障害を伴う過体重/肥満,2型糖尿病を有する/有さない患者において,低脂肪食,地中海食,または低炭水化物食による3つの異なる食事が腎機能に与える影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23690533","http://diabetes.ebm-library.jp/trial/detail/51350" "DiRECT","Diabetes Remission Clinical Trial","Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Stefanetti R, Trenell M, Welsh P, Kean S, Ford I, McConnachie A, Sattar N, Taylor R. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2017 Dec 4. pii: S0140-6736(17)33102-1. ","プライマリケアの場において,集中的な体重管理が2型糖尿病の寛解をもたらすかどうかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29221645","http://diabetes.ebm-library.jp/trial/detail/51697" "DIRECT-Prevent 1/DIRECT-Protect 1","DIabetic REtinopathy Candesartan Trials","Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjolie AK, DIRECT Programme Study Group: Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394-1402.","1型糖尿病患者において,candesartanの網膜症の発症率減少効果および進展抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18823656","http://diabetes.ebm-library.jp/trial/detail/51081" "DIRECT-Protect 2","DIabetic REtinopathy Candesartan Trials","Sjolie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N, DIRECT Programme Study Group: Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008; 372: 1385-1393.","2型糖尿病患者において,candesartanの網膜症進展抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18823658","http://diabetes.ebm-library.jp/trial/detail/51082" "DIRECT-Renal","Diabetic Retinopathy Candesartan Trials","Bilous R, Chaturvedi N, Sjlie AK, Fuller J, Klein R, Orchard T, Porta M, Parving HH: Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med. 2009; 151: 11-20, W3-4.","1型および2型糖尿病患者において,candesartanの微量アルブミン尿および尿中アルブミン排泄率に対する効果を検討した。DIRECT-Prevent 1,DIRECT-Protect 1,DIRECT-Protect 2の統合解析。","https://www.ncbi.nlm.nih.gov/pubmed/19451554","http://diabetes.ebm-library.jp/trial/detail/51125" "DIS","the Diabetes Intervention Study","Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583.","新たにNIDDMと診断された患者の冠動脈心疾患と全死亡のリスク因子を分析した。","https://www.ncbi.nlm.nih.gov/pubmed/8960845","http://diabetes.ebm-library.jp/trial/detail/50097" "DiSC","the Diabetes Stages of Change study","Jones H, Edwards L, Vallis TM, Ruggiero L, Rossi SR, Rossi JS, Greene G, Prochaska JO, Zinman B, Diabetes Stages of Change (DiSC) Study: Changes in diabetes self-care behaviors make a difference in glycemic control: the Diabetes Stages of Change (DiSC) study. Diabetes Care 2003; 26: 732-737.","糖尿病患者において,通常の治療と至適セルフケア誘導プログラムのいずれが,より積極的な生活習慣の改善を促すことができるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12610030","http://diabetes.ebm-library.jp/trial/detail/50581" "DIVINe","Diabetic Intervention with Vitamins to Improve Nephropathy trial","House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD: Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA. 2010; 303: 1603-9.","腎症を有する1型および2型糖尿病患者において,ビタミンB治療が腎症の進展を抑制し,血管合併症を予防するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20424250","http://diabetes.ebm-library.jp/trial/detail/51170" "Douros A, et al.","-","Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ. 2018 Jul 18;362:k2693.","2型糖尿病患者において,metformin後のスルホニル尿素薬使用により,metformin継続に比べて心血管イベントおよび重度低血糖のリスクが上昇するか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30021781","http://diabetes.ebm-library.jp/trial/detail/51731" "DPP","the Diabetes Prevention Program","Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.","2型糖尿病発症の高リスク者で,ライフスタイル介入プログラムあるいはmetformin投与による発症抑制効果を比較検討し,その効果が年齢,性別,人種または民族により異なるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11832527","http://diabetes.ebm-library.jp/trial/detail/50502" "DPP","the Diabetes Prevention Program","Hernan WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, Lachin JM, Engelgau MM, The Diabetes Prevention Program Research Group: Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 2003; 26: 36-47.","metformin投与またはライフスタイル介入プログラムによる2型糖尿病の一次予防に要する費用を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12502656","http://diabetes.ebm-library.jp/trial/detail/50575" "DPP","the Diabetes Prevention Program","Diabetes Prevention Program Research Group: Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003; 26: 977-980.","耐糖能異常患者において,metformin投与の中止が糖尿病発症リスクに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12663559","http://diabetes.ebm-library.jp/trial/detail/50587" "DPP","the Diabetes Prevention Program","Diabetes Prevention Program Research Group: Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003; 26: 2518-2523.","ライフスタイル介入プログラムまたはmetformin投与による2型糖尿病発症予防の費用対効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12941712","http://diabetes.ebm-library.jp/trial/detail/50618" "DPP","the Diabetes Prevention Program","Wing RR, Hamman RF, Bray GA, Delahanty L, Edelstein SL, Hill JO, Horton ES, Hoskin MA, Kriska A, Lachin J, et al.: Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obes Res 2004; 12: 1426-1434.","減量および目標運動量の達成と相関を示す人口統計学的因子,心理社会的因子,行動的因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15483207","http://diabetes.ebm-library.jp/trial/detail/50721" "DPP","Diabetes Prevention Program","Diabetes Prevention Program Research Group: Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program. Diabetes Care 2005; 28: 138-144.","2型糖尿病発症の高リスク例のスクリーニングにおいて,その検出力はリスク因子によりどのような影響を受けるのか,また毛細管血糖高値例を事前に選別することにより検出力はどの程度増強されるのかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15616247","http://diabetes.ebm-library.jp/trial/detail/50718" "DPP","the Diabetes Prevention Program","Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, Temprosa M, Diabetes Prevention Program Research Group: Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005; 28: 888-894.","耐糖能異常患者において,ライフスタイル介入プログラムまたはmetformin投与による心血管疾患のリスク因子修正効果および発症抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15793191","http://diabetes.ebm-library.jp/trial/detail/50737" "DPP","the Diabetes Prevention Program","Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, Diabetes Prevention Program Research Group: The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142: 611-619.","耐糖能異常患者におけるメタボリックシンドロームの有病率を検討し,ライフスタイル介入またはmetformin投与によりメタボリックシンドロームの新規発症抑制効果または有病者の正常化効果が認められるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15838067","http://diabetes.ebm-library.jp/trial/detail/50736" "DPP","the Diabetes Prevention Program","Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE, Diabetes Prevention Program Research Group: Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54: 1150-1156.","2型糖尿病発症の高リスク例において,troglitazoneの発症抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15793255","http://diabetes.ebm-library.jp/trial/detail/50744" "DPP","Diabetes Prevention Program","Rubin RR, Knowler WC, Ma Y, Marrero DG, Edelstein SL, Walker EA, Garfield SA, Fisher EB, Diabetes Prevention Program Research Group: Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants. Diabetes Care 2005; 28: 830-837.","2型糖尿病発症の高リスク例において,抑うつ症の有病率の変化を検討するとともに,糖尿病治療,人口統計学的因子,体重および運動量の変化との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15793181","http://diabetes.ebm-library.jp/trial/detail/50738" "DPP","the Diabetes Prevention Program","Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, Marcovina S, Mather K, Orchard T, Ratner R, et al: Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54: 1566-1572.","耐糖能異常患者において,ライフスタイル介入プログラムおよびmetformin投与が炎症性マーカーおよび凝固マーカーに及ぼす効果,ならびにそれらのマーカーの変化に関与する因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15855347","http://diabetes.ebm-library.jp/trial/detail/50746" "DPP","the Diabetes Prevention Program","Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, Andres R, Saudek C, Edelstein SL, Arakaki R, et al.: Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005; 54: 2404-2414.","耐糖能異常を有する患者において,ベースラインおよび治療後のインスリン抵抗性およびβ細胞機能と2型糖尿病との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16046308","http://diabetes.ebm-library.jp/trial/detail/50800" "DPP","the Diabetes Prevention Program","Brown JS, Wing R, Barrett-Connor E, Nyberg LM, Kusek JW, Orchard TJ, Ma Y, Vittinghoff E, Kanaya AM, Diabetes Prevention Program Research Group: Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program. Diabetes Care 2006; 29: 385-390.","糖尿病リスクの高い過体重の女性において,ライフスタイル介入プログラムまたはmetformin投与により尿失禁リスクが軽減するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16443892","http://diabetes.ebm-library.jp/trial/detail/50821" "DPP","the Diabetes Prevention Program","Carnethon MR, Prineas RJ, Temprosa M, Zhang ZM, Uwaifo G, Molitch ME, Diabetes Prevention Program Research Group: The association among autonomic nervous system function, incident diabetes, and intervention arm in the diabetes prevention program. Diabetes Care 2006; 29: 914-919.","ライフスタイル介入プログラムまたはmetformin投与による自律神経機能改善効果を検討し,自律神経機能のベースライン値およびその変化と糖尿病発症リスクとの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16567837","http://diabetes.ebm-library.jp/trial/detail/50825" "DPP","the Diabetes Prevention Program","Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, et al.: Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006; 29: 2102-2107.","ライフスタイル介入プログラムによる体重,食事,運動量の変化が糖尿病発症リスクに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16936160","http://diabetes.ebm-library.jp/trial/detail/50955" "DPP","the Diabetes Prevention Program","Walker EA, Molitch M, Kramer MK, Kahn S, Ma Y, Edelstein S, Smith K, Johnson MK, Kitabchi A, Crandall J: Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 2006; 29: 1997-2002.","DPPのデータを用いて,薬物療法の遵守状況に関与する因子ならびに遵守状況とアウトカムの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16936143","http://diabetes.ebm-library.jp/trial/detail/50973" "DPP","the Diabetes Prevention Program","Lachin JM, Christophi CA, Edelstein SL, Ehrmann DA, Hamman RF, Kahn SE, Knowler WC, Nathan DM, DDK Research Group: Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes 2007; 56: 1153-1159.","耐糖能異常例において,metformin治療による2型糖尿病発症リスクの低下に関与する因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17395752","http://diabetes.ebm-library.jp/trial/detail/50997" "DPP","Diabetes Prevention Program","Fujimoto WY, Jablonski KA, Bray GA, Kriska A, Barrett-Connor E, Haffner S, Hanson R, Hill JO, Hubbard V, Stamm E, et al.: Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes 2007; 56: 1680-1685.","治療開始後1年間におけるボディサイズおよび体幹部脂肪の減少とその後の2型糖尿病発症リスクの低下との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17363740","http://diabetes.ebm-library.jp/trial/detail/51020" "DPP","Diabetes Prevention Program","Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE, Haffner SM, Price DW, Knowler WC, Diabetes Prevention Program Research Group: Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 2008; 31: 420-426.","DPP試験開始時および試験期間中のうつ症状または抗うつ薬使用と試験期間の糖尿病発症リスクとの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18071002","http://diabetes.ebm-library.jp/trial/detail/51110" "DPP","Diabetes Prevention Program","Perreault L, Ma Y, Dagogo-Jack S, Horton E, Marrero D, Crandall J, Barrett-Connor E; Diabetes Prevention Program: Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care. 2008; 31: 1416-21.","糖尿病リスク因子における性差を調査し,DPP試験で行われたライフスタイル介入の効果における性差を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18356403","http://diabetes.ebm-library.jp/trial/detail/51158" "DPP","Diabetes Prevention Program","Goldberg RB, Temprosa M, Haffner S, Orchard TJ, Ratner RE, Fowler SE, Mather K, Marcovina S, Saudek C, Matulik MJ, et al.; Diabetes Prevention Program Research Group: Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care. 2009; 32: 726-32.","耐糖能異常患者において,血糖値の変化が心血管疾患リスク因子に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19171717","http://diabetes.ebm-library.jp/trial/detail/51173" "DPP","Diabetes Prevention Program","Goldberg RB, Temprosa MG, Mather KJ, Orchard TJ, Kitabchi AE, Watson KE; Diabetes Prevention Program Research Group: Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care. 2014; 37: 2253-60.","DPP試験に参加した糖尿病発症の高リスク患者において,高感度C反応性タンパク質,組織プラスミノーゲン活性化因子,フィブリノゲンに対するmetforminまたは生活習慣介入の長期効果を検討し,これらのマーカーに対する糖尿病発症の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24824548","http://diabetes.ebm-library.jp/trial/detail/51421" "DPP","Diabetes Prevention Program","Sylvetsky AC, Edelstein SL, Walford G, Boyko EJ, Horton ES, Ibebuogu UN, Knowler WC, Montez MG, Temprosa M, Hoskin M, Rother KI, Delahanty LM; Diabetes Prevention Program Research Group. A High-Carbohydrate, High-Fiber, Low-Fat Diet Results in Weight Loss among Adults at High Risk of Type 2 Diabetes. J Nutr. 2017; 147: 2060-6.","2型糖尿病リスクの高い患者において,ベースラインの食事摂取量と体重の関連を評価し,減量の成功を予測する食事関連因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28954840","http://diabetes.ebm-library.jp/trial/detail/51703" "DPPOS","Diabetes Prevention Program Outcomes Study","Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti ENathan DM, ; Diabetes Prevention Program Research Group: 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009; 374: 1677-86.","2型糖尿病発症の高リスク例において認められたライフスタイル介入およびmetforminの糖尿病発症抑制効果が,長期的に認められるかを検討した。DPPの延長試験。","https://www.ncbi.nlm.nih.gov/pubmed/19878986","http://diabetes.ebm-library.jp/trial/detail/51147" "DPPOS","Diabetes Prevention Program (DPP) Outcomes Study","Diabetes Prevention Program Research Group: Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015; 3: 866-75.","DPP試験に参加した糖尿病発症の高リスク患者において,3年間で認められたライフスタイル介入およびmetforminの糖尿病発症予防効果は長期的に認められるかについて検討し,またこれらの介入は糖尿病性細小血管合併症を減少させるかについても検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26377054","http://diabetes.ebm-library.jp/trial/detail/51527" "DPS","the Diabetes Prevention Study","Eriksson J, Lindstrom J, Valle T, Aunola S, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Lauhkonen M, Lehto P, Lehtonen A, Louheranta A, Mannelin M, Martikkala V, Rastas M, Sundvall J, Turpeinen A, Viljanen T, Uusitupa M, Tuomilehto J: Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 1999; 42: 793-801.","IGT患者において,2型糖尿病の発症予防・遅延のための集中的食事運動療法が心血管リスク因子に与える影響を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/10440120","http://diabetes.ebm-library.jp/trial/detail/50256" "DPS","the Finnish Diabetes Prevention Study","Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.","耐糖能異常患者において,生活習慣改善プログラムの2型糖尿病発症抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11333990","http://diabetes.ebm-library.jp/trial/detail/50541" "DPS","the Finnish Diabetes Prevention Study","Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, Uusitupa M, Tuomilehto J, Finnish Diabetes Prevention Study Group: The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003; 26: 3230-3236.","耐糖能異常患者における生活習慣改善プログラムが,食事および運動習慣に及ぼす短期的・長期的変化を追跡し,血糖値および脂質代謝に対する有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14633807","http://diabetes.ebm-library.jp/trial/detail/50625" "DPS","the Finnish Diabetes Prevention Study","Laaksonen DE, Lindstrom J, Lakka TA, Eriksson JG, Niskanen L, Wikstrom K, Aunola S, Keinanen-Kiukaanniemi S, Laakso M, Valle TT, et al: Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes 2005; 54: 158-165.","耐糖能異常患者において,余暇の身体活動による2型糖尿病発症抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15616024","http://diabetes.ebm-library.jp/trial/detail/50714" "DPS","the Finnish Diabetes Prevention Stud","Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M, et al.: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673-1679.","2型糖尿病発症の高リスク例において,強力な生活習慣改善プログラムにより得られた生活習慣の変化および2型糖尿病発症リスクの低下が介入終了後も維持されているかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17098085","http://diabetes.ebm-library.jp/trial/detail/50966" "DPT-1","Diabetes Prevention Trial-Type 1 Diabetes study","Diabetes Prevention Trial-Type 1 Diabetes Study Group: Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346: 1685-1691.","糖尿病患者の親族のうち,顕性糖尿病の5年発症リスクが≧50%の症例に対するインスリンの発症抑制または予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12037147","http://diabetes.ebm-library.jp/trial/detail/50524" "DPT-1","the Diabetes Prevention Trial-Type 1","Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E: Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care 2005; 28: 1068-1076.","糖尿病患者の親族のうち,糖尿病の5年発症リスクが26〜50%の症例に対する経口インスリンの発症抑制または予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15855569","http://diabetes.ebm-library.jp/trial/detail/50764" "DPT-1","the Diabetes Prevention Trial-Type 1 Diabetes","Rhodes ET, Wolfsdorf JI, Cuthbertson DD, Feldman HA, Ludwig DS, DPT-1 Study Group: Effect of low-dose insulin treatment on body weight and physical development in children and adolescents at risk for type 1 diabetes. Diabetes Care 2005; 28: 1948-1953.","1型糖尿病高リスクの小児および青年において,非経口低用量インスリン治療による体重増加および身体発育への影響を検討した。DPT-1試験の二次解析。","https://www.ncbi.nlm.nih.gov/pubmed/16043737","http://diabetes.ebm-library.jp/trial/detail/50787" "DPT-1","Diabetes Prevention Trial-Type 1","Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Mahon J, Greenbaum CJ, Cowie CC, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group: Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1. Diabetes Care. 2009; 32: 1603-7.","膵島細胞自己抗体陽性の正常耐糖能例において,血糖異常の発生率および1型糖尿病発症の予測因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19487644","http://diabetes.ebm-library.jp/trial/detail/51287" "Draeger KE, et al.","-","Draeger KE, Wernicke-Panten K, Lomp HJ, Schuler E, Rosskamp R: Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res 1996; 28: 419-425.","2型糖尿病患者に対するglimepirideの長期治療効果をglibenclamideと比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8911976","http://diabetes.ebm-library.jp/trial/detail/50258" "DREAM","the Diabetes REduction Assessment with ramipril and rosiglitazone Medication trial","DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, , Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-1105.","空腹時血糖異常症例または耐糖能異常症例において,rosiglitazoneの2型糖尿病発症予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16997664","http://diabetes.ebm-library.jp/trial/detail/50837" "DREAM","the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication trial","DREAM Trial Investigators, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, et al.: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562.","空腹時血糖異常症例または耐糖能異常症例において,ramiprilの糖尿病発症予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16980380","http://diabetes.ebm-library.jp/trial/detail/50836" "DREAM","the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication trial","DREAM Trial Investigators, , Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, et al.: Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008; 31: 1007-1014.","空腹時血糖異常症例または耐糖能異常症例において,ramiprilおよびrosiglitazoneの心血管疾患または腎イベントリスク低減効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18268075","http://diabetes.ebm-library.jp/trial/detail/51115" "DREAM","the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication trial","McDonald SD, Yusuf S, Sheridan P, Anand SS, Gerstein HC; Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Trial Investigators: Dysglycemia and a history of reproductive risk factors. Diabetes Care. 2008; 31: 1635-8.","多民族の女性において,血糖異常の生殖リスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18458144","http://diabetes.ebm-library.jp/trial/detail/51143" "Driessen JHM, et al.","-","Driessen JH, van den Bergh JP, van Onzenoort HA, Henry RM, Leufkens HG, de Vries F. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study. Diabetes Obes Metab. 2017; 19: 421-428.","2型糖尿病患者において,DPP-4阻害薬の長期使用と骨折リスクの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27943565","http://diabetes.ebm-library.jp/trial/detail/51621" "DUAL VI trial","-","Harris SB, et al. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes Metab. 2017; 19: 858-65.","インスリン投与歴のない2型糖尿病患者において,インスリンdegludec/liraglutideの簡便な用量調節アルゴリズムの安全性と有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28124817","http://diabetes.ebm-library.jp/trial/detail/51667" "DURABLE","DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy trial","Buse JB, Wolffenbuttel BH, Herman WH, Shemonsky NK, Jiang HH, Fahrbach JL, Scism-Bacon JL, Martin SA: DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care. 2009; 32: 1007-13.","経口血糖降下薬投与下の2型糖尿病患者において,混合型インスリンlispro 25/75とインスリンglargineの安全性および有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/19336625","http://diabetes.ebm-library.jp/trial/detail/51183" "DURATION-1","-","Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L, DURATION-1 Study Group: Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.","2型糖尿病患者において,exenatide週1回皮下注射と1日2回皮下注射の有効性および安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/18782641","http://diabetes.ebm-library.jp/trial/detail/51091" "DURATION-3","-","Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M: Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010; 375: 2234-43.","最大耐用量の血糖降下薬治療で血糖コントロール不良の2型糖尿病患者において,exenatide週1回注射とインスリンglargineを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/20609969","http://diabetes.ebm-library.jp/trial/detail/51193" "DURATION-6","-","Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, Hoogwerf BJ, Gao A, Boardman MK, Fineman M, et al.: Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013; 381: 117-24.","2型糖尿病患者において,exenatide週1回注射とliraglutideの有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/23141817","http://diabetes.ebm-library.jp/trial/detail/51296" "DURATION-8","−","Fras JP, Guja C, Hardy E, Ahmed A, Dong F, hman P, Jabbour SA. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016; 4: 1004-1016. ","metforminでコントロール不良の2型糖尿病患者において,GLP-1受容体作動薬exenatide+SGLT2阻害薬dapagliflozin併用による有効性と安全性を,exenatide単独またはdapagliflozin単独と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/27651331","http://diabetes.ebm-library.jp/trial/detail/51605" "Dutch and German Repaglinide Study","-","Wolffenbuttel BH, Landgraf R: A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999; 22: 463-467.","2型糖尿病患者において,repaglinideおよびglyburideの有効性と安全性を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10097930","http://diabetes.ebm-library.jp/trial/detail/50515" "Dutour A, et al.","-","Dutour A, Abdesselam I, Ancel P, Kober F, Mrad G, Darmon P, Ronsin O, Pradel V, Lesavre N, Martin JC, Jacquier A, Lefur Y, Bernard M, Gaborit B: Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab. 2016; 18: 882-91.","肥満の2型糖尿病患者において,異所性脂肪蓄積に対するexenatideの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27106272","http://diabetes.ebm-library.jp/trial/detail/51592" "ECASS-II","the second European Cooperative Acute Stroke Study","Yong M, Kaste M: Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke. 2008; 39: 2749-55.","急性虚血性半球脳卒中患者において,脳卒中発症後24時間以内の血糖変動を解析し,アウトカムとの関連を検討した。ECASS-II試験のサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18703813","http://diabetes.ebm-library.jp/trial/detail/51131" "EDC","Pittsburgh Epidemiology of Diabetes Complications Study","Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ: The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006; 55: 1463-1469.","1型糖尿病の合併症の30年間にわたる自然史を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16644706","http://diabetes.ebm-library.jp/trial/detail/50941" "EDC","Epidemiology of Diabetes Complications study","Costacou T, Orchard TJ: Differential effect of glycemia on the incidence of hypertension by sex: the epidemiology of diabetes complications study. Diabetes Care. 2013; 36: 77-83.","小児期発症1型糖尿病患者において,HbA1cと強化血糖コントロール,高血圧発症との関連,およびその性差を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22966097","http://diabetes.ebm-library.jp/trial/detail/51322" "EDIC","the Epidemiology of Diabetes Interventions and Complications","Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group: Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes 1999; 48: 383-390.","1型糖尿病の頸動脈壁肥厚に対する強化インスリン療法の効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10334318","http://diabetes.ebm-library.jp/trial/detail/50190" "EDIC","the Epidemiology of Diabetes Interventions and Complications","Writing Team For The Diabetes Control And Complications Trial/Epidemiology Of Diabetes Interventions And Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159-2167.","1型糖尿病患者において,腎機能に対する強化療法と従来療法の長期効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/14570951","http://diabetes.ebm-library.jp/trial/detail/50616" "EDICTA","Estudio sobre diabetes y control de la Tension arterial","Ruilope LM, de la Sierra A, Moreno E, Fernandez R, Garrido J, de la Figuera M, de la Camara AG, Coca A, Luque-Otero M: Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomized trial: the EDICTA study. J Hypertens 1999; 17: 1917-1923.","高血圧を有し,降圧薬の単剤療法でコントロール不良の2型糖尿病患者において,trandolaprilとverapamilの併用療法および単剤療法の降圧効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10703890","http://diabetes.ebm-library.jp/trial/detail/50503" "EDIP","the Early Diabetes Intervention Program","Perry RC, Shankar RR, Fineberg N, McGill J, Baron AD, Early Diabetes Intervention Program (EDIP): HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnositc levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). Diabetes Care 2001; 24: 465-471.","FPGとHbA1cの組合わせが,2型糖尿病の診断感度を改善するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11289469","http://diabetes.ebm-library.jp/trial/detail/50385" "EDIP","the Early Diabetes Intervention Program","Kirkman MS, Shankar RR, Shankar S, Shen C, Brizendine E, Baron A, McGill J: Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program. Diabetes Care 2006; 29: 2095-2101.","早期2型糖尿病患者において,acarboseによる食後高血糖の改善が糖尿病の進行を予防または遅延させるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16936159","http://diabetes.ebm-library.jp/trial/detail/50971" "EDIT","the Early Diabetes Intervention Trial","Albers JW, Brown MB, Sima AA, Greene DA: Frequency of median mononeuropathy in patients with mild diabetic neuropathy in the early diabetes intervention trial (EDIT). Tolrestat Study Group For Edit (Early Diabetes Intervention Trial). Muscle Nerve 1996; 19: 140-146.","Tolrestat studyに参加した糖尿病患者における正中神経障害の相対リスクと手根管症候群発症リスク増加因子との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8559161","http://diabetes.ebm-library.jp/trial/detail/50280" "EDITION","-","Ritzel R, Roussel R, Giaccari A, Vora J, Brulle-Wohlhueter C, Yki-Jrvinen H. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab. 2018; 20: 541-8.","2型糖尿病患者における,glargine 300U/mLとglargin 100U/mLの有効性と安全性を,患者レベルのメタアナリシスにより評価した。","https://www.ncbi.nlm.nih.gov/pubmed/28862801","http://diabetes.ebm-library.jp/trial/detail/51715" "EDITION 2","−","Yki-Jrvinen H, Bergenstal RM, Bolli GB, Ziemen M, Wardecki M, Muehlen-Bartmer I, Maroccia M, Riddle MC: Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension. Diabetes Obes Metab. 2015; 17: 1142-9.","基礎インスリンおよび経口血糖降下薬投与下の2型糖尿病患者において,新たなインスリンglargine 300 U/mLと100U/mLの治療12ヵ月にわたる有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/26172084","http://diabetes.ebm-library.jp/trial/detail/51523" "EDITION 4","−","Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC: New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care. 2015; 38: 2217-25.","1型糖尿病患者において,インスリンglargine 300units/mLと100units/mLの有効性と忍容性を比較し,さらにそのアウトカムが投与のタイミングにより異なるか検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26084341","http://diabetes.ebm-library.jp/trial/detail/51542" "EDITION JP 1","−","Matsuhisa M, Koyama M, Cheng X, Takahashi Y, Riddle MC, Bolli GB, Hirose T; EDITION JP 1 study group: New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Diabetes Obes Metab. 2016; 18: 375-83.","日本人の成人1型糖尿病患者において,インスリンglargine 300 U/mLと100 U/mLの有効性と忍容性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/26662964","http://diabetes.ebm-library.jp/trial/detail/51566" "EHS-CR","the Euro Heart Survey on Coronary Revascularization","Breeman A, Bertrand ME, Ottervanger JP, Hoeks S, Lenzen M, Sechtem U, Legrand V, de Boer MJ, Wijns W, Boersma E: Diabetes does not influence treatment decisions regarding revascularization in patients with stable coronary artery disease. Diabetes Care 2006; 29: 2003-2011.","安定狭心症患者において,血行再建術に関する選択が糖尿病の有無に影響されるか否かを検討し,また糖尿病が予後に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16936144","http://diabetes.ebm-library.jp/trial/detail/50975" "Eliasson B, et al.","−","Eliasson B, et al. Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. Lancet Diabetes Endocrinol. 2015; 3: 847-54.","肥満の糖尿病患者において,肥満外科手術実施後の心血管リスクおよび全死亡リスクを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26429401","http://diabetes.ebm-library.jp/trial/detail/51528" "ELIXA","Evaluation of Lixisenatide in Acute Coronary Syndrome","Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kber LV, Lawson FC, Ping L, Wei X, Lewis EF, et al.; ELIXA Investigators: Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015; 373: 2247-57.","最近の急性冠動脈イベント既往を有する2型糖尿病患者において,GLP-1受容体作動薬lixisenatideが心血管アウトカムを抑制するか検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26630143","http://diabetes.ebm-library.jp/trial/detail/51538" "Elleri D, et al","−","Elleri D, Biagioni M, Allen JM, Kumareswaran K, Leelarathna L, Caldwell K, Nodale M, Wilinska ME, Haidar A, Calhoun P, et al.: Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial. Diabetes Obes Metab. 2015; 17: 1173-9.","10代の1型糖尿病患者において,食事のボーラスインスリンは患者自身がカーボカウントに従い注射するクローズドループ制御システム使用時のインスリンボーラス減量の安全性,有効性および糖代謝への影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26257323","http://diabetes.ebm-library.jp/trial/detail/51549" "Elliott RB, et al.","-","Elliott RB, Pilcher CC, Fergusson DM, Stewart AW: A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab 1996 ; 9: 501-509.","膵島細胞抗体テストとnicotinamide治療の小児IDDM発症予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8961125","http://diabetes.ebm-library.jp/trial/detail/50359" "ELSA-Brasil","Brazilian Longitudinal Study of Adult Health","Yarmolinsky J, Duncan BB, Chambless LE, Bensenor IM, Barreto SM, Goulart AC, Santos IS, Diniz Mde F, Schmidt MI: Artificially Sweetened Beverage Consumption Is Positively Associated with Newly Diagnosed Diabetes in Normal-Weight but Not in Overweight or Obese Brazilian Adults. J Nutr. 2016; 146: 290-7.","ブラジル人において,人工甘味料飲料摂取量と新規診断糖尿病およびグルコースホメオスタシスの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26661840","http://diabetes.ebm-library.jp/trial/detail/51561" "Emdin CA, et al.","−","Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A: Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015; 313: 603-15.","2型糖尿病患者において,降圧治療と血管疾患との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25668264","http://diabetes.ebm-library.jp/trial/detail/51449" "EMERALD","the Enhanced Myocardial Efficacy and Removal by Aspiration of Liberated Debris trial","Marso SP, Miller T, Rutherford BD, Gibbons RJ, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Mehran R, Krucoff MW, et al.: Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). Am J Cardiol 2007; 100: 206-210.","経皮的冠インターベンションを施行されたST上昇型急性心筋梗塞患者において,心筋血流,梗塞サイズ,予後を糖尿病の有無により比較した。","https://www.ncbi.nlm.nih.gov/pubmed/17631071","http://diabetes.ebm-library.jp/trial/detail/51037" "Emerging Risk Factors Collaboration","-","Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, et al.; Emerging Risk Factors Collaboration: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375: 2215-22.","糖尿病および空腹時血糖値と,冠動脈心疾患および脳卒中リスクとの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20609967","http://diabetes.ebm-library.jp/trial/detail/51194" "Emerging Risk Factors Collaboration","−","Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, Kaptoge S, Kondapally Seshasai SR, Thompson A, Sarwar N, Willeit P, et al.; Emerging Risk Factors Collaboration: Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014; 311: 1225-33.","糖尿病の既往のない中高年齢者において,従来の心血管危険因子にHbA1c値を加えた場合,心血管疾患初回発症の予測能が改善するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24668104","http://diabetes.ebm-library.jp/trial/detail/51470" "EMPA-REG BP","-","Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ; EMPA-REG BP Investigators: Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015; 38: 420-8.","高血圧を有する2型糖尿病患者において,empagliflozinの有効性,安全性,忍容性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25271206","http://diabetes.ebm-library.jp/trial/detail/51468" "EMPA-REG METSU trial","-","Hring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC; EMPA-REG METSU Trial Investigators: Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013; 36: 3396-404.","metformin+スルホニル尿素薬で血糖コントロール不良の2型糖尿病患者において,empagliflozin追加の有効性,安全性,忍容性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23963895","http://diabetes.ebm-library.jp/trial/detail/51369" "EMPA-REG OUTCOME","-","Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al.; EMPA-REG OUTCOME Investigators: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; ","心血管イベントのリスクが高く,かつ標準治療を受けている2型糖尿病患者において,empagliflozinとプラセボの心血管疾患の発症率および死亡率に対する影響を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/26378978","http://diabetes.ebm-library.jp/trial/detail/51506" "EMPA-REG OUTCOME","-","Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators: Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375: 323-334.","心血管イベント高リスクの2型糖尿病患者において,empagliflozinの腎臓に対する長期的作用を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27299675","http://diabetes.ebm-library.jp/trial/detail/51580" "EMPA-REG OUTCOME","-","Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017; 5: 610-21.","心血管リスクの高い2型糖尿病患者において,アルブミン尿に対するempagliflozinの短期的および長期的効果をベースラインのアルブミン尿レベル別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28666775","http://diabetes.ebm-library.jp/trial/detail/51650" "EMPA-REG OUTCOME","Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients","Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; EMPA-REG OUTCOME Investigators: Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 2018; 137: 119-29.","心血管疾患と腎症を有する2型糖尿病患者において,empagliflozinの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28904068","http://diabetes.ebm-library.jp/trial/detail/51705" "EMPIRE","-","Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ, Strow LJ: Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin 2005; 21: 2029-2035.","2型糖尿病患者において,最大用量以下のmetforimin+rosiglitazone併用投与と最大用量のmetformin単独投与の有効性,安全性,忍容性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/16368054","http://diabetes.ebm-library.jp/trial/detail/50801" "ENDIT","European Nicotinamide Diabetes Intervention Trial","Gale EA, Bingley PJ, Emmett CL, Collier T, European Nicotinamide Diabetes Intervention Trial (ENDIT) Group: European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004; 363: 925-931.","1型糖尿病患者の一親等親族において,高用量nicotinamide投与による1型糖尿病の発症予防または遅延効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15043959","http://diabetes.ebm-library.jp/trial/detail/50640" "ENDIT","European Nicotinamide Diabetes Intervention Trial","Bingley PJ, Mahon JL, Gale EA, European Nicotinamide Diabetes Intervention Trial Group: Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2008; 31: 146-150.","1型糖尿病発症の高リスク例において,インスリン抵抗性が1型糖尿病発症リスクの評価に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17959864","http://diabetes.ebm-library.jp/trial/detail/51043" "EPIC","European Prospective Investigation into Cancer and Nutrition","Grote VA, Rohrmann S, Nieters A, Dossus L, Tjnneland A, Halkjr J, Overvad K, Fagherazzi G, Boutron-Ruault MC, Morois S, et al.: Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia. 2011; 54: 3037-46.","膵がんと診断される前の血清HbA1cおよびCペプチドのレベルと膵がんリスクの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21953276","http://diabetes.ebm-library.jp/trial/detail/51224" "Epic-InterAct","European Prospective Investigation into Cancer and Nutrition InterAct ","van Nielen M, Feskens EJ, Mensink M, Sluijs I, Molina E, Amiano P, Ardanaz E, Balkau B, Beulens JW, Boeing H, et al.; InterAct Consortium: Dietary protein intake and incidence of type 2 diabetes in Europe: the EPIC-InterAct Case-Cohort Study. Diabetes Care. 2014; 37: 1854-62.","総タンパク質,動物性タンパク質,植物性タンパク質の各摂取量と,2型糖尿病の新規発症リスクとの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24722499","http://diabetes.ebm-library.jp/trial/detail/51414" "Epic-InterAct","European Prospective Investigation into Cancer and Nutrition InterAct ","Spijkerman AM, van der A DL, Nilsson PM, Ardanaz E, Gavrila D, Agudo A, Arriola L, Balkau B, Beulens JW, Boeing H, et al.; InterAct Consortium: Smoking and long-term risk of type 2 diabetes: the EPIC-InterAct study in European populations. Diabetes Care. 2014; 37: 3164-71.","喫煙と2型糖尿病発症リスクとの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25336749","http://diabetes.ebm-library.jp/trial/detail/51447" "EPIC-Postdam","European Prospective Investigation Into Cancer and Nutrition-Postdam Study","Ford ES, Schulze MB, Bergmann MM, Thamer C, Joost HG, Boeing H: Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care. 2008; 31: 1138-43.","GGTおよびALTと糖尿病発症の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18346992","http://diabetes.ebm-library.jp/trial/detail/51175" "Eppenga WL, et al.","-","Eppenga WL, Lalmohamed A, Geerts AF, Derijks HJ, Wensing M, Egberts A, De Smet PA, de Vries F: Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study. Diabetes Care. 2014; 37: 2218-24.","腎障害を有するmetformin使用の糖尿病患者において,乳酸アシドーシスまたは乳酸濃度上昇のリスクを検討し,metformin使用歴のない患者と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24842984","http://diabetes.ebm-library.jp/trial/detail/51420" "Eriksson JW, et al.","-","Eriksson JW, Bodegard J, Nathanson D, Thuresson M, Nystrm T, Norhammar A: Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Res Clin Pract. 2016; 117: 39-47.","2型糖尿病患者において,2次治療としてのmetformin+スルホニル尿素薬またはmetformin+DPP-4阻害薬の心血管疾患,全死亡,重度低血糖のリスクを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/27329021","http://diabetes.ebm-library.jp/trial/detail/51582" "Erqou S, et al.","-","Erqou S, Lee CC, Adler AI: Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2014; 57: 2444-52.","糖尿病患者において,血糖コントロールに対するスタチン治療の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25245638","http://diabetes.ebm-library.jp/trial/detail/51469" "ESC-HFA Heart Failure Long-Term Registry","European Society of Cardiology-Heart Failure Association Heart Failure Long-Term Registry"," Dauriz M, Targher G, Laroche C, Temporelli PL, Ferrari R, Anker S, Coats A, Filippatos G, Crespo-Leiro M, Mebazaa A, Piepoli MF, Maggioni AP, Tavazzi L; ESC-HFA Heart Failure Long-Term Registry. Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care. 2017; 40: 671-678.","慢性心不全患者において,糖尿病と1年間の有害アウトカムの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28255009","http://diabetes.ebm-library.jp/trial/detail/51642" "Esposito K, et al.","-","Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group; Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110:214-9.","2型糖尿病患者において,インスリン分泌促進剤repaglinideとglyburideの食後血糖値および内膜-中膜壁肥厚(CIMT)と全身性血管炎症に対する効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/15197140","http://diabetes.ebm-library.jp/trial/detail/51211" "ESPRIT","the European Study for the Prevention of Renal disease in Type 1 diabetes","The European Study for the Prevention of Renal Disease in Type 1 Diabetes Study Group.: Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT). Diabetes 2001; 50: 843-850.","アルブミン尿が認められる正常血圧の1型糖尿病患者において,enalaprilまたはnifedipineによる降圧療法の腎微細構造に及ぼす影響を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11289051","http://diabetes.ebm-library.jp/trial/detail/50387" "ESPRIT","the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy trial","Labinaz M, Madan M, O'Shea JO, Kilaru R, Chin W, Pieper K, McGuire DK, Saucedo JF, Talley JD, Lui H, Kitt MM, Califf RM, Tcheng JT; ESPRIT Investigators: Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial). Am J Cardiol 2002; 90: 585-590.","非緊急冠動脈ステント植込み術を施行された糖尿病および非糖尿病患者において,eptifibatideの虚血性合併症に対する効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12231081","http://diabetes.ebm-library.jp/trial/detail/50552" "ETDRS 8","the Early Treatment Diabetic Retinopathy Study","Early Treatment Diabetic Retinopathy Study Research Group.: Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Ophthalmology 1991; 98: 757-765.","aspirinが糖尿病網膜症に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/2062511","http://diabetes.ebm-library.jp/trial/detail/50131" "ETDRS 9","the Early Treatment Diabetic Retinopathy Study","Early Treatment Diabetic Retinopathy Study Research Group.: Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991; 98: 766-785.","糖尿病網膜症における網膜光凝固の開始時期,および黄斑浮腫に対する網膜光凝固の有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/2062512","http://diabetes.ebm-library.jp/trial/detail/50132" "ETDRS 12","the Early Treatment Diabetic Retinopathy Study","Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991; 98: 823-833.","増殖糖尿病網膜症への進展のリスク因子と糖尿病網膜症の病期分類を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/2062515","http://diabetes.ebm-library.jp/trial/detail/50133" "ETDRS 13","the Early Treatment Diabetic Retinopathy Study","Early Treatment Diabetic Retinopathy Study Research Group. Fluorescein angiographic risk factors for progression of diabetic retinopathy. ETDRS report number 13. Ophthalmology 1991; 98: 834-840.","糖尿病網膜症の増殖糖尿病網膜症への進展のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/2062516","http://diabetes.ebm-library.jp/trial/detail/50134" "ETDRS 17","the Early Treatment Diabetic Retinopathy Study","Flynn HW Jr, Chew EY, Simons BD, Barton FB, Remaley NA, Ferris FL 3d: Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1992; 99: 1351-1357.","硝子体手術施行に至る術前の状態,視力予後を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/1407968","http://diabetes.ebm-library.jp/trial/detail/50136" "ETDRS 18","the Early Treatment Diabetic Retinopathy Study","Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, Ferris FL 3rd, Knatterud GL: Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998; 39: 233-252.","高リスク増殖糖尿病網膜症への進展のリスク因子,高度視力障害もしくは硝子体手術への進展のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9477980","http://diabetes.ebm-library.jp/trial/detail/50101" "ETDRS 22","the Early Treatment Diabetic Retinopathy Study","Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, Hoogwerf BJ, Miller D: Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996; 114: 1079-1084.","空腹時血清脂質値と硬性白斑および視力の相関について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8790092","http://diabetes.ebm-library.jp/trial/detail/50049" "ETDRS 25","the Early Treatment Diabetic Retinopathy Study","Chew EY, Benson WE, Remaley NA, Lindley AA, Burton TC, Csaky K, Williams GA, Ferris FL 3rd: Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25. Arch Ophthalmol 1999; 117: 1600-1606.","白内障手術と視力予後との相関について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10604663","http://diabetes.ebm-library.jp/trial/detail/50053" "ETDRS 27","the Early Treatment Diabetic Retinopathy Study","Cusick M, Meleth AD, Agron E, Fisher MR, Reed GF, Knatterud GL, Barton FB, Davis MD, Ferris FL, Chew EY, et al: Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care 2005; 28: 617-625.","網膜症を有する糖尿病患者において,糖尿病性合併症と死亡の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15735198","http://diabetes.ebm-library.jp/trial/detail/50711" "EUCLID","the EURODIAB Controlled trial of Lisinopril in Insulin dependent Diabetes","The EUCLID Study Group.: Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.","糖尿病性腎症のIDDM患者に対するlisinoprilの腎保護作用を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9269212","http://diabetes.ebm-library.jp/trial/detail/50277" "EUCLID","the EURODIAB Controlled trial of Lisinopril in Insulin dependent Diabetes","Chaturvedi N, Fuller JH, Pokras F, Rottiers R, Papazoglou N, Aiello LP; EUCLID Study Group: Circulating plasma vascular endothelial growth factor and microvascularcomplications of type 1 diabetes mellitus: the influence of ACE inhibition. Diabet Med 2001; 18: 288-294.","主に正常アルブミン尿で正常血圧の1型糖尿病患者において,細小血管障害と血漿中VEGF濃度の関係と,細小血管障害に対するlisinopril投与による血漿中VEGF濃度の変化を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11437859","http://diabetes.ebm-library.jp/trial/detail/50470" "EUCLID","the EURODIAB Controlled trial of Lisinopril in Insulin dependent Diabetes","Schalkwijk CG, Chaturvedi N, Twaafhoven H, van Hinsbergh VW, Stehouwer CD, EUCLID Study Group: Amadori-albumin correlates with microvascular complications and precedes nephropathy in type 1 diabetic patients. Eur J Clin Invest 2002; 32: 500-506.","1型糖尿病患者において,グリコアルブミン値と早期腎症および網膜症の関係,それらの関係における慢性の軽度炎症の関与を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12153550","http://diabetes.ebm-library.jp/trial/detail/50566" "Eurich DT, et al.","−","Eurich DT, Simpson S, Senthilselvan A, Asche CV, Sandhu-Minhas JK, McAlister FA: Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ. 2013; 346: f2267.","新規治療の2型糖尿病患者において,sitagliptinによる臨床転帰を他の血糖降下薬と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23618722","http://diabetes.ebm-library.jp/trial/detail/51358" "EURODIAB IDDM Complications Study","-","Giunti S, Bruno G, Veglio M, Gruden G, Webb DJ, Livingstone S, Chaturvedi N, Fuller JH, Perin PC, Eurodiab IDDM Complications Study: Electrocardiographic left ventricular hypertrophy in type 1 diabetes: prevalence and relation to coronary heart disease and cardiovascular risk factors: the Eurodiab IDDM Complications Study. Diabetes Care 2005; 28: 2255-2257.","1型糖尿病患者において,心電図所見による左室肥大の有病率を検討し,さらに左室肥大と冠動脈心疾患,細小血管障害,QT間隔およびそのばらつきとの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16123503","http://diabetes.ebm-library.jp/trial/detail/50802" "EURODIAB Prospective Complications Study","-","Porta M, Sjoelie AK, Chaturvedi N, Stevens L, Rottiers R, Veglio M, Fuller JH; EURODIAB Prospective Complications Study Group: Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 2001; 44: 2203-2209.","増殖糖尿病網膜症発症のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11793022","http://diabetes.ebm-library.jp/trial/detail/50538" "EURODIAB Prospective Complications Study","-","Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, Stehouwer CD, EURODIAB Prospective Complications Study: Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2003; 26: 2165-2173.","1型糖尿病患者において,炎症活性の決定因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12832330","http://diabetes.ebm-library.jp/trial/detail/50611" "EURODIAB Prospective Complications Study","-","Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferriss B, Reboldi P, Michel G, Manes C, Fuller JH, EURODIAB Prospective Complications Study Group: Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care 2004; 27: 530-537.","1型糖尿病患者において,冠動脈心疾患のリスク因子を検討し,男女間の相違を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14747240","http://diabetes.ebm-library.jp/trial/detail/50633" "EURODIAB Prospective Complications Study","-","Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Tesfaye S, Tesfaye S, EURODIAB Prospective Complications Study Group: Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-350.","1型糖尿病患者において,末梢神経障害発症のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15673800","http://diabetes.ebm-library.jp/trial/detail/50702" "EURODIAB Prospective Complications Study","-","van Hecke MV, Dekker JM, Stehouwer CD, Polak BC, Fuller JH, Sjolie AK, Kofinis A, Rottiers R, Porta M, Chaturvedi N: Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes Care 2005; 28: 1383-1389.","1型糖尿病患者において,非増殖および増殖網膜症と全死亡および心血管疾患発症の関係を検討し,それに関連する心血管リスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15920056","http://diabetes.ebm-library.jp/trial/detail/50762" "EURODIAB Prospective Complications Study","-","Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH; EURODIAB Prospective Complications Study Group: Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care. 2008; 31: 1360-6.","1型糖尿病患者において,全死亡のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18375412","http://diabetes.ebm-library.jp/trial/detail/51135" "EURODIAB Prospective Complications Study","-","Engelen L, Soedamah-Muthu SS, Geleijnse JM, Toeller M, Chaturvedi N, Fuller JH, Schalkwijk CG, Stehouwer CD: Higher dietary salt intake is associated with microalbuminuria, but not with retinopathy in individuals with type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia. 2014; 57: 2315-23.","1型糖尿病患者において,ナトリウムおよびカリウム摂取量と微量アルブミン尿,マクロアルブミン尿,非増殖性網膜症,増殖性網膜症の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25172228","http://diabetes.ebm-library.jp/trial/detail/51438" "European Insulin Glargine Study","-","Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A, European Insulin Glargine Study Group: A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev 2005; 21: 545-553.","1型糖尿病患者において,インスリンglargineの血糖コントロール効果および安全性をNPHインスリンと比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16021649","http://diabetes.ebm-library.jp/trial/detail/50791" "European Microalbuminuria Captopril Study","-","Viberti G, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271: 275-279.","微量アルブミン尿を伴うIDDM患者に対するcaptoprilの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8295285","http://diabetes.ebm-library.jp/trial/detail/50110" "EXAMINE","Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial","White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, et al.; the EXAMINE Investigators: Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med. 2013; 369: 1327-1335.","最近の急性冠症候群の既往があり,かつ標準的な糖尿病治療薬投与下の2型糖尿病患者において,DPP-4阻害薬alogliptinとプラセボの心血管アウトカムを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/23992602","http://diabetes.ebm-library.jp/trial/detail/51341" "EXAMINE","Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial","Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, et al.; EXAMINE Investigators: Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015; 385: 2067-76.","急性冠症候群を最近発症した2型糖尿病患者において,DPP-4阻害薬alogliptinとプラセボの心不全アウトカムを比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25765696","http://diabetes.ebm-library.jp/trial/detail/51472" "EXAMINE","Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care","Heller SR, Bergenstal RM, White W, Kupfer S, Bakris GL, Cushman WC, Mehta CR, Nissen SE, Wilson CA, Zannad F, Liu Y, Gourlie NM, Cannon CP; EXAMINE Investigators.","急性冠症候群を最近発症した2型糖尿病患者において,ベースライン,治療1ヵ月後,および最終HbA1cと低血糖イベントの既往/発生は,主要有害心血管イベント発生リスクと関連するか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28058763","http://diabetes.ebm-library.jp/trial/detail/51631" "EXSCEL","Exenatide Study of Cardiovascular Event Lowering Study","Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, hman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377: 1228-39.","2型糖尿病患者において,exenatideの心血管に関する長期の安全性と有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28910237","http://diabetes.ebm-library.jp/trial/detail/51683" "ExTRACT-TIMI 25","the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25","Morrow DA, Antman EM, Murphy SA, Qin J, Ruda M, Guneri S, Jacob AJ, Budaj A, Braunwald E, TIMI Study Group: Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. Am Heart J 2007; 154: 1078-84, 1084.e1.","糖尿病を有する高リスクのST上昇型心筋梗塞患者において,enoxaparinの有効性および安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18035078","http://diabetes.ebm-library.jp/trial/detail/51058" "FACET","the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial","Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.","高血圧のNIDDM患者において,fosinoprilとamlodipineが血清脂質と糖尿病コントロールに及ぼす効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9571349","http://diabetes.ebm-library.jp/trial/detail/50319" "Fagot JP, et al.","-","Fagot JP, Blotire PO, Ricordeau P, Weill A, Alla F, Allemand H: Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases. Diabetes Care. 2013; 36: 294-301.","2型糖尿病患者において,インスリンglargine投与は他の基礎インスリンと比べ,癌発症リスク,とくに乳癌発症リスクと関連するかを検討。","https://www.ncbi.nlm.nih.gov/pubmed/22966091","http://diabetes.ebm-library.jp/trial/detail/51325" "FDS","the Fremantle Diabetes Study","Norman PE, Davis WA, Bruce DG, Davis TM: Peripheral arterial disease and risk of cardiac death in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2006; 29: 575-580.","2型糖尿病患者における末梢動脈疾患の有病率および新規発症率を検討し,心臓死リスクへの影響および適切なリスク因子の管理について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16505509","http://diabetes.ebm-library.jp/trial/detail/50822" "FDS1","Fremantle Diabetes Study Phase 1","Davis TM, Chubb SA, Bruce DG, Davis WA: Metabolic memory and all-cause death in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. Diabetes Obes Metab. 2016; 18: 598-606.","最近2型糖尿病と診断された患者において,厳格な血糖コントロールが死亡を抑制するか,また長期間にわたる糖尿病罹病は死亡リスクの増加と関連するかを検証した。","https://www.ncbi.nlm.nih.gov/pubmed/26936654","http://diabetes.ebm-library.jp/trial/detail/51574" "Ferrannini E, et al.","−","Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle HJ, Broedl UC: Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013; 36: 4015-21.","2型糖尿病患者において,sitagliptin,metformin,およびSGLT2阻害薬empagliflozinの長期安全性と有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24186878","http://diabetes.ebm-library.jp/trial/detail/51380" "FIELD","the Fenofibrate Intervention and Event Lowering in Diabetes study","Leinonen ES, Salonen JT, Salonen RM, Koistinen RA, Leinonen PJ, Sarna SS, Taskinen MR: Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes. Diabetes Care 2002; 25: 1807-1812.","中高年の2型糖尿病患者において,頸動脈内膜-中膜壁肥厚予測におけるインスリン様成長因子および脂質パラメータの役割を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12351482","http://diabetes.ebm-library.jp/trial/detail/50580" "FIELD","the Fenofibrate Intervention and Event Lowering in Diabetes study","Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, et al: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.","2型糖尿病患者において,fenofibrateの心血管疾患イベントに対する有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16310551","http://diabetes.ebm-library.jp/trial/detail/50784" "FIELD","the Fenofibrate Intervention and Event Lowering in Diabetes study","Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, et al.: Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-1697.","2型糖尿病患者において,fenofibrateによる長期的な脂質低下療法が糖尿病性網膜症の進行およびレーザー治療への移行を抑制するか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17988728","http://diabetes.ebm-library.jp/trial/detail/51017" "FIELD","Fenofibrate Intervention and Event Lowering in Diabetes study","Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators: Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009; 32: 493-8.","2型糖尿病患者において,fenofibrateの心血管疾患イベント低減効果を,メタボリックシンドロームの項目別に検討した。FIELDのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18984774","http://diabetes.ebm-library.jp/trial/detail/51167" "FIELD","the Fenofibrate Intervention and Event Lowering in Diabetes study","Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M, Baker JR, Keech AC, FIELD study investigators: Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373: 1780-1788.","2型糖尿病患者において,fenofibrate治療の下肢切断イベントに対する効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19465233","http://diabetes.ebm-library.jp/trial/detail/51112" "FIELD","Fenofibrate Intervention and Event Lowering in Diabetes study","Sullivan D, Forder P, Simes J, Whiting M, Kritharides L, Merrifield A, Donoghoe M, Colman PG, Graham N, Haapamki H, et al.; FIELD Study Investigators: Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study. Diabetes Res Clin Pract. 2011; 94: 284-90.","2型糖尿病患者において,ベースラインのmetforminまたはスルホニル尿素薬の使用と,ベースラインの心血管疾患リスク因子,試験中の心血管疾患イベントリスクの相関を検討し,fenofibrateの効果に対するそれら薬剤の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21862166","http://diabetes.ebm-library.jp/trial/detail/51256" "FIELD","Fenofibrate Intervention and Event Lowering in Diabetes","d'Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, Stuckey BG, Park K, Saltevo J, Keech AC; FIELD Study Investigators: Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2014; 57: 2296-303.","FIELD試験参加者を対象に,fenofibrateの脂質値に対する影響およびCVD抑制効果に性差がみられるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25149070","http://diabetes.ebm-library.jp/trial/detail/51425" "FinnDiane","the Finnish Diabetic Nephropathy Study","Ronnback M, Fagerudd J, Forsblom C, Pettersson-Fernholm K, Reunanen A, Groop PH, Finnish Diabetic Nephropathy (FinnDiane) Study Group: Altered age-related blood pressure pattern in type 1 diabetes. Circulation 2004; 110: 1076-1082.","加齢による血圧の変化に対する1型糖尿病の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15326070","http://diabetes.ebm-library.jp/trial/detail/50688" "FinnDiane","the Finnish Diabetic Nephropathy study","Waden J, Tikkanen H, Forsblom C, Fagerudd J, Pettersson-Fernholm K, Lakka T, Riska M, Groop PH, FinnDiane Study Group: Leisure time physical activity is associated with poor glycemic control in type 1 diabetic women: the FinnDiane study. Diabetes Care 2005; 28: 777-782.","成人1型糖尿病患者において,余暇における身体活動と血糖コントロール,インスリン用量,インスリン感受性の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15793172","http://diabetes.ebm-library.jp/trial/detail/50751" "FinnDiane","the Finnish Diabetic Nephropathy Study","Saraheimo M, Forsblom C, Fagerudd J, Teppo AM, Pettersson-Fernholm K, Frystyk J, Flyvbjerg A, Groop PH, FinnDiane study group: Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 2005; 28: 1410-1414.","腎症の進行度の異なる1型糖尿病患者において,血清アディポネクチン値と腎機能,軽度炎症性マーカー,代謝コントロール,インスリン抵抗性の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15920060","http://diabetes.ebm-library.jp/trial/detail/50774" "FinnDiane","the Finnish Diabetic Nephropathy study","Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, Waden J, Ronnback M, Rosengard-Barlund M, Bjorkesten CG, et al.: Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005; 28: 2019-2024.","フィンランド人の1型糖尿病患者におけるメタボリックシンドロームの有病率を検討し,メタボリックシンドロームと糖尿病性腎症および血糖コントロールとの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16043748","http://diabetes.ebm-library.jp/trial/detail/50806" "FinnDiane","the Finnish Diabetic Nephropathy study","Thorn LM, Forsblom C, Fagerudd J, Pettersson-Fernholm K, Kilpikari R, Groop PH, FinnDiane Study Group: Clustering of risk factors in parents of patients with type 1 diabetes and nephropathy. Diabetes Care 2007; 30: 1162-1167.","1型糖尿病患者において,両親の持つリスク因子が患者の糖尿病性腎症に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17337502","http://diabetes.ebm-library.jp/trial/detail/50992" "FinnDiane","Finnish Diabetic Nephropathy study","Thorn LM, Forsblom C, Wadn J, Saraheimo M, Tolonen N, Hietala K, Groop PH; Finnish Diabetic Nephropathy (FinnDiane) Study Group: Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2009; 32: 950-2.","1型糖尿病患者において,メタボリックシンドロームの心血管イベント,心血管および糖尿病関連死,腎症の進展についての予測能を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19196885","http://diabetes.ebm-library.jp/trial/detail/51180" "FinnDiane","Finnish Diabetic Nephropathy","Hgg S, Thorn LM, Putaala J, Liebkind R, Harjutsalo V, Forsblom CM, Gordin D, Tatlisumak T, Groop PH; FinnDiane Study Group: Incidence of stroke according to presence of diabetic nephropathy and severe diabetic retinopathy in patients with type 1 diabetes. Diabetes Care. 2013; 36: 4140-6.","1型糖尿病患者における脳卒中発症率を調査し,糖尿病腎症(DN)と糖尿病網膜症(SDR)が脳卒中発症に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24101700","http://diabetes.ebm-library.jp/trial/detail/51377" "FinnDiane","the Finnish Diabetic Nephropathy Study","Lithovius R, Harjutsalo V, Forsblom C, Saraheimo M, Groop PH; FinnDiane Study Group: Antihypertensive treatment and resistant hypertension in patients with type 1 diabetes by stages of diabetic nephropathy. Diabetes Care. 2014; 37: 709-17.","1型糖尿病の腎症患者において,高血圧コントロール不良および抵抗性高血圧の罹患が,腎症をさらに増大させるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24170765","http://diabetes.ebm-library.jp/trial/detail/51392" "FinnDiane","Finnish Diabetic Nephropathy Study","Thorn LM, Gordin D, Harjutsalo V, Hgg S, Masar R, Saraheimo M, Tolonen N, Wadn J, Groop PH, Forsblom CM; FinnDiane Study Group: The Presence and Consequence of Nonalbuminuric Chronic Kidney Disease in Patients With Type 1 Diabetes. Diabetes Care. 2015; 38: 2128-33.","1型糖尿病患者において,正常アルブミン尿の慢性腎臓病の有病率とその後のアウトカムを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26310691","http://diabetes.ebm-library.jp/trial/detail/51534" "FinnDiane","Finnish Diabetic Nephropathy Study","Hgg-Holmberg S, Thorn LM, Forsblom CM, Gordin D, Elonen N, Harjutsalo V, Liebkind R, Putaala J, Tatlisumak T, Groop PH; FinnDiane Study Group. Prognosis and Its Predictors After Incident Stroke in Patients With Type 1 Diabetes. Diabetes Care. 2017; 40: 1394-1400.","1型糖尿病患者において,脳卒中発症後の予後を評価し,生存の予測因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28811283","http://diabetes.ebm-library.jp/trial/detail/51678" "FinnDiane Study","Finnish Diabetic Nephropathy study","Jansson FJ, Forsblom C, Harjutsalo V, Thorn LM, Wadn J, Elonen N, Ahola AJ, Saraheimo M, Groop PH; FinnDiane Study Group. Regression of albuminuria and its association with incident cardiovascular outcomes and mortality in type 1 diabetes: the FinnDiane Study. Diabetologia. 2018; 61: 1203-11.","1型糖尿病患者において,アルブミン尿の退縮を評価し,心血管イベントおよび全死亡/心血管死に対するアルブミン尿の退縮の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29423580","http://diabetes.ebm-library.jp/trial/detail/51720" "Finne P, et al.","-","Finne P, Reunanen A, Stenman S, Groop PH, Gronhagen-Riska C: Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005; 294: 1782-1787.","1型糖尿病患者における終末期腎不全の長期リスクを検討し,さらに1型糖尿病の診断時年齢,診断時期,性別が長期リスクに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16219881","http://diabetes.ebm-library.jp/trial/detail/50808" "FINRISK and DPS","-","Ilanne-Parikka P, Eriksson JG, Lindstrom J, Hamalainen H, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Rastas M, Salminen V, et al: Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort. Diabetes Care 2004; 27: 2135-2140.","フィンランドで実施された2試験の中年のコホートにおいて,メタボリックシンドロームの有病率を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15333474","http://diabetes.ebm-library.jp/trial/detail/50670" "FIT","the Fracture Intervention Trial","Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL: Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care 2004; 27: 1547-1553.","2型糖尿病を有し,骨密度低値の閉経後女性において,alendronateが骨密度に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15220226","http://diabetes.ebm-library.jp/trial/detail/50660" "FLAT-SUGAR trial","FLuctuATion reduction with inSUlin and GLP-1 Added togetheR trial","FLAT-SUGAR Trial Investigators: Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care. 2016; 39: 973-81.","心血管リスクの高いインスリン療法を要する2型糖尿病患者において,exenatide追加による血糖変動性とHbA1cへの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27208320","http://diabetes.ebm-library.jp/trial/detail/51573" "Foghsgaard S, et al.","-","Foghsgaard S, Andreasen C, Vedtofte L, Andersen ES, Bahne E, Strandberg C, Buhl T, Holst JJ, Svare JA, Clausen TD, Mathiesen ER, Damm P, Gluud LL, Knop FK, Vilsbll T. Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference. ","妊娠糖尿病の既往のある女性において,非アルコール性脂肪性肝疾患の有病率,耐糖能障害・インスリン抵抗性・脂肪分布との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27810989","http://diabetes.ebm-library.jp/trial/detail/51612" "Foley JE, et al..","-","Foley JE, Bunck MC, Mller-Goede DL, Poelma M, Nijpels G, Eekhoff EM, Schweizer A, Heine RJ, Diamant M: Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia. 2011; 54: 1985-91.","drug-naiveの2型糖尿病患者において,DPP-4阻害薬vildagliptinによる治療期間終了後および,washout期間後のインスリン分泌能を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21547496","http://diabetes.ebm-library.jp/trial/detail/51206" "Forbes A, et al.","-","Forbes A, Murrells T, Mulnier H, Sinclair AJ. Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018; 6: 476-86.","≧70歳の糖尿病患者において,平均HbA1cおよび経時的HbA1c変動性と死亡の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29674135","http://diabetes.ebm-library.jp/trial/detail/51719" "Four Nations Diabetic Retinopathy Screening Study","−","Leese GP, Stratton IM, Land M, Bachmann MO, Jones C, Scanlon P, Looker HC, Ferguson B; Four Nations Diabetic Retinopathy Screening Study Group: Progression of diabetes retinal status within community screening programs and potential implications for screening intervals. Diabetes Care. 2015; 38: 488-94.","ルーチンに網膜検査を実施している糖尿病患者において,糖尿病網膜症への進行率を推定し,異なるリスク層の患者に対する最適な検査間隔を探索した。","https://www.ncbi.nlm.nih.gov/pubmed/25524948","http://diabetes.ebm-library.jp/trial/detail/51485" "Framingham Heart Study","-","Fox CS, Sullivan L, D'Agostino RB, Wilson PW: The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diabetes Care 2004; 27: 704-708.","2型糖尿病の罹病期間が冠動脈心疾患の罹病率および死亡率に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14988289","http://diabetes.ebm-library.jp/trial/detail/50650" "Framingham Heart Study","-","Fox CS, Coady S, Sorlie PD, D'Agostino RB, Pencina MJ, Vasan RS, Meigs JB, Levy D, Savage PJ: Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007; 115: 1544-1550.","過去50年間に糖尿病に起因する心血管疾患の割合が増大しているという仮説について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17353438","http://diabetes.ebm-library.jp/trial/detail/50993" "Framingham Heart Study","-","Molenaar EA, Hwang SJ, Vasan RS, Grobbee DE, Meigs JB, D'Agostino RB, Levy D, Fox CS: Burden and rates of treatment and control of cardiovascular disease risk factors in obesity: the Framingham Heart Study. Diabetes Care. 2008; 31: 1367-72.","肥満の程度と心血管疾患リスク因子の治療との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18375414","http://diabetes.ebm-library.jp/trial/detail/51133" "Framingham Heart Study","-","Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D'Agostino RB: Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care. 2008; 31: 1582-4.","心血管疾患の生涯リスクを,糖尿病および肥満の有無により検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18458146","http://diabetes.ebm-library.jp/trial/detail/51137" "Framingham Heart Study","-","Preis SR, Pencina MJ, Mann DM, D'Agostino RB Sr, Savage PJ, Fox CS: Early-adulthood cardiovascular disease risk factor profiles among individuals with and without diabetes in the Framingham Heart Study. Diabetes Care. 2013; 36: 1590-6.","糖尿病患者において,糖尿病診断前30年間の心血管疾患(CVD)リスク因子の負荷を,非糖尿病例と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/23340887","http://diabetes.ebm-library.jp/trial/detail/51353" "Framingham Offspring Study","-","Najarian RM, Sullivan LM, Kannel WB, Wilson PW, D'Agostino RB, Wolf PA: Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med 2006; 166: 106-111.","メタボリックシンドロームおよび2型糖尿病と脳卒中発症リスクとの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16401818","http://diabetes.ebm-library.jp/trial/detail/50827" "Framingham Offspring Study","-","Meigs JB, O'donnell CJ, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, Nathan DM, Sullivan LM, D'Agostino RB, Wilson PW: Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 2006; 55: 530-537.","内皮機能障害の止血マーカー(プラスミノーゲン活性化抑制因子-1,von Willebrand因子)が他のリスク因子とは独立した2型糖尿病発症予測能を有するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16443791","http://diabetes.ebm-library.jp/trial/detail/50839" "Framingham Offspring Study","-","Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB: Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007; 167: 1068-1074.","もっとも有効な2型糖尿病発症予測モデルを構築することを目的とした。","https://www.ncbi.nlm.nih.gov/pubmed/17533210","http://diabetes.ebm-library.jp/trial/detail/51000" "Framingham Offspring Study","-","Meigs JB, Larson MG, Fox CS, Keaney JF, Vasan RS, Benjamin EJ: Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care. 2007; 30: 2529-35.","非糖尿病症例において,酸化ストレスとインスリン抵抗性の関連を検討。","https://www.ncbi.nlm.nih.gov/pubmed/17586736","http://diabetes.ebm-library.jp/trial/detail/51087" "Framingham Offspring Study","-","Clair C, Rigotti NA, Porneala B, Fox CS, D'Agostino RB, Pencina MJ, Meigs JB: Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA. 2013; 309: 1014-21.","心血管疾患のない成人において,禁煙後4年間の体重増加と心血管疾患イベントの関連を糖尿病の有無別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23483176","http://diabetes.ebm-library.jp/trial/detail/51336" "Framingham Study","-","Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. The Framingham study. Ann Intern Med 1977; 87: 393-397.","冠動脈心疾患高リスク患者における糖尿病,血中脂質,肥満との関連を観察調査した。","https://www.ncbi.nlm.nih.gov/pubmed/199096","http://diabetes.ebm-library.jp/trial/detail/50356" "Framingham Study","-","Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-2038.","糖尿病の心血管イベントへの影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/430798","http://diabetes.ebm-library.jp/trial/detail/50355" "Frandsen CS, et al.","−","Frandsen CS, Dejgaard TF, Holst JJ, Andersen HU, Thorsteinsson B, Madsbad S: Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study. Diabetes Care. 2015; 38: 2250-7.","正常体重のコントロール不良1型糖尿病患者において,インスリン治療にliraglutide 1.2mg 1日1回を追加した場合の有効性と安全性をプラセボと比較した。","https://www.ncbi.nlm.nih.gov/pubmed/26486191","http://diabetes.ebm-library.jp/trial/detail/51540" "FREEDOM","Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease trial","Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, et al.; FREEDOM Trial Investigators: Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012; 367: 2375-84.","多枝冠動脈病変を有する糖尿病患者において,冠動脈バイパス形成術と薬剤溶出ステントを用いた経皮的冠インターベンションを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/23121323","http://diabetes.ebm-library.jp/trial/detail/51303" "Fukuoka Diabetes Registry","-","Ohkuma T, Fujii H, Iwase M, Kikuchi Y, Ogata S, Idewaki Y, Ide H, Doi Y, Hirakawa Y, Nakamura U, et al.: Impact of sleep duration on obesity and the glycemic level in patients with type 2 diabetes: the Fukuoka Diabetes Registry. Diabetes Care. 2013; 36: 611-7.","日本人の2型糖尿病患者において,睡眠時間と肥満,血糖レベルの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23150286","http://diabetes.ebm-library.jp/trial/detail/51352" "Fulcher GR, et al.","-","Fulcher GR, Christiansen JS, Bantwal G, Polaszewska-Muszynska M, Mersebach H, Andersen TH, Niskanen LK; BOOST: Intensify Premix I Investigators: Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care. 2014; 37: 2084-90.","1日1回または1日2回のインスリン治療±経口糖尿病治療薬でコントロール不良の2型糖尿病患者において,insulin degludec/insulin aspartと二相性insulin aspart 30の有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24812432","http://diabetes.ebm-library.jp/trial/detail/51418" "Funagata study","-","Sekikawa A, Tominaga M, Takahashi K, Eguchi H, Igarashi M, Ohnuma H, Sugiyama K, Manaka H, Sasaki H, Fukuyama H, et al: Prevalence of diabetes and impaired glucose tolerance in Funagata area, Japan. Diabetes Care 1993; 16: 570-574.","山形県舟形町住民における糖尿病と耐糖能異常の有病率を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8462380","http://diabetes.ebm-library.jp/trial/detail/50536" "Funagata study","-","Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22: 920-924.","耐糖能異常が心血管死のリスク因子であることを確認するとともに,空腹時血糖異常も心血管死のリスク因子であるか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10372242","http://diabetes.ebm-library.jp/trial/detail/50496" "Funagata study","-","Sekikawa A, Eguchi H, Tominaga M, Igarashi K, Abe T, Manaka H, Sasaki H, Fukuyama H, Kato T, Kiyohara Y, Fujishima M: Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in a rural area of Japan. The Funagata diabetes study. J Diabetes Complications 2000; 14: 78-83.","山形県舟形町住民における2型糖尿病および耐糖能異常の有病率を検討し,福岡県久山町の有病率と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/10959069","http://diabetes.ebm-library.jp/trial/detail/50557" "Funagata study","-","Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H, Ohnuma H, Igarashi M, Tominaga M, Kato T: Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care 2003; 26: 2015-2020.","日本人において,血漿アディポネクチン低値が2型糖尿病発症の独立したリスク因子であるか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12832305","http://diabetes.ebm-library.jp/trial/detail/50604" "Gallwitz B.","-","Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, Dugi KA, Woerle HJ: 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012; 380: 475-83.","metforminでコントロール不良の2型糖尿病患者において,linagliptinとglimepirideの長期有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/22748821","http://diabetes.ebm-library.jp/trial/detail/51271" "Gallwitz B, et al.","Assessment of Weekly AdministRation of LY2189265 in Diabetes trial","Gallwitz B, Dagogo-Jack S, Thieu V, Garcia-Perez LE, Pavo I, Yu M, Robertson KE, Zhang N Giorgino F. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetes Obes Metab. 2018; 20: 409-18.","2型糖尿病患者において,週1回dulaglutide(1.5mg,0.75mg)の有効性と安全性を男女別,糖尿病罹病期間,ベースラインのHbA1c別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28817231","http://diabetes.ebm-library.jp/trial/detail/51712" "Garber AJ, et al.","-","Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL: Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103: 491-497.","2型糖尿病患者に対するmetforminの効果と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9428832","http://diabetes.ebm-library.jp/trial/detail/50351" "GEMINI","the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives trial","Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227-2236.","レニン-アンジオテンシン系阻害薬投与下の高血圧を有する糖尿病患者において,carvedilolとmetoprololの血糖コントロールおよびその他の心血管リスク因子に対する有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/15536109","http://diabetes.ebm-library.jp/trial/detail/50691" "GEMINI","the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives trial","Messerli FH, Bell DS, Fonseca V, Katholi RE, McGill JB, Phillips RA, Raskin P, Wright JT, Bangalore S, Holdbrook FK, et al.: Body weight changes with beta-blocker use: results from GEMINI. Am J Med 2007; 120: 610-615.","高血圧を有する2型糖尿病患者において,carvedilolおよびmetoprololが体重に及ぼす影響を検討した。GEMINIの二次解析。","https://www.ncbi.nlm.nih.gov/pubmed/17602935","http://diabetes.ebm-library.jp/trial/detail/51047" "GEMINI","Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives trial","Fonseca V, Bakris GL, Bell DS, McGill JB, Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT, Waterhouse B, et al.: Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med 2007; 24: 759-763.","2型糖尿病および高血圧を有する患者において,carvedilolおよびmetoprololのインスリン抵抗性改善効果に対し,チアゾリジンジオン系薬剤またはmetforminの併用が影響を及ぼすかを検討した。GEMINIのレトロスペクティブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/17451422","http://diabetes.ebm-library.jp/trial/detail/51042" "German Diabetes and Dialysis Study","-","Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.","血液透析を受けている2型糖尿病患者において,atorvastatinの心血管イベントに対する有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16034009","http://diabetes.ebm-library.jp/trial/detail/50758" "German Humalog-CSII Study","the German Humalog Continuous Subcutaneous Insulin Infusion study","Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R: Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 1999; 22: 784-788.","1型糖尿病の持続的皮下インスリン注入治療におけるinsulin lisproの有効性と忍容性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10332682","http://diabetes.ebm-library.jp/trial/detail/50226" "GISSI-3","Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico","Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G: Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997; 96: 4239-4245.","急性心筋梗塞発症24時間以内の糖尿病患者において,lisinoprilおよびnitroglycerin投与が,死亡率と罹患率を低下させるかどうかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9416888","http://diabetes.ebm-library.jp/trial/detail/50308" "GISSI-Prevenzione Trial","the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico- Prevenzione Trial","Levantesi G, Macchia A, Marfisi R, Franzosi MG, Maggioni AP, Nicolosi GL, Schweiger C, Tavazzi L, Tognoni G, Valagussa F, et al: Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2005; 46: 277-283.","心筋梗塞患者において,メタボリックシンドロームおよび糖尿病の有病率を検討し,心血管イベントとの関連性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16022955","http://diabetes.ebm-library.jp/trial/detail/50768" "Giugliano D, et al.","-","Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Ceriello A, Esposito K: Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care. 2011; 34: 510-7.","2型糖尿病患者において,インスリンアナログを用いた基礎インスリン,二相性インスリン,食前インスリン,ベーサル-ボーラスインスリンレジメンのHbA1c目標値<7%達成効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21216850","http://diabetes.ebm-library.jp/trial/detail/51261" "GLAL","-","Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquhart R, Tan MH, Tan MH, GLAL Study Group: Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005; 28: 544-550.","2型糖尿病患者において,pioglitazoneとgliclazideの血糖コントロール維持における有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/15735185","http://diabetes.ebm-library.jp/trial/detail/50730" "Glimepiride Combination","-","Riddle MC, Schneider J: Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998; 21: 1052-1057.","glimepiride単独療法で血糖コントロール不良の肥満の2型糖尿病患者において,夕食前70/30インスリン+glimepiride療法とインスリン単独療法を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9653594","http://diabetes.ebm-library.jp/trial/detail/50213" "Glimepiride Protocol #201 Study","-","Goldberg RB, Holvey SM, Schneider J: A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care 1996; 19: 849-856.","NIDDM治療におけるglimepirideの有効性,安全性,用量反応関係,最少有効量を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8842603","http://diabetes.ebm-library.jp/trial/detail/50200" "Gokhale M, et al.","-","Gokhale M, Buse JB, Jonsson Funk M, Lund J, Pate V, Simpson RJ, Strmer T. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives. Diabetes Obes Metab. 2017; 19: 970-8.","スルホニル尿素薬およびチアゾリジン薬と比較した場合のDPP-4阻害薬の心血管リスクを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28195389","http://diabetes.ebm-library.jp/trial/detail/51669" "Gmez-Ambrosi J, et al.","−","Gmez-Ambrosi J, Cataln V, Rodrguez A, Andrada P, Ramrez B, Ibez P, Vila N, Romero S, Margall MA, Gil MJ, et al.: Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy. Diabetes Care. 2014; 37: 2813-21.","代謝的に健康な肥満または代謝的に異常な肥満の患者において,耐糖能異常(IGT)および2型糖尿病の罹患率および心血管代謝/炎症プロファイルを比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25011950","http://diabetes.ebm-library.jp/trial/detail/51424" "Gordon J, et al.","-","Gordon J, McEwan P, Evans M, Puelles J, Sinclair A. Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes. Diabetes Obes Metab. 2017; 19: 644-653.","metformin単独療法の増強を要する高齢の2型糖尿病患者において,2次療法の健康アウトカムと経済アウトカムを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/28026911","http://diabetes.ebm-library.jp/trial/detail/51645" "Goto A, et al.","−","Goto A, Arah OA, Goto M, Terauchi Y, Noda M: Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013; 347: f4533.","2型糖尿病患者において,重症低血糖症と心血管疾患リスクとの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23900314","http://diabetes.ebm-library.jp/trial/detail/51357" "GREACE","the GREek Atorvastatin and Coronary Heart Disease Evaluation study","Athyros VG, Papageorgiou AA, Symeonidis AN, Didangelos TP, Pehlivanidis AN, Bouloukos VI, Mikhailidis DP, GREACE Study Collaborative Group: Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 2003; 54: 679-690.","糖尿病を有する冠動脈心疾患患者において,atorvastatinを用いた脂質代謝異常に対する構造化ケアの有効性を,通常ケアと比較した。","https://www.ncbi.nlm.nih.gov/pubmed/14666956","http://diabetes.ebm-library.jp/trial/detail/50637" "Guest JF, et al.","-","Guest JF, Panca M, Sladkevicius E, Taheri S, Stradling J: Clinical outcomes and cost-effectiveness of continuous positive airway pressure to manage obstructive sleep apnea in patients with type 2 diabetes in the U.K. Diabetes Care. 2014; 37: 1263-71.","閉塞性睡眠時無呼吸(OSA)を有する2型糖尿病患者において, CPAP(持続的気道陽圧法)治療の臨床アウトカムと費用対効果を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/24705611","http://diabetes.ebm-library.jp/trial/detail/51403" "GUSTO","Growing Up in Singapore Toward healthy Outcomes","Pang WW, Colega M, Cai S, Chan YH, Padmapriya N, Chen LW, Soh SE, Han WM, Tan KH, Lee YS, Saw SM, Gluckman PD, Godfrey KM, Chong YS, van Dam RM, Chong MF. Higher Maternal Dietary Protein Intake Is Associated with a Higher Risk of Gestational Diabetes Mellitus in a Multiethnic Asian Cohort. J Nutr. 2017;147:653-660.","アジア系多民族の女性において,妊娠中の食事からのタンパク質摂取量と妊娠糖尿病リスクの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28275101","http://diabetes.ebm-library.jp/trial/detail/51626" "GUSTO-I","Global Utilization of Streptokinase and t-PA for Occluded coronary arteries trial","Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ: Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30: 171-179.","糖尿病患者で急性心筋梗塞を生じた患者において,血栓溶解療法と糖尿病との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9207639","http://diabetes.ebm-library.jp/trial/detail/50324" "GUSTO-IIb Angioplasty Substudy","-","Hasdai D, Granger CB, Srivatsa SS, Criger DA, Ellis SG, Califf RM, Topol EJ, Holmes DR: Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes. J Am Coll Cardiol 2000; 35: 1502-1512.","急性心筋梗塞患者に対する初回血管形成術の有効性を糖尿病例と非糖尿病例で比較し,糖尿病例において初回血管形成術と血栓溶解療法の有効性を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10807453","http://diabetes.ebm-library.jp/trial/detail/50377" "GUSTO V","the Global Use of Strategies to Open Occluded Coronary Arteries V trial","Gurm HS, Lincoff AM, Lee D, Tang WH, Jia G, Booth JE, Califf RM, Ohman EM, Van de Werf F, Armstrong PW, et al: Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. J Am Coll Cardiol 2004; 43: 542-548.","ST上昇を伴う急性心筋梗塞患者において,糖尿病例と非糖尿病例のアウトカムを比較し,それらのアウトカムに対するreteplase(半分量)およびabciximabの併用療法と標準的な血栓溶解療法の有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/14975461","http://diabetes.ebm-library.jp/trial/detail/50647" "GWAA","-","Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, GWAA Study Group: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-569.","経口血糖降下薬投与下で血糖コントロール不良の2型糖尿病患者において,exenatideまたはインスリンglargineを追加投与した場合の効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/16230722","http://diabetes.ebm-library.jp/trial/detail/50793" "HAAS","the Honolulu-Asia Aging Study","Korf ES, White LR, Scheltens P, Launer LJ: Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. Diabetes Care 2006; 29: 2268-2274.","老化に伴う脳の病理学的変化のマーカーと2型糖尿病の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17003305","http://diabetes.ebm-library.jp/trial/detail/50982" "Hamada S and Gulliford MC.","−","Hamada S, Gulliford MC: Mortality in Individuals Aged 80 and Older with Type 2 Diabetes Mellitus in Relation to Glycosylated Hemoglobin, Blood Pressure, and Total Cholesterol. J Am Geriatr Soc. 2016;64:1425-31.","超高齢の2型糖尿病患者において,HbA1c低値,血圧低値,および総コレステロール低値は,全死亡リスクの低下と関連するか検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27295278","http://diabetes.ebm-library.jp/trial/detail/51597" "Haneda M, et al.","-","Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, Kakiuchi H, Sato Y, Sakai S, Samukawa Y. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Clin Ther. 2016; 38: 66-88.","日本人2型糖尿病患者において,luseogliflozinの有効性と安全性に対する腎機能の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26718606","http://diabetes.ebm-library.jp/trial/detail/51638" "HAPO","Hyperglycemia and Adverse Pregnancy Outcomes study","HAPO Study Cooperative Research Group, , Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, et al.: Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358: 1991-2002.","母体の耐糖能異常による不良な妊娠アウトカムのリスクを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18463375","http://diabetes.ebm-library.jp/trial/detail/51079" "HAPO FUS","Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study","Lowe WL Jr, Scholtens DM, Kuang A, Linder B, Lawrence JM, Lebenthal Y, McCance D, Hamilton J, Nodzenski M, Talbot O, Brickman WJ, Clayton P, Ma RC, Tam WH, Dyer AR, Catalano PM, Lowe LP, Metzger BE; HAPO Follow-up Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): Maternal Gestational Diabetes Mellitus and Childhood Glucose Metabolism. Diabetes Care. 2019; 42: 372-80.","妊娠中の母体の血糖値と子どもの血糖アウトカムの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30655380","http://diabetes.ebm-library.jp/trial/detail/51764" "Harrison LB, et al.","-","Harrison LB, Adams-Huet B, Raskin P, Lingvay I: β-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012; 35: 1406-12.","2型糖尿病患者において,インスリン+metforminまたは3剤経口療法(metformin,glyburide,pioglitazone)による強化療法を3.5年実施後のβ細胞機能保持を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/22723578","http://diabetes.ebm-library.jp/trial/detail/51278" "Health 2000 Health Examination Survey/Health 2011 study","-","Ekblad LL, Rinne JO, Puukka P, Laine H, Ahtiluoto S, Sulkava R, Viitanen M, Jula A. Insulin Resistance Predicts Cognitive Decline: An 11-Year Follow-up of a Nationally Representative Adult Population Sample. Diabetes Care. 2017; 40: 751-8.","フィンランドの健康診断調査の参加者において,インスリン抵抗性が認知機能低下の独立した予測因子であるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28381479","http://diabetes.ebm-library.jp/trial/detail/51663" "Health Economics Research","-","Witthaus E, Stewart J, Bradley C: Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabet Med 2001; 18: 619-625.","1型糖尿病患者において,インスリンglargine治療とNPHインスリン治療に対する満足度および心理的幸福感を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11553198","http://diabetes.ebm-library.jp/trial/detail/50500" "Health Professionals Follow-up Study","-","Joosten MM, Pai JK, Bertoia ML, Rimm EB, Spiegelman D, Mittleman MA, Mukamal KJ: Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA. 2012; 308: 1660-7.","男性において,従来の心血管リスク因子(喫煙,高血圧,高コレステロール血症,2型糖尿病)と末梢動脈疾患リスクの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23093164","http://diabetes.ebm-library.jp/trial/detail/51284" "Heart and Soul Study","-","van Melle JP, Bot M, de Jonge P, de Boer RA, van Veldhuisen DJ, Whooley MA: Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care. 2010; 33: 2084-9.","心不全を認めない安定冠動脈疾患患者において,糖尿病およびHbA1c値と心不全発症との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20805280","http://diabetes.ebm-library.jp/trial/detail/51198" "HEART2D","Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus","Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, et al.: Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009; 32: 381-386.","急性心筋梗塞発症後の2型糖尿病患者において,食後血糖コントロールまたは空腹時血糖コントロールを目的としたインスリン療法の心疾患アウトカムに及ぼす影響を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19246588","http://diabetes.ebm-library.jp/trial/detail/51108" "Heerspink HJL, et al.","-","Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjstrm CD: Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab. 2016; 18: 590-7.","レニン-アンジオテンシン系阻害薬を投与されている高血圧を有する2型糖尿病患者において,アルブミン尿と推算糸球体濾過量に対するSGLT2阻害薬dapagliflozinの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26936519","http://diabetes.ebm-library.jp/trial/detail/51572" "Helsinki Heart Study","-","Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH: Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-825.","NIDDMを伴う血清脂質異常患者に対するgemfibrozilの脂質改善効果とCHD発症リスク低下効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/1516498","http://diabetes.ebm-library.jp/trial/detail/50077" "Hermann LS, et al.","-","Hermann LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A: Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17: 1100-1109.","NIDDM患者に対するmetformin,glyburideの効果,安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/7821128","http://diabetes.ebm-library.jp/trial/detail/50082" "Hermida RC, et al.","-","Hermida RC, Ayala DE, Mojn A, Fernndez JR: Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011; 34: 1270-6.","高血圧を有する2型糖尿病患者において,1つ以上の高血圧治療薬の就寝時投与が,全高血圧治療薬を朝投与する従来の治療よりも良好な血糖コントロールと心血管リスクの減少をもたらすか検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21617110","http://diabetes.ebm-library.jp/trial/detail/51253" "Hero C, et al.","-","Hero C, Rawshani A, Svensson AM, Franzn S, Eliasson B, Eeg-Olofsson K, Gudbjrnsdottir S: Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes. Diabetes Care. 2016; 39: 996-1003.","1型糖尿病患者において,心血管疾患および死亡に対する一次予防での脂質低下療法の効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27208327","http://diabetes.ebm-library.jp/trial/detail/51575" "Hippisley-Cox J, et al.","-","Minor PD, Dimmock NJ: Inhibition of synthesis of influenza virus proteins: evidence of two host-cell-dependent events during multiplication. Virology. 1975; 67: 114-23.","25〜84歳の糖尿病患者における失明と下肢切断の絶対10年リスクを定量化するリスク予測式を作成し,外部妥当性を検討した。","","http://diabetes.ebm-library.jp/trial/detail/51536" "Hirsch IB, et al.","-","Hirsch IB, Bode B, Courreges JP, Dykiel P, Franek E, Hermansen K, King A, Mersebach H, Davies M: Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care. 2012; 35: 2174-81.","insulin degludec/insulin aspart(IDegAsp)共製剤+insulin aspart(IAsp)併用療法と,insulin detemir(IDet)+IAspによるベーサルボーラス療法の有効性と忍容性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/22933438","http://diabetes.ebm-library.jp/trial/detail/51309" "Hisayama study","-","Ohmura T, Ueda K, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Nomiyama K, Ohmori S, Yoshitake T, Shinkawu A, et al.: Prevalence of type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: the Hisayama Study. Diabetologia 1993; 36: 1198-1203.","日本人での2型糖尿病およびIGTの有病率を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8270136","http://diabetes.ebm-library.jp/trial/detail/50248" "Hisayama study","-","Ohmura T, Ueda K, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Nomiyama K, Ohmori S, Yoshitake T, Shinkawa A, et al.: The association of the insulin resistance syndrome with impaired glucose tolerance and NIDDM in the Japanese general population: the Hisayama study. Diabetologia 1994; 37: 897-904.","日本人の耐糖能低下を引き起こすリスク因子を明らかにするため,特にインスリン抵抗性症候群に関連した因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/7806019","http://diabetes.ebm-library.jp/trial/detail/50249" "Hisayama study","-","Yamagata H, Kiyohara Y, Nakamura S, Kubo M, Tanizaki Y, Matsumoto T, Tanaka K, Kato I, Shirota T, Iida M: Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population: the Hisayama study. Diabetes Care 2005; 28: 789-794.","日本人において,空腹時血漿ブドウ糖値と胃癌発症の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15793174","http://diabetes.ebm-library.jp/trial/detail/50745" "Hisayama study","-","Doi Y, Kiyohara Y, Kubo M, Tanizaki Y, Okubo K, Ninomiya T, Iwase M, Iida M: Relationship between C-reactive protein and glucose levels in community-dwelling subjects without diabetes: the Hisayama Study. Diabetes Care 2005; 28: 1211-1213.","糖尿病を認めない日本人においてC反応性蛋白値と血糖値との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15855593","http://diabetes.ebm-library.jp/trial/detail/50742" "Hisayama study","-","Doi Y, Kiyohara Y, Kubo M, Ninomiya T, Wakugawa Y, Yonemoto K, Iwase M, Iida M: Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 2005; 28: 2497-2500.","糖尿病を認めない日本人において,高感度C反応性蛋白値と糖尿病発症の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16186286","http://diabetes.ebm-library.jp/trial/detail/50812" "Hisayama study","-","Doi Y, Ninomiya T, Hirakawa Y, Takahashi O, Mukai N, Hata J, Iwase M, Kitazono T, Oike Y, Kiyohara Y: Angiopoietin-like protein 2 and risk of type 2 diabetes in a general Japanese population: the Hisayama study. Diabetes Care. 2013; 36: 98-100.","日本人での新規炎症サイトカインangiopoietin-like protein(ANGPTL)2と2型糖尿病進展の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22966088","http://diabetes.ebm-library.jp/trial/detail/51308" "Hisayama Study","-","Mukai N, Ninomiya T, Hata J, Hirakawa Y, Ikeda F, Fukuhara M, Hotta T, Koga M, Nakamura U, Kang D, et al.: Association of hemoglobin A1c and glycated albumin with carotid atherosclerosis in community-dwelling Japanese subjects: the Hisayama Study. Cardiovasc Diabetol. 2015; 14: 84.","日本人において,HbA1c,糖化アルブミン,1,5-アンヒドログルシトール,空腹時血糖,食後2時間血糖と頸動脈内膜-中膜複合体肥厚の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26099223","http://diabetes.ebm-library.jp/trial/detail/51484" "Hisayama Study","-","Hirabayashi N, Hata J, Ohara T, Mukai N, Nagata M, Shibata M, Gotoh S, Furuta Y, Yamashita F, Yoshihara K, et al.: Association Between Diabetes and Hippocampal Atrophy in Elderly Japanese: The Hisayama Study. Diabetes Care. 2016; 39: 1543-9.","日本人の高齢者において,糖尿病と脳萎縮または海馬萎縮の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27385328","http://diabetes.ebm-library.jp/trial/detail/51589" "HOE 901/2004 study","-","HOE 901/2004 Study Investigators Group: Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diabet Med 2003; 20: 545-551.","経口血糖降下薬投与下の2型糖尿病患者において,2種類のインスリンglargineとNPHインスリンの有効性および安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/12823235","http://diabetes.ebm-library.jp/trial/detail/50624" "HOE 901/4001 Study","-","Fritsche A, Schweitzer MA, Haring HU, 4001 Study Group: Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952-959.","2型糖尿病患者において,朝または就寝時投与のglimepiride+インスリンglargine,および就寝時投与のglimepiride+NPHインスリンの有効性と安全性を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12809451","http://diabetes.ebm-library.jp/trial/detail/50600" "HOE 901/4007 Study","-","Hamann A, Matthaei S, Rosak C, Silvestre L, HOE901/4007 Study Group: A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003; 26: 1738-1744.","1型糖尿病患者において,インスリンglargineの朝食前投与,夕食前投与,就寝時投与の有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/12766103","http://diabetes.ebm-library.jp/trial/detail/50643" "HOME","Hyperinsulinemia: the Outcome of its Metabolic Effects","Kooy A, de Jager J, Lehert P, Bets D, Wulffel MG, Donker AJ, Stehouwer CD: Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009; 169: 616-25.","インスリン治療を受けている2型糖尿病患者において,metforminの代謝および心血管疾患に対する長期効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19307526","http://diabetes.ebm-library.jp/trial/detail/51181" "HOME","Hyperinsulinaemia: the Outcome of its Metabolic Effects","de Jager J, Kooy A, Lehert P, Wulffel MG, van der Kolk J, Bets D, Verburg J, Donker AJ, Stehouwer CD: Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010; 340: c2181.","インスリン治療を受けている2型糖尿病患者において,metforminのビタミンB12,葉酸,ホモシステインの血清濃度に対する効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20488910","http://diabetes.ebm-library.jp/trial/detail/51186" "Hong Kong Diabetes Registry","-","Yang X, So WY, Ma RC, Kong AP, Lee HM, Yu LW, Chow CC, Ozaki R, Ko GT, Chan JC: Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care. 2011; 34: 375-80.","HDL-C低値の2型糖尿病患者において,metforminの抗がん作用を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20980414","http://diabetes.ebm-library.jp/trial/detail/51216" "Honolulu Heart Program","-","Abbott RD, Donahue RP, MacMahon SW, Reed DM, Yano K: Diabetes and the risk of stroke. The Honolulu Heart Program. JAMA 1987; 257: 949-952.","日系人男性の糖尿病における脳卒中のリスクを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/3806877","http://diabetes.ebm-library.jp/trial/detail/50329" "Honolulu Heart Program","-","Donahue RP, Abbott RD, Reed DM, Yano K: Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987; 36: 689-692.","50g糖負荷試験による1時間後血糖値と,致死性冠動脈心疾患および非致死性心筋梗塞発症率との関係について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/3569669","http://diabetes.ebm-library.jp/trial/detail/50311" "Honolulu Heart Program","-","Rodriguez BL, Lau N, Burchfiel CM, Abbott RD, Sharp DS, Yano K, Curb JD: Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care 1999; 22: 1262-1265.","耐糖能低下とその後発症した冠動脈心疾患,CHD死亡,全死亡との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10480768","http://diabetes.ebm-library.jp/trial/detail/50320" "Honolulu Heart Program","-","Rodriguez BL, Abbott RD, Fujimoto W, Waitzfelder B, Chen R, Masaki K, Schatz I, Petrovitch H, Ross W, Yano K, Blanchette PL, Curb JD: The American Diabetes Association and World Health Organization classifications for diabetes: their impact on diabetes prevalence and total and cardiovascular disease mortality in elderly Japanese-American men. Diabetes Care 2002; 25: 951-955.","高齢日系人男性で,ADAおよびWHO基準による有病率の比較および全死亡と心血管死との関係の検討を行い,空腹時血糖値と75g OGTT 2時間値のいずれが全死亡と心血管死の予測因子であるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12032097","http://diabetes.ebm-library.jp/trial/detail/50527" "Hoorn Study","-","Alssema M, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ: Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study. Diabetes Care 2005; 28: 860-865.","インスリン値,プロインスリン値,インスリン抵抗性と全死亡および心血管疾患死との関係を検討し,さらにインスリン値またはプロインスリン値と死亡との関係におけるインスリン抵抗性および耐糖能の関与について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15793186","http://diabetes.ebm-library.jp/trial/detail/50748" "Hoorn Study","-","Snijder MB, Heine RJ, Seidell JC, Bouter LM, Stehouwer CD, Nijpels G, Funahashi T, Matsuzawa Y, Shimomura I, Dekker JM: Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the hoorn study. Diabetes Care 2006; 29: 2498-2503.","アディポネクチンレベルと2型糖尿病および糖代謝異常リスクの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17065691","http://diabetes.ebm-library.jp/trial/detail/50985" "Hoorn Study","-","Rijkelijkhuizen JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Dekker JM: High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. Diabetes Care 2007; 30: 332-336.","米国糖尿病学会では,空腹時血糖異常のカットオフ値を2003年に引き下げたが,この改訂が心血管疾患死リスクの評価に及ぼした影響を検討し,さらに,空腹時血糖異常から2型糖尿病への進行と心血管疾患死リスクの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17259503","http://diabetes.ebm-library.jp/trial/detail/50994" "HOPE","the Heart Outcomes Prevention Evaluation study","Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.","左室機能障害もしくは心不全のない高リスク患者に対するramiprilの心血管イベント抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10639539","http://diabetes.ebm-library.jp/trial/detail/50458" "HOPE","the Heart Outcomes Prevention Evaluation study","Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE Study Investigators: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.","微量アルブミン尿を有する糖尿病および非糖尿病患者の心血管イベントリスクを評価し,微量アルブミン尿の閾値以下のアルブミン尿で心血管リスクが増加するかどうかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11466120","http://diabetes.ebm-library.jp/trial/detail/50494" "HOPE","the Heart Outcome Prevention Evaluation trial","Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B, HOPE Study Investigators: Ramipril and the development of diabetes. JAMA 2001; 286: 1882-1885.","糖尿病の高リスク患者において,ramiprilの糖尿病発症抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11597291","http://diabetes.ebm-library.jp/trial/detail/50554" "HOPE","the Heart Outcomes and Prevention Evaluation study","Mann JF, Gerstein HC, Yi QL, Lonn EM, Hoogwerf BJ, Rashkow A, Yusuf S: Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14: 641-647.","心血管疾患のリスクを有する糖尿病および非糖尿病患者において,微量アルブミン尿が臨床的蛋白尿の予測因子であるか否かを検討し,ramiprilの腎障害に対する有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12595499","http://diabetes.ebm-library.jp/trial/detail/50613" "HOPE","the Heart Outcomes Prevention Evaluation study","Gerstein HC, Pogue J, Mann JF, Lonn E, Dagenais GR, McQueen M, Yusuf S, HOPE investigators: The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005; 48: 1749-1755.","糖尿病患者および非糖尿病患者において,空腹時血漿ブドウ糖値およびHbA1c値と心血管イベント,全死亡,心不全,顕性腎症との関係を検討した。HOPEのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/16059716","http://diabetes.ebm-library.jp/trial/detail/50826" "HOPE-TOO","the Heart Outcomes Prevention Evaluation study-The Ongoing Outcomes","Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S, HOPE/HOPE-TOO Study Investigators: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112: 1339-1346.","HOPE試験で認められたramiprilの心血管イベントリスク減少および糖尿病新規発症減少に対する有効性が,より長期の観察においても認められるかを検討し,その有効性をベースライン時のリスクおよび他の薬物治療によるサブグループにおいて検討した(HOPE延長試験)。","https://www.ncbi.nlm.nih.gov/pubmed/16129815","http://diabetes.ebm-library.jp/trial/detail/50766" "Horie I, et al.","−","Horie I, Kawasaki E, Sakanaka A, Takashima M, Maeyama M, Ando T, Hanada H, Kawakami A: Efficacy of nutrition therapy for glucose intolerance in Japanese women diagnosed with gestational diabetes based on IADPSG criteria during early gestation. Diabetes Res Clin Pract. 2015; 107: 400-6.","妊娠初期に妊娠糖尿病を発症した女性において,適切な栄養療法は妊娠中期における耐糖能障害を改善するかを後向きに検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25631609","http://diabetes.ebm-library.jp/trial/detail/51463" "HOT","the Hypertension Optimal Treatment study","Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.","糖尿病を伴う高血圧患者の至適拡張期血圧,低用量aspirinによる心血管合併症予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9635947","http://diabetes.ebm-library.jp/trial/detail/50012" "HPFS","the Health Professionals' Follow-up Study","Tanasescu M, Leitzmann MF, Rimm EB, Hu FB: Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation 2003; 107: 2435-2439.","2型糖尿病患者において,身体活動レベル,ウォーキングおよびその速度と,心血管疾患および死亡との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12719277","http://diabetes.ebm-library.jp/trial/detail/50597" "Hsu PF, et al.","-","Hsu PF, Sung SH, Cheng HM, Yeh JS, Liu WL, Chan WL, Chen CH, Chou P, Chuang SY: Association of clinical symptomatic hypoglycemia with cardiovascular events and total mortality in type 2 diabetes: a nationwide population-based study. Diabetes Care. 2013; 36: 894-900.","2型糖尿病患者において,軽症/重症の低血糖が,臨床転帰に与える影響を検討する。","https://www.ncbi.nlm.nih.gov/pubmed/23223349","http://diabetes.ebm-library.jp/trial/detail/51324" "Huang CC, et al.","−","Huang CC, Weng SF, Tsai KT, Chen PJ, Lin HJ, Wang JJ, Su SB, Chou W, Guo HR, Hsu CC: Long-term Mortality Risk After Hyperglycemic Crisis Episodes in Geriatric Patients With Diabetes: A National Population-Based Cohort Study. Diabetes Care. 2015; 38: 746-51.","高齢の2型糖尿病患者において,高血糖緊急症エピソード(HCE)後の長期間における死亡リスクを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25665811","http://diabetes.ebm-library.jp/trial/detail/51487" "Huxley RR, et al.","−","Huxley RR, Peters SA, Mishra GD, Woodward M: Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015; 3: 198-206.","1型糖尿病と全死亡および死因別死亡との関連に性差がみられるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25660575","http://diabetes.ebm-library.jp/trial/detail/51455" "HypoCOMPaSS","-","Little SA, Leelarathna L, Walkinshaw E, Tan HK, Chapple O, Lubina-Solomon A, Chadwick TJ, Barendse S, Stocken DD, Brennand C, et al.: Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care. 2014; 37: 2114-22.","","https://www.ncbi.nlm.nih.gov/pubmed/24854041","http://diabetes.ebm-library.jp/trial/detail/51419" "IDES_2","Italian Diabetes and Exercise Study 2","Balducci S, D'Errico V, Haxhi J, Sacchetti M, Orlando G, Cardelli P, Vitale M, Bollanti L, Conti F, Zanuso S, Lucisano G, Nicolucci A, Pugliese G; Italian Diabetes and Exercise Study 2 (IDES_2) Investigators. Effect of a Behavioral Intervention Strategy on Sustained Change in Physical Activity and Sedentary Behavior in Patients With Type 2 Diabetes: The IDES_2 Randomized Clinical Trial. JAMA. 2019; 321: 880-90.","2型糖尿病患者において,行動介入は身体活動の持続的な増加および座位時間の減少をもたらすか否かを検証した。","https://www.ncbi.nlm.nih.gov/pubmed/30835309","http://diabetes.ebm-library.jp/trial/detail/51762" "IDNT","the Irbesartan Diabetic Nephropathy Trial","Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.","2型糖尿病患者において,irbesartanまたはamlodipineの降圧作用とは独立した腎障害進展抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11565517","http://diabetes.ebm-library.jp/trial/detail/50483" "IDNT","the Irbesartan Diabetic Nephropathy Trial","Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, et al: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003; 138: 542-549.","顕性腎症を有し,従来の降圧療法を受けている2型糖尿病患者において,irbesartanまたはamlodipineを併用した場合の心血管イベントに対する有効性を,プラセボと比較した。","https://www.ncbi.nlm.nih.gov/pubmed/12667024","http://diabetes.ebm-library.jp/trial/detail/50586" "IDNT","the Irbesartan Diabetic Nephropathy Trial","Friedman AN, Hunsicker LG, Selhub J, Bostom AG, Collaborative Study Group: C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy. Kidney Int 2005; 68: 773-778.","腎症を伴う2型糖尿病患者において,C反応性蛋白値と動脈硬化性アウトカムおよびうっ血性心不全との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16014055","http://diabetes.ebm-library.jp/trial/detail/50782" "IDNT","the Irbesartan Diabetic Nephropathy Trial","Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, et al.: Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027-3037.","腎症および高血圧を有する2型糖尿病患者において,腎症進展抑制および全死亡率低下を図るための至適血圧を決定し,降圧薬の腎保護作用および達成血圧値と腎アウトカムの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16120823","http://diabetes.ebm-library.jp/trial/detail/50814" "IDNT","the Irbesartan Diabetic Nephropathy Trial","Friedman AN, Hunsicker LG, Selhub J, Bostom AG, Collaborative Study Group: Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. J Am Soc Nephrol 2005; 16: 3397-3402.","心血管リスクが高く,腎症を有する2型糖尿病患者において,血清ホモシステイン値と動脈硬化性アウトカムおよびうっ血性心不全との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16162814","http://diabetes.ebm-library.jp/trial/detail/50797" "Idorn T, et al.","-","Idorn T, Knop FK, Jrgensen MB, Jensen T, Resuli M, Hansen PM, Christensen KB, Holst JJ, Hornum M, Feldt-Rasmussen B: Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. Diabetes Care. 2016; 39: 206-13.","末期腎疾患を有する2型糖尿病患者におけるliraglutideの安全性と有効性に関連するパラメータを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26283739","http://diabetes.ebm-library.jp/trial/detail/51546" "IDPP-1","the Indian Diabetes Prevention Programme","Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, Indian Diabetes Prevention Programme (IDPP): The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49: 289-297.","耐糖能異常を認めるインド人において,ライフスタイル介入プログラムまたはmetformin投与による2型糖尿病発症抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16391903","http://diabetes.ebm-library.jp/trial/detail/50816" "IDPP","Indian Diabetes Prevention Programme","Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V: Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians--Result of Indian diabetes prevention programme. Diabetes Res Clin Pract 2007; 76: 215-218.","インド人の耐糖能異常患者において,メタボリックシンドロームの有病率を検討し,メタボリックシンドロームが糖尿病への進行リスクを増大させるか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16982107","http://diabetes.ebm-library.jp/trial/detail/51036" "ILLUMINATE","-","Kashiwagi A, Kazuta K, Goto K, Yoshida S, Ueyama E, Utsuno A. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2015 Mar;17(3):304-8.","日本人2型糖尿病患者において,metforminへのipragliflozin追加の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24919820","http://diabetes.ebm-library.jp/trial/detail/51662" "IMPACT","the Improving Mood-Promoting Access to Collaborative Treatment study","Williams JW, Katon W, Lin EH, Noel PH, Worchel J, Cornell J, Harpole L, Fultz BA, Hunkeler E, Mika VS, et al: The effectiveness of depression care management on diabetes-related outcomes in older patients. Ann Intern Med 2004; 140: 1015-1024.","抑うつ症状を有する高齢の糖尿病患者において,抑うつ症状の積極的ケアが精神面,機能面,糖尿病関連のアウトカムを改善するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15197019","http://diabetes.ebm-library.jp/trial/detail/50658" "IMPERIUM","Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus","Heller SR, Pratley RE, Sinclair A, Festa A, Kiljaski J, Brusko CS, Duan R, Heine RJ. Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM). Diabetes Obes Metab. 2018; 20: 148-56.","食事/運動療法および経口血糖低下薬治療下でコントロール不良の脆弱な高齢2型糖尿病患者において,2種類の血糖降下療法を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/28671753","http://diabetes.ebm-library.jp/trial/detail/51702" "Inaba M, et al.","-","Inaba M, Maekawa K, Okuno S, Imanishi Y, Hayashino Y, Emoto M, Shoji T, Ishimura E, Yamakawa T, Nishizawa Y: Impact of atherosclerosis on the relationship of glycemic control and mortality in diabetic patients on hemodialysis. Clin Nephrol. 2012; 78: 273-80.","維持血液透析を受けている2型糖尿病患者において,心血管疾患の合併が,生存における血糖コントロール改善のベネフィットに与える影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22541674","http://diabetes.ebm-library.jp/trial/detail/51330" "Inagaki N, et al.","-","Inagaki N, Goda M, Yokota S, Maruyama N, Iijima H. Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study. Expert Opin Pharmacother. 2015; 16: 1577-91.","日本人2型糖尿病患者において,canagliflozinの安全性と有効性をBMI別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26104600","http://diabetes.ebm-library.jp/trial/detail/51648" "Inagaki N, et al.","-","Inagaki N, Harashima S, Maruyama N, Kawaguchi Y, Goda M, Iijima H. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2016; 15: 89.","インスリン/食事/運動療法でコントロール不良の日本人2型糖尿病患者における,インスリンと併用したcanagliflozinの有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27316668","http://diabetes.ebm-library.jp/trial/detail/51651" "Indianapolis-Ibadan Dementia Project","-","Wessels AM, Lane KA, Gao S, Hall KS, Unverzagt FW, Hendrie HC: Diabetes and cognitive decline in elderly African Americans: a 15-year follow-up study. Alzheimers Dement. 2011; 7: 418-24.","高齢のアフリカ系米国人において,糖尿病により認知機能低下が加速するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21784353","http://diabetes.ebm-library.jp/trial/detail/51295" "INNOVATION","Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy","Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S, INNOVATION Study Group: Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30: 1577-1578.","日本人2型糖尿病患者において,早期腎症から顕性腎症への進行に対するtelmisartanの抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17389334","http://diabetes.ebm-library.jp/trial/detail/51022" "INNOVATION","Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy","Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S, INNOVATION Study Group: Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res 2008; 31: 657-664.","正常血圧の日本人2型糖尿病患者において,telmisartanが微量アルブミン尿から顕性腎症への進行を抑制するか否かを検討。INNOVATIONのpost-hoc解析。","https://www.ncbi.nlm.nih.gov/pubmed/18633177","http://diabetes.ebm-library.jp/trial/detail/51074" "INSIGHT","the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment study","Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Palmer CR, Rosenthal T, Ruilope LM: Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension 2000; 35: 1038-1042.","高血圧以外のリスク因子や高血圧のタイプが,降圧治療に応答する血圧値に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10818061","http://diabetes.ebm-library.jp/trial/detail/50384" "INSIGHT","the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment study","Mancia G, Brown M, Castaigne A, De Leeuw P, Palmer CR, Rosenthal T, Wagener G, Ruilope LM: Outcomes With Nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431-436.","高血圧を有する糖尿病患者において,co-amilozideおよびnifedipineの心血管死および心血管疾患に対する有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12623939","http://diabetes.ebm-library.jp/trial/detail/50570" "Insulin Glargine in Type 1 Diabetes","-","Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA: Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23: 639-643.","1型糖尿病患者において,インスリンglargineの血糖コントロールおよび低血糖発症抑制効果をNPHインスリンと比較した。","https://www.ncbi.nlm.nih.gov/pubmed/10834423","http://diabetes.ebm-library.jp/trial/detail/50398" "inTandem3 trial","-","Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, Pozzilli P, Gesty-Palmer D, Lapuerta P, Sim R, Danne T, McGuire DK, Kushner JA, Peters A, Strumph P. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med. 2017; 377: 2337-48.","インスリン療法を行っている成人1型糖尿病患者において,sotagliflozin追加の安全性と有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28899222","http://diabetes.ebm-library.jp/trial/detail/51700" "INTERVAL","Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy","Strain WD, Lukashevich V, Kothny W, Hoellinger MJ, Paldnius PM: Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet. 2013; 382: 409-16.","高齢の2型糖尿病患者において,DPP-4阻害薬vildagliptinを用いた24週後の個別目標の設定と達成の実現可能性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23706759","http://diabetes.ebm-library.jp/trial/detail/51349" "Inukai K, et al.","-","Inukai K, Watanabe M, Nakashima Y, Sawa T, Takata N, Tanaka M, Kashiwabara H, Yokota K, Suzuki M, Kurihara S, et al: Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diabetes Res Clin Pract 2005; 68: 250-257.","従来のスルホニル尿素薬投与下で血糖コントロール不良の日本人2型糖尿病患者において,glimepirideの有効性を検討。","https://www.ncbi.nlm.nih.gov/pubmed/15936468","http://diabetes.ebm-library.jp/trial/detail/50794" "INVEST","the INternational VErapamil SR-Trandolapril STudy","Cooper-Dehoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, Pepine CJ, INVEST Investigators: Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol 2006; 98: 890-894.","降圧薬投与下の冠動脈疾患患者において,糖尿病発症の予測因子を検討した。INVESTのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/16996868","http://diabetes.ebm-library.jp/trial/detail/50963" "INVEST","International Verapamil SR-Trandolapril Study","Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ: Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010; 304: 61-8.","高血圧と冠動脈疾患を有する糖尿病患者において,目標SBP値達成と心血管アウトカムの関連を検討した。INVESTの二次解析。","https://www.ncbi.nlm.nih.gov/pubmed/20606150","http://diabetes.ebm-library.jp/trial/detail/51190" "IOLITE","−","Ishihara H, Yamaguchi S, Nakao I, Okitsu A, Asahina S. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study. Diabetes Obes Metab. 2016; 18: 1207-1216.","インスリン治療の早期ステージの日本人2型糖尿病患者において,ipragliflozin追加の有効性と安全性を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/27436788","http://diabetes.ebm-library.jp/trial/detail/51622" "Iowa Women's Health Study","-","Pereira MA, Parker ED, Folsom AR: Coffee consumption and risk of type 2 diabetes mellitus: an 11-year prospective study of 28 812 postmenopausal women. Arch Intern Med 2006; 166: 1311-1316.","コーヒー摂取量と2型糖尿病発症リスクの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16801515","http://diabetes.ebm-library.jp/trial/detail/50838" "IRAS","the Insulin Resistance Atherosclerosis Study","Haffner SM, Agostino RD, Saad MF, O'Leary DH, Savage PJ, Rewers M, Selby J, Bergman RN, Mykkanen L: Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study). Am J Cardiol 2000; 85: 1395-1400.","冠動脈疾患を認めない糖尿病患者において,アテローム性動脈硬化の進行状態を検討するため,総頸動脈および内頸動脈の内膜-中膜壁肥厚を糖尿病および冠動脈疾患の有無により比較した。","https://www.ncbi.nlm.nih.gov/pubmed/10856382","http://diabetes.ebm-library.jp/trial/detail/50729" "IRAS","the Insulin Resistance Atherosclerosis Study","D'Agostino RB, Hamman RF, Karter AJ, Mykkanen L, Wagenknecht LE, Haffner SM, Insulin Resistance Atherosclerosis Study Investigators: Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care 2004; 27: 2234-2240.","心血管疾患のリスク因子が2型糖尿病発症に関する予測因子となるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15333490","http://diabetes.ebm-library.jp/trial/detail/50669" "IRAS","Insulin Resistance Atherosclerosis Study","Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB, Kempf J, Zinman B, Haffner SM, insulin resistance atherosclerosis study: Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004; 53: 2623-2632.","肝機能マーカー上昇と2型糖尿病発症リスクとの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15448093","http://diabetes.ebm-library.jp/trial/detail/50684" "IRAS","the Insulin Resistance Atherosclerosis Study","Foy CG, Bell RA, Farmer DF, Goff DC, Wagenknecht LE: Smoking and incidence of diabetes among U.S. adults: findings from the Insulin Resistance Atherosclerosis Study. Diabetes Care 2005; 28: 2501-2507.","喫煙と糖尿病発症との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16186287","http://diabetes.ebm-library.jp/trial/detail/50803" "IRAS","the Insulin Resistance Atherosclerosis Study","Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM: Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 2006; 113: 1753-1759.","プラスミノーゲン活性化抑制因子-1およびフィブリノーゲンの変化と2型糖尿病新規発症との関係を検討した。IRASのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/16585388","http://diabetes.ebm-library.jp/trial/detail/50830" "IRMA2","Irbesartan in patients with type 2 diabetes and Microalbuminuria study","Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.","2型糖尿病および微量アルブミン尿を有する高血圧患者において,irbesartanの腎保護作用を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/11565519","http://diabetes.ebm-library.jp/trial/detail/50485" "ISAR-DIABETES","the Intracoronary Stenting and Angiographic Results: Do Diabetic Patients Derive Similar Benefit from Paclitaxel-Eluting and Sirolimus-Eluting Stents study","Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A, et al: Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663-670.","冠動脈疾患を有する糖尿病患者において,paclitaxel溶出ステントとsirolimus溶出ステントの有効性を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16105990","http://diabetes.ebm-library.jp/trial/detail/50772" "ISAR-SMART","Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries","Mehilli J, Kastrati A, Dirschinger J, Dotzer F, Pache J, Hausleiter J, Kramer W, Schuhlen H, Schomig A: Comparison of stenting with balloon angioplasty for lesions of small coronary vessels in patients with diabetes mellitus. Am J Med 2002; 112: 13-18.","糖尿病患者の細い冠血管病変において,ステント植込み術とPTCAの効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11812401","http://diabetes.ebm-library.jp/trial/detail/50504" "ISAR-SWEET","Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics study","Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, et al.: Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004; 110: 3627-3635.","高用量のclopidogrelの前投与後に待機的経皮的冠動脈インターベンションを施行された糖尿病患者において,abciximabのアウトカムに対する有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15531766","http://diabetes.ebm-library.jp/trial/detail/50753" "Italian Microalbuminuria Study","-","Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, Spalluto A, Vanasia A, Villa GM, Nosadini R: Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Microalbuminuria Study Group in IDDM. Diabetes Care 1998; 21: 104-110.","正常血圧IDDM患者の微量アルブミン尿から顕性蛋白尿への進展に対するlisinoprilとnifedipineの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9538979","http://diabetes.ebm-library.jp/trial/detail/50212" "Italian Multicenter Lispro Study","-","Valle D, Santoro D, Bates P, Scarpa L; Italian Multicentre Lispro Study Group: Italian multicentre study of intensive therapy with insulin lispro in 1184 patients with Type 1 diabetes. Diabetes Nutr Metab 2001; 14: 126-132.","1型糖尿病患者において,insulin lisproとヒトレギュラーインスリンの臨床効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11476359","http://diabetes.ebm-library.jp/trial/detail/50499" "Ito D, et al.","-","Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, Inukai K, Akiyama Y, Morimoto Y, Noda M, Shimada A. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. Diabetes Care. 2017; 40: 1364-72.","非アルコール性脂肪性肝疾患を合併した2型糖尿病患者において,ipragliflozinとpioglitazoneの有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/28751548","http://diabetes.ebm-library.jp/trial/detail/51679" "Iwamoto J, et al.","-","Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H: Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Diabetes Res Clin Pract. 2011; 93: 166-73.","骨粗鬆症を有する日本人の閉経後女性において,3年間のビスホスホネート製剤alendronate(ALN)治療のアウトカムを糖尿病例と非糖尿病例で比較した。","https://www.ncbi.nlm.nih.gov/pubmed/21524811","http://diabetes.ebm-library.jp/trial/detail/51243" "Iwao T, et al.","-","Iwao T, Sakai K, Ando E: Upper limit of fasting plasma glucose level defined by oral glucose tolerance test in Japanese subjects. Diabetes Res Clin Pract. 2013; 99: 272-6.","日本人において,75g経口糖負荷試験で評価した正常空腹時血漿グルコースの上限値を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23317759","http://diabetes.ebm-library.jp/trial/detail/51323" "J-DOIT3","Japan Diabetes Optimal Treatment study for 3 major risk factors of cardiovascular diseases","Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, et al.; J-DOIT3 Study Group: Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017; 5: 951-64.","2型糖尿病患者において,血管合併症と死亡の予防のための強化統合的介入の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29079252","http://diabetes.ebm-library.jp/trial/detail/51690" "J-LIT","the Japan Lipid Intervention Trial","Shimamoto K, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Itakura H, et al.: Effects of hypertension and type 2 diabetes mellitus on the risk of total cardiovascular events in Japanese patients with hypercholesterolemia: implications from the Japan Lipid Intervention Trial (J-LIT). Hypertens Res 2007; 30: 119-123.","日本人の高コレステロール血症患者において,心血管イベントと糖尿病および血圧レベルとの関係を検討した。J-LITのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/17460381","http://diabetes.ebm-library.jp/trial/detail/51001" "J-MIND","the Japan Multicenter Investigation of Antihypertensive Treatment For Nephropathy in Diabetics","Baba S; The J-MIND Study Group: Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001; 54: 191-201.","高血圧を有する2型糖尿病患者において,nifedipine(徐放錠)の腎症発症および進展抑制効果と安全性をenalaprilと比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11689274","http://diabetes.ebm-library.jp/trial/detail/50501" "J-STEP/INS","-","Terauchi Y, Tamura M, Senda M, Gunji R, Kaku K. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. Diabetes Obes Metab. 2017; 19: 1397-407. ","インスリン治療下でコントロール不良の2型糖尿病患者において,tofogliflozin追加の有効性と安全性を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/28371205","http://diabetes.ebm-library.jp/trial/detail/51685" "James C, et al.","-","James C, Bullard KM, Rolka DB, Geiss LS, Williams DE, Cowie CC, Albright A, Gregg EW: Implications of alternative definitions of prediabetes for prevalence in U.S. adults. Diabetes Care. 2011; 34: 387-91.","HbA1c,FPG,OGTTの基準により前糖尿病の有病率を比較し,各基準の一致度を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21270196","http://diabetes.ebm-library.jp/trial/detail/51255" "Janghorbani M, et al.","-","Janghorbani M, Jones RB, Gilmour WH, Hedley AJ, Zhianpour M: A prospective population based study of gender differential in mortality from cardiovascular disease and "all causes" in asymptomatic hyperglycaemics. J Clin Epidemiol 1994; 47: 397-405.","無症候性高血糖の心血管疾患や全死因の死亡率に対する影響を男女に分けて検討した。","https://www.ncbi.nlm.nih.gov/pubmed/7730865","http://diabetes.ebm-library.jp/trial/detail/50327" "Japan CDM","Japan Cholesterol and Diabetes Mellitus Study","Hayashi T, Kawashima S, Itoh H, Yamada N, Sone H, Watanabe H, Hattori Y, Ohrui T, Yokote K, Nomura H, et al.; Japan CDM Group: Low HDL cholesterol is associated with the risk of stroke in elderly diabetic individuals: changes in the risk for atherosclerotic diseases at various ages. Diabetes Care. 2009; 32: 1221-3.","日本人の2型糖尿病患者において,脂質値,血糖値,血圧と虚血性心疾患および脳血管疾患の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19509009","http://diabetes.ebm-library.jp/trial/detail/51199" "JAPAN-IDDM","Japanese trial of ACE inhibitors on renal protection against nephropathy in IDDMs","Katayama S, Kikkawa R, Isogai S, Sasaki N, Matsuura N, Tajima N, Urakami T, Uchigata Y, Ohashi Y: Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Res Clin Pract 2002; 55: 113-121.","日本人の1型糖尿病患者におけるcaptoprilおよびimidaprilの腎保護作用を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11796177","http://diabetes.ebm-library.jp/trial/detail/50518" "Japanese American Community Diabetes Study","-","Hayashi T, Boyko EJ, McNeely MJ, Leonetti DL, Kahn SE, Fujimoto WY: Minimum waist and visceral fat values for identifying Japanese Americans at risk for the metabolic syndrome. Diabetes Care 2007; 30: 120-127.","日系アメリカ人において,メタボリックシンドローム例を特定する際の腹部肥満に関する至適カットオフ値を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17192344","http://diabetes.ebm-library.jp/trial/detail/50972" "Japanese American Community Diabetes Study","−","Hwang YC, Hayashi T, Fujimoto WY, Kahn SE, Leonetti DL, McNeely MJ, Boyko EJ: Differential Association Between HDL Subclasses and the Development of Type 2 Diabetes in a Prospective Study of Japanese Americans. Diabetes Care. 2015; 38: 2100-5.","非糖尿病の日系アメリカ人において,HDL-Cおよびそのサブクラス(HDL2-C,HDL3-C)と2型糖尿病発症リスクとの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26384391","http://diabetes.ebm-library.jp/trial/detail/51530" "Japanese-Brazilian Diabetes Study","-","Freire RD, Cardoso MA, Gimeno SG, Ferreira SR, Japanese-Brazilian Diabetes Study Group: Dietary fat is associated with metabolic syndrome in Japanese Brazilians. Diabetes Care 2005; 28: 1779-1785.","代謝異常の高リスクである日系ブラジル人において,栄養摂取量とメタボリックシンドロームとの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15983334","http://diabetes.ebm-library.jp/trial/detail/50790" "JDCS","the Japan Diabetes Complications Study","Sone H, Katagiri A, Ishibashi S, Abe R, Saito Y, Murase T, Yamashita H, Yajima Y, Ito H, Ohashi Y, et al: Effects of lifestyle modifications on patients with type 2 diabetes: the Japan Diabetes Complications Study (JDCS) study design, baseline analysis and three year-interim report. Horm Metab Res 2002; 34: 509-515.","2型糖尿病患者において,長期にわたる生活習慣改善プログラムにより血糖コントロールが改善し,糖尿病合併症を予防するか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12384828","http://diabetes.ebm-library.jp/trial/detail/50572" "JDCS"," the Japan Diabetes Complications Study","Sone H, Mizuno S, Fujii H, Yoshimura Y, Yamasaki Y, Ishibashi S, Katayama S, Saito Y, Ito H, Ohashi Y, et al.: Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care 2005; 28: 1463-1471.","日本人の2型糖尿病患者において,WHO基準およびNCEP基準によるメタボリックシンドロームの有病率を検討し,メタボリックシンドロームが心血管疾患の予測能を有するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15920069","http://diabetes.ebm-library.jp/trial/detail/50761" "JDCS","Japan Diabetes Complications Study","Sone H, Tanaka S, Iimuro S, Tanaka S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Yamashita H, et al.; Japan Diabetes Complications Study Group: Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia. 2010; 53: 419-28.","糖尿病患者において,生活習慣改善のための治療的介入は,血管合併症の発症を抑制するか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20054522","http://diabetes.ebm-library.jp/trial/detail/51413" "JDCS","Japan Diabetes Complications Study","Katayama S, Moriya T, Tanaka S, Tanaka S, Yajima Y, Sone H, Iimuro S, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study Group: Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS). Diabetologia. 2011; 54: 1025-31.","日本人の2型糖尿病患者において,正常および軽度な微量アルブミン尿から糖尿病性腎症への移行率および関連因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21286682","http://diabetes.ebm-library.jp/trial/detail/51220" "JDCS","Japan Diabetes Complications Study","Kawasaki R, Tanaka S, Tanaka S, Yamamoto T, Sone H, Ohashi Y, Akanuma Y, Yamada N, Yamashita H; Japan Diabetes Complications Study Group: Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow-up study of the Japan Diabetes Complications Study (JDCS). Diabetologia. 2011; 54: 2288-94.","日本人の2型糖尿病患者において,糖尿病網膜症の発症率および進展率,それらのリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21630126","http://diabetes.ebm-library.jp/trial/detail/51268" "JDCS","Japan Diabetes Complications Study","Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Ohashi Y, et al.; Japan Diabetes Complications Study Group: Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab. 2011; 96: 3448-56.","日本人の2型糖尿病患者において,冠動脈疾患(CHD)と脳卒中の発症およびリスク因子の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21865372","http://diabetes.ebm-library.jp/trial/detail/51384" "JDCS","Japan Diabetes Complications Study","Sone H, Tanaka S, Tanaka S, Suzuki S, Seino H, Hanyu O, Sato A, Toyonaga T, Okita K, Ishibashi S, et al.; Japan Diabetes Complications Study Group: Leisure-time physical activity is a significant predictor of stroke and total mortality in Japanese patients with type 2 diabetes: analysis from the Japan Diabetes Complications Study (JDCS). Diabetologia. 2013; 56: 1021-30.","日本人の2型糖尿病患者において,余暇の運動と心血管イベントおよび全死亡の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23443242","http://diabetes.ebm-library.jp/trial/detail/51306" "JDCS","Japan Diabetes Complications Study","Moriya T, Tanaka S, Kawasaki R, Ohashi Y, Akanuma Y, Yamada N, Sone H, Yamashita H, Katayama S; Japan Diabetes Complications Study Group: Diabetic retinopathy and microalbuminuria can predict macroalbuminuria and renal function decline in Japanese type 2 diabetic patients: Japan Diabetes Complications Study. Diabetes Care. 2013; 36: 2803-9.","2型糖尿病患者において,糖尿病網膜症と糖尿病腎症の相互関係を検討し,糖尿病網膜症と微量アルブミンが,顕性アルブミン尿発症および腎機能低下に与える影響を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/23620478","http://diabetes.ebm-library.jp/trial/detail/51360" "JDCS","Japan Diabetes Complications Study","Tanaka S, Yoshimura Y, Kamada C, Tanaka S, Horikawa C, Okumura R, Ito H, Ohashi Y, Akanuma Y, Yamada N, et al.; Japan Diabetes Complications Study Group: Intakes of dietary fiber, vegetables, and fruits and incidence of cardiovascular disease in Japanese patients with type 2 diabetes. Diabetes Care. 2013; 36: 3916-22.","日本人の2型糖尿病患者において,食物繊維(水溶性食物繊維,不溶性食物繊維),野菜,および果実の摂取量と,脳卒中発症および冠動脈性心疾患発症との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24170762","http://diabetes.ebm-library.jp/trial/detail/51378" "JDCS","Japan Diabetes Complications Study","Horikawa C, Kamada C, Tanaka S, Tanaka S, Araki A, Ito H, Matsunaga S, Fujihara K, Yoshimura Y, Ohashi Y, Akanuma Y, Sone H; Japan Diabetes Complications Study Group. Meat intake and incidence of cardiovascular disease in Japanese patients with type 2 diabetes: analysis of the Japan Diabetes Complications Study (JDCS). Eur J Nutr. 2017 Dec 8. doi: 10.1007/s00394-017-1592-y.","日本人2型糖尿病患者において,肉の摂取量と心血管疾患発症の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29222638","http://diabetes.ebm-library.jp/trial/detail/51698" "JDCS/J-EDIT","Japan Diabetes Complications Study/Japanese Elderly Diabetes Intervention Trial","Tanaka S, Tanaka S, Iimuro S, Yamashita H, Katayama S, Akanuma Y, Yamada N, Araki A, Ito H, Sone H, et al.; Japan Diabetes Complications Study GroupJapanese Elderly Diabetes Intervention Trial Group: Predicting macro- and microvascular complications in type 2 diabetes: the Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care. 2013; 36: 1193-9.","2型糖尿病における大血管合併症および細小血管合併症のリスク算出のためのリスクエンジンを開発し,妥当性を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/23404305","http://diabetes.ebm-library.jp/trial/detail/51344" "JDDM 11","the Japan Diabetes Clinical Data Management Study","Hirao K, Arai K, Yamauchi M, Takagi H, Kobayashi M, Japan Diabetes Clinical Data Management Study Group: Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). Diabetes Res Clin Pract 2008; 79: 171-176.","インスリン投与歴のない日本人2型糖尿病患者において,二相性インスリンaspart 30の1日2回皮下注とインスリンaspartの1日頻回皮下注の血糖コントロールを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/17919762","http://diabetes.ebm-library.jp/trial/detail/51049" "JDDM36","Japan Diabetes Clinical Data Management study","Yokoyama H, Araki S, Kawai K, Hirao K, Oishi M, Sugimoto K, Sone H, Maegawa H, Kashiwagi A; Japan Diabetes Clinical Data Management Study Group: Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36). Diabetes Res Clin Pract. 2015; 109: 485-92.","心血管疾患のない2型糖尿病患者において,心血管イベントと死亡に対するpioglitazoneの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26261056","http://diabetes.ebm-library.jp/trial/detail/51500" "JGSG","Japan Gestational Diabetes Study Group","Sugiyama T, Metoki H, Hamada H, Nishigori H, Saito M, Yaegashi N, Kusaka H, Kawano R, Ichihara K, Yasuhi I, et al.; Japan Gestational Diabetes Study Group: A retrospective multi-institutional study of treatment for mild gestational diabetes in Japan. Diabetes Res Clin Pract. 2014; 103: 412-8.","日本における軽度妊娠糖尿病の治療は妊娠アウトカムを改善するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24485857","http://diabetes.ebm-library.jp/trial/detail/51387" "Ji L, et al.","-","Ji L, Li H, Guo X, Li Y, Hu R, Zhu Z: Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial. PLoS One. 2013; 8: e57222.","新規診断2型糖尿病患者において,metformin単独療法の有効性を,正常体重例,過体重例,肥満例で比較した。","https://www.ncbi.nlm.nih.gov/pubmed/23468941","http://diabetes.ebm-library.jp/trial/detail/51345" "Jin SM, et al.","-","Jin SM, Park SW, Yoon KH, Min KW, Song KH, Park KS, Park JY, Park IB, Chung CH, Baik SH, Choi SH, Lee HW, Lee IK, Kim DM, Lee MK. Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension. Diabetes Obes Metab. 2015; 17: 511-5.","コントロール不良の2型糖尿病患者において,metforminへの追加療法としてのanagliptinとsitagliptinの有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/25523633","http://diabetes.ebm-library.jp/trial/detail/51649" "JMIC-B","the Japan Multicenter Investigation for Cardiovascular Diseases-B","Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, et al: Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis. Hypertens Res 2004; 27: 449-456.","冠動脈疾患を有する日本人高血圧患者において,nifedipine(徐放錠)とACE阻害薬の心イベント抑制効果を,糖尿病例と非糖尿病例で比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15302980","http://diabetes.ebm-library.jp/trial/detail/50707" "JMS Cohort Study","Jichi Medical School Cohort Study","Yano Y, Kario K, Ishikawa S, Ojima T, Gotoh T, Kayaba K, Tsutsumi A, Shimada K, Nakamura Y, Kajii E; JMS Cohort Study Group: Associations between diabetes, leanness, and the risk of death in the Japanese general population: the jichi medical school cohort study. Diabetes Care. 2013; 36: 1186-92.","日本人の一般集団において,糖尿病と全死亡・心血管疾患死・癌死リスクの関連を,BMIの影響を考慮して検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23250802","http://diabetes.ebm-library.jp/trial/detail/51321" "Johnson JA.","","Johnson JA, Bowker SL: Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia. 2011; 54: 25-31.","2型糖尿病患者において,血糖コントロールの改善ががん発生またはがん死亡率のリスクを低下させるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20959956","http://diabetes.ebm-library.jp/trial/detail/51223" "Johnson JA.","-","Johnson JA, Bowker SL, Richardson K, Marra CA: Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011; 54: 2263-71.","2型糖尿病患者において,糖尿病発症後の追跡期間における各測定時で,特定部位のがんのリスクを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21748485","http://diabetes.ebm-library.jp/trial/detail/51218" "Joslin Proteinuria Cohort study","-","Skupien J, Warram JH, Smiles AM, Niewczas MA, Gohda T, Pezzolesi MG, Cantarovich D, Stanton R, Krolewski AS: The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int. 2012; 82: 589-97.","腎機能正常で蛋白尿を認める1型糖尿病患者において,早期の推算糸球体濾過量低下と末期腎疾患の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22622493","http://diabetes.ebm-library.jp/trial/detail/51331" "JPAD","Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes trial","Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y, Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators: Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300: 2134-2141.","日本人の2型糖尿病患者において,低用量aspirin治療の動脈硬化性イベントに対する一次予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18997198","http://diabetes.ebm-library.jp/trial/detail/51113" "JPAD","Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes trial","Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, Jinnouchi H, Waki M, Soejima H, Sugiyama S, et al.; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial Investigators: Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care. 2011; 34: 280-5.","腎機能障害を認める日本人の2型糖尿病患者において,動脈硬化イベントの一次予防における低用量aspirinの有効性を検討した(JPAD試験のサブ解析)。","https://www.ncbi.nlm.nih.gov/pubmed/21270185","http://diabetes.ebm-library.jp/trial/detail/51234" "JPAD","Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes","Saito Y, Okada S, Ogawa H, Soejima H, Sakuma M, Nakayama M, Doi N, Jinnouchi H, Waki M, Masuda I, et al.; JPAD Trial Investigators: Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial. Circulation. 2017; 135: 659-670.","日本人2型糖尿病患者を対象に,低用量aspirinの心血管疾患一次予防における長期の有効性および安全性を検討した。JPADの延長試験。","https://www.ncbi.nlm.nih.gov/pubmed/27881565","http://diabetes.ebm-library.jp/trial/detail/51639" "JPHC","Japan Public Health Center-Based Prospective Study","Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S: Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006; 166: 1871-1877.","日本で実施された大規模コホート研究のデータを用いて,糖尿病の既往と癌発症リスクの関係について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17000944","http://diabetes.ebm-library.jp/trial/detail/50967" "JPHC","Japan Public Health Center-based Prospective Study","Kurotani K, Nanri A, Goto A, Mizoue T, Noda M, Oba S, Kato M, Matsushita Y, Inoue M, Tsugane S; for the Japan Public Health Center-based Prospective Study Group: Red meat consumption is associated with the risk of type 2 diabetes in men but not in women: a Japan Public Health Center-based Prospective Study. Br J Nutr. 2013; 1-9.","肉類(全肉類,全赤身肉,未加工の赤身肉,加工肉,鶏肉)の摂取と2型糖尿病発症リスクとの関連を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/23651531","http://diabetes.ebm-library.jp/trial/detail/51329" "JPHC","Japan Public Health Centerbased Prospective Study","Akter S, Kurotani K, Kashino I, Goto A, Mizoue T, Noda M, Sawada N, Tsugane S; Japan Public Health Centerbased Prospective Study Group: High Dietary Acid Load Score Is Associated with Increased Risk of Type 2 Diabetes in Japanese Men: The Japan Public Health Center-based Prospective Study. J Nutr. 2016 ;146:1076-83.","日本の成人において,食事の酸性度と2型糖尿病発症との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27052540","http://diabetes.ebm-library.jp/trial/detail/51598" "JUPITER","Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin","Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ: Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012; 380: 565-71.","一次予防におけるスタチン療法の心血管ベネフィットと糖尿病リスクを検討した(JUPITER試験のサブ解析)。","https://www.ncbi.nlm.nih.gov/pubmed/22883507","http://diabetes.ebm-library.jp/trial/detail/51276" "Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study","-","Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, , Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, et al.: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359: 1464-1476.","成人および小児の1型糖尿病患者において,持続的血糖モニタリングの有効性および安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18779236","http://diabetes.ebm-library.jp/trial/detail/51096" "Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study","-","Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care. 2009; 32: 1378-83.","強化インスリン療法によりHbA1c値<7.0%が達成されている成人および小児の1型糖尿病患者において,持続的血糖モニタリングの有効性および安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19429875","http://diabetes.ebm-library.jp/trial/detail/51172" "Kadowaki T, et al.","-","Kadowaki T, Sarai N, Hirakawa T, Taki K, Iwasaki K, Urushihara H. Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis. Diabetes Obes Metab. 2018; 20: 2830-9.","日本人2型糖尿病患者において,経口糖尿病治療薬のクラス別に治療継続性,患者特性,腎障害重症度を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/29974673","http://diabetes.ebm-library.jp/trial/detail/51742" "Kadowaki T, et al.","-","Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Iijima H, Watanabe Y, Gouda M. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017; 19: 874-82.","コントロール不良の日本人2型糖尿病患者において,teneligliptinへのcanagliflozin追加の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28177187","http://diabetes.ebm-library.jp/trial/detail/51668" "Kadowaki T, et al.","-","Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Watanabe Y, Gouda M, Iijima H. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.","teneligliptin単独療法でコントロール不良の2型糖尿病患者において,canagliflozin追加の長期安全性および有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28608617","http://diabetes.ebm-library.jp/trial/detail/51701" "Kahleova H, et al.","-","Kahleova H, Belinova L, Malinska H, Oliyarnyk O, Trnovska J, Skop V, Kazdova L, Dezortova M, Hajek M, Tura A, et al.: Eating two larger meals a day (breakfast and lunch) is more effective than six smaller meals in a reduced-energy regimen for patients with type 2 diabetes: a randomised crossover study. Diabetologia. 2014; 57: 1552-60.","2型糖尿病患者において,1日6食と1日2食の食事回数で,体重,肝脂肪量,インスリン抵抗性,β細胞機能を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24838678","http://diabetes.ebm-library.jp/trial/detail/51394" "Kaku K, et al.","-","Kaku K, Haneda M, Tanaka Y, Lee G, Shiki K, Miyamoto Y, Solimando F, Lee J, Lee C, George J. Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial. Diabetes Obes Metab. 2019; 21: 136-45.","empagliflozin単独療法でコントロール不良の日本人2型糖尿病患者において,empagliflozin/linagliptin固定用量合剤の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30091172","http://diabetes.ebm-library.jp/trial/detail/51743" "Kansai Healthcare Study","-","Sato KK, Hayashi T, Kambe H, Nakamura Y, Harita N, Endo G, Yoneda T: Walking to work is an independent predictor of incidence of type 2 diabetes in Japanese men: the Kansai Healthcare Study. Diabetes Care 2007; 30: 2296-2298.","日本人男性において,徒歩による通勤時間と2型糖尿病の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17536075","http://diabetes.ebm-library.jp/trial/detail/51016" "Kansai Healthcare Study","-","Sato KK, Hayashi T, Nakamura Y, Harita N, Yoneda T, Endo G, Kambe H: Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care. 2008; 31: 1230-6.","日本人男性において,アルコール消費量および肝酵素と2型糖尿病の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18316395","http://diabetes.ebm-library.jp/trial/detail/51191" "Kansai Healthcare Study","-","Harita N, Hayashi T, Sato KK, Nakamura Y, Yoneda T, Endo G, Kambe H: Lower serum creatinine is a new risk factor of type 2 diabetes: the Kansai healthcare study. Diabetes Care. 2009; 32: 424-6.","日本人男性において,血清クレアチニン値と2型糖尿病との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19074997","http://diabetes.ebm-library.jp/trial/detail/51166" "Kashiwa Study","-","Yamada T, Komatsu M, Komiya I, Miyahara Y, Shima Y, Matsuzaki M, Ishikawa Y, Mita R, Fujiwara M, Furusato N, et al: Development, progression, and regression of microalbuminuria in Japanese patients with type 2 diabetes under tight glycemic and blood pressure control: the Kashiwa study. Diabetes Care 2005; 28: 2733-2738.","血圧および血糖コントロール良好の日本人の2型糖尿病患者において,アルブミン尿の長期的予後を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16249548","http://diabetes.ebm-library.jp/trial/detail/50786" "Kautzky-Willer A, et al.","","Kautzky-Willer A, Kosi L, Lin J, Mihaljevic R: Gender-based differences in glycaemic control and hypoglycaemia prevalence in patients with type 2 diabetes: results from patient-level pooled data of six randomized controlled trials. Diabetes Obes Metab. 2015; 17: 533-40.","インスリン治療下の2型糖尿病患者において,性別が血糖コントロールおよび低血糖症発症に与える影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25678212","http://diabetes.ebm-library.jp/trial/detail/51479" "Kawamori R, et al.","-","Ryuzo Kawamori, Kohei Kaku, Toshiaki Hanafusa, Daisuke Kashiwabara, Shigeru Kageyama and Nigishi Hotta; Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus. J Diabetes Invest. 2012; 3: 302-308.","食事療法および運動療法施行歴のある日本人の2型糖尿病患者において,repaglinideとnateglinideの有効性および安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24843581","http://diabetes.ebm-library.jp/trial/detail/51231" "Kawamori R, et al.","-","Kawamori R, Haneda M, Suzaki K, Cheng G, Shiki K, Miyamoto Y, Solimando F, Lee C, Lee J, George J. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2018; 20: 2200-9. ","コントロール不良の日本人2型糖尿病患者において,empagliflozin/linagliptin固定用量合剤の有効性と安全性をlinagliptinと比較した。","https://www.ncbi.nlm.nih.gov/pubmed/29766636","http://diabetes.ebm-library.jp/trial/detail/51737" "Khunti K, et al.","-","Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK: Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015; 38: 316-22.","インスリン治療を行っている1型および2型糖尿病患者において,低血糖,心血管イベント,全死亡の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25492401","http://diabetes.ebm-library.jp/trial/detail/51448" "Kitwitee P, et al.","-","Kitwitee P, Limwattananon S, Limwattananon C, Waleekachonlert O, Ratanachotpanich T, Phimphilai M, Nguyen TV, Pongchaiyakul C: Metformin for the treatment of gestational diabetes: An updated meta-analysis. Diabetes Res Clin Pract. 2015; 109: 521-32.","妊娠糖尿病を有する妊婦において,metforminとインスリンの有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/26117686","http://diabetes.ebm-library.jp/trial/detail/51501" "Klein BE, et al.","-","Klein BE, Moss SE, Klein R: Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990; 13: 34-40.","妊娠が糖尿病網膜症に及ぼす影響を調査した。","https://www.ncbi.nlm.nih.gov/pubmed/2404715","http://diabetes.ebm-library.jp/trial/detail/50346" "KLIS","the Kyushu Lipid Intervention Study","Iwashita M, Matsushita Y, Sasaki J, Arakawa K, Kono S, Kyushu Lipid Intervention Study (KLIS) Group: Relation of serum total cholesterol and other risk factors to risk of coronary events in middle-aged and elderly Japanese men with hypercholesterolemia: the Kyushu Lipid Intervention Study. Circ J 2004; 68: 405-409.","血清総コレステロール値の中等度上昇を認める日本人の中年および老年男性において,冠動脈心疾患イベントと血清総コレステロール値およびその他のリスク因子との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15118279","http://diabetes.ebm-library.jp/trial/detail/50689" "KNDP","Korean National Diabetes Program","Chin SO, Rhee SY, Chon S, Baik SH, Park Y, Nam MS, Lee KW, Chun KH, Woo JT, Kim YS. Hypoglycemia is associated with dementia in elderly patients with type 2 diabetes mellitus: An analysis based on the Korea National Diabetes Program Cohort. Diabetes Res Clin Pract. 2016; 122: 54-61.","2型糖尿病患者において,低血糖と認知症および認知機能障害との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27810686","http://diabetes.ebm-library.jp/trial/detail/51623" "Kodama S, et al.","−","Kodama S, Tanaka S, Heianza Y, Fujihara K, Horikawa C, Shimano H, Saito K, Yamada N, Ohashi Y, Sone H: Association between physical activity and risk of all-cause mortality and cardiovascular disease in patients with diabetes: a meta-analysis. Diabetes Care. 2013; 36: 471-9.","糖尿病患者において,習慣的な身体活動が全死亡および心血管疾患の発生に与える影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23349151","http://diabetes.ebm-library.jp/trial/detail/51340" "KoGES","Korean Genome Epidemiology Study","Son JW, Lee SS, Kim SR, Yoo SJ, Cha BY, Son HY, Cho NH. Low muscle mass and risk of type 2 diabetes in middle-aged and older adults: findings from the KoGES. Diabetologia. 2017; 60: 865-872.","中高年の一般住民において,低筋肉量と2型糖尿病発症との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28102434","http://diabetes.ebm-library.jp/trial/detail/51634" "Kohan DE, et al.","−","Kohan DE, Fioretto P, Tang W, List JF: Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014; 85: 962-71.","中等度腎機能障害を伴う2型糖尿病患者において,dapagliflozinの有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24067431","http://diabetes.ebm-library.jp/trial/detail/51399" "KOPS","Kyushu and Okinawa Population Study","Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H, Schaefer EJ, Hayashi J: Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS). Diabetologia. 2011; 54: 3028-36.","日本人において,グリコアルブミンの基準値を検討し,2型糖尿病の診断に対する有用性を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/21947435","http://diabetes.ebm-library.jp/trial/detail/51267" "KPNC","Kaiser Permanente Northern California diabetes registry","Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL: Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011; 34: 916-22.","糖尿病患者において,pioglitazone治療による膀胱癌リスクを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21447663","http://diabetes.ebm-library.jp/trial/detail/51217" "Kramer CK, et al.","−","Kramer CK, Choi H, Zinman B, Retnakaran R: Glycemic variability in patients with early type 2 diabetes: the impact of improvement in β-cell function. Diabetes Care. 2014; 37: 1116-23.","","https://www.ncbi.nlm.nih.gov/pubmed/24550219","http://diabetes.ebm-library.jp/trial/detail/51398" "Kramer CK, et al.","-","Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia. 2019; 62: 905-14.","妊娠糖尿病がその後の心血管疾患発症リスクに与える影響について検討し,さらにその影響は2型糖尿病発症と関連するか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30843102","http://diabetes.ebm-library.jp/trial/detail/51761" "Kumamoto study","-","Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin- dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.","NIDDMに対する強化インスリン療法の細小血管合併症発症・進展予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/7587918","http://diabetes.ebm-library.jp/trial/detail/50240" "Kumamoto study","-","Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23: B21-B29.","2型糖尿病の至適コントロールを検討した熊本スタディの8年追跡の結果。","https://www.ncbi.nlm.nih.gov/pubmed/10860187","http://diabetes.ebm-library.jp/trial/detail/50431" "Kumamoto study","-","Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri M: Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract 2000; 48: 201-210.","日本人の2型糖尿病に対する糖尿病性合併症予防を目的とした強化インスリン療法の費用対効果について:熊本スタディ10年追跡の結果。","https://www.ncbi.nlm.nih.gov/pubmed/10802159","http://diabetes.ebm-library.jp/trial/detail/50440" "Kuo HK, et al.","-","Kuo HK, Al Snih S, Kuo YF, Raji MA: Cross-sectional associations of albuminuria and C-reactive protein with functional disability in older adults with diabetes. Diabetes Care. 2011; 34: 710-7.","高齢の糖尿病患者において,アルブミン尿,炎症,機能障害の相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21300788","http://diabetes.ebm-library.jp/trial/detail/51254" "Kuusisto J, et al.","-","Kuusisto J, Mykkanen L, Pyorala K, Laakso M: Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 1994; 25: 1157-1164.","NIDDMにおける代謝コントロール,罹病期間,およびインスリン値が脳卒中の予測因子となるかどうかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8202973","http://diabetes.ebm-library.jp/trial/detail/50341" "Kwon SS, et al.","-","Kwon SS, Kwon JY, Park YW, Kim YH, Lim JB: HbA1c for diagnosis and prognosis of gestational diabetes mellitus. Diabetes Res Clin Pract. 2015; 110: 38-43.","妊婦において,HbA1cの妊娠糖尿病の診断能,および分娩後の糖尿病発症の予測能を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26344325","http://diabetes.ebm-library.jp/trial/detail/51537" "L-STEP","Linagliptin Study of Effects on Postprandial blood glucose","Fujitani Y, et al. Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP). Diabetes Res Clin Pract. 2016; 121: 146-156. ","食事・運動療法でコントロール不十分の日本人2型糖尿病患者において,血糖パラメータに対するlinagliptin 1日1回の12週間投与とvoglibose 1日3回の12週間投与の有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/27710821","http://diabetes.ebm-library.jp/trial/detail/51606" "Landgraf R, et al.","-","Landgraf R, Bilo HJ, Mller PG; A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol. 1999;55:165-71.","スルホニル尿素薬治療歴のある2型糖尿病患者において,repaglinideとglibenclamideの有効性および安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/10379630","http://diabetes.ebm-library.jp/trial/detail/51228" "Langer O, et al.","-","Langer O, Rodriguez DA, Xenakis EM, McFarland MB, Berkus MD, Arrendondo F: Intensified versus conventional management of gestational diabetes. Am J Obstet Gynecol 1994; 170: 1036-1047.","妊娠糖尿病における厳格な血糖コントロールの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8166187","http://diabetes.ebm-library.jp/trial/detail/50001" "LANTERN","Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment","Kashiwagi A, Takahashi H, Ishikawa H, Yoshida S, Kazuta K, Utsuno A, Ueyama E. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab. 2015; 17: 152-60.","腎機能障害を伴う2型糖尿病患者において,ipragliflozinの有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25347938","http://diabetes.ebm-library.jp/trial/detail/51635" "Larsson SC, et al.","―","Larsson SC, Wolk A: Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia. 2011; 54: 1013-8.","糖尿病と腎臓がん発生リスクの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21274512","http://diabetes.ebm-library.jp/trial/detail/51221" "LEAD","LANTUS Evaluation in Asian Diabetics study","Pan CY, Sinnassamy P, Chung KD, Kim KW, LEAD Study Investigators Group: Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diabetes Res Clin Pract 2007 :76 111-118.","経口血糖降下薬投与下でコントロール不良のアジア人2型糖尿病患者において,インスリンglargineとNPHインスリンの血糖コントロール効果および安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/17011662","http://diabetes.ebm-library.jp/trial/detail/51032" "LEAD-2","Liraglutide Effect and Action in Diabetes-2 study","Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Dring M, Matthews DR; LEAD-2 Study Group: Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009; 32: 84-90.","経口血糖降下薬治療を受けている2型糖尿病患者において,metformin+liraglutide併用の有効性および安全性を,metformin単独またはmetformin+glimepiride併用と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/18931095","http://diabetes.ebm-library.jp/trial/detail/51159" "LEAD-5 met+SU","Liraglutide Effect and Action in Diabetes 5 met+SU Study","Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Sim R; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group: Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009; 52: 2046-55.","metforminおよびglimepiride投与下でコントロール不良の2型糖尿病患者において,liraglutideの有効性および安全性をインスリンglargineと比較した。","https://www.ncbi.nlm.nih.gov/pubmed/19688338","http://diabetes.ebm-library.jp/trial/detail/51146" "LEAD-6","Liraglutide Effect and Action in Diabetes 6 study","Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374: 39-47.","metforminおよびglimepiride投与下でコントロール不良の2型糖尿病患者において,liraglutideの有効性および安全性をexenatideと比較した。","https://www.ncbi.nlm.nih.gov/pubmed/19515413","http://diabetes.ebm-library.jp/trial/detail/51148" "LEADER","Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results","Marso SP, et al.; LEADER Steering Committee on behalf of the LEADER Trial Investigators: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375: 311-22.","心血管疾患リスクの高い2型糖尿病患者において,liraglutideの心血管アウトカムに対する長期効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27295427","http://diabetes.ebm-library.jp/trial/detail/51586" "LEADER","Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results","Mann JFE, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. Circulation. 2018; 138: 2908-18.","2型糖尿病患者において,心血管アウトカムに対するliraglutideの効果を腎機能別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30566006","http://diabetes.ebm-library.jp/trial/detail/51745" "Lebovitz HE, et al.","-","Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA, et al.: Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45: S150-S155.","高血圧NIDDM患者の尿中アルブミン排泄量がenalaprilの腎保護効果に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8158885","http://diabetes.ebm-library.jp/trial/detail/50147" "Li J, et al.","-","Li J, Tian H, Li Q, Wang N, Wu T, Liu Y, Ni Z, Yu H, Liang J, Luo R, et al.: Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes Obes Metab. 2007; 9: 558-65.","2型糖尿病患者において,nateglinideとrepaglinideの血糖コントロールにおける有効性,インスリン抵抗性およびβ細胞機能に対する効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/17587398","http://diabetes.ebm-library.jp/trial/detail/51232" "LIFE","the Losartan Intervention For Endpoint reduction in hypertension study","Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S; The LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.","高血圧および左室肥大を有する糖尿病患者において,losartanとatenololの心血管疾患罹患および死亡に対する効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11937179","http://diabetes.ebm-library.jp/trial/detail/50525" "LIFE","the Losartan Intervention For Endpoint reduction in hypertension study","Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, et al: Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-1886.","左室肥大を有する高血圧患者において,糖尿病新規発症のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12195132","http://diabetes.ebm-library.jp/trial/detail/50564" "LIFE","the Losartan Intervention For Endpoint reduction in hypertension study","Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, Beevers G, de Faire U, et al: Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901-906.","左室肥大を有する高血圧患者において,アルブミン尿と心血管リスクとの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14644892","http://diabetes.ebm-library.jp/trial/detail/50639" "LIFE","-","Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, et al: Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation 2006; 113: 1588-1596.","左室肥大を有する高血圧患者において,降圧薬治療による心電図上の肥大退縮に糖尿病が及ぼす影響を検討し,さらに心血管イベントおよび全死亡に対する糖尿病の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16534012","http://diabetes.ebm-library.jp/trial/detail/50815" "LIFE","the Losartan Intervention For Endpoint reduction in Hypertension study","Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Snapinn SM, Wan Y, Lyle PA: Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 2006; 29: 595-600.","高血圧および左室肥大を有する糖尿病患者において,尿中アルブミン・クレアチニン比の心血管アウトカム予測能を検討し,アルブミン尿の減少が心血管イベント減少につながるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16505512","http://diabetes.ebm-library.jp/trial/detail/50817" "LIFE","Losartan Intervention For Endpoint reduction in Hypertension study","Fossum E, Gleim GW, Kjeldsen SE, Kizer JR, Julius S, Devereux RB, Brady WE, Hille DA, Lyle PA, Dahlof B: The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. J Intern Med 2007; 262: 439-448.","高血圧および左室肥大を有する患者において,ベースラインにおける身体活動量とその後の心血管イベントおよび糖尿病の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17875180","http://diabetes.ebm-library.jp/trial/detail/51045" "Lin JJ, et al.","−","Lin JJ, Gallagher EJ, Sigel K, Mhango G, Galsky MD, Smith CB, LeRoith D, Wisnivesky JP: Survival of patients with stage IV lung cancer with diabetes treated with metformin. Am J Respir Crit Care Med. 2015; 191: 448-54.","非小細胞肺がんIV期の糖尿病患者において,metformin投与は全生存期間を延長するか検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25522257","http://diabetes.ebm-library.jp/trial/detail/51457" "Lind M, et al.","−","Lind M, Svensson AM, Kosiborod M, Gudbjrnsdottir S, Pivodic A, Wedel H, Dahlqvist S, Clements M, Rosengren A: Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014; 371: 1972-82.","1型糖尿病患者において,血糖コントロールが死亡リスクに与える影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25409370","http://diabetes.ebm-library.jp/trial/detail/51440" "LIPID","the Long-Term Intervention with Pravastatin in Ischemic Disease trial","Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, et al.: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26: 2713-2721.","冠動脈心疾患を有する糖尿病患者および空腹時血糖異常患者において,pravastatinによる脂質低下療法の心血管イベントに対する有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14514569","http://diabetes.ebm-library.jp/trial/detail/50617" "LIPS","the Lescol Intervention Prevention Study","Arampatzis CA, Goedhart D, Serruys PW, Saia F, Lemos PA, de Feyter P, LIPS Investigators: Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy. Am Heart J 2005; 149: 329-335.","経皮的冠インターベンションを施行された糖尿病患者において,fluvastatinの主要有害心イベントに対する長期的有効性を検討した。LIPS試験のサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/15846273","http://diabetes.ebm-library.jp/trial/detail/50781" "Lipscombe LL, et al.","-","Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA: Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298: 2634-2643.","高齢糖尿病患者においてチアゾリジンジオン系薬剤治療に伴ううっ血性心不全,急性心筋梗塞,死亡のリスクを他の経口血糖降下薬による治療と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/18073359","http://diabetes.ebm-library.jp/trial/detail/51040" "Lipscombe LL, et al.","-","Lipscombe LL, Fischer HD, Austin PC, Fu L, Jaakkimainen RL, Ginsburg O, Rochon PA, Narod S, Paszat L: The association between diabetes and breast cancer stage at diagnosis: a population-based study. Breast Cancer Res Treat. 2015; 150: 613-20.","乳がん患者において,診断時の病期を糖尿病の有無で比較した。","https://www.ncbi.nlm.nih.gov/pubmed/25779100","http://diabetes.ebm-library.jp/trial/detail/51476" "Lipska KJ, et al.","−","Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA: Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med. 2015; 175: 356-62.","高齢の糖尿病患者において,血糖管理レベルの値を健康状態別に調査し,糖尿病の潜在的過剰治療率を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/25581565","http://diabetes.ebm-library.jp/trial/detail/51460" "Lira-1","-","Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, Jensen T, Jensen AK, Holst JJ, Tarnow L, et al.: Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016; 4: 221-32.","血糖コントロール不良で過体重の1型糖尿病患者において,インスリンへのliraglutide追加の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26656289","http://diabetes.ebm-library.jp/trial/detail/51558" "LIRA-SWITCH","−","Bailey TS, Takcs R, Tinahones FJ, Rao PV, Tsoukas GM, Thomsen AB, Kaltoft MS, Maislos M. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial. Diabetes Obes Metab. 2016; 18: 1191-1198.","2型糖尿病患者において,sitagliptinからliraglutide 1.8mg/日への切り替えは,sitagaliptinの継続よりも血糖コントロールが良好か否かを検証した。","https://www.ncbi.nlm.nih.gov/pubmed/27381275","http://diabetes.ebm-library.jp/trial/detail/51624" "Liu C, et al.","−","Liu C, Wu D, Zheng X, Li P, Li L: Efficacy and Safety of Metformin for Patients with Type 1 Diabetes Mellitus: A Meta-Analysis. Diabetes Technol Ther. 2014; ","1型糖尿病患者において,metforminの臨床的有効性と安全性をメタアナリシスにて検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25369141","http://diabetes.ebm-library.jp/trial/detail/51435" "Liverpool Diabetic Eye Study","-","Younis N, Broadbent DM, Vora JP, Harding SP, Liverpool Diabetic Eye Study: Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003; 361: 195-200.","2型糖尿病患者において,網膜症の発症率を調査し,網膜症重症度に応じた適切なスクリーニング実施間隔を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12547541","http://diabetes.ebm-library.jp/trial/detail/50565" "Logue J, et al.","-","Logue J, Walker JJ, Leese G, Lindsay R, McKnight J, Morris A, Philip S, Wild S, Sattar N; Scottish Diabetes Research Network Epidemiology Group: Association between BMI measured within a year after diagnosis of type 2 diabetes and mortality. Diabetes Care. 2013; 36: 887-93.","2型糖尿病患者において,診断後1年以内のBMI値と死亡リスクとの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23139375","http://diabetes.ebm-library.jp/trial/detail/51327" "Lomonaco R, et al.","-","Lomonaco R, Bril F, Portillo-Sanchez P, Ortiz-Lopez C, Orsak B, Biernacki D, Lo M, Suman A, Weber MH, Cusi K: Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. Diabetes Care. 2016; 39: 632-8.","肥満の2型糖尿病患者において,非アルコール性脂肪性肝炎の代謝的影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26861926","http://diabetes.ebm-library.jp/trial/detail/51576" "Look AHEAD","Look Action for Health in Diabetes","Look AHEAD Research Group, , Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, et al.: Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30: 1374-1383.","2型糖尿病患者において,強力な生活習慣改善プログラムによる減量が心血管疾患リスク因子に及ぼす効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17363746","http://diabetes.ebm-library.jp/trial/detail/51014" "Look AHEAD","Look Action for Health in Diabetes","Bertoni AG, Clark JM, Feeney P, Yanovski SZ, Bantle J, Montgomery B, Safford MM, Herman WH, Haffner S, Look AHEAD Research Group: Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study. J Diabetes Complications 2008; 22: 1-9.","過体重または肥満の成人2型糖尿病患者において,血糖値,血圧値,LDL-C値のコントロールに関連する背景因子を検討した。Look AHEAD試験のサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18191071","http://diabetes.ebm-library.jp/trial/detail/51078" "Look AHEAD","Look Action for Health in Diabetes","Raynor HA, Jeffery RW, Ruggiero AM, Clark JM, Delahanty LM, Look AHEAD (Action for Health in Diabetes) Research Group: Weight loss strategies associated with BMI in overweight adults with type 2 diabetes at entry into the Look AHEAD (Action for Health in Diabetes) trial. Diabetes Care 2008; 31: 1299-1304.","過体重の2型糖尿病患者が用いている減量の方法を調査し,それらの方法とBMIの関係を検討した。Look AHEAD試験のサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18375417","http://diabetes.ebm-library.jp/trial/detail/51076" "Look AHEAD","Look Action for Health in Diabetes","Curtis JM, Horton ES, Bahnson J, Gregg EW, Jakicic JM, Regensteiner JG, Ribisl PM, Soberman JE, Stewart KJ, Espeland MA; Look AHEAD Research Group: Prevalence and predictors of abnormal cardiovascular responses to exercise testing among individuals with type 2 diabetes: the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care. 2010; 33: 901-7.","過体重または肥満の2型糖尿病患者において,運動誘発性心臓障害の有病率および関連要因を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20056948","http://diabetes.ebm-library.jp/trial/detail/51169" "Look AHEAD","Look Action for Health in Diabetes trial","Wing RR, ; Look AHEAD Research Group: Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010; 170: 1566-75.","2型糖尿病患者において,ライフスタイル介入プログラムによる体重,fitness,血糖コントロール,心血管疾患リスク因子の変化を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20876408","http://diabetes.ebm-library.jp/trial/detail/51202" "Look AHEAD","Look Action for Health in Diabetes","Rejeski WJ, Ip EH, Bertoni AG, Bray GA, Evans G, Gregg EW, Zhang Q; Look AHEAD Research Group: Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med. 2012; 366: 1209-17.","2型糖尿病患者において,生活習慣の高度介入による減量と体力の改善が,運動機能喪失を抑制するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22455415","http://diabetes.ebm-library.jp/trial/detail/51266" "Look AHEAD","Look Action for Health for Diabetes study","Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J, Pownall HJ, Johnson KC, Safford MM, Kitabchi AE, et al.; Look AHEAD Research Group: Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012; 308: 2489-96.","過体重の2型糖尿病患者において,長期の強化ライフスタイル介入と寛解の関連を検討した。Look AHEADの補助的解析。","https://www.ncbi.nlm.nih.gov/pubmed/23288372","http://diabetes.ebm-library.jp/trial/detail/51307" "Look AHEAD","Look Action for Health in Diabetes","Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, et al.; Look AHEAD Research Group: Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013; 369: 145-54.","過体重/肥満の成人2型糖尿病患者において,カロリー摂取制限および身体活動増強による減量を目的とした強化ライフスタイル介入は,心血管疾患罹患率および死亡率を低下させるか検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23796131","http://diabetes.ebm-library.jp/trial/detail/51338" "Look AHEAD","the Look Action for Health in Diabetes trial","Look AHEAD Research Group: Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial. Diabetes Care. 2014; 37: 1544-53.","過体重/肥満の2型糖尿病患者において,うつ症状,抗うつ薬(ADM)使用および健康に関するQOLの長期間での変化に対し,強化ライフスタイル介入と糖尿病サポート・教育介入の効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24855155","http://diabetes.ebm-library.jp/trial/detail/51405" "Look AHEAD","the Look Action in Health for Diabetes trial","Lipkin EW, Schwartz AV, Anderson AM, Davis C, Johnson KC, Gregg EW, Bray GA, Berkowitz R, Peters AL, Hodges A, et al.; Look AHEAD Research Group: The Look AHEAD Trial: bone loss at 4-year follow-up in type 2 diabetes. Diabetes Care. 2014; 37: 2822-9.","過体重/肥満の2型糖尿病患者において,減量維持およびfitness向上のための強化ライフスタイル介入が,4年後の骨量減少と関連しているかどうかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25048381","http://diabetes.ebm-library.jp/trial/detail/51430" "Look AHEAD","Look Action for Health in Diabetes","Look AHEAD Research Group. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016; 4: 913-921.","過体重/肥満の成人2型糖尿病患者において,体重変化またはフィットネスの変化は,心血管疾患発症リスクに影響するかどうかを検証した。","https://www.ncbi.nlm.nih.gov/pubmed/27595918","http://diabetes.ebm-library.jp/trial/detail/51602" "Look AHEAD Brain","Look Action for Health in Diabetes Brain Magnetic Resonance Imaging study","Espeland MA, Erickson K, Neiberg RH, Jakicic JM, Wadden TA, Wing RR, Desiderio L, Erus G, Hsieh MK, Davatzikos C, et al.; Action for Health in Diabetes Brain Magnetic Resonance Imaging (Look AHEAD Brain) Ancillary Study Research Group: Brain and White Matter Hyperintensity Volumes After 10 Years of Random Assignment to Lifestyle Intervention. Diabetes Care. 2016; 39: 764-71.","過体重または肥満の2型糖尿病患者において,10年間の強化生活習慣介入(ILI)による脳構造の変化を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27208378","http://diabetes.ebm-library.jp/trial/detail/51579" "Look AHEAD-C","Look Action for Health in Diabetes Continuation study","Look AHEAD Research Group. Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD study. Diabetologia. 2017; 60: 980-8.","過体重または肥満の2型糖尿病患者において,糖尿病末梢神経障害の発症または進展に対する強化ライフスタイル介入プログラムと糖尿病サポート・教育プログラムの長期的な効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28349174","http://diabetes.ebm-library.jp/trial/detail/51671" "Louisiana State University Hospital-Based Longitudinal Study","Louisiana State University Hospital-Based Longitudinal Study","Li N, Katzmarzyk PT, Horswell R, Zhang Y, Li W, Zhao W, Wang Y, Johnson J, Hu G: BMI and coronary heart disease risk among low-income and underinsured diabetic patients. Diabetes Care. 2014; 37: 3204-12.","25249653","https://www.ncbi.nlm.nih.gov/pubmed/25249653","http://diabetes.ebm-library.jp/trial/detail/51445" "Lu CH, et al.","−","Lu CH, Min KW, Chuang LM, Kokubo S, Yoshida S, Cha BS. Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial. J Diabetes Investig. 2016; 7: 366-73.","アジア人2型糖尿病患者において,ipragliflozinをmetforminと併用した場合の有効性と安全性を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/27330723","http://diabetes.ebm-library.jp/trial/detail/51636" "Ludvigsson J, et al.","-","Ludvigsson J, Krisky D, Casas R, Battelino T, Castao L, Greening J, Kordonouri O, Otonkoski T, Pozzilli P, Robert JJ, et al.: GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med. 2012; 366: 433-42.","発症後間もない1型糖尿病患者において,GAD65アルミ製剤により,β細胞機能が保持されるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22296077","http://diabetes.ebm-library.jp/trial/detail/51265" "Lung TW, et al.","−","Lung TW, Petrie D, Herman WH, Palmer AJ, Svensson AM, Eliasson B, Clarke PM: Severe hypoglycemia and mortality after cardiovascular events for type 1 diabetic patients in Sweden. Diabetes Care. 2014; 37: 2974-81.","1型糖尿病患者において,重症低血糖イベントの既往が,主要心血管イベント発症後の全死亡リスクと関連するか検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25092684","http://diabetes.ebm-library.jp/trial/detail/51446" "Ly TT, et al.","-","Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW: Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013; 310: 1240-7.","1型糖尿病患者において,センサーでとらえた低血糖時にインスリン注入を停止する機能付きのインスリンポンプ療法と標準インスリンポンプ療法の重症・中等症低血糖の発症頻度を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24065010","http://diabetes.ebm-library.jp/trial/detail/51362" "Maastricht Study","−","Srensen BM, Houben AJ, Berendschot TT, Schouten JS, Kroon AA, van der Kallen CJ, Henry RM, Koster A, Sep SJ, Dagnelie PC, Schaper NC, Schram MT, Stehouwer CD. Prediabetes and Type 2 Diabetes Are Associated With Generalized Microvascular Dysfunction: The Maastricht Study. Circulation. 2016; 134: 1339-1352.","前糖尿病および2型糖尿病の患者において,細小血管機能(flicker light誘導による網膜細動脈の拡張反応,熱誘導による皮膚血流値)を評価し,前糖尿病患者ではすでに細小血管機能障害がみられ,2型糖尿病患者ではさらにそれが重症化しているという仮説を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/27678264","http://diabetes.ebm-library.jp/trial/detail/51596" "Mainorino MI, et al.","−","Maiorino MI, Chiodini P, Bellastella G, Capuano A, Esposito K, Giugliano D. Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2017; 40: 614-624.","成人2型糖尿病患者において,基礎インスリン+GLP-1受容体作動薬併用治療による代謝コントロールを,他の糖尿病注射薬と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/28325801","http://diabetes.ebm-library.jp/trial/detail/51627" "Malmo Preventive Trial","-","Eriksson KF, Lindgarde F: Diabetologia 1998; 41: 1010-1016.","耐糖能異常患者において,生活習慣改善(食事療法,運動療法)により2型糖尿病発症を抑制することで死亡率が低下するかを検討し,また死亡の予測因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9754818","http://diabetes.ebm-library.jp/trial/detail/50568" "Manson JE, et al.","-","Manson JE, Rimm EB, Stampfer MJ, Colditz GA, Willett WC, Krolewski AS, Rosner B, Hennekens CH, Speizer FE: Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 1991; 338: 774-778.","基礎疾患のない女性において,運動が糖尿病発症予防効果をもつかどうかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/1681160","http://diabetes.ebm-library.jp/trial/detail/50276" "Manzella D, et al.","-","Manzella D, Grella R, Abbatecola AM, Paolisso G: Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care. 2005; 28: 366-71.","血糖コントロール不良の2型糖尿病患者において,短時間作用型インスリン分泌促進薬repaglinideおよび長時間作用型インスリン分泌促進薬glibenclamideが酸化状態および内皮機能に与える影響を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/15677794","http://diabetes.ebm-library.jp/trial/detail/51334" "Marbury T, et al.","-","Marbury T, Huang WC, Strange P, Lebovitz H: Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract. 1999; 43: 155-66.","2型糖尿病患者において,repaglinideとglyburideの長期有効性および安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/10369424","http://diabetes.ebm-library.jp/trial/detail/51230" "Marso SP, et al.","-","Marso SP, Ellis SG, Tuzcu M, Whitlow PL, Franco I, Raymond RE, Topol EJ: The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. J Am Coll Cardiol 1999; 33: 1269-1277.","経皮的冠動脈形成術後の死亡率・イベント再発率を糖尿病・蛋白尿の有無で比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10193727","http://diabetes.ebm-library.jp/trial/detail/50102" "MARVAL","the MicroAlbuminuria Reduction With VALsartan study","Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.","微量アルブミン尿を伴う2型糖尿病患者において,valsartanが降圧効果とは独立した尿中アルブミン排泄率改善効果を有するか,amlodipineと比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12163426","http://diabetes.ebm-library.jp/trial/detail/50537" "Mathieu C, et al.","-","Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, Chen H, Hansen L, Iqbal N: Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. Diabetes Care. 2015; 38: 2009-17.","saxagliptin+metforminでコントロール不良の2型糖尿病患者において,dapagliflozin追加の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26246458","http://diabetes.ebm-library.jp/trial/detail/51517" "Matthaei S, et al.","-","Matthaei S, Catrinoiu D, Celiski A, Ekholm E, Cook W, Hirshberg B, Chen H, Iqbal N, Hansen L: Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes. Diabetes Care. 2015; 38: 2018-24.","dapagliflozin+metformin でコントロール不良の2型糖尿病患者において,saxagliptin追加の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26324329","http://diabetes.ebm-library.jp/trial/detail/51518" "Max MB, et al.","-","Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250-1256.","糖尿病性神経障害による痛みに対する抗うつ薬の効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/1560801","http://diabetes.ebm-library.jp/trial/detail/50121" "MDC-CC","Malmo Diet and Cancer study-Cardiovascular Cohort","Melander O, Maisel AS, Almgren P, Manjer J, Belting M, Hedblad B, Engstrm G, Kilger U, Nilsson P, Bergmann A, et al.: Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA. 2012; 308: 1469-75.","空腹時血漿プロニューロテンシン濃度と糖尿病,心血管疾患,乳癌の発症および死亡との相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23047361","http://diabetes.ebm-library.jp/trial/detail/51285" "MDC-CC","Malmo Diet and Cancer cardiovascular cohort","Muhammad IF, Born Y, stling G, Kennbck C, Gottster M, Persson M, Nilsson PM, Engstrm G. Arterial Stiffness and Incidence of Diabetes: A Population-Based Cohort Study. Diabetes Care. 2017; 40: 1739-45.","動脈硬化と糖尿病発症の相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28971963","http://diabetes.ebm-library.jp/trial/detail/51696" "MDRD","the Modification of Diet in Renal Disease study","Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877-884.","慢性腎疾患に対する食事性蛋白の制限と血圧管理の効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8114857","http://diabetes.ebm-library.jp/trial/detail/50283" "MDUTIS","the Manitoba Diabetes Urinary Tract Infection Study","Harding GK, Zhanel GG, Nicolle LE, Cheang M; Manitoba Diabetes Urinary Tract Infection Study Group: Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med 2002; 347: 1576-1583.","糖尿病女性患者において,無症候性細菌尿のスクリーニングおよびその治療により,尿路感染症に起因する合併症を抑制できるか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12432044","http://diabetes.ebm-library.jp/trial/detail/50551" "Medalist study","-","Musen G, Tinsley LJ, Marcinkowski KA, Pober D, Sun JK, Khatri M, Huynh R, Lu A, King GL, Keenan HA. Cognitive Function Deficits Associated With Long-Duration Type 1 Diabetes and Vascular Complications. Diabetes Care. 2018; 41: 1749-56.","1型糖尿病患者,2型糖尿病患者,非糖尿病者における認知障害を比較し,1型糖尿病患者における認知機能と合併症の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29871904","http://diabetes.ebm-library.jp/trial/detail/51726" "MELANY","the Metabolic, Lifestyle, and Nutrition Assessment in Young Adults study","Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T, Kochba I, Rudich A, Israeli Diabetes Research Group: Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005; 353: 1454-1462.","正常血糖値の若年男性において,空腹時血漿ブドウ糖値と2型糖尿病発症の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16207847","http://diabetes.ebm-library.jp/trial/detail/50771" "Melidonis A, et al.","-","Melidonis A, Dimopoulos V, Lempidakis E, Hatzissavas J, Kouvaras G, Stefanidis A, Foussas S: Angiographic study of coronary artery disease in diabetic patients in comparison with nondiabetic patients. Angiology 1999; 50: 997-1006.","糖尿病患者の冠動脈疾患を血管造影により非糖尿病患者と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10609766","http://diabetes.ebm-library.jp/trial/detail/50300" "MEMO study","Microalbuminuria Education and Medication Optimisation Study","Crasto W, Jarvis J, Khunti K, Skinner TC, Gray LJ, Brela J, Troughton J, Daly H, Lawrence IG, McNally PG, et al.: Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study. Diabetes Res Clin Pract. 2011; 93: 328-36.","微量アルブミン尿を有する2型糖尿病患者において,構造化教育による心血管リスク因子のコントロールが,実際に通常治療よりも心血管リスク因子の改善をもたらすか検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21640424","http://diabetes.ebm-library.jp/trial/detail/51251" "MERIT-HF","the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure","Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, Kjekshus J, Spinar J, Vitovec J, Stanbrook H, et al: Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005; 149: 159-167.","糖尿病患者におけるmetoprolol CR/XLの有効性および忍容性を検討するとともに,糖尿病患者の生存率に関するβ遮断薬の有効性を3試験のメタアナリシスで検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15660048","http://diabetes.ebm-library.jp/trial/detail/50712" "MERLIN-TIMI 36","Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis in Myocardial Infarction 36 trial","Morrow DA, Scirica BM, Chaitman BR, McGuire DK, Murphy SA, Karwatowska-Prokopczuk E, McCabe CH, Braunwald E; MERLIN-TIMI 36 Investigators: Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009; 119: 2032-9.","急性冠症候群患者において,抗狭心症薬ranolazineの血糖に対する効果を,糖尿病の有無で比較した。MERLIN-TIMI 36のサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/19349325","http://diabetes.ebm-library.jp/trial/detail/51141" "MESA","the Multi-Ethnic Study of Atherosclerosis","Katz R, Wong ND, Kronmal R, Takasu J, Shavelle DM, Probstfield JL, Bertoni AG, Budoff MJ, O'Brien KD: Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 2006; 113: 2113-2119.","大動脈弁石灰化とメタボリックシンドロームおよび糖尿病との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16636166","http://diabetes.ebm-library.jp/trial/detail/50831" "MESA","Multi-Ethnic Study of Atherosclerosis","McNeely MJ, McClelland RL, Bild DE, Jacobs DR Jr, Tracy RP, Cushman M, Goff DC Jr, Astor BC, Shea S, Siscovick DS: The association between A1C and subclinical cardiovascular disease: the multi-ethnic study of atherosclerosis. Diabetes Care. 2009; 32: 1727-33.","心血管疾患または糖尿病を認めない例において,HbA1c値と無症候性心血管疾患の相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19549732","http://diabetes.ebm-library.jp/trial/detail/51288" "MICRO-HOPE","the Microalbuminuria, Cardiovascular, and Renal Outcomes HOPE substudy","Heart Outcomes Prevention Evaluation Study Investigators.: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.","糖尿病を伴う高リスク患者に対するramiprilの心血管イベントおよび顕性腎症抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10675071","http://diabetes.ebm-library.jp/trial/detail/50336" "Microalbuminuria Captopril Study","-","The Microalbuminuria Captopril Study Group.: Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587-593.","IDDMに対するcaptoprilの腎症発症抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8739919","http://diabetes.ebm-library.jp/trial/detail/50253" "Microalbuminuria Collaborative Study","-","Microalbuminuria Collaborative Study Group, United Kingdom.: Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 1995; 311: 973-977.","微量アルブミン尿を呈するIDDM患者に対する強化インスリン療法の顕性蛋白尿進展抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/7580637","http://diabetes.ebm-library.jp/trial/detail/50167" "MiG","Metformin in Gestational Diabetes trial","Rowan JA, Hague WM, Gao W, Battin MR, Moore MP, MiG Trial Investigators: Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358: 2003-2015.","妊娠糖尿病患者において,metforminの有効性および安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18463376","http://diabetes.ebm-library.jp/trial/detail/51080" "MiG","Metformin in Gestational Diabetes trial","Barrett HL, Gatford KL, Houda CM, De Blasio MJ, McIntyre HD, Callaway LK, Dekker Nitert M, Coat S, Owens JA, Hague WM, et al.: Maternal and neonatal circulating markers of metabolic and cardiovascular risk in the metformin in gestational diabetes (MiG) trial: responses to maternal metformin versus insulin treatment. Diabetes Care. 2013; 36: 529-36.","metforminまたはinsulin治療下の妊娠糖尿病患者と胎児の臍帯血漿の血糖,脂質,C反応性蛋白を比較し,これらのマーカーと新生児の出生時サイズとの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23048188","http://diabetes.ebm-library.jp/trial/detail/51314" "Mimouni F, et al.","-","Mimouni F, Miodovnik M, Whitsett JA, Holroyde JC, Siddiqi TA, Tsang RC: Respiratory distress syndrome in infants of diabetic mothers in the 1980s: no direct adverse effect of maternal diabetes with modern management. Obstet Gynecol 1987; 69: 191-195.","もはや母親の妊娠糖尿病が新生児呼吸促迫症候群進展の独立したリスク因子とはならないという仮説を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/3808504","http://diabetes.ebm-library.jp/trial/detail/50125" "MIRACL","the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering trial","Schwartz GG, Olsson AG, Szarek M, Sasiela WJ: Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care 2005; 28: 2508-2513.","急性冠症候群発症後において,メタボリックシンドロームが虚血性イベントの早期再発リスクおよび強力な早期スタチン治療の効果に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16186288","http://diabetes.ebm-library.jp/trial/detail/50798" "Mogensen UM, et al.","−","Mogensen UM, Andersson C, Fosbl EL, Schramm TK, Vaag A, Scheller NM, Torp-Pedersen C, Gislason G, Kber L: Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study. Diabetologia. 2015; 58: 50-8.","2型糖尿病患者において,インスリンとスルホニル尿素(SU)薬を併用した場合の心血管疾患および死亡リスクについて,インスリンとmetforminを併用した場合と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/25205223","http://diabetes.ebm-library.jp/trial/detail/51451" "Mohan V, et al. ","-","Mohan V, Shanthi Rani CS, Amutha A, Dhulipala S, Anjana RM, Parathasarathy B, Unnikrishnan R: Clinical profile of long-term survivors and nonsurvivors with type 2 diabetes. Diabetes Care. 2013; 36: 2190-7.","2型糖尿病患者の長期生存例の臨床プロフィールを対照例と比較し,非長期生存例の死亡原因および両者における合併症の発症率を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23564913","http://diabetes.ebm-library.jp/trial/detail/51354" "Monami M, et al.","-","Monami M, Colombi C, Balzi D, Dicembrini I, Giannini S, Melani C, Vitale V, Romano D, Barchielli A, Marchionni N, et al.: Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care. 2011; 34: 129-31.","インスリン治療を行っている2型糖尿病患者において,癌発生率に対するmetforminの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20980415","http://diabetes.ebm-library.jp/trial/detail/51215" "Monami M, et al.","-","Monami M, Dicembrini I, Antenore A, Mannucci E: Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011; 34: 2474-6.","2型糖尿病患者において,骨折に対するDPP-4阻害薬の効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22025784","http://diabetes.ebm-library.jp/trial/detail/51212" "Monami M, et al.","-","Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, Mannucci E. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obes Metab. 2017; 19: 1233-41.","2型糖尿病患者において,膵炎,膵がん,胆石症に対するGLP-1受容体作動薬の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28244632","http://diabetes.ebm-library.jp/trial/detail/51682" "Morgan CLI, et al.","−","Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ: Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study. Diabetes Obes Metab. 2014; 16: 957-62.","2型糖尿病患者において,一次治療としてのスルホニル尿素薬(SU)単独投与とmetformin単独投与が全死亡および主要有害心血管イベント(MACE)に与える影響を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24720708","http://diabetes.ebm-library.jp/trial/detail/51433" "Morgan CLI, et al.","−","Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ: Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab. 2014; 16: 977-83.","2型糖尿病患者において,metformin+スルホニル尿素薬併用と,metformin+DPP-4阻害薬併用の主要有害心血管イベントおよび全死亡のリスクを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24762119","http://diabetes.ebm-library.jp/trial/detail/51429" "MRC/BHF Heart Protection Study","-","Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.","冠動脈心疾患の高リスク患者において,simvastatinによる脂質低下療法の有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12114036","http://diabetes.ebm-library.jp/trial/detail/50532" "MRC/BHF Heart Protection Study","-","Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.","糖尿病患者において,simvastatinによる脂質低下療法の血管イベントに対する有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12814710","http://diabetes.ebm-library.jp/trial/detail/50607" "MRFIT","the Multiple Risk Factor Intervention Trial","Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.","糖尿病男性における心血管疾患死亡の予知因子を評価し,糖尿病がCVD死亡のリスクに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8432214","http://diabetes.ebm-library.jp/trial/detail/50315" "MRFIT","the Multiple Risk Factor Intervention Trial","Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ: Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997; 278: 2069-2074.","糖尿病に関連した末期腎不全の相対リスクを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9403420","http://diabetes.ebm-library.jp/trial/detail/50331" "MRFIT","the Multiple Risk Factor Intervention Trial","Eberly LE, Cohen JD, Prineas R, Yang L, Intervention Trial Research group: Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience. Diabetes Care 2003; 26: 848-854.","最新の診断基準による糖尿病発症および非致死性心血管疾患発症が,全死亡,心血管疾患死,冠動脈心疾患死の長期リスクに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12610048","http://diabetes.ebm-library.jp/trial/detail/50578" "MRFIT","the Multiple Risk Factor Intervention Trial","Vaccaro O, Eberly LE, Neaton JD, Yang L, Riccardi G, Stamler J, Multiple Risk Factor Intervention Trial Research Group: Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med 2004; 164: 1438-1443.","糖尿病または心筋梗塞の既往を有する男性の死亡パターンを比較するとともに,年齢,心血管リスク因子,追跡期間がそれに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15249353","http://diabetes.ebm-library.jp/trial/detail/50665" "MRFIT","the Multiple Risk Factor Intervention Trial","Davey Smith G, Bracha Y, Svendsen KH, Neaton JD, Haffner SM, Kuller LH, Multiple Risk Factor Intervention Trial Research Group: Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med 2005; 142: 313-322.","耐糖能異常を認めない男性において,包括的な生活習慣改善プログラムの糖尿病発症予防効果を検討するとともに,喫煙の有無によりそれらの効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/15738450","http://diabetes.ebm-library.jp/trial/detail/50713" "Multicenter Insulin Lispro Study","-","Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R: Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 1997; 157: 1249-1255.","NIDDM患者に対するinsulin lisproの食後高血糖や低血糖発作に対する効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9183237","http://diabetes.ebm-library.jp/trial/detail/50162" "Multicenter Metformin Study","-","DeFronzo RA, Goodman AM: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-549.","中等度肥満NIDDM患者におけるmetforminの効果をスルホニル尿素と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/7623902","http://diabetes.ebm-library.jp/trial/detail/50284" "Muraki I, et al.","−","Muraki I, Imamura F, Manson JE, Hu FB, Willett WC, van Dam RM, Sun Q: Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies. BMJ. 2013; 347: f5001.","果物の摂取が2型糖尿病発症に与える影響について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23990623","http://diabetes.ebm-library.jp/trial/detail/51383" "MUSASHI","Multicenter Study for Aggressive Lipid-lowering Strategy by HMG-CoA Reductase Inhibitors","Kojima S, Sakamoto T, Ogawa H, Kitagawa A, Matsui K, Shimomura H, Kimura K, Ogata Y, Sakaino N; Multicenter Study for Aggressive Lipid-lowering Strategy by HMG-CoA Reductase Inhibitors Investigators: Standard-dose statin therapy provides incremental clinical benefits in normocholesterolemic diabetic patients. Circ J. 2010; 74: 779-85.","日本人の正常コレステロール値の冠動脈心疾患患者において,標準用量のスタチン治療の心血管イベント低減効果を糖尿病の有無により検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20160396","http://diabetes.ebm-library.jp/trial/detail/51192" "Nachum Z, et al.","-","Nachum Z, Ben-Shlomo I, Weiner E, Shalev E: Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. BMJ 1999; 319: 1223-1227.","妊娠糖尿病患者において,インスリン処方の違いによるアウトカムの差を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10550081","http://diabetes.ebm-library.jp/trial/detail/50057" "Nachum Z, et al.","-","Nachum Z, Zafran N, Salim R, Hissin N, Hasanein J, Gam Ze Letova Y, Suleiman A, Yefet E. Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study. Diabetes Care. 2017; 40: 332-337.","娠糖尿病患者において,スルホニル尿素薬glyburideとmetforminの有効性と安全性を比較し,さらに有害事象による薬剤変更後または治療無効による薬剤追加後の血糖コントロール改善を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28077460","http://diabetes.ebm-library.jp/trial/detail/51619" "NAFLD Database study","Nonalcoholic Fatty Liver Disease Database study","Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R: Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care. 2015; 38: 1347-55.","非アルコール性脂肪肝疾患を伴う2型糖尿病患者のうち,優先的に肝臓専門医に照会し治療すべき患者を特定するため,非アルコール性脂肪肝炎(NASH)および線維化進展に関連する因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25887357","http://diabetes.ebm-library.jp/trial/detail/51490" "Nagahama study","-","Tabara Y, Arai H, Hirao Y, Takahashi Y, Setoh K, Kawaguchi T, Kosugi S, Ito Y, Nakayama T, Matsuda F; Nagahama study group. Different inverse association of large high-density lipoprotein subclasses with exacerbation of insulin resistance and incidence of type 2 diabetes: The Nagahama study. Diabetes Res Clin Pract. 2017; 127: 123-131.","一般日本人において,インスリン抵抗性増悪と2型糖尿病発症についてのHDLサブクラスの予後的重要性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28365559","http://diabetes.ebm-library.jp/trial/detail/51644" "Nagano Study","-","Katakura M, Naka M, Kondo T, Nishii N, Komatsu M, Sato Y, Yamauchi K, Hiramatsu K, Ikeda M, Aizawa T, et al.: Prospective analysis of mortality, morbidity, and risk factors in elderly diabetic subjects: Nagano study. Diabetes Care 2003; 26: 638-644.","厳格にコントロールされている高齢2型糖尿病患者において,死亡率および合併症発症率を明らかにするとともに,それらの予測因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12610014","http://diabetes.ebm-library.jp/trial/detail/50576" "Nakatani S, et al.","−","Nakatani S, Ishimura E, Naganuma T, Nakatani A, Ichii M, Fukumoto S, Mori K, Emoto M, Nakatani T, Inaba M: Poor glycemic control and decreased renal function are associated with increased intrarenal RAS activity in Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2014; 105: 40-6.","2型糖尿病患者において,腎臓内のレニン-アンジオテンシン系(RAS)の活性を評価し,臨床パラメータとの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24846444","http://diabetes.ebm-library.jp/trial/detail/51401" "Nauck M, et al.","-","Nauck M, Rizzo M, Johnson A, Bosch-Traberg H, Madsen J, Cariou B: Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. Diabetes Care. 2016; 39: 1501-9.","metformin単独療法で血糖コントロール不良の2型糖尿病患者において,liraglutide追加とlixisenatide追加の有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/27311491","http://diabetes.ebm-library.jp/trial/detail/51591" "NAVIGATOR","Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research","McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, et al.; NAVIGATOR Study Group: Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362: 1477-90.","耐糖能障害患者において,valsartanの糖尿病発症および心血管イベント低減効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20228403","http://diabetes.ebm-library.jp/trial/detail/51164" "NAVIGATOR","Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research","Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, et al.; NAVIGATOR Study Group: Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362: 1463-76.","耐糖能障害患者において,nateglinideの糖尿病発症および心血管イベント低減効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20228402","http://diabetes.ebm-library.jp/trial/detail/51165" "NAVIGATOR","Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research","Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P, Leiter LA, Charbonnel B, Mareev V, Horton ES, et al.: Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ. 2013; 347: f6745.","耐糖能異常で心血管リスク因子を有する患者において,β遮断薬,スタチン,および利尿薬の使用が新規糖尿病発症リスクに与える影響を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24322398","http://diabetes.ebm-library.jp/trial/detail/51385" "NESTOR","Natrilix SR versus Enalapril Study in hypertensive Type 2 diabetics with MicrOalbumiuRia","Marre M, Puig JG, Kokot F, Fernandez M, Jermendy G, Opie L, Moyseev V, Scheen A, Ionescu-Tirgoviste C, Saldanha MH, et al: Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004; 22: 1613-1622.","高血圧および微量アルブミン尿を有する2型糖尿病患者において,indapamide徐放剤とenalaprilの微量アルブミン尿抑制効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/15257186","http://diabetes.ebm-library.jp/trial/detail/50703" "NESTOR","the Natrilix SR versus Enalapril Study in hypertensive Type 2 diabetics with MicrOalbumiuRia study","Puig JG, Marre M, Kokot F, Fernandez M, Jermendy G, Opie L, Moyseev V, Scheen A, Ionescu-Tirgoviste C, Saldanha MH, et al.: Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am J Hypertens 2007; 20: 90-97.","高血圧および微量アルブミン尿を有する高齢2型糖尿病患者において,indapamide徐放剤およびenalaprilの血圧および微量アルブミン尿に対する効果を比較した。NESTORのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/17198918","http://diabetes.ebm-library.jp/trial/detail/50984" "NHANES","National Health and Nutrition Examination Survey","Laiteerapong N, John PM, Nathan AG, Huang ES: Public health implications of recommendations to individualize glycemic targets in adults with diabetes. Diabetes Care. 2013; 36: 84-9.","米国の成人糖尿病患者において,2012年の米国糖尿病学会ガイドラインおよびIsmail-Beigi法による個別の目標HbA1Cの該当率を推定した。","https://www.ncbi.nlm.nih.gov/pubmed/22961575","http://diabetes.ebm-library.jp/trial/detail/51316" "NHIRD","National Health Insurance Research Database","Kang EY, Chen TH, Garg SJ, Sun CC, Kang JH, Wu WC, Hung MJ, Lai CC, Cherng WJ, Hwang YS. Association of Statin Therapy With Prevention of Vision-Threatening Diabetic Retinopathy. JAMA Ophthalmol. 2019; 137: 363-71.","脂質異常症を有する糖尿病患者において,スタチン療法と糖尿病網膜症への進展との関連を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/30629109","http://diabetes.ebm-library.jp/trial/detail/51763" "NHS","Nurses' Health Study","Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH: A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141-1147.","成人発症糖尿病と心血管疾患発症,心血管死,全死亡との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/2043016","http://diabetes.ebm-library.jp/trial/detail/50302" "NHS","Nurses' Health Study","Hu FB, Sigal RJ, Rich-Edwards JW, Colditz GA, Solomon CG, Willett WC, Speizer FE, Manson JE: Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. JAMA 1999; 282: 1433-1439.","女性において,全身運動と2型糖尿病発症の関係を検討するとともに,ウォーキングとより強度の運動の有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/10535433","http://diabetes.ebm-library.jp/trial/detail/50567" "NHS","Nurses' Health Study","Al-Delaimy WK, Willett WC, Manson JE, Speizer FE, Hu FB: Smoking and Mortality Among Women With Type 2 Diabetes: The Nurses' Health Study cohort. Diabetes Care 2001; 24: 2043-2048.","2型糖尿病の女性患者における喫煙と死亡の相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11723080","http://diabetes.ebm-library.jp/trial/detail/50493" "NHS","Nurses' Health Study","Hu FB, Li TY, Colditz GA, Willett WC, Manson JE: Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA 2003; 289: 1785-1791.","女性において,座位行動(特に長時間のテレビ鑑賞)と肥満および2型糖尿病のリスクの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12684356","http://diabetes.ebm-library.jp/trial/detail/50584" "NHS","Nurses' Health Study","Logroscino G, Kang JH, Grodstein F: Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ 2004; 328: 548-551.","女性において,2型糖尿病と認知機能低下の関係を検討し,それに対する糖尿病治療薬の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14980984","http://diabetes.ebm-library.jp/trial/detail/50656" "NHS","Nurses' Health Study","Schulze MB, Manson JE, Ludwig DS, Colditz GA, Stampfer MJ, Willett WC, Hu FB: Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA 2004; 292: 927-934.","若年〜中年女性において,加糖飲料の摂取と体重増加および2型糖尿病リスクとの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15328324","http://diabetes.ebm-library.jp/trial/detail/50672" "NHS","the Nurse's Health Study","Janghorbani M, Feskanich D, Willett WC, Hu F: Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study. Diabetes Care 2006 :29 1573-1578.","女性の1型または2型糖尿病患者において,大腿骨頸部骨折リスクを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16801581","http://diabetes.ebm-library.jp/trial/detail/50960" "NHS","the Nurses' Health Study","Shai I, Jiang R, Manson JE, Stampfer MJ, Willett WC, Colditz GA, Hu FB: Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes Care 2006; 29: 1585-1590.","中年女性において,2型糖尿病発症リスクの人種差について,食事および生活習慣を考慮して検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16801583","http://diabetes.ebm-library.jp/trial/detail/50958" "NHS","the Nurse's Health Study","Janghorbani M, Hu FB, Willett WC, Li TY, Manson JE, Logroscino G, Rexrode KM: Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses' Health Study. Diabetes Care 2007; 30: 1730-1735.","女性において,1型および2型糖尿病と各タイプの脳卒中リスクとの関係について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17389335","http://diabetes.ebm-library.jp/trial/detail/51015" "NHS","Nurses’ Health Study","Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Willett WC, Manson JE, Rexrode KM, Ascherio A, Hu FB: Increased mortality risk in women with depression and diabetes mellitus. Arch Gen Psychiatry. 2011; 68: 42-50.","中高年の女性において,うつ病と糖尿病の併発により,全死亡および心血管疾患死リスクが上昇するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21199964","http://diabetes.ebm-library.jp/trial/detail/51299" "NHS","Nurses’ Health Study","Li Y, Hu Y, Ley SH, Rajpathak S, Hu FB: Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. Diabetes Care. 2014; 37: 3106-13.","2型糖尿病の女性において,スルホニル尿素(SU)薬使用と心血管疾患(CVD)発症の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25150157","http://diabetes.ebm-library.jp/trial/detail/51443" "NHS/HPFS","Nurses’ Health Study/Health Professionals Follow-Up Study","Graff RE, Sanchez A, Tobias DK, Rodrguez D, Barrisford GW, Blute ML, Li Y, Sun Q, Preston MA, Wilson KM, Cho E. Type 2 Diabetes in Relation to the Risk of Renal Cell Carcinoma Among Men and Women in Two Large Prospective Cohort Studies. Diabetes Care. 2018; 41: 1432-7.","2型糖尿病と腎細胞癌がんの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29678810","http://diabetes.ebm-library.jp/trial/detail/51724" "NHS/NHS II/HPFS","Nurses’ Health Study/Nurses’ Health Study II/Health Professionals Follow-up Study","Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, Willett WC, Manson JE, Hu FB, Sun Q. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. N Engl J Med. 2018; 379: 623-32.","禁煙者において,2型糖尿病,心血管疾患死,全死亡のリスク軌跡を,禁煙後の体重変化別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30110591","http://diabetes.ebm-library.jp/trial/detail/51732" "NHS/NHS II/HPFS","Nurses’ Health Study/Nurses’ Health Study II/Health Professionals Follow-up Study","Huang T, Lin BM, Stampfer MJ, Tworoger SS, Hu FB, Redline S. A Population-Based Study of the Bidirectional Association Between Obstructive Sleep Apnea and Type 2 Diabetes in Three Prospective U.S. Cohorts. Diabetes Care. 2018; 41: 2111-9.","閉塞性睡眠時無呼吸と2型糖尿病の双方向性の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30072403","http://diabetes.ebm-library.jp/trial/detail/51736" "Nielsen SF and Nordestgaard BG","−","Nielsen SF, Nordestgaard BG: Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol. 2014; 2: 894-900.","糖尿病患者では,スタチンを使用すると糖尿病網膜症,糖尿病神経障害,糖尿病腎症,および足壊疽の発症リスクが上昇するという仮説を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/25217178","http://diabetes.ebm-library.jp/trial/detail/51478" "NIPPON DATA90","National Integrated Project for Prospective Observation of Noncommunicable Disease and Its Trends in the Aged","Kadota A, Hozawa A, Okamura T, Kadowak T, Nakmaura K, Murakami Y, Hayakawa T, Kita Y, Okayama A, Nakamura Y, et al.: Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA90, 1990-2000. Diabetes Care 2007; 30: 1533-1538.","日本人において,代謝関連リスク因子の集積と心血管疾患死の関係を高血糖および肥満の有無別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17363755","http://diabetes.ebm-library.jp/trial/detail/51019" "NIPPON DATA 90","National Integrated Project for Prospective Observation of Noncommunicable Disease And its Trends in the Aged","Sakurai M, Saitoh S, Miura K, Nakagawa H, Ohnishi H, Akasaka H, Kadota A, Kita Y, Hayakawa T, Ohkubo T, et al.; NIPPON DATA90 Research Group: HbA1c and the Risks for All-Cause and Cardiovascular Mortality in the General Japanese Population: NIPPON DATA90. Diabetes Care. 2013; 36: 3759-65.","一般日本人において,HbA1cと全死亡および心血管疾患死リスクの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23877989","http://diabetes.ebm-library.jp/trial/detail/51368" "NOMAS","Northern Manhattan Study","Boden-Albala B, Cammack S, Chong J, Wang C, Wright C, Rundek T, Elkind MS, Paik MC, Sacco RL: Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: findings from the Northern Manhattan Study (NOMAS). Diabetes Care. 2008; 31: 1132-7.","糖尿病患者において,空腹時血糖値と虚血性脳卒中リスクの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18339972","http://diabetes.ebm-library.jp/trial/detail/51132" "North American Microalbuminuria Study","-","Laffel LM, McGill JB, Gans DJ: The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995; 99: 497-504.","IDDMに対するcaptoprilの腎症発症予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/7485207","http://diabetes.ebm-library.jp/trial/detail/50156" "North-East Italy Microalbuminuria Study","-","Trevisan R, Tiengo A: Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995; 8: 876-883.","正常血圧NIDDM患者の微量アルブミン尿に対する低用量ramiprilの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8541002","http://diabetes.ebm-library.jp/trial/detail/50151" "Nyberg ST, et al.","-","Nyberg ST, Fransson EI, Heikkil K, Ahola K, Alfredsson L, Bjorner JB, Borritz M, Burr H, Dragano N, Goldberg M, et al.; IPD-Work Consortium: Job strain as a risk factor for type 2 diabetes: a pooled analysis of 124,808 men and women. Diabetes Care. 2014; 37: 2268-75.","","https://www.ncbi.nlm.nih.gov/pubmed/25061139","http://diabetes.ebm-library.jp/trial/detail/51427" "OBSERVE-4D","-","Ryan PB, Buse JB, Schuemie MJ, DeFalco F, Yuan Z, Stang PE, Berlin JA, Rosenthal N. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13424.","2型糖尿病患者において,心不全による入院および膝下/下肢切断のリスクに対するcanagliflozin,他のSGLT2阻害薬,SGLT2阻害薬以外の血糖降下薬の効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/29938883","http://diabetes.ebm-library.jp/trial/detail/51723" "O'Connor PJ, et al.","-","O'Connor PJ, Vazquez-Benitez G, Schmittdiel JA, Parker ED, Trower NK, Desai JR, Margolis KL, Magid DJ: Benefits of early hypertension control on cardiovascular outcomes in patients with diabetes. Diabetes Care. 2013; 36: 322-7.","最近発症した高血圧を有する糖尿病患者において,主要心血管イベント発症に対する早期の血圧コントロールの影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22966094","http://diabetes.ebm-library.jp/trial/detail/51375" "Odawara M, et al.","-","Odawara M, Miyagawa J, Iwamoto N, Takita Y, Imaoka T, Takamura T: Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52weeks of treatment in a randomized phase III study. Diabetes Obes Metab. 2016; 18: 249-57.","日本人の2型糖尿病患者において,dulaglutide 0.75mg週1回とliraglutide 0.9mg/日(分1)の有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/26661514","http://diabetes.ebm-library.jp/trial/detail/51559" "ODES","Oslo Diet and Exercise Study","Anderssen SA, Hjermann I, Urdal P, Torjesen PA, Holme I: Improved carbohydrate metabolism after physical training and dietary intervention in individuals with the "atherothrombogenic syndrome". Oslo Diet and Exercise Study (ODES). A randomized trial. J Intern Med 1996; 240: 203-209.","粥状血栓形成症候群の患者において,1年間の食事療法と運動療法の糖代謝改善効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8918511","http://diabetes.ebm-library.jp/trial/detail/50268" "ODYSSEY DM-INSULIN","-","Leiter LA, Cariou B, Mller-Wieland D, Colhoun HM, Del Prato S, Tinahones FJ, Ray KK, Bujas-Bobanovic M, Domenger C, Mandel J, Samuel R, Henry RR. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab. 2017; 19: 1781-92.","インスリン治療中で,心血管の高リスク,かつ最大用量のスタチン治療下でLDL-コレステロール高値の1型および2型糖尿病患者において,alirobumabの有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28905478","http://diabetes.ebm-library.jp/trial/detail/51677" "OmniHeart","Optimal Macronutrient Intake Trial to Prevent Heart Disease","Gadgil MD, Appel LJ, Yeung E, Anderson CA, Sacks FM, Miller ER 3rd: The effects of carbohydrate, unsaturated fat, and protein intake on measures of insulin sensitivity: results from the OmniHeart trial. Diabetes Care. 2013; 36: 1132-7.","高炭水化物食,高タンパク食,高不飽和脂肪食のインスリン感受性に対する効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23223345","http://diabetes.ebm-library.jp/trial/detail/51355" "ONTARGET","the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial","ONTARGET Investigators, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.","心不全を有さない血管疾患または高リスク糖尿病の患者において,telmisartanがramiprilよりも劣っていないかを検討し,また,それら薬剤の併用がramipril単独投与よりも優れているか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18378520","http://diabetes.ebm-library.jp/trial/detail/51061" "ONTARGET","the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial","Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.","動脈硬化性血管疾患患者または終末器官障害を有する糖尿病患者において,telmisartan,ramipril,およびそれら薬剤の併用の腎アウトカムに対する効果を検討した。ONTARGETのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18707986","http://diabetes.ebm-library.jp/trial/detail/51072" "ONTARGET","ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial","Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Bhm M, et al.; ONTARGET Investigators: Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012; 59: 74-83.","糖尿病患者と非糖尿病患者で,心血管保護のための降圧の安全性と有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/22192672","http://diabetes.ebm-library.jp/trial/detail/51263" "ONTARGET","Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial","Dunkler D, Kohl M, Heinze G, Teo KK, Rosengren A, Pogue J, Gao P, Gerstein H, Yusuf S, Oberbauer R, et al.; ONTARGET Investigators: Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. Kidney Int. 2015; 87: 784-91.","2型糖尿病患者において,修正可能な生活習慣および社会的要因と,早期慢性腎臓病(CKD)への進展/発症との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25493953","http://diabetes.ebm-library.jp/trial/detail/51464" "ONTARGET/TRANSCEND","Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease","Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K, ONTARGET/TRANSCEND Investigators: Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 2007; 115: 1371-1375.","心血管疾患発症の高リスク例において,空腹時血漿ブドウ糖値とうっ血性心不全による入院リスクの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17339550","http://diabetes.ebm-library.jp/trial/detail/50980" "ONTARGET/TRANSCEND","-","Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, Commerford P, Dyal L, Schumacher H, Pogue J, et al.; ONTARGET and TRANSCEND Investigators: Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011; 10: 43-53.","55歳以上の臓器障害を有する粥状動脈硬化性心血管疾患患者または糖尿病患者において,レニン-アンジオテンシン系阻害が認知機能に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20980201","http://diabetes.ebm-library.jp/trial/detail/51304" "OpT2mise","−","Aronson R, Reznik Y, Conget I, Castaeda JA, Runzis S, Lee SW, Cohen O; OpT2mise Study Group. Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial. Diabetes Obes Metab. 2016; 18: 500-7. ","基礎インスリン+食事時にインスリンアナログを投与している2型糖尿病患者において,インスリンポンプ療法と1日複数回注射療法(MDI)の有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/26854123","http://diabetes.ebm-library.jp/trial/detail/51600" "OPUS-TIMI 16","Oral Glycoprotein IIb/IIIa Inhibition with Orbofiban in Patients with Unstable Coronary syndromes trial","Ray KK, Cannon CP, Morrow DA, Kirtane AJ, Buros J, Rifai N, McCabe CH, Gibson CM, Braunwald E: Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18. Eur Heart J. 2007; 28: 806-13.","非ST上昇型急性冠症候群患者において,糖尿病と炎症の関係,および高血糖と炎症が臨床アウトカムに及ぼす相乗作用について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17403721","http://diabetes.ebm-library.jp/trial/detail/51062" "ORIGIN","Outcome Reduction with an Initial Glargine Intervention trial","Bosch J, Gerstein HC, Dagenais GR, Daz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, et al.; ORIGIN Trial Investigators: n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012; 367: 309-18.","2型糖尿病,空腹時血糖異常,耐糖能異常で心血管イベント高リスクの患者において,n-3脂肪酸長期補充による心血管イベント抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22686415","http://diabetes.ebm-library.jp/trial/detail/51269" "ORIGIN","Outcome Reduction with an Initial Glargine Intervention trial","Gerstein HC, Bosch J, Dagenais GR, Daz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, et al.; ORIGIN Trial Investigators: Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 367: 319-28.","2型糖尿病,空腹時血糖異常,耐糖能異常で心血管リスク因子を有する患者において,インスリンglargineの標準治療に比した心血管イベント抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22686416","http://diabetes.ebm-library.jp/trial/detail/51270" "ORIGIN","Outcome Reduction with an Initial Glargine Intervention trial","Gilbert RE, Mann JF, Hanefeld M, Spinas G, Bosch J, Yusuf SGerstein HC, ; ORIGIN trial investigators: Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia. 2014; 57: 1325-31.","血糖調節異常患者において,細小血管アウトカムに対するインスリン製剤glargineの効果を,ベースラインのHbA1c別に検討した。ORIGIN試験のサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/24771090","http://diabetes.ebm-library.jp/trial/detail/51409" "ORLS","Oxford Record Linkage Study","Wotton CJ, Yeates DG, Goldacre MJ: Cancer in patients admitted to hospital with diabetes mellitus aged 30years and over: record linkage studies. Diabetologia. 2011; 54: 527-34.","30歳以上の糖尿病入院患者におけるがんリスクについて検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21116605","http://diabetes.ebm-library.jp/trial/detail/51222" "Osaka Health Survey","-","Suematsu C, Hayashi T, Fujii S, Endo G, Tsumura K, Okada K, Morii H: Impaired fasting glucose and the risk of hypertension in Japanese men between the 1980s and the 1990s. The Osaka Health Survey. Diabetes Care 1999; 22: 228-232.","日本人において,空腹時血糖異常により高血圧発症リスクが増大するかどうかを年代別に調査した。 ","https://www.ncbi.nlm.nih.gov/pubmed/10333938","http://diabetes.ebm-library.jp/trial/detail/50222" "Osaka Health Survey","-","Hayashi T, Tsumura K, Suematsu C, Endo G, Fujii S, Okada K: High normal blood pressure, hypertension, and the risk of type 2 diabetes in Japanese men. The Osaka Health Survey. Diabetes Care 1999; 22: 1683-1687.","日本人の高値正常血圧または高血圧と2型糖尿病発症リスクとの関係を調査した。","https://www.ncbi.nlm.nih.gov/pubmed/10526735","http://diabetes.ebm-library.jp/trial/detail/50228" "Overbeek JA, et al.","-","Overbeek JA, van Herk-Sukel MPP, Vissers PAJ, van der Heijden AAWA, Bronsveld HK, Herings RMC, Schmidt MK, Nijpels G. Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy Registries. Diabetes Care. 2019; 42: 434-42.","浸潤性乳がんの女性において,2型糖尿病と乳がん特性の関連を評価し,インスリン(アナログ)使用の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30679303","http://diabetes.ebm-library.jp/trial/detail/51754" "Owens DR, et al.","-","Owens DR, Bolli GB, Charbonnel B, Haak T, Landgraf W, Porcellati F, Traylor L, Kautzky-Willer A. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100U/mL added to oral antidiabetes agents in type 2 diabetes. Diabetes Obes Metab. 2017; 19: 1546-54.","インスリンglargine投与を開始した2型糖尿病患者において,標準化された臨床アウトカムに対する患者背景および経口糖尿病治療薬の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28449412","http://diabetes.ebm-library.jp/trial/detail/51684" "Oyen N, et al.","−","yen N, Diaz LJ, Leirgul E, Boyd HA, Priest J, Mathiesen ER, Quertermous T, Wohlfahrt J, Melbye M: Prepregnancy Diabetes and Offspring Risk of Congenital Heart Disease: A Nationwide Cohort Study. Circulation. 2016; 133: 2243-53.","母体の糖尿病は出生児の先天性心疾患リスクの増加と関連するかを検証した。","https://www.ncbi.nlm.nih.gov/pubmed/27166384","http://diabetes.ebm-library.jp/trial/detail/51571" "Palmer SC, et al.","−","Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheeler DC, Strippoli GF: Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015; 385: 2047-56.","18歳以上の糖尿病を合併した慢性腎臓病(CKD)患者において,さまざまな降圧薬の相対的効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26009228","http://diabetes.ebm-library.jp/trial/detail/51471" "Pan A, et al.","−","Pan A, Wang Y, Talaei M, Hu FB: Relation of Smoking With Total Mortality and Cardiovascular Events Among Patients With Diabetes Mellitus: A Meta-Analysis and Systematic Review. Circulation. 2015; 132: 1795-804.","糖尿病患者において,能動的喫煙と全死亡および心血管イベント発症リスクとの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26311724","http://diabetes.ebm-library.jp/trial/detail/51526" "Papa G, et al.","−","Papa G, Fedele V, Rizzo MR, Fioravanti M, Leotta C, Solerte SB, Purrello F, Paolisso G: Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial. Diabetes Care. 2006; 29: 1918-20.","血糖コントロール不良境界域の高齢2型糖尿病患者において,repaglinideおよびglibenclamideによる低血糖イベントおよび有害イベントの発生を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/16873803","http://diabetes.ebm-library.jp/trial/detail/51337" "Pape GA, et al.","-","Pape GA, Hunt JS, Butler KL, Siemienczuk J, LeBlanc BH, Gillanders W, Rozenfeld Y, Bonin K: Team-based care approach to cholesterol management in diabetes mellitus: two-year cluster randomized controlled trial. Arch Intern Med. 2011; 171: 1480-6.","プライマリーケアの糖尿病患者において,通信回線を介した医師-薬剤師によるチーム主体の医療がLDL-Cコントロールに及ぼす効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21911633","http://diabetes.ebm-library.jp/trial/detail/51239" "Paprott R, et al.","−","Paprott R, Schaffrath Rosario A, Busch MA, Du Y, Thiele S, Scheidt-Nave C, Heidemann C: Association between hemoglobin A1c and all-cause mortality: results of the mortality follow-up of the German National Health Interview and Examination Survey 1998. Diabetes Care. 2015; 38: 249-56.","血糖状態(HbA1c値)と全死亡との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25414153","http://diabetes.ebm-library.jp/trial/detail/51444" "PARADIGM-HF","Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial","Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017; 5: 333-340.","駆出率の低下した心不全を有する糖尿病患者において,sacubitril/valsartanとenalaprilのHbA1c低下作用,インスリンまたは経口糖尿病治療薬開始までの期間を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/28330649","http://diabetes.ebm-library.jp/trial/detail/51640" "Paris Prospective Study","-","Fontbonne A, Charles MA, Thibult N, Richard JL, Claude JR, Warnet JM, Rosselin GE, Eschwege E: Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991; 34: 356-361.","冠動脈心疾患死の独立した予測因子を,特に血漿インスリン値について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/1864491","http://diabetes.ebm-library.jp/trial/detail/50517" "Paris Prospective Study","-","Fontbonne A, Thibult N, Eschwege E, Ducimetiere P: Body fat distribution and coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes mellitus: the Paris Prospective Study, 15-year follow-up. Diabetologia 1992; 35: 464-468.","耐糖能異常または糖尿病を有する中年男性において冠動脈心疾患死の予測因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/1521729","http://diabetes.ebm-library.jp/trial/detail/50535" "Paris Prospective Study","-","Eschwege E, Charles MA, Simon D, Thibult N, Balkau B; Paris Prospective Study: Reproducibility of the diagnosis of diabetes over a 30-month follow-up: the Paris Prospective Study. Diabetes Care 2001; 24: 1941-1944.","空腹時血漿ブドウ糖値を用いた糖尿病の診断と,負荷後2時間のみの高血糖を用いた診断の精度を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11679461","http://diabetes.ebm-library.jp/trial/detail/50540" "PATHWAY-3","Prevention and Treatment of Hypertension with Algorithm-based Therapy 3","Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, Ford I, McInnes G, Sever P, Salsbury J, et al.; British Hypertension Society's PreventionTreatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group: Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016; 4: 136-47.","サイアザイド系利尿薬にカリウム保持性利尿薬amilorideを追加または置き換えた場合,耐糖能異常が予防され,血圧コントロールが改善するか検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26489809","http://diabetes.ebm-library.jp/trial/detail/51556" "Pathways Study","-","Katon WJ, Von Korff M, Lin EH, Simon G, Ludman E, Russo J, Ciechanowski P, Walker E, Bush T: The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry 2004; 61: 1042-1049.","うつ病を有する糖尿病患者において,うつ病ケアの質の向上がうつ病のアウトカムおよび血糖コントロールを改善させるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15466678","http://diabetes.ebm-library.jp/trial/detail/50698" "Patterson D, et al.","-","Patterson D, Abell T, Rothstein R, Koch K, Barnett J: A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999; 94: 1230-1234.","症候性糖尿病性胃不全麻痺患者での消化管機能改善薬domperidoneとmetoclopramideの効果と副作用を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/10235199","http://diabetes.ebm-library.jp/trial/detail/50026" "PCAT-2","the Primary Coronary Angioplasty vs Thrombolysis-2 Trial","Timmer JR, Ottervanger JP, de Boer MJ, Boersma E, Grines CL, Westerhout CM, Simes RJ, Granger CB, Zijlstra F, Primary Coronary Angioplasty vs Thrombolysis-2 Trialists Collaborators Group: Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. Arch Intern Med 2007; 167: 1353-1359.","糖尿病患者において,ST上昇型心筋梗塞に対するprimary PCIと血栓溶解療法の有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/17620527","http://diabetes.ebm-library.jp/trial/detail/51005" "PDHS","Penn Diabetes Heart Study","Mulvey CK, McNeill AM, Girman CJ, Churchill TW, Terembula K, Ferguson JF, Shah R, Mehta NN, Qasim AN, Rickels MR, et al.: Differential associations of oral glucose tolerance test-derived measures of insulin sensitivity and pancreatic β-cell function with coronary artery calcification and microalbuminuria in type 2 diabetes. Diabetes Care. 2014; 37: 124-33.","心血管疾患または腎疾患を認めない2型糖尿病患者において,経口糖負荷試験で評価したインスリン感受性および膵β細胞機能と合併症発生率の関連を検討した。PDHSのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/23949560","http://diabetes.ebm-library.jp/trial/detail/51389" "PERISCOPE","Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation trial","Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochelliere R, Staniloae CS, Mavromatis K, et al.: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573.","冠動脈疾患を有する2型糖尿病患者において,pioglitazoneとglimepirideのアテローム性動脈硬化抑制効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/18378631","http://diabetes.ebm-library.jp/trial/detail/51055" "PERSUADE","the PERindopril SUbstudy in Coronary Artery Disease and DiabEtes study","Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML, EUROPA Investigators: The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26: 1369-1378.","冠動脈疾患を有し,心不全を認めない糖尿病患者において,perindoprilの心血管イベント抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15860521","http://diabetes.ebm-library.jp/trial/detail/50780" "Peters SAE, et al.","-","Peters SA, Huxley RR, Woodward M: Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014; 57: 1542-51.","最新のエビデンスを含むメタアナリシスにより,糖尿病の女性と糖尿病の男性で,冠動脈心疾患発症リスクを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24859435","http://diabetes.ebm-library.jp/trial/detail/51408" "Pettersson B, et al.","-","Pettersson B, Rosenqvist U, Deleskog A, Journath G, Wndell P: Self-reported experience of hypoglycemia among adults with type 2 diabetes mellitus (Exhype). Diabetes Res Clin Pract. 2011; 92: 19-25.","metformin+スルホニル尿素(SU)薬の併用療法を受けた2型糖尿病患者において,低血糖の経験と,QOLおよび低血糖に対する心労に与える影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21195501","http://diabetes.ebm-library.jp/trial/detail/51247" "PHS","Physicians' Health Study","Manson JE, Nathan DM, Krolewski AS, Stampfer MJ, Willett WC, Hennekens CH: A prospective study of exercise and incidence of diabetes among US male physicians. JAMA 1992; 268: 63-67.","運動によるNIDDM発症予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/1608115","http://diabetes.ebm-library.jp/trial/detail/50271" "PHS","Physicians' Health Study","Ajani UA, Gaziano JM, Lotufo PA, Liu S, Hennekens CH, Buring JE, Manson JE: Alcohol consumption and risk of coronary heart disease by diabetes status. Circulation 2000; 102: 500-505.","糖尿病男性における適量の飲酒と冠動脈心疾患の関係を,非糖尿病男性と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10920060","http://diabetes.ebm-library.jp/trial/detail/50430" "PHS","Physicians’ Health Study","Kochar J, Gaziano JM, Djouss L: Nut consumption and risk of type II diabetes in the Physicians' Health Study. Eur J Clin Nutr. 2010; 64: 75-9.","米国の男性医師において,ナッツ消費量と2型糖尿病発症リスクとの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19756028","http://diabetes.ebm-library.jp/trial/detail/51185" "Pijls LT, et al.","-","Pijls LT, de Vries H, Donker AJ, van Eijk JT: The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Nephrol Dial Transplant 1999; 14: 1445-1453.","2型糖尿病患者に対する蛋白制限食の腎機能障害発症遅延効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10383006","http://diabetes.ebm-library.jp/trial/detail/50123" "Pima Indians","-","Knowler WC, Bennett PH, Ballintine EJ: Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians. N Engl J Med 1980; 302: 645-650.","糖尿病のピマインディアンにおいて,網膜症発症のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/6986550","http://diabetes.ebm-library.jp/trial/detail/50281" "Pima Indians","-","Nelson RG, Gohdes DM, Everhart JE, Hartner JA, Zwemer FL, Pettitt DJ, Knowler WC: Lower-extremity amputations in NIDDM. 12-yr follow-up study in Pima Indians. Diabetes Care 1988; 11: 8-16.","糖尿病のピマインディアンにおける下肢切断を調査し,リスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/3338381","http://diabetes.ebm-library.jp/trial/detail/50192" "Pima Indians","-","Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG: Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA 2006; 296: 421-426.","ピマインディアンにおいて,2型糖尿病の発症年齢が糖尿病性末期腎不全の発生および自然死に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16868300","http://diabetes.ebm-library.jp/trial/detail/50834" "Pima Indians","-","Pavkov ME, Hanson RL, Knowler WC, Bennett PH, Krakoff J, Nelson RG: Changing patterns of type 2 diabetes incidence among Pima Indians. Diabetes Care 2007; 30: 1758-1763.","1965〜2003年におけるピマインディアンの2型糖尿病発症率の推移を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17468358","http://diabetes.ebm-library.jp/trial/detail/51023" "PIONEER 3","Peptide Innovation for Early Diabetes Treatment 3"," ","metformin単剤投与下またはスルホニル尿素薬併用の2型糖尿病患者において,GLP-1受容体作動薬semaglutideを追加で経口投与した場合の有効性および長期有害イベントのプロフィールをsitagliptin経口投与と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/30903796","http://diabetes.ebm-library.jp/trial/detail/51770" "POPADAD","the Prevention of Progression of Arterial Disease and Diabetes trial","Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, et al.: The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.","無症候性末梢動脈疾患を有する糖尿病患者において,aspirinと抗酸化療法の併用療法またはそれぞれの単独療法の心血管イベント低減効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18927173","http://diabetes.ebm-library.jp/trial/detail/51101" "PPP","the Primary Prevention Project trial","Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, PPP Collaborative Group: Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26: 3264-3272.","2型糖尿病患者において,心血管疾患の一次予防における低用量aspirinおよびビタミンEの有効性を検討し,その有効性を非糖尿病患者と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/14633812","http://diabetes.ebm-library.jp/trial/detail/50628" "PREDIMED","Prevencion con Dieta Mediterranea","Estruch R, Ros E, Salas-Salvad J, Covas MI, Corella D, Ars F, Gmez-Gracia E, Ruiz-Gutirrez V, Fiol M, Lapetra J, et al.; PREDIMED Study Investigators: Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013; 368: 1279-90.","2型糖尿病または心血管疾患の危険因子を3つ以上有する心血管疾患の既往のない患者において,地中海食の心血管疾患抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23432189","http://diabetes.ebm-library.jp/trial/detail/51339" "PREFER","-","Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B; PREFER Study Group: Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab. 2009; 11: 45-52.","経口血糖低下薬でコントロール不良の2型糖尿病患者において,2種類のインスリン療法の有効性および安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/18643839","http://diabetes.ebm-library.jp/trial/detail/51142" "Preiss D. ","-","Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, et al.: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011; 305: 2556-64.","中等量スタチン療法と比較して,高用量のスタチン療法が,糖尿病の新規発症リスクの増加と関連しているかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21693744","http://diabetes.ebm-library.jp/trial/detail/51207" "PREMIER","Preterax in Albuminuria Regression study","Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, Widimsky J, Sareli P, Taton J, Rull J, et al: Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063-1071.","高血圧およびアルブミン尿を認める2型糖尿病患者において,低用量perindoprilおよびindapamide併用療法とenalapril単独療法の尿中アルブミン排泄率に対する有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/12654706","http://diabetes.ebm-library.jp/trial/detail/50614" "PRESTO","the Prevention of REStenosis with Tranilast and its Outcomes trial","Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes DR: Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004; 109: 476-480.","経皮的冠動脈形成術を施行された患者において,9ヵ月後のアウトカムに対する糖尿病の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14732749","http://diabetes.ebm-library.jp/trial/detail/50644" "PREVEND","the Prevention of Renal and Vascular End Stage Disease study","Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT, PREVEND Study Group: Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 2005; 28: 2525-2530.","2型糖尿病の発症予測における尿中アルブミン排泄量,C反応性蛋白,メタボリックシンドロームの関係について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16186291","http://diabetes.ebm-library.jp/trial/detail/50796" "Primary Prevention Trial Study","-","Novak M, Bjrck L, Giang KW, Heden-Sthl C, Wilhelmsen L, Rosengren A: Perceived stress and incidence of Type 2 diabetes: a 35-year follow-up study of middle-aged Swedish men. Diabet Med. 2013; 30: e8-16.","スウェーデンの中年男性住民において,ベースライン時の自己認識ストレスと糖尿病発症の関連を,35年以上の長期追跡で検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23075206","http://diabetes.ebm-library.jp/trial/detail/51313" "PRISM-PLUS","the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms study","Theroux P, Alexander J Jr, Pharand C, Barr E, Snapinn S, Ghannam AF, Sax FL: Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation 2000; 102: 2466-2472.","不安定狭心症か非ST上昇心筋梗塞の患者に対する抗血栓療法に,tirofibanによる血小板療法の追加効果を検討したPRISM-PLUS試験において,患者を糖尿病と非糖尿病に分けてサブ解析した。","https://www.ncbi.nlm.nih.gov/pubmed/11076818","http://diabetes.ebm-library.jp/trial/detail/50380" "PRISMA","Preferred Reporting Items for Systematic Reviews and Meta-Analyses","Qian F, Korat AA, Malik V, Hu FB: Metabolic Effects of Monounsaturated Fatty Acid-Enriched Diets Compared With Carbohydrate or Polyunsaturated Fatty Acid-Enriched Diets in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2016; 39: 1448-57.","2型糖尿病患者において,高cis型一価不飽和脂肪酸食が代謝危険因子に与える影響を高炭水化物食または高多価不飽和脂肪酸食と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/27457635","http://diabetes.ebm-library.jp/trial/detail/51594" "PROactive","PROspective Pioglitazone Clinical Trial In Macrovascular Events","Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, et al: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.","高リスクの2型糖尿病患者において,pioglitazoneによる大血管障害の発生および死亡の減少効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16214598","http://diabetes.ebm-library.jp/trial/detail/50778" "PROactive","PROspective pioglitAzone Clinical Trial In macroVascular Events","Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J, PROactive Investigators: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38: 865-873.","大血管疾患の既往を有する2型糖尿病患者において,pioglitazoneの大血管イベントに対する効果を,脳卒中の既往の有無により比較した。PROactiveのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/17290029","http://diabetes.ebm-library.jp/trial/detail/50989" "PROactive","PROspective pioglitAzone Clinical Trial In macroVascular Events study","Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM, PROactive Investigators: The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49: 1772-1780.","心筋梗塞の既往を有する2型糖尿病患者において,pioglitazoneの死亡および大血管障害に対する有効性を検討した。PROactiveのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/17466227","http://diabetes.ebm-library.jp/trial/detail/51003" "PROactive","PROspective pioglitAzone Clinical Trial In macroVascular Events","Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, Tan M, Spanheimer R, Standl E, Dormandy JA, et al.: Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007; 30: 2773-2778.","心血管疾患を有する2型糖尿病患者において,pioglitazone治療における心不全の発症を検討した。PROactiveのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/17666462","http://diabetes.ebm-library.jp/trial/detail/51102" "PROactive","PROspective pioglitAzone Clinical Trial In macroVascular Events","Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L; PROactive investigators: Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11). Atherosclerosis. 2009; 202: 272-81.","大血管障害を有する2型糖尿病患者において,末梢動脈疾患の心血管疾患アウトカムへの影響を検討し,さらにpioglitazone治療の効果への影響を検討した。PROactiveの事後解析。","https://www.ncbi.nlm.nih.gov/pubmed/18538774","http://diabetes.ebm-library.jp/trial/detail/51128" "PROactive","Prospective Pioglitazone Clinical Trial in Macrovascular Events","Spanheimer R, Betteridge DJ, Tan MH, Ferrannini E, Charbonnel B; PROactive Investigators: Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Am J Cardiol. 2009; 104: 234-9.","心血管疾患リスクの高い2型糖尿病患者において,metformin,スルホニル尿素,インスリンによる糖尿病治療およびスタチン薬の使用により,pioglitazoneの脂質への効果が影響されるかを検討した。PROactiveのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/19576353","http://diabetes.ebm-library.jp/trial/detail/51134" "PROCAM","the Prospective Cardiovascular Munster study","Assmann G, Schulte H: The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116: 1713-1724.","ドイツ人における高血圧,糖尿病,高脂血症の罹病率とCHDとの関連を解析した。","https://www.ncbi.nlm.nih.gov/pubmed/3202078","http://diabetes.ebm-library.jp/trial/detail/50013" "PROSPECT","Prevention of Suicide in Primary Care Elderly Collaborative Trial","Bogner HR, Morales KH, Post EP, Bruce ML: Diabetes, depression, and death: a randomized controlled trial of a depression treatment program for older adults based in primary care (PROSPECT). Diabetes Care 2007; 30: 3005-3010.","うつ病を有する高齢糖尿病患者において,プライマリケアにおけるうつ病マネジメントプログラムの実施が死亡リスクに及ぼす効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17717284","http://diabetes.ebm-library.jp/trial/detail/51027" "PROVE IT-TIMI 22","the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction","Ahmed S, Cannon CP, Murphy SA, Braunwald E: Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J 2006; 27: 2323-2329.","糖尿病を伴う急性冠症候群患者において,スタチン系薬剤による強化脂質低下療法の効果を検討した。PROVE IT-TIMI 22のサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/16954134","http://diabetes.ebm-library.jp/trial/detail/50978" "PSC/APCSC","Prospective Studies Collaboration/Asia Pacific Cohort Studies Collaboration","Prospective Studies Collaboration and Asia Pacific Cohort Studies Collaboration. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980793 adults from 68 prospective studies. Lancet Diabetes Endocrinol. 2018; 6: 538-46.","糖尿病と閉塞性血管死リスクの関連を男女別に評価し,糖尿病と関連する因子の閉塞性血管死への影響が糖尿病の有無により異なるか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29752194","http://diabetes.ebm-library.jp/trial/detail/51722" "QUARTET","-","Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, QUARTET Study Group: A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005; 22: 399-405.","経口血糖降下薬未投与の2型糖尿病患者において,pioglitazoneおよびgliclazideが糖代謝コントロールおよび脂質値に及ぼす効果を比較。","https://www.ncbi.nlm.nih.gov/pubmed/15787663","http://diabetes.ebm-library.jp/trial/detail/50776" "RAVEL","Randomized Study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions","Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, Geert-Jan L, Abizaid AS, Sousa AG, Wuelfert E, et al: Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial. Eur Heart J 2004; 25: 107-112.","sirolimus溶出ステント留置が糖尿病患者のアウトカムに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14720526","http://diabetes.ebm-library.jp/trial/detail/50675" "Ravid M, et al.","-","Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow- up study. Arch Intern Med 1996; 156: 286-289.","腎障害の進行したNIDDM患者におけるenalaprilの長期治療効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8572838","http://diabetes.ebm-library.jp/trial/detail/50303" "Ravid M, et al.","-","Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998; 128: 982-988.","2型糖尿病患者におけるenalaprilの腎機能低下予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9625684","http://diabetes.ebm-library.jp/trial/detail/50039" "RCAV","Racial and Cardiovascular Risk Anomalies in CKD study","Increased Risk of Incident Chronic Kidney Disease, Cardiovascular Disease, and Mortality in Patients With Diabetes With Comorbid Depression. Increased Risk of Incident Chronic Kidney Disease, Cardiovascular Disease, and Mortality in Patients With Diabetes With Comorbid Depression. Diabetes Care. 2016; 39: 1940-1947. ","2型糖尿病患者において,うつ病の合併は,慢性腎臓病(CKD),死亡,および心血管イベント発症リスクと関連するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27311494","http://diabetes.ebm-library.jp/trial/detail/51603" "RECORD","the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","Home PD, Jones NP, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Komajda M, Curtis P, RECORD Study Group: Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007; 24: 626-634.","2型糖尿病患者において,rosiglitazone+metforminまたはrosiglitazone+スルホニル尿素薬の血糖コントロール効果をmetformin+スルホニル尿素薬と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/17517066","http://diabetes.ebm-library.jp/trial/detail/51012" "RECORD","the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes trial","Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ, RECORD Study Group: Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med 2007; 357: 28-38.","2型糖尿病患者において,rosiglitazoneが心血管アウトカムに及ぼす影響を検討した。RECORDの中間解析。","https://www.ncbi.nlm.nih.gov/pubmed/17551159","http://diabetes.ebm-library.jp/trial/detail/50999" "RECORD","Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A, Jones NP, Gomis R, Home PD, RECORD Study Group: Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovasc Diabetol 2008; 7: 10.","2型糖尿病患者において,6〜12ヵ月間のrosiglitazoneとmetforminまたはSU薬併用およびmetforminとSU薬併用が24時間自由行動下血圧に及ぼす効果を比較した。RECORDのABPM サブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18435852","http://diabetes.ebm-library.jp/trial/detail/51075" "RECORD","Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes trial","Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373: 2125-35.","2型糖尿病患者において,rosiglitazoneをmetforminまたはスルホニル尿素薬と併用した場合の心血管アウトカムに対する効果を,metformin+スルホニル尿素薬併用と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19501900","http://diabetes.ebm-library.jp/trial/detail/51117" "Reed M, et al.","-","Reed M, Huang J, Graetz I, Brand R, Hsu J, Fireman B, Jaffe M: Outpatient electronic health records and the clinical care and outcomes of patients with diabetes mellitus. Ann Intern Med. 2012; 157: 482-9.","糖尿病患者において,市販の認定電子カルテの導入と臨床治療プロセスおよび糖尿病コントロール改善との相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23027319","http://diabetes.ebm-library.jp/trial/detail/51286" "Reichard P, et al.","-","Reichard P, Nilsson BY, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-309.","IDDMにおける強化インスリン療法の糖尿病性細小血管合併症進展抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8147960","http://diabetes.ebm-library.jp/trial/detail/50122" "RENAAL","the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study","Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.","腎症を伴う2型糖尿病患者において,losartanの腎および心血管保護効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11565518","http://diabetes.ebm-library.jp/trial/detail/50484" "RENAAL","the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study","Souchet T, Durand Zaleski I, Hannedouche T, Rodier M, Gaugris S, Passa P, RENAAL study: An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. Diabetes Metab 2003; 29: 29-35.","2型糖尿病の終末期腎不全に対する有効性が証明されたlosartan治療について,フランスのデータを用いて費用対効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12629445","http://diabetes.ebm-library.jp/trial/detail/50615" "RENAAL","the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study","Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, Cook JR, Keane WF, Brenner BM: Losartan Reduces the Costs Associated With Diabetic End-Stage Renal Disease: The RENAAL study economic evaluation. Diabetes Care 2003; 26: 683-687.","腎症を伴う2型糖尿病患者において,losartan投与が終末期腎不全関連の医療費に及ぼす効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12610022","http://diabetes.ebm-library.jp/trial/detail/50574" "RENAAL","the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study","Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, Burgess E, Hille DA, Dickson TZ, Shahinfar S, et al: Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003; 26: 1402-1407.","腎症を伴う2型糖尿病患者において,losartanの代謝パラメータに対する影響を検討し,ベースライン時の代謝パラメータと一次エンドポイントまたは末期腎不全との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12716796","http://diabetes.ebm-library.jp/trial/detail/50589" "RENAAL","the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study","Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM, RENAAL Study Group: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163: 1555-1565.","糖尿病性腎症に対する血圧の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12860578","http://diabetes.ebm-library.jp/trial/detail/50608" "RENAAL","the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study","Chan JC, Wat NM, So WY, Lam KS, Chua CT, Wong KS, Morad Z, Dickson TZ, Hille D, Zhang Z, et al.: Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: an Asian perspective from the RENAAL study. Diabetes Care 2004; 27: 874-879.","腎症を伴うアジア人2型糖尿病患者において,losartanの腎および心血管アウトカムに対する有効性および忍容性を検討し,腎エンドポイントの予測因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15047641","http://diabetes.ebm-library.jp/trial/detail/50641" "RENAAL","the Reduction in End Points in Noninsulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan","de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.","腎症を伴う2型糖尿病患者において,ベースライン時のアルブミン尿が独立した腎リスクの指標となるかを検討し,losartan治療による初期のアルブミン尿減少が長期的な腎保護効果の指標となり,治療後のアルブミン尿が腎リスクの指標となるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15149345","http://diabetes.ebm-library.jp/trial/detail/50710" "RENAAL","the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study","de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927.","腎症を伴う2型糖尿病患者において,losartan投与による短期的なアルブミン尿の減少により,長期的な心保護効果を予測しうるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15302780","http://diabetes.ebm-library.jp/trial/detail/50704" "RENAAL","the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan trial","Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, Shahinfar S, Carides GW, Brenner BM, RENAAL Study Group: Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004; 15: 3117-3125.","腎症を伴う2型糖尿病患者において,losartanの有効性および忍容性をベースライン時の腎機能別に検討した。RENAAL試験のpost hoc解析。","https://www.ncbi.nlm.nih.gov/pubmed/15579515","http://diabetes.ebm-library.jp/trial/detail/50739" "RENAAL","the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan trial","Boner G, Cooper ME, McCarroll K, Brenner BM, de Zeeuw D, Kowey PR, Shahinfar S, Dickson T, Crow RS, Parving HH, et al.: Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia 2005; 48: 1980-1987.","腎症を伴う2型糖尿病患者において,左室肥大が腎および心血管アウトカムに及ぼす影響を検討し,さらにそれらに対するlosartan治療の有効性を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/16082528","http://diabetes.ebm-library.jp/trial/detail/50788" "RENAAL","the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study","Kurokawa K, Chan JC, Cooper ME, Keane WF, Shahinfar S, Zhang Z: Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin Exp Nephrol 2006; 10: 193-200.","RENAAL試験で示された腎症を伴う2型糖尿病患者に対するlosartanの効果が日本人患者においても認められるかを検討した。RENAALのpost hoc解析。","https://www.ncbi.nlm.nih.gov/pubmed/17009077","http://diabetes.ebm-library.jp/trial/detail/50964" "RENAAL","the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan study","Winkelmayer WC, Zhang Z, Shahinfar S, Cooper ME, Avorn J, Brenner BM: Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care 2006; 29: 2210-2217.","高齢糖尿病患者において,losaratanの腎保護効果および安全性を検討した。RENAALのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/17003295","http://diabetes.ebm-library.jp/trial/detail/50977" "RENAAL","the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan trial","Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, et al.: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546.","腎症を伴う高血圧の2型糖尿病患者において,losartanのSBPおよびアルブミン尿に対する効果を検討し,さらにそれらの腎アウトカムに対する影響を検討した。RENAALのpost hoc解析。","https://www.ncbi.nlm.nih.gov/pubmed/17409317","http://diabetes.ebm-library.jp/trial/detail/51008" "Renfrew and Paisley Survey","-","Whiteley L, Padmanabhan S, Hole D, Isles C: Should diabetes be considered a coronary heart disease risk equivalent?: results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care 2005; 28: 1588-1593.","糖尿病が冠動脈心疾患と同等の死亡リスクを有することを証明し,さらに死亡率における性差を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15983305","http://diabetes.ebm-library.jp/trial/detail/50770" "Repaglinide/Pioglitazone Study","-","Jovanovic L, Hassman DR, Gooch B, Jain R, Greco S, Khutoryansky N, Hale PM: Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract 2004; 63: 127-134.","2型糖尿病患者において,repaglinideとpioglitazoneの併用投与の有効性および安全性を,repaglinide単独およびpioglitazone単独投与と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/14739053","http://diabetes.ebm-library.jp/trial/detail/50648" "Repaglinide Versus Nateglinide Comparison Study","-","Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM; Repaglinide Versus Nateglinide Comparison Study Group: Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care. 2004; 27: 1265-70.","過去に食事療法と運動療法を受けた2型糖尿病患者において,repaglinide単剤治療とnateglinide単剤治療の有効性と安全性を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15161773","http://diabetes.ebm-library.jp/trial/detail/51249" "Repaglinide vs. Nateglinide Metformin Combination Study","-","Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM; Repaglinide vs. Nateglinide Metformin Combination Study Group: Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care. 2003; 26: 2063-8.","2型糖尿病患者を対象に,metforminとの併用療法におけるrepaglinideとnateglinideの有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/12832314","http://diabetes.ebm-library.jp/trial/detail/51242" "REPLACE-2","the Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events-2 trial","Gurm HS, Sarembock IJ, Kereiakes DJ, Young JJ, Harrington RA, Kleiman N, Feit F, Wolski K, Bittl JA, Wilcox R, et al: Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. J Am Coll Cardiol 2005; 45: 1932-1938.","経皮的冠動脈形成術施行後のbivalirudinの短期的および長期的有効性をGP IIb/IIIa受容体拮抗薬と比較し,またその結果を糖尿病患者と非糖尿病患者で比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15963389","http://diabetes.ebm-library.jp/trial/detail/50759" "REPLACE-BG Study","−","Aleppo G, Ruedy KJ, Riddlesworth TD, Kruger DF, Peters AL, Hirsch I, Bergenstal RM, Toschi E, Ahmann AJ, Shah VN, Rickels MR, Bode BW, Philis-Tsimikas A, Pop-Busui R, Rodriguez H, Eyth E, Bhargava A, Kollman C, Beck RW; REPLACE-BG Study Group. REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes. Diabetes Care. 2017; 40: 538-545.","コントロール良好な成人1型糖尿病患者において,血糖モニタリングによる確認を行わずに持続血糖モニターを実施した場合の安全性と有効性を,CGMに加えてBGMによる確認を行った場合と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/28209654","http://diabetes.ebm-library.jp/trial/detail/51628" "RESULT","the Rosiglitazone Early vs. SULphonylurea Titration study","Rosenstock J, Goldstein BJ, Vinik AI, O'neill MC, Porter LE, Heise MA, Kravitz B, Dirani RG, Freed MI, RESULT Study Group: Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metab 2006; 8: 49-57.","最大用量以下のスルホニル尿素薬投与下でコントロール不良の高齢2型糖尿病患者において,rosiglitazone併用とスルホニル尿素薬増量の有効性,安全性,忍容性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/16367882","http://diabetes.ebm-library.jp/trial/detail/50832" "REWIND","Researching Cardiovascular Events with a Weekly Incretin in Diabetes","Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydn L, et al.; REWIND Investigators: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394: 121-130.","中年〜高齢の2型糖尿病患者において,既存の糖尿病治療薬レジメンにGLP-1受容体作動薬dulaglutideを追加した場合の,主要心血管イベントに対する効果を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/31189511","http://diabetes.ebm-library.jp/trial/detail/51767" "RIACE","Renal Insufficiency and Cardiovascular Events study","Orsi E, Solini A, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Morano S, Nicolucci A, Penno G, Pugliese G; Renal Insufficiency and Cardiovascular Events (RIACE) Study Group. Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes. Diabetes Obes Metab. 2018; 20: 1885-93.","2型糖尿病患者において,HbA1c変動性の様々な指標が平均HbA1cに比べて全死亡の独立した予測因子であるか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29582548","http://diabetes.ebm-library.jp/trial/detail/51728" "RIACE Italian Multicenter Study","Renal Insufficiency And Cardiovascular Events Italian Multicenter Study","Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Morano S, Cavalot F, Lamacchia O, Laviola L, et al.; Renal Insufficiency And Cardiovascular Events Study Group: HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care. 2013; 36: 2301-10.","2型糖尿病患者において,HbA1c変動性と細小血管合併症の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23491522","http://diabetes.ebm-library.jp/trial/detail/51373" "RIAD","the Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study","Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T: Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in impaired glucose tolerance for atherosclerosis and diabetes study. Diabetes Care 2003; 26: 868-874.","空腹時血糖異常症例および耐糖能異常症例を,インスリン分泌異常とインスリン抵抗性の観点から比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12610051","http://diabetes.ebm-library.jp/trial/detail/50577" "Riccardi G, et al.","-","Riccardi G, Giacco R, Parillo M, Turco S, Rivellese AA, Ventura MR, Contadini S, Marra G, Monteduro M, Santeusanio F, Brunetti P, Librenti MC, Pontiroli AE, Vedani P, Pozza G, Bergamini L, Bianchi C: Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diabet Med 1999; 16: 228-232.","1型糖尿病患者に対するacarboseの効果と,またその効果が食事(特に炭水化物と繊維の摂取)から受ける影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10227568","http://diabetes.ebm-library.jp/trial/detail/50180" "RIO-Diabetes","-","Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, RIO-Diabetes Study Group: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660-1672.","metforminまたはスルホニル尿素薬投与下でコントロール不良の過体重または肥満の2型糖尿病患者において,rimonabantの有効性および安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17098084","http://diabetes.ebm-library.jp/trial/detail/50965" "ROADMAP","Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study","Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Izzo JL, Katayama S, Ito S, Mimran A, Menne J, Rump LC, et al.: Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia. 2010; 53: 49-57.","正常アルブミン尿の2型糖尿病患者において,尿中アルブミン排泄率の決定因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19876613","http://diabetes.ebm-library.jp/trial/detail/51178" "ROADMAP","the Randomized Olmesartan and Diabetes Microalbuminuria Prevention","Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, ROADMAP Trial Investigators.; ROADMAP Trial Investigators: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011; 364: 907-17.","正常アルブミン尿の2型糖尿病患者において,ARBの使用によって微量アルブミン尿の発症が抑制または遅延されるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21388309","http://diabetes.ebm-library.jp/trial/detail/51209" "Roche MM and Wang PP.","−","Roche MM, Wang PP: Sex differences in all-cause and cardiovascular mortality, hospitalization for individuals with and without diabetes, and patients with diabetes diagnosed early and late. Diabetes Care. 2013; 36: 2582-90.","性差,糖尿病の有無,および糖尿病診断の時期(早期/晩期)が,死亡リスク(全死亡,心血管死,急性心筋梗塞,脳卒中)および入院リスクに与える影響を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/23564923","http://diabetes.ebm-library.jp/trial/detail/51363" "Ronnemaa T, et al.","-","Ronnemaa T, Hamalainen H, Toikka T, Liukkonen I: Evaluation of the impact of podiatrist care in the primary prevention of foot problems in diabetic subjects. Diabetes Care 1997; 20: 1833-1837.","糖尿病患者のフットケアに対する意識やフットケア専門医の重要性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9405902","http://diabetes.ebm-library.jp/trial/detail/50085" "Rosenstock J, et al.","-","Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N: Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015; 38: 376-83.","metforminでコントロール不良の2型糖尿病患者において,saxagliptin+dapagliflozin追加による3剤療法の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25352655","http://diabetes.ebm-library.jp/trial/detail/51467" "Rosenstock J, et al.","−","Rosenstock J, Franco D, Korpachev V, Shumel B, Ma Y, Baughman R, Amin N, McGill JB; Affinity 2 Study Group: Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Nave Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents. Diabetes Care. 2015; 38: 2274-81.","インスリン投与歴がなく,経口糖尿病治療薬でコントロール不良の2型糖尿病患者において,速効型吸入インスリンTechnosphereの有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26253730","http://diabetes.ebm-library.jp/trial/detail/51539" "Rotterdam Study","-","van Woudenbergh GJ, Kuijsten A, Tigcheler B, Sijbrands EJ, van Rooij FJ, Hofman A, Witteman JC, Feskens EJ: Meat consumption and its association with C-reactive protein and incident type 2 diabetes: the Rotterdam Study. Diabetes Care. 2012; 35: 1499-505.","非糖尿病のオランダ人において,赤身肉・加工肉・鶏肉摂取量と血中C反応性蛋白および2型糖尿病リスクの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22596177","http://diabetes.ebm-library.jp/trial/detail/51282" "Rotterdam Study","-","Ligthart S, van Herpt TT, Leening MJ, Kavousi M, Hofman A, Stricker BH, van Hoek M, Sijbrands EJ, Franco OH, Dehghan A: Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol. 2016; 4: 44-51.","45歳以上の成人において前糖尿病,2型糖尿病,インスリン使用の生涯リスクを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26575606","http://diabetes.ebm-library.jp/trial/detail/51552" "Roumie CL, et al.","-","Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, Elasy TA, Griffin MR: Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012; 157: 601-10.","2型糖尿病患者において,スルホニル尿素薬とmetforminの心血管疾患アウトカムまたは死亡に対する効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/23128859","http://diabetes.ebm-library.jp/trial/detail/51290" "Sacks FM, et al.","−","Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, Wanner C, Al-Rubeaan K, Aronson R, Barzon I, et al.: Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation. 2014; 129: 999-1008.","2型糖尿病でLDL-C≦130mg/dLの患者において,HDL-C低値およびトリグリセリド高値は,独立して糖尿病腎症または網膜症と関連するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24352521","http://diabetes.ebm-library.jp/trial/detail/51381" "Saku study","-","Morimoto A, Tatsumi Y, Deura K, Mizuno S, Ohno Y, Miyamatsu N, Watanabe S: Impact of impaired insulin secretion and insulin resistance on the incidence of type 2 diabetes mellitus in a Japanese population: the Saku study. Diabetologia. 2013; 56: 1671-9.","日本人において,2型糖尿病発症に対するインスリン分泌不全およびインスリン抵抗性の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23680915","http://diabetes.ebm-library.jp/trial/detail/51346" "Sakurai M, et al.","-","Sakurai M, Nakamura K, Miura K, Takamura T, Yoshita K, Nagasawa SY, Morikawa Y, Ishizaki M, Kido T, Naruse Y, et al.: Sugar-sweetened beverage and diet soda consumption and the 7-year risk for type 2 diabetes mellitus in middle-aged Japanese men. Eur J Nutr. 2013; ","日本人の中年男性において,砂糖入り飲料およびダイエット炭酸飲料の摂取量と2型糖尿病発症率の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23575771","http://diabetes.ebm-library.jp/trial/detail/51333" "Salmeron J, et al.","-","Salmeron J, Ascherio A, Rimm EB, Colditz GA, Spiegelman D, Jenkins DJ, Stampfer MJ, Wing AL, Willett WC: Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care 1997; 20: 545-550.","炭水化物摂取によるNIDDM発症のリスクが食物繊維摂取により低下するかどうかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9096978","http://diabetes.ebm-library.jp/trial/detail/50203" "San Antonio Heart Study","-","Lorenzo C, Williams K, Hunt KJ, Haffner SM: Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. Diabetes Care 2006; 29: 625-630.","メタボリックシンドロームの有病率の推移を検討し,さらにメタボリックシンドロームの心血管疾患に対する影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16505517","http://diabetes.ebm-library.jp/trial/detail/50820" "SANDS","Stop Atherosclerosis in Native Diabetics Study","Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, Howard WJ, Lee ET, Mete M, Poolaw B, et al.: Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008; 299: 1678-1689.","成人2型糖尿病患者において,LDL-CおよびSBPの厳格な目標値と標準的な目標値が潜在性アテローム性動脈硬化の進行に及ぼす効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18398080","http://diabetes.ebm-library.jp/trial/detail/51095" "Sasaki A, et al.","-","Sasaki A, Horiuchi N, Hasegawa K, Uehara M: Mortality and causes of death in type 2 diabetic patients. A long-term follow-up study in Osaka District, Japan. Diabetes Res Clin Pract 1989; 7: 33-40.","日本の2型糖尿病患者の死亡率とその関連リスク因子,死亡原因を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/2752888","http://diabetes.ebm-library.jp/trial/detail/50230" "Sasaki A, et al.","-","Sasaki A, Horiuchi N, Hasagawa K, Uehara M: Persistent albuminuria as an index of diabetic nephropathy in type 2 diabetic patients in Osaka, Japan-incidence, risk factors, prognosis and causes of death. Diabetes Res Clin Pract 1989; 7: 299-306.","日本の2型糖尿病患者における糖尿病性腎症の一般的特徴と,腎症発症率,関連リスク因子,予後,死亡原因を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/2612344","http://diabetes.ebm-library.jp/trial/detail/50231" "Sasaki A, et al.","-","Sasaki A, Okamoto N: Epidemiology of childhood diabetes in Osaka District, Japan, using the documents from the medical benefits system specific for childhood diabetes. Diabetes Res Clin Pract 1992; 18: 191-196.","大阪府の小児糖尿病について医療費支給申請書をもとに調査した。","https://www.ncbi.nlm.nih.gov/pubmed/1289020","http://diabetes.ebm-library.jp/trial/detail/50234" "Sasaki A, et al.","-","Sasaki A, Horiuchi N, Hasegawa K, Uehara M: The proportion of death certificates of diabetic patients that mentioned diabetes in Osaka District, Japan. Diabetes Res Clin Pract 1993; 20: 241-246.","死亡診断書に記載された2型糖尿病患者の死因の正確さを調査した。","https://www.ncbi.nlm.nih.gov/pubmed/8404458","http://diabetes.ebm-library.jp/trial/detail/50235" "Sasaki A, et al.","-","Sasaki A, Kamado K, Uehara M: Changes in causes of death in diabetic patients based on death certificates during a 30-year period in Osaka District, Japan, with special reference to cancer mortality. Diabetes Res Clin Pract 1994; 24: 103-112.","大阪地区における糖尿病患者の死因の変化を30年間の死亡診断書より分析した。","https://www.ncbi.nlm.nih.gov/pubmed/7956707","http://diabetes.ebm-library.jp/trial/detail/50236" "Sasaki A, et al.","-","Sasaki A, Uehara M, Horiuchi N, Hasegawa K, Shimizu T: A 15 year follow-up study of patients with non-insulin dependent diabetes mellitus (NIDDM) in Osaka, Japan. Long-term prognosis and causes of death. Diabetes Res Clin Pract 1996; 34: 47-55.","大阪地区のNIDDM患者の自然経過を15年間追跡し,死亡率と死因の変化を調査した。","https://www.ncbi.nlm.nih.gov/pubmed/8968690","http://diabetes.ebm-library.jp/trial/detail/50241" "SAVE","Survival And Ventricular Enlargement","Solomon SD, St John Sutton M, Lamas GA, Plappert T, Rouleau JL, Skali H, Moye L, Braunwald E, Pfeffer MA, Survival And Ventricular Enlargement (SAVE) Investigators: Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation 2002; 106: 1251-1255.","糖尿病患者において,心筋梗塞発症後の左室拡張と心不全の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12208801","http://diabetes.ebm-library.jp/trial/detail/50548" "SAVE","the Survival And Ventricular Enlargement trial","Murcia AM, Hennekens CH, Lamas GA, Jimenez-Navarro M, Rouleau JL, Flaker GC, Murcia AM, Murcia AM, Murcia AM, Murcia AM: Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 2004; 164: 2273-2279.","急性心筋梗塞発症後,左室機能不全を認める患者において,糖尿病が長期的な心血管イベントおよび死亡に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15534166","http://diabetes.ebm-library.jp/trial/detail/50695" "SAVOR-TIMI 53","Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 trial"," Mosenzon O, Leibowitz G, Bhatt DL, Cahn A, Hirshberg B, Wei C, Im K, Rozenberg A, Yanuv I, Stahre C, Ray KK, Iqbal N, Braunwald E, Scirica BM, Raz I. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care. 2017; 40: 69-76.","心血管(CV)リスクの高い2型糖尿病患者において,DPP-4阻害薬saxagliptinの腎安全性と有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27797925","http://diabetes.ebm-library.jp/trial/detail/51617" "SAVOR-TIMI 53","Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes MellitusThrombolysis in Myocardial Infarction 53 trial","Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al.; the SAVOR-TIMI 53 Steering Committee and Investigators: Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med. 2013; 369: 1317-1326.","心血管イベントのリスクが高い2型糖尿病患者において,DPP-4阻害薬saxagliptinの有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23992601","http://diabetes.ebm-library.jp/trial/detail/51342" "SAVOR-TIMI 53","Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes MellitusThrombolysis in Myocardial Infarction 53","Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, et al.; SAVOR-TIMI 53 Steering Committee and Investigators*: Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014; 130: 1579-88.","心血管イベントのリスクが高い2型糖尿病患者において,心不全による入院の危険因子について検討した。また,心不全による入院とDDP-4阻害薬saxagliptin治療,ベースラインのナトリウム利尿ペプチド値(NT-proBNP),および心不全既往との関連について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25189213","http://diabetes.ebm-library.jp/trial/detail/51439" "SAVOR-TIMI 53","Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53","Leiter LA, Teoh H, Braunwald E, Mosenzon O, Cahn A, Kumar KM, Smahelova A, Hirshberg B, Stahre C, Frederich R, et al.; SAVOR-TIMI 53 Steering Committee and Investigators: Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care. 2015; 38: 1145-53.","心血管疾患の既往/複数の血管疾患の危険因子を有する2型糖尿病患者のうち,高齢者(65歳以上)または超高齢者(75歳以上)におけるsaxagliptinの安全性と心血管系への影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25758769","http://diabetes.ebm-library.jp/trial/detail/51493" "SAVOR-TIMI 53","Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53","Mosenzon O, Wei C, Davidson J, Scirica BM, Yanuv I, Rozenberg A, Hirshberg B, Cahn A, Stahre C, Strojek K, et al.: Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial. Diabetes Care. 2015; 38: 2142-50.","2型糖尿病患者において,saxagliptinの骨折リスクを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26358285","http://diabetes.ebm-library.jp/trial/detail/51532" "SAVOR-TIMI 53","Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 trial","Cahn A, Raz I, Mosenzon O, Leibowitz G, Yanuv I, Rozenberg A, Iqbal N, Hirshberg B, Sjostrand M, Stahre C, et al.: Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. Diabetes Care. 2016; 39: 1329-37.","2型糖尿病患者において,従来治療へのDPP-4阻害薬saxagliptin追加による低血糖リスクを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27222508","http://diabetes.ebm-library.jp/trial/detail/51588" "Sawatkar GU, et al.","-","Sawatkar GU, Kanwar AJ, Dogra S, Bhadada SK, Dayal D: Spectrum of cutaneous manifestations of type 1 diabetes mellitus in 500 south Asian patients. Br J Dermatol. 2014; ","南アジアの1型糖尿病患者において,皮膚病の特徴,罹病期間と長期血糖コントロールの影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24773124","http://diabetes.ebm-library.jp/trial/detail/51396" "SCALE Obesity and Prediabetes study","-","SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017: 389: 1399-1409.","肥満の前糖尿病患者において,2型糖尿病発症までの期間と体重減少に対する3年間のliraglutideの効果および安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28237263","http://diabetes.ebm-library.jp/trial/detail/51625" "Scandinavian Repaglinide Group","-","Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A; Scandinavian Repaglinide Group: Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study. Diabet Med. 2001; 18: 395-401.","2型糖尿病患者において,repaglinideの長期的有効性および安全性を,glipizideと比較した。","https://www.ncbi.nlm.nih.gov/pubmed/11472451","http://diabetes.ebm-library.jp/trial/detail/51229" "Schievink B, et al.","-","Schievink B, Krpelin T, Mulder S, Parving HH, Remuzzi G, Dwyer J, Vemer P, de Zeeuw D, Lambers Heerspink HJ: Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. Diabetes Obes Metab. 2016; 18: 64-71.","糖尿病腎臓病の進展を発症早期から末期腎疾患までシミュレーションするモデルを作成して検証し,末期腎疾患に対するレニン・アンジオテンシン系介入の効果を介入の時期別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26434564","http://diabetes.ebm-library.jp/trial/detail/51553" "Schnack C, et al.","-","Schnack C, Hoffmann W, Hopmeier P, Schernthaner G: Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia 1996; 39: 1611-1616.","高血圧NIDDMにおけるramipril,atenololのアルブミン排泄率に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8960851","http://diabetes.ebm-library.jp/trial/detail/50252" "Schramm TK, et al.","-","Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbl EL, Kber L, Norgaard ML, Madsen M, et al.: Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011; 32: 1900-8.","2型糖尿病患者において,インスリン分泌促進薬(ISs)と死亡率および心血管リスクの関連を検討し,metforminと比較した。","https://www.ncbi.nlm.nih.gov/pubmed/21471135","http://diabetes.ebm-library.jp/trial/detail/51225" "Schwabing Insulin Prophylaxis Pilot Trial","-","Fuchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG: Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 1998; 41: 536-541.","1型糖尿病の高リスク集団において,予防的インスリン療法の発症遅延効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9628270","http://diabetes.ebm-library.jp/trial/detail/50099" "Schwartz AV, et al.","-","Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, Donaldson MG, Cauley JA, Harris TB, Koster A, et al.; Study of Osteoporotic Fractures (SOF) Research GroupOsteoporotic Fractures in Men (MrOS) Research GroupHealth, Aging, and Body Composition (Health ABC) Research Group: Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011; 305: 2184-92.","高齢の2型糖尿病患者において,大腿骨頸部骨密度のT scoreと世界保健機関(WHO)の骨折リスクアルゴリズムFRAX scoreが,大腿骨頸部骨折と非脊椎骨折のリスクと関連しているかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21632482","http://diabetes.ebm-library.jp/trial/detail/51208" "SDIS","the Stockholm Diabetes Intervention Study","Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U: Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 1991; 230: 101-108.","IDDM患者に対する5年間の強化インスリン療法の効果と副作用を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/1865159","http://diabetes.ebm-library.jp/trial/detail/50107" "SDIS","the Stockholm Diabetes Intervention Study","Reichard P, Pihl M: Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes 1994; 43: 313-317.","長期間の強化インスリン療法の死亡率に及ぼす効果および副作用を標準的インスリン療法と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8288056","http://diabetes.ebm-library.jp/trial/detail/50068" "SEARCH","SEARCH for Diabetes in Youth","Hood KK, Lawrence JM, Anderson A, Bell R, Dabelea D, Daniels S, Rodriguez B, Dolan LM; SEARCH for Diabetes in Youth Study Group: Metabolic and inflammatory links to depression in youth with diabetes. Diabetes Care. 2012; 35: 2443-6.","糖尿病の小児および青年において,うつ病リスクと代謝および炎症マーカーの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23033243","http://diabetes.ebm-library.jp/trial/detail/51301" "Seattle Diabetic Foot Study","-","Boyko EJ, Ahroni JH, Cohen V, Nelson KM, Heagerty PJ: Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle Diabetic Foot Study. Diabetes Care 2006; 29: 1202-1207.","一般的な臨床情報を用いた糖尿病性足潰瘍の予測について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16731996","http://diabetes.ebm-library.jp/trial/detail/50949" "Seattle Japanese-American Community Diabetes Study","-","Fujimoto WY, Bergstrom RW, Boyko EJ, Chen KW, Leonetti DL, Newell-Morris L, Shofer JB, Wahl PW: Visceral adiposity and incident coronary heart disease in Japanese-American men. The 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. Diabetes Care 1999; 22: 1808-1812.","日系2世の米国人男性において,冠動脈心疾患発症のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10546012","http://diabetes.ebm-library.jp/trial/detail/50491" "SECURE","the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E","Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley W, Teo K: Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-925.","心血管イベント高リスク患者において,ramiprilとvitamin Eの長期投与による動脈硬化の進展抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11181464","http://diabetes.ebm-library.jp/trial/detail/50370" "Seino Y, et al.","-","Seino Y, Kaku K, Inagaki N, Haneda M, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Endocr J. 2015; 62: 593-603.","食事および運動療法でコントロール不良の日本人2型糖尿病患者において,luseogliflozin単独療法の長期安全性と有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25971406","http://diabetes.ebm-library.jp/trial/detail/51637" "Seino Y, et al.","-","Seino Y, Terauchi Y, Osonoi T, Yabe D, Abe N, Nishida T, Zacho J, Kaneko S. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018; 20: 378-88.","日本人2型糖尿病患者において,週1回semaglutide皮下注と1日1回sitagliptin経口投与の安全性と有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/28786547","http://diabetes.ebm-library.jp/trial/detail/51711" "Selby JV, et al.","-","Selby JV, Zhang D: Risk factors for lower extremity amputation in persons with diabetes. Diabetes Care 1995; 18: 509-516.","糖尿病の集団における下肢切断の予測因子を調査した。","https://www.ncbi.nlm.nih.gov/pubmed/7497861","http://diabetes.ebm-library.jp/trial/detail/50197" "SENDCAP","the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention study","Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD: Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998; 21: 641-648.","2型糖尿病患者において,従来の糖尿病治療にbezafibrateによる血清脂質低下療法を追加した場合の,心血管アウトカムに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9571357","http://diabetes.ebm-library.jp/trial/detail/50516" "Seven Countries Study","-","Stengard JH, Tuomilehto J, Pekkanen J, Kivinen P, Kaarsalo E, Nissinen A, Karvonen MJ: Diabetes mellitus, impaired glucose tolerance and mortality among elderly men: the Finnish cohorts of the Seven Countries Study. Diabetologia 1992; 35: 760-765.","高齢者における耐糖能異常が総死亡,原因別死亡に与える影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/1511803","http://diabetes.ebm-library.jp/trial/detail/50246" "Seven Countries Study","-","Feskens EJ, Tuomilehto J, Stengard JH, Pekkanen J, Nissinen A, Kromhout D: Hypertension and overweight associated with hyperinsulinaemia and glucose tolerance: a longitudinal study of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetologia 1995; 38: 839-847.","耐糖能異常・空腹時高インスリン血症の有無が高血圧,肥満と関連するかどうかを解析した。","https://www.ncbi.nlm.nih.gov/pubmed/7556987","http://diabetes.ebm-library.jp/trial/detail/50251" "Seven Countries Study","-","Feskens EJ, Virtanen SM, Rasanen L, Tuomilehto J, Stengard J, Pekkanen J, Nissinen A, Kromhout D: Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 1995; 18: 1104-1112.","耐糖能およびNIDDMをもたらす長期の食事習慣について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/7587845","http://diabetes.ebm-library.jp/trial/detail/50198" "Shan Z, et al.","−","Shan Z, Ma H, Xie M, Yan P, Guo Y, Bao W, Rong Y, Jackson CL, Hu FB, Liu L: Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care. 2015; 38: 529-37.","睡眠時間の長短が2型糖尿病発症に及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25715415","http://diabetes.ebm-library.jp/trial/detail/51486" "SHDS II","Shanghai Diabetes Study II","Bao Y, Ma X, Li H, Zhou M, Hu C, Wu H, Tang J, Hou X, Xiang K, Jia W: Glycated haemoglobin A1c for diagnosing diabetes in Chinese population: cross sectional epidemiological survey. BMJ. 2010; 340: c2249.","中国人において,HbA1c値の糖尿病診断基準を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20478961","http://diabetes.ebm-library.jp/trial/detail/51182" "SHEP","the Systolic Hypertension in the Elderly Program","Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276: 1886-1892.","老年者収縮期高血圧のNIDDM患者に対する低用量利尿薬の心血管疾患予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8968014","http://diabetes.ebm-library.jp/trial/detail/50111" "SHEP","the Systolic Hypertension in the Elderly Program","Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR, SHEP Collaborative Research Group: Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95: 29-35.","利尿薬をベースとした降圧療法が心血管疾患イベントに及ぼす長期的な影響を糖尿病の有無により比較検討した(SHEP延長試験)。","https://www.ncbi.nlm.nih.gov/pubmed/15619390","http://diabetes.ebm-library.jp/trial/detail/50708" "SHEP","the Systolic Hypertension in the Elderly Program","Shafi T, Appel LJ, Miller ER, Klag MJ, Parekh RS: Changes in serum potassium mediate thiazide-induced diabetes. Hypertension 2008; 52: 1022-1029.","高血圧患者において,サイアザイド誘導の血清カリウム値の変化がサイアザイド系利尿薬の糖尿病発症に対する効果を仲介するか否かを検討した。SHEPのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18981326","http://diabetes.ebm-library.jp/trial/detail/51103" "SHHS","the Sleep Heart Health Study","Resnick HE, Redline S, Shahar E, Gilpin A, Newman A, Walter R, Ewy GA, Howard BV, Punjabi NM, Sleep Heart Health Study: Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. Diabetes Care 2003; 26: 702-709.","糖尿病と睡眠時呼吸障害の関係を検討するとともに,糖尿病患者の呼吸障害が中枢型か閉塞型かを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/12610025","http://diabetes.ebm-library.jp/trial/detail/50582" "Shiba T, et al.","-","Shiba T, Ishii S, Okamura T, Mitsuyoshi R, Pfarr E, Koiwai K. Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials. Diabetes Res Clin Pract. 2017; 131: 169-78.","日本人2型糖尿病患者において,empagliflozinの有効性と安全性をBMIおよび年齢別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28753486","http://diabetes.ebm-library.jp/trial/detail/51681" "Shimizu M, et al.","-","Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, Iijima M, Takekawa H, Usui I, Hiraishi H, Aso Y. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019; 21: 285-92.","非アルコール性脂肪性肝疾患を有する2型糖尿病患者において,肝脂肪変性および肝線維化に対するdapagliflozinの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30178600","http://diabetes.ebm-library.jp/trial/detail/51759" "SHOCK","SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? trial","Shindler DM, Palmeri ST, Antonelli TA, Sleeper LA, Boland J, Cocke TP, Hochman JS: Diabetes mellitus in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36: 1097-1103.","心原性ショックを併発した急性心筋梗塞患者における糖尿病の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10985711","http://diabetes.ebm-library.jp/trial/detail/50379" "Shorr RI, et al.","-","Shorr RI, Ray WA, Daugherty JR, Griffin MR: Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997; 278: 40-43.","インスリンまたはスルホニル尿素で治療している高齢者の重症低血糖発症リスクに対する各種降圧薬の効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9207336","http://diabetes.ebm-library.jp/trial/detail/50332" "Shurraw S, et al.","-","Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, Bello A, James M, Turin TC, Tonelli M; Alberta Kidney Disease Network: Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med. 2011; 171: 1920-7.","ステージ3〜4の慢性腎臓病を有する糖尿病患者において,HbA1c値が臨床アウトカムと独立して相関するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22123800","http://diabetes.ebm-library.jp/trial/detail/51240" "SIDESTEP","-","Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA: Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005; 366: 1695-1703.","下肢感染症を有する糖尿病患者において,ertapenemとpiperacillin/tazobactamの有効性および安全性を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16291062","http://diabetes.ebm-library.jp/trial/detail/50789" "Sildenafil Diabetes Study","-","Rendell MS, Rajfer J, Wicker PA, Smith MD: Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999; 281: 421-426.","糖尿病男性患者の勃起不全治療における経口sildenafil投与の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9952201","http://diabetes.ebm-library.jp/trial/detail/50509" "Simpson RW, et al.","-"," Simpson RW, Wlodarczyk JH: Transdermal Buprenorphine Relieves Neuropathic Pain: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial in Diabetic Peripheral Neuropathic Pain. Diabetes Care. 2016; 39: 1493-500.","糖尿病性末梢神経痛患者において,経皮buprenorphineの有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27311495","http://diabetes.ebm-library.jp/trial/detail/51590" "Singapore Longitudinal Aging Study","−","Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B: Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis. 2014; 41: 61-8.","糖尿病の高齢患者において,metformin投与が認知症発症リスクにおよぼす影響,さらにアルツハイマー病に関連するAPOE-4遺伝子多型によりその影響に差がみられるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24577463","http://diabetes.ebm-library.jp/trial/detail/51426" "Singh S, et al.","-","Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB: Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013; 173: 534-9.","2型糖尿病患者において,exenatideまたはsitagliptin治療と急性膵炎リスクの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23440284","http://diabetes.ebm-library.jp/trial/detail/51332" "SIRIUS","SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions trial","Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, et al: Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004; 109: 2273-2278.","sirolimus(rapamycin)溶出ステント留置によるアウトカムを糖尿病患者および非糖尿病患者で比較した。","https://www.ncbi.nlm.nih.gov/pubmed/15123524","http://diabetes.ebm-library.jp/trial/detail/50664" "Skupien J, et al.","-","Skupien J, Warram JH, Smiles AM, Stanton RC, Krolewski AS. Patterns of Estimated Glomerular Filtration Rate Decline Leading to End-Stage Renal Disease in Type 1 Diabetes.","末期腎疾患を発症した1型糖尿病患者において,推算糸球体濾過量低下の軌道を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27647852","http://diabetes.ebm-library.jp/trial/detail/51608" "SMART","●この論文は撤回されました","●この論文は撤回されました
Shiga Microalbuminuria Reduction Trial (SMART) Group, , Sawaguchi M, Maegawa H, Kashiwagi A: Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007; 30: 1581-1583.","論文撤回","https://www.ncbi.nlm.nih.gov/pubmed/17363751","http://diabetes.ebm-library.jp/trial/detail/51021" "SMART","Second Manifestations of ARTerial disease","Sharif S, van der Graaf Y, Nathoe HM, de Valk HW, Visseren FL, Westerink J; SMART Study Group: HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care. 2016; 39: 1424-30.","脂質低下療法でLDL-C治療目標値を達成した2型糖尿病患者において,HDL-C低値が心血管疾患と死亡の残存リスク因子であるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27222511","http://diabetes.ebm-library.jp/trial/detail/51587" "SMILE","the Survival of Myocardial Infarction Long-Term Evaluation trial","Borghi C, Bacchelli S, Esposti DD, Ambrosioni E, SMILE Study: Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. Diabetes Care 2003; 26: 1862-1868.","前壁急性心筋梗塞を発症した糖尿病患者において,zofenoprilの有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12766124","http://diabetes.ebm-library.jp/trial/detail/50642" "SMOOTH","the Study of Micardis (telmisartan) in Overweight/Obese patients with Type 2 diabetes and Hypertension","Sharma AM, Davidson J, Koval S, Lacourciere Y: Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol 2007; 6: 28.","過体重または肥満の高血圧を有する2型糖尿病患者において,telmisartan+hydrochlorothiazide併用およびvalsartan+hydrochlorothiazide併用の早朝血圧に対する効果を自由行動下血圧測定により比較した。","https://www.ncbi.nlm.nih.gov/pubmed/17910747","http://diabetes.ebm-library.jp/trial/detail/51034" "Sfteland Ek, et al.","-"," Sfteland E, Meier JJ, Vangen B, Toorawa R, Maldonado-Lutomirsky M, Broedl UC. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial. Diabetes Care. 2017; 40: 201-209.","linagliptinおよびmetforminでコントロール不良の2型糖尿病患者において,empagliflozin追加投与の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27913576","http://diabetes.ebm-library.jp/trial/detail/51613" "SOLVD","the Studies of Left Ventricular Dysfunction","Capes SE, Gerstein HC, Negassa A, Yusuf S: Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care 2000; 23: 377-380.","左室機能障害をもつ糖尿病および非糖尿病患者において,enalaprilの蛋白尿発現抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10868869","http://diabetes.ebm-library.jp/trial/detail/50400" "SOLVD","the Studies Of Left Ventricular Dysfunction","Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC, Studies Of Left Ventricular Dysfunction: Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107: 1291-1296.","左室機能障害を有する患者において,enalaprilの糖尿病発症抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12628950","http://diabetes.ebm-library.jp/trial/detail/50571" "Sorbinil Retinopathy Trial","-","Sorbinil Retinopathy Trial Research Group.: A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990; 108: 1234-1244.","sorbinilの糖尿病網膜症に対する効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/2119168","http://diabetes.ebm-library.jp/trial/detail/50015" "SOS","Swedish Obese Subjects study","Carlsson LM, Peltonen M, Ahlin S, Anveden , Bouchard C, Carlsson B, Jacobson P, Lnroth H, Maglio C, Nslund I, et al.: Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012; 367: 695-704.","スウェーデン人の肥満患者において,肥満手術の2型糖尿病予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22913680","http://diabetes.ebm-library.jp/trial/detail/51274" "SOS","Swedish Obese Subjects study","Sjstrm L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden , Bouchard C, Carlsson B, Karason K, Lnroth H, et al.: Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014; 311: 2297-304.","肥満の2型糖尿病患者において,肥満手術後の長期糖尿病寛解率,細小血管および大血管合併症の累積発症率を標準治療と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24915261","http://diabetes.ebm-library.jp/trial/detail/51406" "SOS","Swedish Obese Subject study","Sjholm K, Pajunen P, Jacobson P, Karason K, Sjstrm CD, Torgerson J, Carlsson LM, Sjstrm L, Peltonen M: Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study. Diabetologia. 2015; 58: 1448-53.","肥満患者において,2型糖尿病の発生率と寛解率をベースラインのBMIと体重変化別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25924987","http://diabetes.ebm-library.jp/trial/detail/51482" "SOS","Swedish Obese Subjects study","Carlsson LM, Sjholm K, Karlsson C, Jacobson P, Andersson-Assarsson JC, Svensson PA, Larsson I, Hjorth S, Neovius M, Taube M, Carlsson B, Peltonen M. Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study. Lancet Diabetes Endocrinol. 2017; 5: 271-279.","肥満患者において,肥満手術による細小血管合併症の抑制効果を,ベースライン時の血糖値レベル別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28237791","http://diabetes.ebm-library.jp/trial/detail/51633" "SPEAD-A","Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis trial","Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Shimomura I, Watada H; Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial. Diabetes Care. 2016; 39: 139-48.","心血管疾患既往のない2型糖尿病患者において,頸動脈内膜中膜壁肥厚に対するalogliptinの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26628419","http://diabetes.ebm-library.jp/trial/detail/51657" "SPIKE","Sitagliptin Preventive Study of Intima-Media Thickness Evaluation trial","Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N, Osonoi T, Kaneto H, Kosugi K, Umayahara Y, Yamamoto T, Matsumoto K, Yokoyama H, Tsugawa M, Gosho M, Shimomura I, Watada H; Collaborators on the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE) Trial. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial. Diabetes Care. 2016; 39: 455-64.","インスリン治療を行っている2型糖尿病患者において,頸動脈内膜中膜壁肥厚に対するsitagliptin追加の効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26822324","http://diabetes.ebm-library.jp/trial/detail/51656" "SPLINT","the Specialist Nurse-Led Intervention to Treat and Control Hypertension and Hyperlipidemia in Diabetes trial","New JP, Mason JM, Freemantle N, Teasdale S, Wong LM, Bruce NJ, Burns JA, Gibson JM: Specialist nurse-led intervention to treat and control hypertension and hyperlipidemia in diabetes (SPLINT): a randomized controlled trial. Diabetes Care 2003; 26: 2250-2255.","通院中の糖尿病患者において,高血圧および高脂血症に関する専門看護師による患者指導の有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12882844","http://diabetes.ebm-library.jp/trial/detail/50621" "SPREAD-DIMCAD","Study on the Prognosis and Effect of Antidiabetic Drugs on Type 2 Diabetes Mellitus with Coronary Artery Disease","Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, Zhou Z, Tang W, Zhao J, Cui L, et al.; SPREAD-DIMCAD Investigators: Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013; 36: 1304-11.","冠動脈疾患既往のある中国人2型糖尿病患者において,主要心血管イベントに対するmetforminとglipizideの長期有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/23230096","http://diabetes.ebm-library.jp/trial/detail/51318" "SPRINT","Systolic Blood Pressure Intervention Trial","Bress AP, King JB, Kreider KE, Beddhu S, Simmons DL, Cheung AK, Zhang Y, Doumas M, Nord J, Sweeney ME, Taylor AA, Herring C, Kostis WJ, Powell J, Rastogi A, Roumie CL, Wiggers A, Williams JS, Yunis R, Zias A, Evans GW, Greene T, Rocco MV, Cushman WC, Reboussin DM, Feinglos MN, Papademetriou V; SPRINT Research Group. Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care. 2017 Aug 9. pii: dc170885.","ベースラインの前糖尿病例と空腹時血糖正常例で,収縮期血圧低下のための強化療法と標準療法の効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/28793997","http://diabetes.ebm-library.jp/trial/detail/51674" "STAMPEDE","Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently trial","Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ES, Nissen SE, et al.; STAMPEDE Investigators: Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med. 2014; 370: 2002-13.","コントロール不良で肥満の2型糖尿病患者において,肥満手術と強化薬物療法の3年間の有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24679060","http://diabetes.ebm-library.jp/trial/detail/51407" "STAR","the Study of Trandolapril/Verapamil SR And Insulin Resistance","Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J, STAR Investigators: Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-2597.","耐糖能異常を認める高血圧患者において,固定用量のtrandolapril/verapamil徐放剤併用およびlosartan/hydrochlorothiazide併用の耐糖能に対する効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/17130190","http://diabetes.ebm-library.jp/trial/detail/50974" "STAR 3","Sensor-Augmented Pump Therapy for A1C Reduction 3","Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, et al.; the STAR 3 Study Group: Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. N Engl J Med. 2010; 363: 311-20.","コントロール不良の1型糖尿病患者において,センサー増強ポンプ療法と頻回インスリン注射療法の有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/20587585","http://diabetes.ebm-library.jp/trial/detail/51188" "STEADINESS","the Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability Study","Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, et al: Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004; 27: 1081-1087.","1型糖尿病患者において,長時間作用型インスリンdetemirとNPHインスリンの血糖コントロールに対する有効性および投与タイミングを比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15111525","http://diabetes.ebm-library.jp/trial/detail/50701" "Steno-2 Study","-","Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.","微量アルブミン尿を認める2型糖尿病患者において,集中的多因子治療の全死亡および心血管死に対する有効性を検討した。Steno-2の延長観察試験。","https://www.ncbi.nlm.nih.gov/pubmed/18256393","http://diabetes.ebm-library.jp/trial/detail/51053" "Steno-2 study","-","Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O: Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care. 2008; 31: 1510-5.","微量アルブミン尿を認める2型糖尿病患者において,強化療法と標準療法の費用対効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18443195","http://diabetes.ebm-library.jp/trial/detail/51161" "Steno type 2 randomised study","-","Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622.","微量アルブミン尿が認められる2型糖尿病患者において,集中的多因子治療が細小血管障害の発現および進行に及ぼす効果を標準療法と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10030326","http://diabetes.ebm-library.jp/trial/detail/50118" "Steno type 2 randomised study","-","Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.","微量アルブミン尿が認められる2型糖尿病患者において,集中的多因子治療が心血管疾患の修正可能なリスク因子に及ぼす効果を標準療法と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12556541","http://diabetes.ebm-library.jp/trial/detail/50563" "Stewart ZA, et al.","−","Stewart ZA, Wilinska ME, Hartnell S, Temple RC, Rayman G, Stanley KP, Simmons D, Law GR, Scott EM, Hovorka R, Murphy HR. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. N Engl J Med. 2016; 375: 644-54.","1型糖尿病の妊婦において,クローズドループインスリン注入システム(クローズドループ療法)とセンサー付きポンプ療法の有効性と安全性を比較した。また,妊婦における24時間クローズドループ療法の実現可能性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27532830","http://diabetes.ebm-library.jp/trial/detail/51599" "STOP Hypertension-2","the Swedish Trial in Old Patients with Hypertension-2","Lindholm LH, Hansson L, Ekbom T, Dahlof B, Lanke J, Linjer E, Schersten B, Wester PO, Hedner T, de Faire U: Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000; 18: 1671-1675.","高血圧の高齢糖尿病患者において,従来の降圧薬(利尿薬,β遮断薬)と新規降圧薬(Ca拮抗薬,ACE阻害薬)の心血管イベント抑制効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11081782","http://diabetes.ebm-library.jp/trial/detail/50450" "STOP-NIDDM","the Study to Prevent Non-insulin-dependent diabetes mellitus","Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077.","耐糖能異常から2型糖尿病への進展に対するacarboseの抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12086760","http://diabetes.ebm-library.jp/trial/detail/50530" "STOP-NIDDM","the Study to Prevent Non-insulin-dependent diabetes mellitus","Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494.","耐糖能異常患者において,acarbose投与による食後高血糖の減少が,心血管疾患および高血圧のリスクに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12876091","http://diabetes.ebm-library.jp/trial/detail/50606" "STOP-NIDDM","the Study to Prevent Non-insulin-dependent diabetes mellitus","Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T: Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073-1078.","耐糖能異常を有する患者において,acarboseの内膜-中膜壁肥厚進展抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15073402","http://diabetes.ebm-library.jp/trial/detail/50649" "STOP-NIDDM","the Study to Prevent Non-insulin-dependent diabetes mellitus","Hanefeld M, Karasik A, Koehler C, Westermeier T, Chiasson JL: Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial. Diab Vasc Dis Res. 2009; 6: 32-7.","耐糖能異常患者において,メタボリックシンドロームおよびその各要素と糖尿病発症リスクとの関係を検討した。STOP-NIDDMの二次解析。","https://www.ncbi.nlm.nih.gov/pubmed/19156626","http://diabetes.ebm-library.jp/trial/detail/51120" "Stracke H, et al.","-","Stracke H, Meyer UE, Schumacher HE, Federlin K: Mexiletine in the treatment of diabetic neuropathy. Diabetes Care 1992; 15: 1550-1555.","激しい疼痛を伴う糖尿病多発性神経障害におけるmexiletineの有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/1468285","http://diabetes.ebm-library.jp/trial/detail/50078" "STRESS","Stent Restenosis Study","Savage MP, Fischman DL, Schatz RA, Leon MB, Baim DS, Brinker J, Hirshfeld J, Goldberg S, STRESS Investigators. Stent Restensosis Study: Coronary intervention in the diabetic patient: improved outcome following stent implantation compared with balloon angioplasty. Clin Cardiol 2002; 25: 213-217.","冠動脈に新規病変を有する糖尿病患者において,ステント植込み術およびバルーン血管形成術後のアウトカムを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/12018879","http://diabetes.ebm-library.jp/trial/detail/50562" "Strong Heart Study","-","Zhang Y, Howard BV, Cowan LD, Yeh J, Schaefer CF, Wild RA, Wang W, Lee ET: The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in american Indian postmenopausal women : the strong heart study. Diabetes Care 2002; 25: 500-504.","アメリカインディアンの閉経後女性において,estrogen投与がインスリン値および血糖値,2型糖尿病の発症リスクに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11874937","http://diabetes.ebm-library.jp/trial/detail/50522" "Strong Heart Study","-","Sosenko JM, Hu D, Welty T, Howard BV, Lee E, Robbins DC, Strong Heart Study: Albuminuria in recent-onset type 2 diabetes: the Strong Heart Study. Diabetes Care 2002; 25: 1078-1084.","2型糖尿病発症後早期におけるアルブミン排泄異常の発現率と,その発現に2型糖尿病が及ぼす影響について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12032118","http://diabetes.ebm-library.jp/trial/detail/50529" "Strong Heart Study","-","Palmieri V, Tracy RP, Roman MJ, Liu JE, Best LG, Bella JN, Robbins DC, Howard BV, Devereux RB, Strong Heart Study: Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study. Diabetes Care 2003; 26: 2764-2769.","成人の2型糖尿病において,左室肥大と炎症性マーカー(フィブリノーゲン,高感度C反応性蛋白)の関係を評価するとともに,それらの関係に対するアルブミン尿の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14514577","http://diabetes.ebm-library.jp/trial/detail/50623" "Strong Heart Study","-","Lee JS, Chang PY, Zhang Y, Kizer JR, Best LG, Howard BV. Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study. Diabetes Care. 2017; 40: 529-537.","肥満と糖尿病の有病率が高いアメリカ先住民の地域住民において,空腹時血漿トリグリセライド高値かつHDL-C低値は冠動脈疾患および虚血性脳卒中の危険因子であり,この関係の強さは糖尿病状態,性別,LDL-C値に依存するという仮説を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/28122840","http://diabetes.ebm-library.jp/trial/detail/51629" "Styrian Vitamin D Hypertension trial","−","Grbler MR, Gaksch M, Kienreich K, Verheyen N, Schmid J, Hartaigh B, Richtig G, Scharnagl H, Meinitzer A, Fahrleitner-Pammer A, Mrz W, Tomaschitz A, Pilz S. Effects of vitamin D supplementation on glycated haemoglobin and fasting glucose levels in hypertensive patients: a randomized controlled trial. Diabetes Obes Metab. 2016; 18: 1006-12.","動脈性高血圧の肥満患者において,ビタミンD補給の血糖コントロールに対する有効性を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/27334070","http://diabetes.ebm-library.jp/trial/detail/51604" "Suissa S, et al.","-","Suissa S, Azoulay L, Dell'Aniello S, Evans M, Vora J, Pollak M: Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia. 2011; 54: 2254-62.","女性2型糖尿病患者におけるインスリンglargineの長期使用と乳がんリスクの関連について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21614572","http://diabetes.ebm-library.jp/trial/detail/51219" "Sun F, et al.","-","Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L, Zhan S: Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015; 110: 26-37.","2型糖尿病患者において,血圧,心拍数,高血圧に対するGLP-1受容体作動薬の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26358202","http://diabetes.ebm-library.jp/trial/detail/51535" "SUSTAIN 1","−","Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbl JD, Hansen T, Bain SC. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017; 5: 251-260.","食事療法と運動療法で血糖コントロール不良の2型糖尿病患者において,新規GLP-1受容体作動薬semaglutideの週1回皮下投与による単剤療法の有効性,安全性,忍容性を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/28110911","http://diabetes.ebm-library.jp/trial/detail/51632" "SUSTAIN 2","-","Ahrn B, Masmiquel L, Kumar H, Sargin M, Karsbl JD, Jacobsen SH, Chow F. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017; 5: 341-354.","metformin,チアゾリジン薬または両剤でコントロール不良の2型糖尿病患者において,新規GLP-1受容体作動薬semaglutideとsitagliptinの有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/28385659","http://diabetes.ebm-library.jp/trial/detail/51641" "SUSTAIN","-","Ahrn B, Atkin SL, Charpentier G, Warren ML, Wilding JPH, Birch S, Holst AG, Leiter LA. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab. 2018; 20: 2210-9.","2型糖尿病患者において,semaglutideによる体重減少をベースラインのBMI別および悪心/嘔吐の有無別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29766634","http://diabetes.ebm-library.jp/trial/detail/51738" "SUSTAIN 3","Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes 3 trial","Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018; 41: 258-66.","経口糖尿病治療薬の治療下でコントロール不良の2型糖尿病患者において,週1回semaglutide 1.0mg皮下注と週1回徐放性exenatide 2.0mg皮下注の有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/29246950","http://diabetes.ebm-library.jp/trial/detail/51709" "SUSTAIN 4","-","Aroda VR, Bain SC, Cariou B, Pileti M, Rose L, Axelsen M, Rowe E, DeVries JH. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017; 5: 355-366.","metforminでコントロール不良かつインスリン投与歴のない2型糖尿病患者において,semaglutideの有効性,安全性,忍容性をインスリンglargineと比較した。","https://www.ncbi.nlm.nih.gov/pubmed/28344112","http://diabetes.ebm-library.jp/trial/detail/51647" "SUSTAIN 5","Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes 5 trial","Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, Araki E, Chu PL, Wijayasinghe N, Norwood P. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.","基礎インスリン療法でコントロール不良の2型糖尿病患者において,semaglutide追加による血糖コントロール改善の,プラセボ追加に対する優越性について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29688502","http://diabetes.ebm-library.jp/trial/detail/51747" "SUSTAIN 6","-","Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jdar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, et al.; SUSTAIN-6 Investigators: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375: 1834-1844.","2型糖尿病患者において,GLP-1受容体作動薬semaglutideの心血管に関する安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27633186","http://diabetes.ebm-library.jp/trial/detail/51654" "SUSTAIN 7","-","Pratley RE, Aroda VR, Lingvay I, Ldemann J, Andreassen C, Navarria A, Viljoen A; SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018; 6: 275-86.","metformin単独療法でコントロール不良の2型糖尿病患者において,低用量および高用量のsemaglutideとdulaglutideの有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/29397376","http://diabetes.ebm-library.jp/trial/detail/51748" "SUSTAIN 9","-","Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, Thrasher J, Woo V, Philis-Tsimikas A. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019; 7: 356-67.","90日以上のSGLT2阻害薬投与下でコントロール不良の2型糖尿病患者において,semaglutide追加の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30833170","http://diabetes.ebm-library.jp/trial/detail/51755" "Svanstrm H, et al.","-","Svanstrm H, Ueda P, Melbye M, Eliasson B, Svensson AM, Franzn S, Gudbjrnsdottir S, Hveem K, Jonasson C, Pasternak B. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden. Lancet Diabetes Endocrinol. 2019; 7: 106-14.","日常診療を受けている2型糖尿病患者において,liraglutideの心血管有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30527909","http://diabetes.ebm-library.jp/trial/detail/51751" "Svensson E, et al.","-","Svensson E, Baggesen LM, Johnsen SP, Pedersen L, Nrrelund H, Buhl ES, Haase CL, Thomsen RW. Early Glycemic Control and Magnitude of HbA1c Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin Initiators. Diabetes Care. 2017; 40: 800-7.","metforminを開始した2型糖尿病患者において,早期のHbA1c達成レベルおよびHbA1c低下の程度とその後の心血管イベントまたは死亡リスクとの相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28404659","http://diabetes.ebm-library.jp/trial/detail/51664" "Swedish Military Conscription Registry","-","Crump C, Sundquist J, Winkleby MA, Sundquist K: Stress resilience and subsequent risk of type 2 diabetes in 1.5 million young men. Diabetologia. 2016; 59: 728-33.","男性において,晩期思春期の精神的回復力と成人期の2型糖尿病発症リスクの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26758065","http://diabetes.ebm-library.jp/trial/detail/51564" "Swedish National Diabetes Register","-","Rawshani A, Rawshani A, Franzn S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjrnsdottir S. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018; 379: 633-44.","2型糖尿病患者における死亡および心血管アウトカムのリスク上昇を,治療ガイドライン目標範囲内のリスク因子数により検討した。","https://www.ncbi.nlm.nih.gov/pubmed/30110583","http://diabetes.ebm-library.jp/trial/detail/51733" "SWITCH 1","-","Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, Nielsen TSS, Warren M; Group Information; SWITCH 1. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA. 2017; 318: 33-44.","1型糖尿病患者において,インスリンdegludecによる症候性低血糖エピソード率の低下がインスリンglargine U100に対して非劣性であるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28672316","http://diabetes.ebm-library.jp/trial/detail/51659" "SYNCHRONY","-","Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M: Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009; 374: 126-35.","2型糖尿病患者において,aleglitazarの血糖および脂質に対する有効性,安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19515415","http://diabetes.ebm-library.jp/trial/detail/51123" "Syst-China","the Systolic Hypertension in China trial","Wang JG, Staessen JA, Gong L, Liu L: Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000; 160: 211-220.","収縮期高血圧の高齢中国人において,段階的降圧療法の有用性を性別・心血管系合併症既往により比較し,心血管疾患の罹患率・死亡率に対する年齢,血圧,喫煙・飲酒,糖尿病の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10647760","http://diabetes.ebm-library.jp/trial/detail/50533" "Syst-Eur","the Systolic hypertension in Europe trial","Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677-684.","nitrendipineによる心血管イベント抑制効果を非糖尿病患者と比較分析した。","https://www.ncbi.nlm.nih.gov/pubmed/10053176","http://diabetes.ebm-library.jp/trial/detail/50339" "Syst-Eur","the Systolic hypertension in Europe trial","Voyaki SM, Staessen JA, Thijs L, Wang JG, Efstratopoulos AD, Birkenhager WH, de Leeuw PW, Leonetti G, Nachev C, Rodicio JL, Tuomilehto J, Fagard R: Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J Hypertens 2001; 19: 511-519.","Syst-Eurに参加した収縮期高血圧患者について,糖尿病または蛋白尿を有する場合のnitrendipineによる降圧治療の腎機能への影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11288822","http://diabetes.ebm-library.jp/trial/detail/50451" "T1D Exchange Clinic Network","-\","Rickels MR, Ruedy KJ, Foster NC, Pich CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, et al.; T1D Exchange Intranasal Glucagon Investigators: Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care. 2016; 39: 264-70.","成人1型糖尿病患者において,インスリン誘発性低血糖に対する無針経鼻グルカゴン製剤と筋注グルカゴンの有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/26681725","http://diabetes.ebm-library.jp/trial/detail/51554" "T1D Exchange Clinic Network","-","Weinstock RS, DuBose SN, Bergenstal RM, Chaytor NS, Peterson C, Olson BA, Munshi MN, Perrin AJ, Miller KM, Beck RW, et al.; T1D Exchange Severe Hypoglycemia in Older Adults With Type 1 Diabetes Study Group: Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. Diabetes Care. 2016; 39: 603-10.","高齢の1型糖尿病患者において,重度低血糖のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26681721","http://diabetes.ebm-library.jp/trial/detail/51563" "T1D Exchange Clinic Network Metformin RCT Study","-","Libman IM, Miller KM, DiMeglio LA, Bethin KE, Katz ML, Shah A, Simmons JH, Haller MJ, Raman S, Tamborlane WV, et al.; T1D Exchange Clinic Network Metformin RCT Study Group: Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2015; 314: 2241-50.","1型糖尿病を有する過体重/肥満の青年において,基礎-ボーラスインスリン治療へのmetformin追加の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26624824","http://diabetes.ebm-library.jp/trial/detail/51541" "T1D Exchange Clinic Registry","-","Miller KM, Beck RW, Bergenstal RM, Goland RS, Haller MJ, McGill JB, Rodriguez H, Simmons JH, Hirsch IB; T1D Exchange Clinic Network: Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care. 2013; 36: 2009-14.","小児および成人の1型糖尿病患者において,1日あたりの血糖自己測定(SMBG)の回数とHbA1cの関係,およびSMBG測定回数に関連する因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23378621","http://diabetes.ebm-library.jp/trial/detail/51348" "Tanabe M, et al.","-","Tanabe M, Nomiyama T, Motonaga R, Murase K, Yanase T: Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database. BMC Endocr Disord. 2015; 15: 49.","医療費会計データベースを用いて,2型糖尿病患者を対象に,経口血糖降下薬(OHA)の種類別に心血管疾患(CVD)リスクへの影響を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/26382923","http://diabetes.ebm-library.jp/trial/detail/51502" "Tanaka K, et al.","−","Tanaka K, Saisho Y, Kawai T, Tanaka M, Meguro S, Irie J, Imai T, Shigihara T, Morimoto J, Yajima K, et al.: Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes. Endocr J. 2015; ","過体重/肥満の日本人2型糖尿病患者において,liraglutide単独療法の有効性と安全性をmetformin単独療法と比較した。","https://www.ncbi.nlm.nih.gov/pubmed/25739726","http://diabetes.ebm-library.jp/trial/detail/51458" "Tanno and Sobetsu study","-","Ohnishi H, Saitoh S, Takagi S, Ohata J, Isobe T, Kikuchi Y, Takeuchi H, Shimamoto K: Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose: the Tanno and Sobetsu study. Diabetes Care 2003; 26: 437-440.","空腹時血糖異常患者におけるアテローム性動脈硬化の指標として,上腕-足首脈波伝播速度が有用であるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12547876","http://diabetes.ebm-library.jp/trial/detail/50605" "Tanno and Sobetsu study","-","Ohnishi H, Saitoh S, Takagi S, Katoh N, Chiba Y, Akasaka H, Nakamura Y, Shimamoto K: Incidence of type 2 diabetes in individuals with central obesity in a rural Japanese population: The Tanno and Sobetsu study. Diabetes Care 2006; 29: 1128-1129.","日本の農村部住民において,腹部肥満および全般的肥満と2型糖尿病の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16644653","http://diabetes.ebm-library.jp/trial/detail/50940" "TARGET","Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial","Roffi M, Moliterno DJ, Meier B, Powers ER, Grines CL, DiBattiste PM, Herrmann HC, Bertrand M, Harris KE, Demopoulos LA, Topol EJ; TARGET Investigators: Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation 2002; 105: 2730-2736.","ステント植込みを伴う経皮的冠動脈インターベンションを施行された糖尿病患者に対するabciximabとtirofibanの虚血性イベント抑制効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/12057986","http://diabetes.ebm-library.jp/trial/detail/50531" "Targher G, et al.","-","Targher G, Mantovani A, Pichiri I, Mingolla L, Cavalieri V, Mantovani W, Pancheri S, Trombetta M, Zoppini G, Chonchol M, et al.: Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2014; 37: 1729-36.","1型糖尿病患者において,非アルコール性脂肪性肝疾患が慢性腎臓病発症の増大と関連するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24696459","http://diabetes.ebm-library.jp/trial/detail/51400" "TART","the Troglitazone Atherosclerosis Regression Trial","Zheng L, Hodis HN, Buchanan TA, Li Y, Mack WJ: Effect of antihypertensive therapy on progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Am J Cardiol 2007; 99: 956-960.","2型糖尿病患者において,降圧療法と頸動脈内膜-中膜壁肥厚の変化の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17398191","http://diabetes.ebm-library.jp/trial/detail/51033" "TAXUS-IV","-","Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, Russell ME, Ellis SG, Mehran R, Stone GW, et al: Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005; 45: 1172-1179.","糖尿病患者において,ポリマーベースのpaclitaxel溶出ステントの有効性および安全性をベアメタルステントと比較した。","https://www.ncbi.nlm.nih.gov/pubmed/15837245","http://diabetes.ebm-library.jp/trial/detail/50741" "TECOS","Trial Evaluating Cardiovascular Outcomes with Sitagliptin","Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, et al.; TECOS Study Group: Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015; 373: 232-42.","心血管疾患を有する2型糖尿病患者において,通常治療のみの場合と通常治療にsitagliptinを追加した場合の長期の心血管安全性を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26052984","http://diabetes.ebm-library.jp/trial/detail/51491" "TECOS","Trial Evaluating Cardiovascular Outcomes With Sitagliptin","Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM, Engel SS, Lopes RD, McGuire DK, Riefflin A, Rodbard HW, Sinay I, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care. 2016; 39: 2304-2310.","DPP-4阻害薬sitagliptin治療を行った心血管疾患を有する2型糖尿病患者において,ベースラインの推算糸球体濾過量別にCVアウトカムと慢性腎臓病アウトカムを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27742728","http://diabetes.ebm-library.jp/trial/detail/51609" "TECOS","Trial Evaluating Cardiovascular Outcomes with Sitagliptin","Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, Standl E, Suryawanshi S, Van de Werf F, McGuire DK, et al.; TECOS Study Group: Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care. 2017; 40: 494-501.","心血管疾患を伴う2型糖尿病患者において,75歳以上の患者のsitagliptinによる臨床アウトカムを75歳未満と比較し,さらに75歳以上の患者におけるsitagliptinの有効性と安全性を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/28057693","http://diabetes.ebm-library.jp/trial/detail/51618" "TECOS","Trial Evaluating Cardiovascular Outcomes with Sitagliptin","Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group. Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Diabetes Obes Metab. 2017; 19: 1587-93.","慢性腎臓病を有する2型糖尿病患者において,sitagliptinの糖尿病性合併症発生率と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28432745","http://diabetes.ebm-library.jp/trial/detail/51689" "TECOS","Trial Evaluating Cardiovascular Outcomes with Sitagliptin","Alfredsson J, Green JB, Stevens SR, Reed SD, Armstrong PW, Angelyn Bethel M, Engel SS, McGuire DK, Van de Werf F, Hramiak I, White HD, Peterson ED, Holman RR; TECOS Study Group. Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. Diabetes Obes Metab. 2018; 20: 2379-88.","動脈硬化性心血管疾患を有する2型糖尿病患者を対象に,ベースライン特性,心血管リスク因子の管理,心血管アウトカムにおける性差を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29923323","http://diabetes.ebm-library.jp/trial/detail/51739" "Tennant PW, et al.","−","Tennant PW, Bilous RW, Prathapan S, Bell R: Risk and recurrence of serious adverse outcomes in the first and second pregnancies of women with preexisting diabetes. Diabetes Care. 2015; 38: 610-9.","既存の糖尿病で2回の妊娠・出産を経験した女性において,重篤な有害妊娠アウトカム発生の絶対リスクおよび再発リスクを調査した。","https://www.ncbi.nlm.nih.gov/pubmed/25573880","http://diabetes.ebm-library.jp/trial/detail/51461" "Thabit H, et al.","-","Thabit H, Tauschmann M, Allen JM, Leelarathna L, Hartnell S, Wilinska ME, Acerini CL, Dellweg S, Benesch C, Heinemann L, et al.; APCam ConsortiumAP@home Consortium: Home Use of an Artificial Beta Cell in Type 1 Diabetes. N Engl J Med. 2015; 373: 2129-40.","1型糖尿病患者において,自宅での人工β細胞(閉鎖ループインスリン注入システム)使用の実現可能性,安全性,有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26379095","http://diabetes.ebm-library.jp/trial/detail/51543" "Theilade S.","-","Theilade S, Lajer M, Persson F, Joergensen C, Rossing P: Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes. Diabetes Care. 2013; 36: 715-21.","1型糖尿病患者において,動脈壁硬化と糖尿病合併症発症リスク(アルブミン尿,心血管疾患,血圧上昇,網膜症,自律神経障害)の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23193205","http://diabetes.ebm-library.jp/trial/detail/51326" "THIN","Health Improvement Network ","Hoffstad O, Mitra N, Walsh J, Margolis DJ: Diabetes, Lower-Extremity Amputation, and Death. Diabetes Care. 2015; 38: 1852-7.","糖尿病患者における死亡と関連する心血管疾患や腎障害などの合併症が,下肢切断(LEA)を受けた患者の高い死亡率を十分に説明するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26203063","http://diabetes.ebm-library.jp/trial/detail/51505" "TIMAD","the Ticlopidine Microangiopathy of Diabetes study","The TIMAD Study Group.: Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 1990; 108: 1577-1583.","ticlopidineの糖尿病網膜症に対する効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/2244843","http://diabetes.ebm-library.jp/trial/detail/50046" "TIMI","Thrombolysis in Myocardial Infarction study","Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM: Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298: 765-775.","急性冠症候群発症後の死亡に対する糖尿病の影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17699010","http://diabetes.ebm-library.jp/trial/detail/51004" "TINSAL-T2D","Targeting Inflammation Using Salsalate in Type 2 Diabetes","Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team: Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013; 159: 1-12.","2型糖尿病患者において,salsalateの有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23817699","http://diabetes.ebm-library.jp/trial/detail/51374" "TNT","Treating to New Targets study","Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, et al.: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006; 29: 1220-1226.","冠動脈心疾患患者において認められた強化脂質低下療法(atorvastatin 80mg/日)による心血管イベント抑制効果が,糖尿病を合併する患者においても同様に認められるかを検討した。TNTのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/16731999","http://diabetes.ebm-library.jp/trial/detail/50946" "TNT","Treating to New Targets study","Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK, et al.: Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 2008; 83: 870-879.","冠動脈疾患および2型糖尿病に患者において,高用量のatorvastatinによる強化脂質低下療法の心血管イベントに対する効果を慢性腎疾患併発の有無により比較検討した。TNTのpost-hoc解析。","https://www.ncbi.nlm.nih.gov/pubmed/18674471","http://diabetes.ebm-library.jp/trial/detail/51088" "Tobias DK, et al.","-","Tobias DK, Zhang C, van Dam RM, Bowers K, Hu FB: Physical activity before and during pregnancy and risk of gestational diabetes mellitus: a meta-analysis. Diabetes Care. 2011; 34: 223-9.","妊娠前および妊娠中の運動と妊娠糖尿病発症リスクの相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/20876206","http://diabetes.ebm-library.jp/trial/detail/51237" "Tobias DK, et al. ","-","Tobias DK, Pan A, Jackson CL, O'Reilly EJ, Ding EL, Willett WC, Manson JE, Hu FB: Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014; 370: 233-44.","2つの前向きコホート研究の統合解析を行い,糖尿病患者におけるBMIと死亡率の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24428469","http://diabetes.ebm-library.jp/trial/detail/51382" "Tokyo Study","-","Maruyama T, Shimada A, Kanatsuka A, Kasuga A, Takei I, Yokoyama J, Kobayashi T: Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Ann N Y Acad Sci 2003; 1005: 362-369.","緩徐進行型1型糖尿病において,インスリン少量投与がβ細胞の機能低下に及ぼす有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14679093","http://diabetes.ebm-library.jp/trial/detail/50638" "Tolrestat Study","-","Santiago JV, Snksen PH, Boulton AJ, Macleod A, Beg M, Bochenek W, Graepel GJ, Gonen B: Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group. J Diabetes Complications 1993; 7: 170-178.","重度の糖尿病性末梢神経障害におけるtolrestat長期使用の中止について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8343611","http://diabetes.ebm-library.jp/trial/detail/50360" "Toyota T, et al.","-","Toyota T, Hirata Y, Ikeda Y, Matsuoka K, Sakuma A, Mizushima Y: Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers. Prostaglandins 1993; 46: 453-468.","プロスタグランジンの糖尿病性神経障害に対する有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8278621","http://diabetes.ebm-library.jp/trial/detail/50140" "TRACE","the Trandolapril Cardiac Evaluation study","Gustafsson I, Torp-Pedersen C, Kober L, Gustafsson F, Hildebrandt P: Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. J Am Coll Cardiol 1999; 34: 83-89.","急性心筋梗塞後の左室機能障害を伴う糖尿病患者におけるtrandolaprilの長期治療効果をTRACE試験のデータより評価した。","https://www.ncbi.nlm.nih.gov/pubmed/10399995","http://diabetes.ebm-library.jp/trial/detail/50325" "TRANSCEND","Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease","Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, , Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P: Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174-1183.","心不全を有さない心血管疾患または高リスクの糖尿病患者のうち,ACE阻害薬に対して忍容性のない例において,通常治療にtelmisartanを併用した場合の有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/18757085","http://diabetes.ebm-library.jp/trial/detail/51090" "TRANSCEND","Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease study","Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, et al.; TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators: Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med. 2009; 151: 1-10, W1-2.","高リスクの糖尿病患者において,telmisartanの長期的な腎アウトカムへの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19451556","http://diabetes.ebm-library.jp/trial/detail/51124" "TRAVEND","-","Fernandez R, Puig JG, Rodriguez-Perez JC, Garrido J, Redon J; TRAVEND Study Group: Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15: 849-856.","高血圧とアルブミン尿の2型糖尿病患者で,verapamil+trandolaprilとenalapril+hydrochlorothiazideの代謝コントロールとアルブミン尿に対する効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/11773987","http://diabetes.ebm-library.jp/trial/detail/50510" "TREAT","Trial to Reduce Cardiovascular Events with Aranesp Therapy","Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, et al.; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019-32.","慢性腎疾患で貧血を有する2型糖尿病において,darbepoetin alfaの臨床アウトカムへの効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19880844","http://diabetes.ebm-library.jp/trial/detail/51144" "Treat-to-Target study","-","Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P: A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.","経口血糖降下薬投与下でコントロール不良の2型糖尿病患者において,インスリンdetemirまたはNPHインスリンの追加併用ならびに厳密な用量調整の有効性および忍容性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16732007","http://diabetes.ebm-library.jp/trial/detail/50950" "Treat-to-Target Trial","-","Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.","経口血糖降下薬投与下の2型糖尿病患者において,インスリンglargineまたはヒトNPH インスリンを追加併用した場合の血糖低下効果および低血糖リスクを比較した。","https://www.ncbi.nlm.nih.gov/pubmed/14578243","http://diabetes.ebm-library.jp/trial/detail/50626" "Trevest K, et al.","−","Trevest K, Treadway H, Hawkins-van der Cingel G, Bailey C, Abdelhafiz AH: Prevalence and determinants of anemia in older people with diabetes attending an outpatient clinic: a cross-sectional audit. Clin Diabetes. 2014; 32: 158-62.","75歳以上の糖尿病患者において,貧血の罹患状況および決定因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25646941","http://diabetes.ebm-library.jp/trial/detail/51456" "TRIAD","the Translating Research Into Action for Diabetes","McEwen LN, Kim C, Karter AJ, Haan MN, Ghosh D, Lantz PM, Mangione CM, Thompson TJ, Herman WH: Risk factors for mortality among patients with diabetes: the Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care 2007; 30: 1736-1741.","糖尿病患者における全死亡,心血管死,非心血管死の予測因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17468353","http://diabetes.ebm-library.jp/trial/detail/51026" "TRIAD","Translating Research Into Action for Diabetes","McEwen LN, Karter AJ, Curb JD, Marrero DG, Crosson JC, Herman WH: Temporal trends in recording of diabetes on death certificates: results from Translating Research Into Action for Diabetes (TRIAD). Diabetes Care. 2011; 34: 1529-33.","糖尿病患者の死亡診断書における糖尿病の報告について8年間の推移を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21709292","http://diabetes.ebm-library.jp/trial/detail/51214" "TRITON-TIMI 38","Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38","Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, et al.: Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118: 1626-1636.","急性冠症候群患者におけるprasugrelとclopidogrelの有効性を糖尿病の有無により比較検討した。TRITON-TIMI 38のサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18757948","http://diabetes.ebm-library.jp/trial/detail/51100" "Trocha AK, et al.","-","Trocha AK, Schmidtke C, Didjurgeit U, Muhlhauser I, Bender R, Berger M, Sawicki PT: Effects of intensified antihypertensive treatment in diabetic nephropathy: mortality and morbidity results of a prospective controlled 10-year study. J Hypertens 1999; 17: 1497-1503.","高血圧と腎症を伴う1型糖尿病患者の予後に対する強化降圧療法の効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10526912","http://diabetes.ebm-library.jp/trial/detail/50105" "Tseng CH, et al.","-","Tseng CH: Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care. 2011; 34: 616-21.","台湾人の男性において,糖尿病と前立腺癌の相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21273499","http://diabetes.ebm-library.jp/trial/detail/51213" "Tseng YH, et al.","−","Tseng YH, Tsan YT, Chan WC, Sheu WH, Chen PC: Use of an α-Glucosidase Inhibitor and the Risk of Colorectal Cancer in Patients With Diabetes: A Nationwide, Population-Based Cohort Study. Diabetes Care. 2015; 38: 2068-74.","糖尿病患者において,αグルコシダーゼ阻害薬acarboseの大腸がん発症リスク抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26307605","http://diabetes.ebm-library.jp/trial/detail/51531" "Tsuda A, et al.","-","Tsuda A, Ishimura E, Ohno Y, Ichii M, Nakatani S, Machida Y, Mori K, Uchida J, Fukumoto S, Emoto M, et al.: Poor glycemic control is a major factor in the overestimation of glomerular filtration rate in diabetic patients. Diabetes Care. 2014; 37: 596-603.","糖尿病患者における腎機能の過大評価に関連する因子を検討し,正確な推算糸球体濾過量を反映する計算式を作成した。","https://www.ncbi.nlm.nih.gov/pubmed/24130341","http://diabetes.ebm-library.jp/trial/detail/51390" "Tsukuba Kawai Diabetes Registry","-","Saito K, Sone H, Kawai K, Tanaka S, Kodama S, Shu M, Suzuki E, Kondo K, Yamamoto S, Shimano H, et al.: Risk imparted by various parameters of smoking in Japanese men with type 2 diabetes on their development of microalbuminuria: analysis from the Tsukuba Kawai Diabetes Registry. Diabetes Care 2007; 30: 1286-1288.","日本人の2型糖尿病患者において,喫煙習慣と微量アルブミン尿の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17337500","http://diabetes.ebm-library.jp/trial/detail/50991" "Udell JA, et al.","−","Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM: Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2015; 3: 356-66.","2型糖尿病患者,または2型糖尿病発症リスクを有する患者において,さまざまな薬剤/治療戦略による血糖降下療法は心不全発症リスクを増加させるか検討し,さらにそのリスクは血糖/体重コントロールと関連するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25791290","http://diabetes.ebm-library.jp/trial/detail/51466" "UGDP","the University Group Diabetes Program","Kilo C, Miller JP, Williamson JR: The Achilles heel of the University Group Diabetes Program. JAMA 1980; 243: 450-457.","インスリンもしくはスルホニル尿素による血糖コントロールの血管合併症抑制効果を検証した。","https://www.ncbi.nlm.nih.gov/pubmed/6985989","http://diabetes.ebm-library.jp/trial/detail/50328" "UK-based CPRD","UK-based Clinical Practice Research Datalink","Gamble JM, Chibrikov E, Twells LK, Midodzi WK, Young SW, MacDonald D, Majumdar SR. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. Lancet Diabetes Endocrinol. 2017; 5: 43-52. ","2型糖尿病患者において,インスリン用量の増加は,全死亡,心血管イベントリスクと関連するか検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27865756","http://diabetes.ebm-library.jp/trial/detail/51614" "UKPDS 30","the UK Prospective Diabetes Study","Kohner EM, Aldington SJ, Stratton IM, Manley SE, Holman RR, Matthews DR, Turner RC: United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 1998; 116: 297-303.","新規NIDDM患者における網膜症と臨床的,生化学的要因との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9514482","http://diabetes.ebm-library.jp/trial/detail/50052" "UKPDS 33","the UK Prospective Diabetes Study","UK Prospective Diabetes Study (UKPDS) Group.: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.","厳格な血糖コントロールが心血管イベントに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9742976","http://diabetes.ebm-library.jp/trial/detail/50018" "UKPDS 34","the UK Prospective Diabetes Study","UK Prospective Diabetes Study (UKPDS) Group.: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.","肥満2型糖尿病患者に対するmetforminの合併症リスク低下効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9742977","http://diabetes.ebm-library.jp/trial/detail/50019" "UKPDS 35","the UK Prospective Diabetes Study","Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.","2型糖尿病患者において,長期の血糖値と大血管および細小血管合併症の発生リスクとの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10938048","http://diabetes.ebm-library.jp/trial/detail/50507" "UKPDS 36","the UK Prospective Diabetes Study","Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-419.","2型糖尿病患者において,SBPと大血管および細小血管合併症の発生リスクとの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10938049","http://diabetes.ebm-library.jp/trial/detail/50508" "UKPDS 38","the UK Prospective Diabetes Study","UK Prospective Diabetes Study Group.: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.","高血圧の2型糖尿病患者において,厳格な血圧コントロールの,大血管・細小血管合併症予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9732337","http://diabetes.ebm-library.jp/trial/detail/50020" "UKPDS 39","the UK Prospective Diabetes Study","UK Prospective Diabetes Study Group.: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.","高血圧の2型糖尿病患者において,β遮断薬,ACE阻害薬による厳格な血圧コントロールの大血管・細小血管合併症予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9732338","http://diabetes.ebm-library.jp/trial/detail/50021" "UKPDS 40","the UK Prospective Diabetes Study","UK Prospective Diabetes Study Group: Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ 1998; 317: 720-726.","高血圧の2型糖尿病患者において,厳格な血圧コントロールの費用対効果を従来療法と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/9732339","http://diabetes.ebm-library.jp/trial/detail/50549" "UKPDS 41","the UK Prospective Diabetes Study","Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, Stratton I, Adler A, Holman R, Turner R: Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ 2000; 320: 1373-1378.","新規2型糖尿病患者において,厳格な血糖コントロールの費用対効果を従来療法と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10818026","http://diabetes.ebm-library.jp/trial/detail/50534" "UKPDS 44","the UK Prospective Diabetes Study","Holman RR, Cull CA, Turner RC: A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999; 22: 960-964.","2型糖尿病の長期治療に対するacarboseの付加的な治療効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10372249","http://diabetes.ebm-library.jp/trial/detail/50092" "UKPDS 45","the UK Prospective Diabetes Study","Manley SE, Stratton IM, Cull CA, Frighi V, Eeley EA, Matthews DR, Holman RR, Turner RC, Neil HA: Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). UK Prospective Diabetes Study Group. Diabet Med 2000; 17: 518-523.","新規2型糖尿病患者における3ヵ月間の食事療法の血漿脂質およびリポ蛋白に対する効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10972581","http://diabetes.ebm-library.jp/trial/detail/50389" "UKPDS 49","the UK Prospective Diabetes Study","Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.","2型糖尿病患者における食事療法,インスリン,スルホニル尿素,metforminによる目標血糖値達成率を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10359389","http://diabetes.ebm-library.jp/trial/detail/50112" "UKPDS 50","the UK Prospective Diabetes Study","Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR: UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44: 156-163.","2型糖尿病診断後6年間の網膜症の発症および進展に関するリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11270671","http://diabetes.ebm-library.jp/trial/detail/50481" "UKPDS 51","the UK Prospective Diabetes Study","Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, Stratton I, Holman R; UKPDS Group. United Kingdom Prospective Diabetes Study: Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 2001; 44: 298-304.","肥満2型糖尿病患者で,metforminによる厳格な血糖コントロールの費用対効果を従来療法と比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11317659","http://diabetes.ebm-library.jp/trial/detail/50467" "UKPDS 52","the UK Prospective Diabetes Study","Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR; UK ProspectiveDiabetes Study (UKPDS) Group: Relationship between the severity of retinopathy and progression tophotocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 2001; 18: 178-184.","新規2型糖尿病患者において,網膜症の重症度と光凝固術への進展リスクの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11318837","http://diabetes.ebm-library.jp/trial/detail/50471" "UKPDS 54","the UK Prospective Diabetes Study","Gray A, Clarke P, Raikou M, Adler A, Stevens R, Neil A, Cull C, Stratton I, Holman R: An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54). Diabet Med 2001; 18: 438-444.","2型糖尿病の高血圧患者で,captoprilあるいはatenololによる厳格な血圧コントロールの費用対効果を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/11472461","http://diabetes.ebm-library.jp/trial/detail/50488" "UKPDS 55","the UK Prospective Diabetes Study","Davis TM, Cull CA, Holman RR; The U.K. Prospective Diabetes Study (UKPDS) Group: Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55). Diabetes Care 2001; 24: 1167-1174.","2型糖尿病治療における,人種,血糖コントロール,血圧の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11423497","http://diabetes.ebm-library.jp/trial/detail/50479" "UKPDS 57","the UK Prospective Diabetes Study","Wright A, Burden AC, Paisey RB, Cull CA, Holman RR; U.K. Prospective Diabetes Study Group: Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-336.","最大用量のスルホニル尿素投与下で血糖コントロール不良の2型糖尿病患者において,インスリン追加併用の有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11815505","http://diabetes.ebm-library.jp/trial/detail/50526" "UKPDS 59","the UK Prospective Diabetes Study","Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR: UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002; 25: 894-899.","2型糖尿病患者において,高血糖およびその他のリスク因子と末梢血管疾患の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11978687","http://diabetes.ebm-library.jp/trial/detail/50547" "UKPDS 61","the UK Prospective Diabetes Study","Colagiuri S, Cull CA, Holman RR: Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. Prospective Diabetes Study 61. Diabetes Care 2002; 25: 1410-1417.","2型糖尿病診断時の空腹時血漿ブドウ糖値とその後の臨床アウトカムとの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12145243","http://diabetes.ebm-library.jp/trial/detail/50539" "UKPDS 64","the United Kingdom Prospective Diabetes Study","Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.","2型糖尿病患者において,糖尿病診断から腎症の進展および死亡までの経過を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12472787","http://diabetes.ebm-library.jp/trial/detail/50763" "UKPDS 66","the UK Prospective Diabetes Study","Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR: Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004; 27: 201-207.","2型糖尿病患者において,致死性心筋梗塞および致死性脳卒中のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14693990","http://diabetes.ebm-library.jp/trial/detail/50636" "UKPDS 67","the UK Prospective Diabetes Study","Adler AI, Levy JC, Matthews DR, Stratton IM, Hines G, Holman RR: Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67). Diabet Med 2005; 22: 306-311.","2型糖尿病患者において,インスリン抵抗性と心血管疾患発症との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15717879","http://diabetes.ebm-library.jp/trial/detail/50765" "UKPDS 69","UK Prospective Diabetes Study","Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM, UK Prospective Diabetes Study Group: Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004; 122: 1631-1640.","2型糖尿病患者において,厳格な血圧コントロールと糖尿病網膜症関連アウトカムの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15534123","http://diabetes.ebm-library.jp/trial/detail/50694" "UKPDS 73","UK Prospective Diabetes Study","Wright AD, Cull CA, Macleod KM, Holman RR, for the UKPDS Group: Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications 2006; 20: 395-401.","2型糖尿病患者において,6年間の血糖降下療法における低血糖発生状況ならびに低血糖のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17070446","http://diabetes.ebm-library.jp/trial/detail/51046" "UKPDS 74","U.K. Prospective Diabetes Study","Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR: Risk factors for renal dysfunction in type 2 diabetes: u.k. Prospective diabetes study 74. Diabetes 2006; 55: 1832-1839.","2型糖尿病患者において,診断時に有するリスク因子とその後の腎障害発症との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16731850","http://diabetes.ebm-library.jp/trial/detail/50945" "UKPDS 75","the UK Prospective Diabetes Study","Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR: Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006; 49: 1761-1769.","2型糖尿病患者において,血糖値およびSBPが糖尿病性合併症のリスクに及ぼす長期的影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16736131","http://diabetes.ebm-library.jp/trial/detail/50968" "UKPDS 78","United Kingdom Prospective Diabetes Study","Cull CA, Jensen CC, Retnakaran R, Holman RR: Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation 2007; 116: 2119-2126.","新規2型糖尿病患者において,メタボリックシンドロームが糖尿病性合併症リスクに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17967769","http://diabetes.ebm-library.jp/trial/detail/51059" "UKPDS 80","United Kingdom Prospective Diabetes Study","Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.","UKPDS参加患者において,厳格な血糖コントロールによる細小血管障害リスク低下が試験終了10年後にも継続するかを検討し,厳格な血糖コントロールの大血管障害に対する長期的な効果を検討した。UKPDSのpost-trial monitoring試験。","https://www.ncbi.nlm.nih.gov/pubmed/18784090","http://diabetes.ebm-library.jp/trial/detail/51086" "UKPDS 81","United Kingdom Prospective Diabetes Study","Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR: Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-1576.","UKPDSの血圧コントロール試験に参加した患者において,厳格な血圧コントロールによる細小血管障害および大血管障害リスク低下が試験終了10年後にも継続しているかを検討した。UKPDSのpost-trial monitoring試験。","https://www.ncbi.nlm.nih.gov/pubmed/18784091","http://diabetes.ebm-library.jp/trial/detail/51097" "Uppsala Longitudinal Study of Adult Men","-","Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L: Insulin resistance and risk of congestive heart failure. JAMA 2005; 294: 334-341.","インスリン抵抗性のうっ血性心不全に対する予測能を検討し,肥満とCHFの関係におけるインスリン抵抗性の関与について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16030278","http://diabetes.ebm-library.jp/trial/detail/50767" "Ushigome E, et al.","-","Ushigome E, Fukui M, Hamaguchi M, Matsumoto S, Mineoka Y, Nakanishi N, Senmaru T, Yamazaki M, Hasegawa G, Nakamura N: Morning pulse pressure is associated more strongly with elevated albuminuria than systolic blood pressure in patients with type 2 diabetes mellitus: post hoc analysis of a cross-sectional multicenter study. Diabetes Res Clin Pract. 2013; 101: 270-7.","2型糖尿病患者において,家庭で測定した脈圧とアルブミン尿の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23871575","http://diabetes.ebm-library.jp/trial/detail/51372" "VA Cooperative Study","Veterans Administration Cooperative Study","Colwell JA, Bingham SF, Abraira C, Anderson JW, Comstock JP, Kwaan HC, Nuttall F: Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care 1986; 9: 140-148.","壊疽による下肢切断後のNIDDM患者に対するaspirin+dipyridamoleの治療が,主要な血管死に与える効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/3516608","http://diabetes.ebm-library.jp/trial/detail/50073" "VA Cooperative Study","Veterans Administration Cooperative Study","Levin SR, Coburn JW, Abraira C, Henderson WG, Colwell JA, Emanuele NV, Nuttall FQ, Sawin CT, Comstock JP, Silbert CK: Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 2000; 23: 1478-1485.","2型糖尿病患者において,厳格な血糖コントロールの微量アルブミン尿および臨床パラメータに対する有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11023140","http://diabetes.ebm-library.jp/trial/detail/50393" "VA-HIT","the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial","Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162: 2597-2604.","耐糖能およびインスリン抵抗性の程度が異なる冠動脈心疾患を有する男性において,血糖値およびインスリン値と心血管イベントとの関係を検討し,gemfibrozilの心血管イベントに対する有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12456232","http://diabetes.ebm-library.jp/trial/detail/50627" "VA-HIT","the Veterans Affairs High-Density Lipoprotein Intervention Trial","Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JW, Collins D: Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003; 26: 1513-1517.","HDL-C低値の冠動脈心疾患患者において,心血管イベントに対するインスリン抵抗性の影響およびgemfibrozilの有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/12716814","http://diabetes.ebm-library.jp/trial/detail/50588" "VA NEPHRON-D study","Veterans Affairs Nephropathy in Diabetes study","Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, et al.; VA NEPHRON-D Investigators: Combined Angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013; 369: 1892-903.","","https://www.ncbi.nlm.nih.gov/pubmed/24206457","http://diabetes.ebm-library.jp/trial/detail/51376" "VADT","Veterans Affairs Diabetes Trial","Reaven PD, Emanuele N, Moritz T, Klein R, Davis M, Glander K, Duckworth W, Abraira C; Veterans Affairs Diabetes Trial: Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2008; 31: 952-7.","2型糖尿病患者において,網膜症と冠動脈アテローム性動脈硬化の関係を検討した。VADTのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/18316393","http://diabetes.ebm-library.jp/trial/detail/51140" "VADT","Veterans Affairs Diabetes Trial","Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.","罹病期間の長い2型糖尿病患者において,厳格な血糖コントロール治療と標準治療の心血管イベントに対する効果を比較検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19092145","http://diabetes.ebm-library.jp/trial/detail/51098" "VADT","Veterans Affairs Diabetes Trial","Anderson RJ, Bahn GD, Emanuele NV, Marks JB, Duckworth WC; VADT Study Group: Blood Pressure and Pulse Pressure Effects on Renal Outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2014; 37: 2782-8.","2型糖尿病患者において,収縮期血圧,拡張期血圧および脈圧は,腎アウトカムと関連するかどうかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25048382","http://diabetes.ebm-library.jp/trial/detail/51422" "VALIANT","the Valsartan in Acute Myocardial Infarction Trial","Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O'Connor CM, Diaz R, et al: Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004; 110: 1572-1578.","急性心筋梗塞発症後に心不全または左室収縮機能障害を認める患者において,既知または新規糖尿病が死亡および主要心血管イベントに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15364810","http://diabetes.ebm-library.jp/trial/detail/50682" "VALUE","the Valsartan Antihypertensive Long-term Use Evaluation trial","Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, Coca A, Ekman S, Girerd X, Jamerson K, et al.: Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006; 24: 1405-1412.","心血管リスクの高い高血圧患者において,valsartanおよびamlodipineの2型糖尿病発症予防効果を比較した。VALUEのサブ解析。","https://www.ncbi.nlm.nih.gov/pubmed/16794491","http://diabetes.ebm-library.jp/trial/detail/50962" "VALUE","the Valsartan Antihypertensive Long-term Use Evaluation trial","Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S: Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 2007; 50: 467-473.","心血管リスクの高い高血圧患者において,糖尿病の新規発症が心血管アウトカムに及ぼす影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17679652","http://diabetes.ebm-library.jp/trial/detail/51010" "van Bastelaar KM.","-","van Bastelaar KM, Pouwer F, Cuijpers P, Riper H, Snoek FJ: Web-based depression treatment for type 1 and type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2011; 34: 320-5.","1型および2型糖尿病のうつに対するWEBベースの認知行動療法の有効性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21216855","http://diabetes.ebm-library.jp/trial/detail/51260" "van Dijik M, et al.","","Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF; Diabetes Prevention Program Research Group: Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care. 2009; 32: 1583-8.","1型糖尿病患者において,主観的な睡眠の特徴,長期血糖コントロールと睡眠の特徴との関連,および睡眠障害のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19587364","http://diabetes.ebm-library.jp/trial/detail/51205" "Vardarli I, et al.","−","Vardarli I, Arndt E, Deacon CF, Holst JJ, Nauck MA: Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose. Diabetes. 2014; 63: 663-74.","2型糖尿病患者において,DPP-4阻害薬sitagliptin単独,metformin単独,およびsitagliptin+metformin併用療法がインクレチンホルモン分泌とインクレチン作用に及ぼす影響を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24186866","http://diabetes.ebm-library.jp/trial/detail/51437" "VARIATION","Variability of Glucose in Patients with Type 2 Diabetes Treated with Four Different Insulin Combination Regimens study","Bajaj HS, Venn K, Ye C, Patrick A, Kalra S, Khandwala H, Aslam N, Twum-Barima D, Aronson R. Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study). Diabetes Care. 2017; 40: 194-200.","種々のインスリン療法で血糖コントロール良好の2型糖尿病患者において,血糖変動性(GV)を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/27913575","http://diabetes.ebm-library.jp/trial/detail/51611" "Verona Diabetes Complications Study","-","Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, et al: The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004; 21: 52-58.","2型糖尿病患者において,心血管疾患リスクとメタボリックシンドロームの関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14706054","http://diabetes.ebm-library.jp/trial/detail/50735" "VERTIS FACTORIAL","eValuation fo ERTugliflozin efficacy and Safety FACTORIAL","Pratley RE, Eldor R, Raji A, Golm G, Huyck SB, Qiu Y, Sunga S, Johnson J, Terra SG, Mancuso JP, Engel SS, Lauring B. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018; 20: 1111-20.","metformin治療でコントロール不良の2型糖尿病患者において,ertugliflozin+sitagliptinの併用投与はそれぞれの単独投与よりも血糖コントロールが優るか否かを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29266675","http://diabetes.ebm-library.jp/trial/detail/51717" "VERTIS MET","-","Rosenstock J, Frias J, Pll D, Charbonnel B, Pascu R, Saur D, Darekar A, Huyck S, Shi H, Lauring B, Terra SG. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018; 20: 520-9.","metformin単独療法でコントロール不良の成人2型糖尿病患者において,ertugliflozinの有効性と安全性を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/28857451","http://diabetes.ebm-library.jp/trial/detail/51713" "VERTIS MONO","eValuation of ERTugliflozin effIcacy and Safety","Terra SG, Focht K, Davies M, Frias J, Derosa G, Darekar A, Golm G, Johnson J, Saur D, Lauring B, Dagogo-Jack S. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017; 19: 721-728.","食事および運動療法でコントロール不良の2型糖尿病患者において,ertugliflozin単独療法の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28116776","http://diabetes.ebm-library.jp/trial/detail/51646" "VHA","Veterans Health Administration","Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, Elasy TA, Griffin MR: Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014; 311: 2288-96.","metformin治療を受けている糖尿病患者を対象に,インスリンまたはスルホニル尿素を追加した場合の心血管疾患発症/死亡までの時間を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/24915260","http://diabetes.ebm-library.jp/trial/detail/51416" "Virtanen M, et al.","-","Virtanen M, Ervasti J, Mittendorfer-Rutz E, Tinghg P, Lallukka T, Kjeldgrd L, Pentti J, Alexanderson K: Trends of Diagnosis-Specific Work Disability After Newly Diagnosed Diabetes: A 4-Year Nationwide Prospective Cohort Study. Diabetes Care. 2015; 38: 1883-90.","新規診断糖尿病患者において,診断特異的就労不能の推移を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26251407","http://diabetes.ebm-library.jp/trial/detail/51515" "VISS","Vascular Diabetic Complications in Southeast Sweden","Nordwall M, Abrahamsson M, Dhir M, Fredrikson M, Ludvigsson J, Arnqvist HJ: Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS Study (Vascular Diabetic Complications in Southeast Sweden). Diabetes Care. 2015; 38: 308-15.","1型糖尿病患者において,診断後のHbA1cが重度細小血管合併症の予測因子であるかを評価し,HbA1cの治療目標値を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25510400","http://diabetes.ebm-library.jp/trial/detail/51450" "Voglibose Ph-3 Study","-","Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K, Voglibose Ph-3 Study Group: Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009; 373: 1607-1614.","日本人の高リスク耐糖能異常症例において,vogliboseの2型糖尿病発症予防効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19395079","http://diabetes.ebm-library.jp/trial/detail/51106" "Vupputuri S, et al.","-","Vupputuri S, Nichols GA, Lau H, Joski P, Thorp ML: Risk of progression of nephropathy in a population-based sample with type 2 diabetes. Diabetes Res Clin Pract. 2011; 91: 246-52.","2型糖尿病において,腎症の進展と関連する特徴について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21156326","http://diabetes.ebm-library.jp/trial/detail/51246" "Wagner H, et al.","−","Wagner H, Alvarsson M, Mannheimer B, Degerblad M, stenson CG: No Effect of High-Dose Vitamin D Treatment on β-Cell Function, Insulin Sensitivity, or Glucose Homeostasis in Subjects With Abnormal Glucose Tolerance: A Randomized Clinical Trial. Diabetes Care. 2016; 39: 345-52.","前糖尿病または食事療法中の2型糖尿病患者において,高用量ビタミンD3による治療がβ細胞機能,インスリン感受性,耐糖能に与える影響を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26786573","http://diabetes.ebm-library.jp/trial/detail/51569" "Wan EYF, et al.","-","Wan EY, Fung CS, Yu EY, Fong DY, Chen JY, Lam CL. Association of Visit-to-Visit Variability of Systolic Blood Pressure With Cardiovascular Disease and Mortality in Primary Care Chinese Patients With Type 2 Diabetes-A Retrospective Population-Based Cohort Study. Diabetes Care. 2017; 40: 270-279.","プライマリーケアの中国人2型糖尿病患者において,収縮期血圧(SBP)の診察間変動性(visit-to-visit variation[VVV])と心血管疾患(CVD)/死亡リスクの関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27899498","http://diabetes.ebm-library.jp/trial/detail/51616" "Wang W, et al.","-","Wang W, Nevrez L, Filippova E, Song KH, Tao B, Gu L, Wang F, Li P, Yang J. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial. Diabetes Obes Metab. 2019; 21: 234-43.","主にアジア人のmetforminおよび/またはスルホニル尿素薬投与下でコントロール不良の2型糖尿病患者において,週1回dulaglutideとインスリンglargineの有効性と安全性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/30129089","http://diabetes.ebm-library.jp/trial/detail/51757" "Weber MA, et al.","−","Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A: Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016; 4: 211-20.","コントロール不十分な2型糖尿病合併高血圧患者において,SGLT2阻害薬dapagliflozinの血圧作用および血糖作用をプラセボと比較した。","https://www.ncbi.nlm.nih.gov/pubmed/26620248","http://diabetes.ebm-library.jp/trial/detail/51557" "Weisman A, et al.","-","Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017; 5: 501-12.","1型糖尿病患者で,外来における人工膵臓システムの有効性と安全性を評価し,人工膵臓システムの性能に影響する臨床的および技術的な因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28533136","http://diabetes.ebm-library.jp/trial/detail/51661" "Weng J, et al.","-","Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, et al.: Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371: 1753-1760.","新規2型糖尿病患者において,短期的な強化インスリン療法(持続的皮下インスリン注入,インスリン頻回注射)と経口血糖降下薬療法の膵β細胞機能および血糖コントロールに対する有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/18502299","http://diabetes.ebm-library.jp/trial/detail/51067" "WESDR","the Wisconsin Epidemiologic Study of Diabetic Retinopathy","Klein R, Klein BE, Moss SE: Incidence of gross proteinuria in older-onset diabetes. A population-based perspective. Diabetes 1993; 42: 381-389.","成人発症糖尿病患者における顕性蛋白尿の出現率とリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8432408","http://diabetes.ebm-library.jp/trial/detail/50187" "WESDR","the Wisconsin Epidemiologic Study of Diabetic Retinopathy","Klein R, Klein BE, Moss SE, Cruickshanks KJ: Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 1994; 154: 2169-2178.","血糖値と網膜症の罹患・進展との関係について調査した。","https://www.ncbi.nlm.nih.gov/pubmed/7944837","http://diabetes.ebm-library.jp/trial/detail/50161" "WESDR","the Wisconsin Epidemiologic Study of Diabetic Retinopathy","Klein R, Klein BE, Moss SE: Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996; 124: 90-96.","糖尿病患者における血糖コントロールが細小血管合併症に及ぼす効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8554220","http://diabetes.ebm-library.jp/trial/detail/50159" "WHI","Women’s Health Initiative","Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, et al.: Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012; 172: 144-52.","閉経後女性において,スタチン使用と新規糖尿病発症リスクの相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/22231607","http://diabetes.ebm-library.jp/trial/detail/51236" "WHI-OS","Women’s Health Initiative Observational Study","Margolis KL, Wei F, de Boer IH, Howard BV, Liu S, Manson JE, Mossavar-Rahmani Y, Phillips LS, Shikany JM, Tinker LF; Women’s Health Initiative Investigators: A diet high in low-fat dairy products lowers diabetes risk in postmenopausal women. J Nutr. 2011; 141: 1969-74.","糖尿病を合併しない閉経後女性において,乳製品摂取量(とくに低脂肪乳製品)と糖尿病発症の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21940514","http://diabetes.ebm-library.jp/trial/detail/51293" "Whitehall II Cohort Study","−","Virtanen M, Ferrie JE, Tabak AG, Akbaraly TN, Vahtera J, Singh-Manoux A, Kivimki M: Psychological distress and incidence of type 2 diabetes in high-risk and low-risk populations: the Whitehall II Cohort Study. Diabetes Care. 2014; 37: 2091-7.","うつ症状と2型糖尿病発症との関連を検討し,その関連は前糖尿病の有無およびFramingham Offspring 2型糖尿病リスクスコア(FRS)保有状況により異なるかどうかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24784831","http://diabetes.ebm-library.jp/trial/detail/51423" "Whitehall Study","-","Jarrett RJ, Shipley MJ: Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease--putative association via common antecedents; further evidence from the Whitehall Study. Diabetologia 1988; 31: 737-740.","2型糖尿病患者の死亡率を15年間追跡,研究した。","https://www.ncbi.nlm.nih.gov/pubmed/3240834","http://diabetes.ebm-library.jp/trial/detail/50321" "Whitehall Study","-","Brunner EJ, Shipley MJ, Witte DR, Fuller JH, Marmot MG: Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 2006; 29: 26-31.","OGTT 2時間値と冠動脈心疾患死およびその他の死亡との関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/16373891","http://diabetes.ebm-library.jp/trial/detail/50835" "Whitehall Study","-","Batty GD, Kivimaki M, Smith GD, Marmot MG, Shipley MJ: Obesity and overweight in relation to mortality in men with and without type 2 diabetes/impaired glucose tolerance: the original Whitehall Study. Diabetes Care 2007; 30: 2388-2391.","中年男性において,肥満および過体重多の死亡に及ぼす影響について2型糖尿病または耐糖能異常の有無別に検討した。","https://www.ncbi.nlm.nih.gov/pubmed/17623818","http://diabetes.ebm-library.jp/trial/detail/51083" "Whitehall II study","-","Akbaraly TN, Kivimki M, Brunner EJ, Chandola T, Marmot MG, Singh-Manoux A, Ferrie JE: Association between metabolic syndrome and depressive symptoms in middle-aged adults: results from the Whitehall II study. Diabetes Care. 2009; 32: 499-504.","中年男女において,メタボリックシンドロームとうつ症状発症との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19106378","http://diabetes.ebm-library.jp/trial/detail/51168" "Whitehall II study","-","Tabk AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimki M, Witte DR: Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009; 373: 2215-21.","2型糖尿病患者において,発症前の血糖値,インスリン感受性,インスリン分泌について調査した。","https://www.ncbi.nlm.nih.gov/pubmed/19515410","http://diabetes.ebm-library.jp/trial/detail/51122" "Whitehall II Study","-","Ferrie JE, Kivimki M, Akbaraly TN, Tabak A, Abell J, Davey Smith G, Virtanen M, Kumari M, Shipley MJ: Change in Sleep Duration and Type 2 Diabetes: The Whitehall II Study. Diabetes Care. 2015; 38: 1467-72.","睡眠時間の変化と2型糖尿病発症の縦断的な関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/26068863","http://diabetes.ebm-library.jp/trial/detail/51474" "Whitehall Survey","-","Sayegh HA, Jarrett RJ: Oral glucose-tolerance tests and the diagnosis of diabetes: results of a prospective study based on the Whitehall survey. Lancet 1979; 2: 431-433.","糖尿病あるいは境界型糖尿病と診断された患者の6〜8年後の網膜病変の発生を調査した。","https://www.ncbi.nlm.nih.gov/pubmed/89497","http://diabetes.ebm-library.jp/trial/detail/50354" "WHO MSVDD","the WHO Multinational Study of Vascular Disease in Diabetes","Teuscher A, Schnell H, Wilson PW: Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care 1988; 11: 246-251.","糖尿病患者における網膜症の進展とその関連因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/3416678","http://diabetes.ebm-library.jp/trial/detail/50194" "WHO MSVDD","the WHO Multinational Study of Vascular Disease in Diabetes","Head J, Fuller JH: International variations in mortality among diabetic patients: the WHO Multinational Study of Vascular Disease in Diabetics. Diabetologia 1990; 33: 477-481.","糖尿病患者における全死亡,循環器疾患および腎疾患による死亡を数ヵ国で調査した。","https://www.ncbi.nlm.nih.gov/pubmed/2210120","http://diabetes.ebm-library.jp/trial/detail/50322" "WHO MSVDD","the WHO Multinational Study of Vascular Disease in Diabetics","Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H: A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) II: Associated risk factors. Diabetologia 1990; 33: 542-548.","糖尿病患者における潜在的リスク因子と死亡の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/2253831","http://diabetes.ebm-library.jp/trial/detail/50323" "WHO MSVDD","the WHO Multinational Study of Vascular Disease in Diabetes","Stephenson JM, Kenny S, Stevens LK, Fuller JH, Lee E: Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med 1995; 12: 149-155.","糖尿病患者における蛋白尿と死亡率の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/7743762","http://diabetes.ebm-library.jp/trial/detail/50175" "WHO MSVDD","the WHO Multinational Study of Vascular Disease in Diabetes","Wang SL, Head J, Stevens L, Fuller JH: Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The world health organization multinational study of vascular disease in diabetes. Diabetes Care 1996 ;19: 305-312.","糖尿病患者における高血圧および蛋白尿と死亡率との関係を調査した。","https://www.ncbi.nlm.nih.gov/pubmed/8729151","http://diabetes.ebm-library.jp/trial/detail/50343" "WHO MSVDD","the WHO Multinational Study of Vascular Disease in Diabetes","Fuller JH, Stevens LK, Wang SL: International variations in cardiovascular mortality associated with diabetes mellitus: the WHO Multinational Study of Vascular Disease in Diabetes. Ann Med 1996; 28: 319-322.","各国間に認められる糖尿病患者の全死亡率と心血管疾患罹患率の差異について検討した。","https://www.ncbi.nlm.nih.gov/pubmed/8862686","http://diabetes.ebm-library.jp/trial/detail/50362" "WHS","the Women's Health Study","Song Y, Manson JE, Buring JE, Liu S: A prospective study of red meat consumption and type 2 diabetes in middle-aged and elderly women: the women's health study. Diabetes Care 2004; 27: 2108-2115.","赤身肉および食肉加工品の摂取と2型糖尿病発症の関係を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/15333470","http://diabetes.ebm-library.jp/trial/detail/50671" "Willemen MJ.","-","Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG: Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care. 2011; 34: 369-74.","糖尿病患者におけるDPP-4阻害薬の使用と有害薬剤反応としての感染症報告の相関を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/21270195","http://diabetes.ebm-library.jp/trial/detail/51257" "WINGS-7","Women In India with GDM Strategy","Bhavadharini B, Anjana RM, Mahalakshmi MM, Maheswari K, Kayal A, Unnikrishnan R, Ranjani H, Ninov L, Pastakia SD, Usha S, et al.: Glucose tolerance status of Asian Indian women with gestational diabetes at 6weeks to 1year postpartum (WINGS-7). Diabetes Res Clin Pract. 2016; 117: 22-7.","妊娠糖尿病患者において,分娩後の耐糖能を評価し,分娩後血糖異常のリスク因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27329018","http://diabetes.ebm-library.jp/trial/detail/51585" "WOSCOPS","the West of Scotland Coronary Prevention Study","Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-362.","pravastatinの糖尿病発症抑制効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/11157685","http://diabetes.ebm-library.jp/trial/detail/50373" "WOSCOPS","the West of Scotland Coronary Prevention Study","Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, et al: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-419.","修正版NCEP基準によるメタボリックシンドロームが,冠動脈心疾患発症および新規糖尿病発症を予測しうるかを評価した。","https://www.ncbi.nlm.nih.gov/pubmed/12860911","http://diabetes.ebm-library.jp/trial/detail/50705" "WRAP","Wisconsin Registry for Alzheimer’s Prevention","Willette AA, Xu G, Johnson SC, Birdsill AC, Jonaitis EM, Sager MA, Hermann BP, La Rue A, Asthana S, Bendlin BB: Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults. Diabetes Care. 2013; 36: 443-9.","中年の健康人において,インスリン抵抗性とアルツハイマー病感受性脳領域の灰白質容積および認知機能の関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/23069842","http://diabetes.ebm-library.jp/trial/detail/51317" "Wu JHY, et al.","-","Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundstrm J, Neal B: Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016; 4: 411-9.","成人の2型糖尿病患者において,心血管イベント,死亡,安全性アウトカムに対するSGLT2阻害薬の効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27009625","http://diabetes.ebm-library.jp/trial/detail/51577" "Wu JHY, et al.","-","Wu JHY, Marklund M, Imamura F, Tintle N, Ardisson Korat AV, de Goede J, Zhou X, Yang WS, de Oliveira Otto MC, Krger J, Qureshi W, Virtanen JK, Bassett JK, Frazier-Wood AC, Lankinen M, Murphy RA, Rajaobelina K, Del Gobbo LC, Forouhi NG, Luben R, Khaw KT, Wareham N, Kalsbeek A, Veenstra J, Luo J, Hu FB, Lin HJ, Siscovick DS, Boeing H, Chen TA, Steffen B, Steffen LM, Hodge A, Eriksdottir G, Smith AV, Gudnason V, Harris TB, Brouwer IA, Berr C, Helmer C, Samieri C, Laakso M, Tsai MY, Giles GG, Nurmi T, Wagenknecht L, Schulze MB, Lemaitre RN, Chien KL, Soedamah-Muthu SS, Geleijnse JM, Sun Q5, Harris WS, Lind L, rnlv J, Riserus U, Micha R, Mozaffarian D; Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Fatty Acids and Outcomes Research Consortium (FORCE). Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39740 adults from 20 prospective cohort studies. Lancet Diabetes Endocrinol. 2017; 5: 965-74.","リノール酸およびアラキドン酸のバイオマーカーと2型糖尿病発症の関連を評価し,その修正因子を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29032079","http://diabetes.ebm-library.jp/trial/detail/51695" "Wu JW, et al.","-"," Wu JW, Azoulay L, Majdan A, Boivin JF, Pollak M, Suissa S. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. J Clin Oncol. 2017; 35: 3647-53.","2型糖尿病の女性において,長時間作用型インスリンアナログの長期使用により乳がんリスクが上昇するかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/28953430","http://diabetes.ebm-library.jp/trial/detail/51691" "XENDOS","XENical in the prevention of Diabetes in Obese Subjects study","Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161.","肥満者において,生活習慣改善に減量薬を併用することにより,減量および2型糖尿病の発症予防に関してさらなる効果が得られるかを検討した。","https://www.ncbi.nlm.nih.gov/pubmed/14693982","http://diabetes.ebm-library.jp/trial/detail/50667" "Xie Y, et al.","-","Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. Kidney Int. 2018; 93: 741-52.","非糖尿病例において,血中尿素窒素上昇と糖尿病発症リスク上昇の関連性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/29241622","http://diabetes.ebm-library.jp/trial/detail/51704" "Yajima T, et al.","-"," Yajima T, Yajima K, Hayashi M, Takahashi H, Yasuda K. Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring. Diabetes Res Clin Pract. 2016; 122: 78-83. ","血液透析を行っている2型糖尿病患者において,インスリン療法へのDPP-4阻害薬teneligliptin追加の有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/27810689","http://diabetes.ebm-library.jp/trial/detail/51610" "Yang HK, et al.","-","Yang HK, Min KW, Park SW, Chung CH, Park KS, Choi SH, Song KH, Kim DM, Lee MK, Sung YA, Baik SH, Kim IJ, Cha BS, Park JH, Ahn YB, Lee IK, Yoo SJ, Kim J, Park IeB, Park TS, Yoon KH. A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-nave patients with type 2 diabetes. Endocr J. 2015; 62: 449-62.","食事/運動療法で血糖コントロール不良の2型糖尿病患者における,anagliptinの有効性と安全性を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/25819061","http://diabetes.ebm-library.jp/trial/detail/51652" "Yaron M, et al.","−","Yaron M, Roitman E, Aharon-Hananel G, Landau Z, Ganz T, Yanuv I, Rozenberg A, Karp M, Ish-Shalom M, Singer J, et al.: Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes. Diabetes Care. 2019; 42: 1178-1184.","インスリン治療中の2型糖尿病患者において,フラッシュグルコースモニタリング(FGM)システムの効果および治療満足度を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/31036546","http://diabetes.ebm-library.jp/trial/detail/51774" "Yki-Jarvinen H, et al.","-","Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M: Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999; 130: 389-396.","就寝時インスリンが,2型糖尿病患者の体重増加,低血糖の頻度,血糖コントロールに与える効果を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/10068412","http://diabetes.ebm-library.jp/trial/detail/50160" "ZARADEMP","Zaragoza Dementia and Depression Project","Campayo A, de Jonge P, Roy JF, Saz P, de la Cmara C, Quintanilla MA, Marcos G, Santabrbara J, Lobo A; ZARADEMP Project: Depressive disorder and incident diabetes mellitus: the effect of characteristics of depression. Am J Psychiatry. 2010; 167: 580-8.","臨床的に重大なうつ病と糖尿病リスクの関連を検討し,うつ病特性の糖尿病発症に対する影響を評価した。","https://www.ncbi.nlm.nih.gov/pubmed/20123914","http://diabetes.ebm-library.jp/trial/detail/51294" "Zelniker TA, et al.","-","Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393: 31-9.","2型糖尿病患者において,特定の心血管および腎アウトカムに対するSGLT2阻害薬の有効性と安全性についてシステマティックレビューを行い,メタ解析を実施した。","https://www.ncbi.nlm.nih.gov/pubmed/30424892","http://diabetes.ebm-library.jp/trial/detail/51750" "Zhang Y, et al.","-","Zhang Y, McCoy RG, Mason JE, Smith SA, Shah ND, Denton BT: Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care. 2014; 37: 1338-45.","2型糖尿病患者において,metforminの二次治療としての4種類の血糖降下治療の臨床的有効性,QOL,費用を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/24574345","http://diabetes.ebm-library.jp/trial/detail/51395" "Zheng SL, et al.","-","Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA. 2018; 319: 1580-91.","2型糖尿病患者において,SGLT2阻害薬,GLP-1受容体作動薬,DPP-4阻害薬の死亡率および心血管アウトカムに対する有効性を比較した。","https://www.ncbi.nlm.nih.gov/pubmed/29677303","http://diabetes.ebm-library.jp/trial/detail/51721" "ZODIAC-16","Zwolle Outpatient Diabetes project Integrating Available Care study","Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ: Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010; 33: 322-6.","2型糖尿病患者において,metformin治療と癌死亡との関連を検討した。","https://www.ncbi.nlm.nih.gov/pubmed/19918015","http://diabetes.ebm-library.jp/trial/detail/51157" "Zwolle Myocardial Infarction Study","-","Timmer JR, Ottervanger JP, Thomas K, Hoorntje JC, de Boer MJ, Suryapranata H, Zijlstra F, Zwolle Myocardial Infarction Study Group: Long-term, cause-specific mortality after myocardial infarction in diabetes. Eur Heart J 2004; 25: 926-931.","ST上昇を伴う急性心筋梗塞患者において,血栓溶解療法または経皮的冠動脈形成術施行後の長期死亡率を糖尿病の有無により比較した。","https://www.ncbi.nlm.nih.gov/pubmed/15172464","http://diabetes.ebm-library.jp/trial/detail/50683"